Trial Title,Trial Phase,Trial Status,Sponsor,Disease,Patient Segment,MeSH Term,Countries
A Phase Ib/II Open-label Study of Samuraciclib in Combination With Elacestrant in Participants With Metastatic or Locally Advanced Hormone Receptor-positive and Human Epidermal Growth Factor Receptor 2-negative Breast Cancer,I/II,Open,"Menarini Group
Carrick Therapeutics",Oncology: Breast,Estrogen receptor positive; HER2 negative; Progesterone receptor positive; Second line; Stage III; Stage IV,Breast Neoplasms,France; Spain; United Kingdom; United States
"A Phase Ia/Ib, Dose-Escalation/Dose-Expansion Study of NPX267 in Subjects With Solid Tumors Known to Express HHLA-2",I,Planned,NextPoint Therapeutics,"Oncology: Bile Duct (Cholangiocarcinoma); Oncology: Bladder; Oncology: Breast; Oncology: Cervical; Oncology: Colorectal; Oncology: Endometrial; Oncology: Gastric; Oncology: Lung, Non-Small Cell; Oncology: Osteosarcoma; Oncology: Pancreas; Oncology: Prostate; Oncology: Renal; Oncology: Unspecified Solid Tumor",(N/A); EGFR; Line of therapy N/A; Second line; Stage III; Triple receptor negative,"Bile Duct Neoplasms; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Cholangiocarcinoma; Colorectal Neoplasms; Endometrial Neoplasms; Ewing Sarcoma; Kidney Neoplasms; Neoplasms; Osteosarcoma; Pancreatic Neoplasms; Prostatic Neoplasms; Stomach Neoplasms; Urethral Neoplasms; Urinary Bladder Neoplasms; Uterine Cervical Neoplasms; Wilms Tumor",United States
"A Phase 1, Open-label Dose Escalation and Dose-Expansion Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of D3L-001 Monotherapy in Subjects With HER2-Positive Advanced Solid Tumors.",I,Planned,D3 Bio (Wuxi) Co.,Oncology: Breast; Oncology: Esophageal; Oncology: Gastric; Oncology: Unspecified Solid Tumor,HER2 positive; Line of therapy N/A; Stage III; Stage IV,Breast Neoplasms; Esophageal Neoplasms; Neoplasms; Stomach Neoplasms,China; United States
"A Phase I/II, Open-label, Multicenter Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of HB0045 in Patients With Advanced Solid Tumors",I/II,Planned,"MD Anderson Cancer Center University of Texas;
Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute;
(Other Hospital/Academic/Medical Center);
Zhejiang Huahai Pharmaceutical Co./Huabo Biopharm Co.","Oncology: Breast; Oncology: Colorectal; Oncology: Endometrial; Oncology: Fallopian Tube; Oncology: Head/Neck; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Ovarian; Oncology: Pancreas; Oncology: Primary Peritoneal; Oncology: Prostate; Oncology: Renal; Oncology: Soft Tissue Sarcoma; Oncology: Unspecified Solid Tumor",Second line; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Colorectal Neoplasms; Endometrial Neoplasms; Fallopian Tube Neoplasms; Fibrosarcoma; Head and Neck Neoplasms; Kidney Neoplasms; Leiomyosarcoma; Liposarcoma; Liver Neoplasms; Neoplasms; Ovarian Neoplasms; Pancreatic Neoplasms; Peritoneal Neoplasms; Prostatic Neoplasms; Rhabdomyosarcoma; Sarcoma; Synovial Sarcoma; Wilms Tumor",United States
"A Phase Ib/II Study to Evaluate the Novel Combination of Samuraciclib And Vepdegestrant, In Patients Who Have Received Prior CDK4/6i, with ER+, HER2- Metastatic Breast Cancer",I/II,Planned,"Pfizer;
Arvinas;",Oncology: Breast,Estrogen receptor positive; HER2 negative; Progesterone receptor positive; Second line; Stage IV,Breast Neoplasms,United States
"A First-in-human, Multicenter, Open-label, Dose Escalation and Dose Expansion Phase I Study in Patients With Advanced Solid Tumors to Evaluate the Safety of Intravenously Administered ALG.APV-527",I/II,Open,"Alligator Bioscience
Aptevo Therapeutics","Oncology: Bladder; Oncology: Breast; Oncology: Cervical; Oncology: Colorectal; Oncology: Esophageal; Oncology: Gastric; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Ovarian; Oncology: Pancreas; Oncology: Prostate; Oncology: Renal; Oncology: Unspecified Solid Tumor",Line of therapy N/A; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Colorectal Neoplasms; Esophageal Neoplasms; Head and Neck Neoplasms; Kidney Neoplasms; Ovarian Neoplasms; Pancreatic Neoplasms; Prostatic Neoplasms; Stomach Neoplasms; Urethral Neoplasms; Urinary Bladder Neoplasms; Uterine Cervical Neoplasms; Wilms Tumor",United States
"An Open-label, Single-arm, Phase Ib/II  Study to Investigate the Safety, Efficacy and Pharmacokinetics of LS301-IT in Female Patients Undergoing Partial Mastectomy and Sentinel Lymph Node Biopsy (SLNB) for Ductal Carcinoma in Situ (DCIS) or Stage I-II Primary Invasive Breast Cancer",I/II,Open,Integro Theranostics,Oncology: Breast,Line of therapy N/A; Stage I; Stage II,"Breast Neoplasms; Carcinoma; Carcinoma, Ductal; Carcinoma, Ductal, Breast",United States
"A Phase I/IIa, Open-label, Multi-center Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of the DNA Polymerase Theta Inhibitor ART6043 Administered Orally as Monotherapy and in Combination to Patients With Advanced or Metastatic Solid Tumors",I/II,Open,Artios Pharma,Oncology: Breast; Oncology: Unspecified Solid Tumor,HER2 negative; Second line; Stage III; Stage IV,Breast Neoplasms; Neoplasms,United States
"An Open-label, Phase 1, Multicenter Study to Evaluate the Safety and Preliminary Anti-tumor Activity of NT-175 in Human Leukocyte Antigen-A*02:01-Positive Adult Subjects With Unresectable, Advanced and/or Metastatic Solid Tumors That Are Positive for the TP53 R175H Mutation",I,Open,AstraZeneca;/Neogene Therapeutics,"Oncology: Breast; Oncology: Colorectal; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Pancreas; Oncology: Unspecified Solid Tumor",(N/A); First line; Line of therapy N/A; Stage III; Stage IV,"Breast Neoplasms; Carcinoma; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Head and Neck Neoplasms; Pancreatic Neoplasms; Squamous Cell Carcinoma of Head and Neck",United States
A First in Human Clinical Trial to Evaluate CRB091 for the Treatment of Colorectal and Triple-negative Breast Cancers,I,Planned,Cancer Research and Biotechnology,Oncology: Breast; Oncology: Colorectal,(N/A); HER2 negative; Line of therapy N/A; Triple receptor negative,Breast Neoplasms; Colorectal Neoplasms,United States
PRE-Investigation of Serial Studies to Predict Your Therapeutic Response With Imaging And moLecular Analysis: A Phase I/Ib Platform Trial,I,Open,(Other Cooperative Group);,Oncology: Breast; Oncology: Unspecified Solid Tumor,Estrogen receptor positive; HER2 negative; HER2 positive; Line of therapy N/A; Progesterone receptor positive; Stage IV; Triple receptor negative,Breast Neoplasms; Carcinoma; Triple Negative Breast Neoplasms,United States
"A Multi-Regional, Open-Label, Dose Escalation and Dose Expansion Phase Ⅰ Clinical Study to Investigate the Safety, Tolerability, Pharmacokinetics, Immunogenicity and Preliminary Efficacy of HF158K1 in Participants With HER-2 Positive or HER-2 Low Expression Advanced Solid Tumors",I,Planned,Hangzhou HighField Biopharmaceutical Co.,"Oncology: Bladder; Oncology: Breast; Oncology: Cervical; Oncology: Gastric; Oncology: Lung, Non-Small Cell; Oncology: Lung, Small Cell; Oncology: Ovarian; Oncology: Pancreas; Oncology: Prostate; Oncology: Unspecified Solid Tumor",(N/A); HER2 positive; Second line; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Neoplasms; Ovarian Neoplasms; Pancreatic Neoplasms; Prostatic Neoplasms; Small Cell Lung Carcinoma; Stomach Neoplasms; Urethral Neoplasms; Urinary Bladder Neoplasms; Uterine Cervical Neoplasms",China; United States
"A Phase I, Open-label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of ISM3091 in Patients with Advanced Solid Tumors",I,Planned,InSilico Medicine,Oncology: Breast; Oncology: Unspecified Solid Tumor,BRCA; Line of therapy N/A; Stage III; Stage IV,Breast Neoplasms,China; United States
"Phase I/Ib, Open-label, Dose-escalating, Clinical and Pharmacokinetic Study of PM54 Administered Intravenously to Patients With Selected Advanced Solid Tumors.",I,Open,PharmaMar,"Oncology: Bladder; Oncology: Breast; Oncology: Cervical; Oncology: Endometrial; Oncology: Esophageal; Oncology: Fallopian Tube; Oncology: Gastric; Oncology: Lung, Non-Small Cell; Oncology: Lung, Small Cell; Oncology: Melanoma; Oncology: Mesothelioma; Oncology: Neuroendocrine; Oncology: Ovarian; Oncology: Pancreas; Oncology: Primary Peritoneal; Oncology: Prostate; Oncology: Renal; Oncology: Soft Tissue Sarcoma; Oncology: Unspecified Solid Tumor",(N/A); Advanced; BRAF; Estrogen receptor positive; Fourth line or greater; Gastrointestinal; HER2 negative; HER2 positive; High-grade; Pancreas; Progesterone receptor positive; Pulmonary; Second line; Stage III; Stage IV; Third line; Triple receptor negative,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Endometrial Neoplasms; Esophageal Neoplasms; Fallopian Tube Neoplasms; Fibrosarcoma; Kidney Neoplasms; Leiomyosarcoma; Liposarcoma; Melanoma; Mesothelioma; Neoplasms; Neuroendocrine Tumors; Ovarian Neoplasms; Pancreatic Neoplasms; Peritoneal Neoplasms; Prostatic Neoplasms; Rhabdomyosarcoma; Sarcoma; Small Cell Lung Carcinoma; Stomach Neoplasms; Synovial Sarcoma; Urethral Neoplasms; Urinary Bladder Neoplasms; Uterine Cervical Neoplasms; Wilms Tumor",Belgium; Spain; United States
A Phase I Clinical Study of A009 in Patients with HER2-positive breast cancer,I,Planned,Convalife,Oncology: Breast,(N/A); HER2 positive; Line of therapy N/A,Breast Neoplasms,China; United States
A First in Human Dose Escalation of Dendritic Cell Vaccine (DCV) Administered Intrathecally (IT) Primed Against HER2/HER3 in Patients With Leptomeningeal Disease (LMD) From Triple-Negative Breast Cancer (TNBC) or HER2+ Breast Cancer (HER2+BC),I,Open,"H. Lee Moffitt Cancer Center and Research Institute
(Other Hospital/Academic/Medical Center);",Oncology: Breast; Oncology: Metastatic Cancer,(N/A); CNS mets; Line of therapy N/A; Triple receptor negative,Brain Neoplasms; Breast Neoplasms; Central Nervous System Neoplasms; Meningeal Neoplasms; Neoplasm Metastasis; Triple Negative Breast Neoplasms,United States
"Study to Explore the Safety, Tolerability, and Pharmacokinetics of AMG 305 in Subjects With Advanced Solid Tumors.",I,Open,Amgen,"Oncology: Breast; Oncology: Cervical; Oncology: Colorectal; Oncology: Gastric; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Mesothelioma; Oncology: Pancreas; Oncology: Unspecified Solid Tumor",(N/A); First line; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Head and Neck Neoplasms; Mesothelioma; Pancreatic Neoplasms; Stomach Neoplasms; Uterine Cervical Neoplasms",Australia; United States
"A Multiple center, Open label, Dose Escalation Phase I Study of CycloSam For the Treatment of Metastatic Bone Cancer",I,Open,QSAM Biosciences,Oncology: Breast; Oncology: Osteosarcoma,(N/A); Line of therapy N/A; Metastatic,Breast Neoplasms; Ewing Sarcoma; Osteosarcoma,United States
"A Phase I/IIa, Multicenter, Open-Label, Non-Randomized First in Human Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of DB-1310 in Subjects With Advanced/Metastatic Solid Tumors",I/II,Open,Duality Biologics,"Oncology: Breast; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Prostate; Oncology: Unspecified Solid Tumor",Adenocarcinoma; EGFR; HER2 positive; Hormone refractory; Second line; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Head and Neck Neoplasms; Prostatic Neoplasms",China; United States
A Phase 1-2 Dose-escalation and Expansion Study of ST316 in Subjects With Selected Advanced Unresectable and Metastatic Solid Tumors,I/II,Open,Sapience Therapeutics,Oncology: Bile Duct (Cholangiocarcinoma); Oncology: Breast; Oncology: Cervical; Oncology: Colorectal; Oncology: Melanoma; Oncology: Ovarian; Oncology: Pancreas; Oncology: Soft Tissue Sarcoma; Oncology: Unspecified Solid Tumor,(N/A); Line of therapy N/A; Locally advanced; Metastatic; MSI-H/dMMR; PD-L1 Positive; Second line; Stage III; Stage IV; Third line,Bile Duct Neoplasms; Breast Neoplasms; Cholangiocarcinoma; Colorectal Neoplasms; Fibrosarcoma; Leiomyosarcoma; Liposarcoma; Melanoma; Ovarian Neoplasms; Pancreatic Neoplasms; Rhabdomyosarcoma; Sarcoma; Synovial Sarcoma; Uterine Cervical Neoplasms,United States
"First-in-Human Study of STX-478, a Mutant-Selective PI3Kα Inhibitor as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumor",I/II,Open,Scorpion Therapeutics,Oncology: Breast; Oncology: Cervical; Oncology: Head/Neck; Oncology: Ovarian; Oncology: Unspecified Solid Tumor; Oncology: Vaginal; Oncology: Vulvar,Estrogen receptor positive; HER2 negative; Line of therapy N/A; Progesterone receptor positive; Stage III; Stage IV,Breast Neoplasms; Head and Neck Neoplasms; Ovarian Neoplasms; Uterine Cervical Neoplasms; Vaginal Neoplasms; Vulvar Neoplasms,United States
"A Phase I, 2-Part, Multicenter, First-In-Human Dose-Escalation and Dose-Expansion Study of DS-1103a Combination Therapy in Subjects with Advanced Solid Tumors",I,Open,"AstraZeneca;
Daiichi Sankyo","Oncology: Breast; Oncology: Lung, Non-Small Cell; Oncology: Unspecified Solid Tumor",(N/A); Estrogen receptor positive; Line of therapy N/A; Progesterone receptor positive; Second line; Stage III; Stage IV; Third line,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Neoplasms",United States
A Phase I/Ib Study to Evaluate the Safety and Tolerability of AB598 Monotherapy and Combination Therapy in Participants With Advanced Malignancies,I,Open,Arcus Biosciences,"Oncology: Bladder; Oncology: Breast; Oncology: Cervical; Oncology: Esophageal; Oncology: Gastric; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Ovarian; Oncology: Renal; Oncology: Unspecified Cancer",First line; HER2 negative; Line of therapy N/A; Stage III; Stage IV; Triple receptor negative,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Esophageal Neoplasms; Head and Neck Neoplasms; Kidney Neoplasms; Neoplasms; Ovarian Neoplasms; Stomach Neoplasms; Urethral Neoplasms; Urinary Bladder Neoplasms; Uterine Cervical Neoplasms; Wilms Tumor",United States
Phase I/IIa Clinical Trial Evaluating the Safety and Efficacy of Rintatolimod Combined With IFNα2b (Bioferon®) to Enhance the Effectiveness of Pembrolizumab in Patients With Metastatic Triple Negative Breast Cancer,I/II,Planned,Roswell Park Cancer Institute,Oncology: Breast,First line; PD-L1 Positive; Stage III; Stage IV; Triple receptor negative,Breast Neoplasms; Carcinoma; Triple Negative Breast Neoplasms,United States
"A Phase I Study to Investigate the Safety, Tolerability, Pharmacokinetics/Pharmacodynamics, and Antitumor Activity of NM1F as Monotherapy and in Combination With Pembrolizumab in Subjects With Locally Advanced/Metastatic Solid Tumors",I,Open,Hefei TG ImmunoPharma Co.,Oncology: Breast; Oncology: Colorectal; Oncology: Melanoma; Oncology: Ovarian,HER2 negative; Second line; Stage III; Stage IV; Triple receptor negative,Breast Neoplasms; Colorectal Neoplasms; Melanoma; Ovarian Neoplasms; Triple Negative Breast Neoplasms,China; United States
"A Phase I/II, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of INX-315 in Patients With Advanced Cancer",I/II,Open,Incyclix Bio,Oncology: Breast; Oncology: Fallopian Tube; Oncology: Ovarian; Oncology: Primary Peritoneal; Oncology: Unspecified Solid Tumor,Estrogen receptor positive; HER2 negative; Progesterone receptor positive; Second line; Stage III; Stage IV,Breast Neoplasms; Fallopian Tube Neoplasms; Neoplasms; Ovarian Neoplasms; Peritoneal Neoplasms,Australia; United States
"A First-in-Human Study of PI3Kα Inhibitor, RLY-5836, in Combination With Targeted and Endocrine Therapies in Participants With Advanced Breast Cancer and as a Single Agent in Advanced Solid Tumors",I,Open,Relay Therapeutics,Oncology: Breast; Oncology: Unspecified Solid Tumor,Estrogen receptor positive; HER2 negative; Progesterone receptor positive; Second line; Stage III; Stage IV,Breast Neoplasms,United States
A Clinical Study to Evaluate TCC1727 for the Treatment of Various Types of Cancers,I,Planned,Sino Biopharmaceutical/Beijing Tide Pharmaceutical Co.,"Oncology: Breast; Oncology: Lung, Non-Small Cell; Oncology: Lung, Small Cell; Oncology: Ovarian",(N/A); Line of therapy N/A,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Ovarian Neoplasms; Small Cell Lung Carcinoma",United States
Combination Therapy of Niraparib and Irinotecan in Cancers With Mutations in DNA Repair Genes,I,Open,"GlaxoSmithKline
University of California; San Francisco",Oncology: Bile Duct (Cholangiocarcinoma); Oncology: Breast; Oncology: Colorectal; Oncology: Gastric; Oncology: Ovarian; Oncology: Pancreas,Line of therapy N/A; Stage IV,Bile Duct Neoplasms; Breast Neoplasms; Cholangiocarcinoma; Colorectal Neoplasms; Ovarian Neoplasms; Pancreatic Neoplasms; Stomach Neoplasms,United States
"A First-in-Human, Multicenter, Phase I, Open-Label Study of XTX301 in Patients With Advanced Solid Tumors",I,Open,Xilio Therapeutics,"Oncology: Breast; Oncology: Colorectal; Oncology: Endometrial; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Ovarian; Oncology: Pancreas; Oncology: Prostate",HER2 negative; MSI-H/dMMR; MSS/pMMR; Second line; Stage III; Stage IV; Triple receptor negative,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Endometrial Neoplasms; Head and Neck Neoplasms; Melanoma; Neoplasms; Ovarian Neoplasms; Pancreatic Neoplasms; Prostatic Neoplasms",United States
"A Study to Evaluate the Safety and Tolerability of the Covalent Phosphoinositide-3-Kinase (PI3K)-Alpha Inhibitor, TOS-358, in Adult Subjects With Select Solid Tumors",I,Open,Totus Medicines,"Oncology: Bladder; Oncology: Breast; Oncology: Cervical; Oncology: Colorectal; Oncology: Endometrial; Oncology: Gastric; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Ovarian; Oncology: Unspecified Solid Tumor",Fourth line or greater; HER2 negative; Second line; Stage III; Stage IV; Third line,"Breast Neoplasms; Carcinoma; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Endometrial Neoplasms; Head and Neck Neoplasms; Ovarian Neoplasms; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms; Urethral Neoplasms; Urinary Bladder Neoplasms; Uterine Cervical Neoplasms",United States
"A Multicenter, Open-label, Phase I/II Clinical Trial to Evaluate the Safety and Anti-Tumor Activity ofAB-201 in Subjects With Advanced HER2+ Solid Tumors",I/II,Planned,Artiva Biotherapeutics,Oncology: Breast; Oncology: Esophageal; Oncology: Gastric,HER2 positive; Second line; Stage III; Stage IV,Adenocarcinoma; Breast Neoplasms; Esophageal Neoplasms; Stomach Neoplasms,South Korea; United States
Phase I Study Targeting DNA Methyltransferases in Metastatic Triple-Negative Breast Cancer,I,Open,National Institutes of Health/National Cancer Institute;,Oncology: Breast,Fourth line or greater; HER2 negative; PD-1 Refractory; PD-L1 Refractory; Second line; Stage III; Stage IV; Third line; Triple receptor negative,Breast Neoplasms; Carcinoma; Triple Negative Breast Neoplasms,United States
Phase Ib IIT of Heat Shock Protein 90 Inhibitor TAS-116 Combined With Cyclin-dependent Kinase 4/6 Inhibitor Palbociclib in Advanced Breast Cancer Progressing on Palbociclib & Treatment-refractory Solid Tumors With Retinoblastoma Deficiency,I,Planned,Brown University Oncology Group,"Oncology: Bladder; Oncology: Breast; Oncology: Endometrial; Oncology: Lung, Small Cell; Oncology: Neuroendocrine; Oncology: Soft Tissue Sarcoma",(N/A); Estrogen receptor positive; HER2 negative; Progesterone receptor positive; Pulmonary; Second line; Stage III; Stage IV,Breast Neoplasms; Endometrial Neoplasms; Fibrosarcoma; Leiomyosarcoma; Liposarcoma; Neuroendocrine Tumors; Retinoblastoma; Rhabdomyosarcoma; Sarcoma; Small Cell Lung Carcinoma; Synovial Sarcoma; Urethral Neoplasms; Urinary Bladder Neoplasms,United States
"A Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Anti-Tumor Activity of AC699 in Patients With Estrogen Receptor Positive/Human Epidermal Growth Factor Receptor 2 Negative (ER+/HER2-) Locally Advanced or Metastatic Breast Cancer",I,Open,Accutar Biotechnology,Oncology: Breast,Estrogen receptor positive; HER2 negative; Second line; Stage III; Stage IV; Third line,Breast Neoplasms,United States
A Phase Ia/Ib Study of ELVN-002 for the Treatment of Patients With HER2 Mutant Non-Small Cell Lung Cancer,I,Open,Enliven Therapeutics,"Oncology: Breast; Oncology: Colorectal; Oncology: Gastric; Oncology: Lung, Non-Small Cell; Oncology: Unspecified Solid Tumor",Adenocarcinoma; HER2 positive; Large Cell; Second line; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Lung Neoplasms; Stomach Neoplasms",Australia; South Korea; United States
A Study of PARG Inhibitor IDE161 in Participants With Advanced Solid Tumors,I/II,Open,IDEAYA Biosciences,Oncology: Breast; Oncology: Ovarian; Oncology: Pancreas; Oncology: Prostate; Oncology: Unspecified Solid Tumor,BRCA; Second line; Stage III; Stage IV,Breast Neoplasms; Ovarian Neoplasms; Pancreatic Neoplasms; Prostatic Neoplasms,United States
"A First-in-Human, Open-label, Multicenter, Phase 1 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of PYX-201 in Participants With Advanced Solid Tumors",I,Open,Pyxis Oncology,"Oncology: Breast; Oncology: Head/Neck; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Ovarian; Oncology: Pancreas; Oncology: Renal; Oncology: Soft Tissue Sarcoma; Oncology: Thyroid",HER2 positive; Locally advanced; Metastatic; Second line; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Fibrosarcoma; Head and Neck Neoplasms; Kidney Neoplasms; Leiomyosarcoma; Liposarcoma; Liver Neoplasms; Ovarian Neoplasms; Pancreatic Neoplasms; Rhabdomyosarcoma; Sarcoma; Synovial Sarcoma; Thyroid Neoplasms; Wilms Tumor",United States
Phase Ib Study of EZH1/2 Inhibitor Valemetostat in Combination With Trastuzumab Deruxtecan in Subjects With HER2 Low/Ultra-low/Null Metastatic Breast Cancer,I,Open,"MD Anderson Cancer Center University of Texas;
Daiichi Sankyo",Oncology: Breast,HER2 negative; Second line; Stage IV,Breast Neoplasms,United States
"FIH Phase 1A /1B Study of AG01 Antibody Against Progranulin/GP88 in Advanced Solid Tumor Malignancies With Expansion Cohorts in Advanced Triple Negative Breast Ca, Hormone Resistant Breast Ca, Non Small Cell Lung Cancer and Mesothelioma",I,Open,"University of Maryland Greenebaum Cancer Center
A&G Pharmaceutical","Oncology: Breast; Oncology: Lung, Non-Small Cell; Oncology: Mesothelioma; Oncology: Ovarian; Oncology: Unspecified Solid Tumor",(N/A); Estrogen receptor positive; HER2 negative; Line of therapy N/A; PD-1 Refractory; PD-L1 Positive; PD-L1 Refractory; Progesterone receptor positive; Second line; Stage III; Stage IV; Triple receptor negative,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Lung Neoplasms; Mesothelioma; Mesothelioma, Malignant; Neoplasms; Ovarian Neoplasms; Triple Negative Breast Neoplasms",United States
"A Phase I, Open-label, Multicenter Study of BMS-986360/CC-90001 Alone and in Combination With Chemotherapy or Nivolumab in Advanced Solid Tumors",I,Open,Bristol-Myers Squibb,"Oncology: Breast; Oncology: Colorectal; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Osteosarcoma; Oncology: Pancreas; Oncology: Renal; Oncology: Soft Tissue Sarcoma; Oncology: Unspecified Solid Tumor",HER2 negative; Line of therapy N/A; Metastatic; MSS/pMMR; Stage III; Stage IV; Triple receptor negative; Unresectable,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Colorectal Neoplasms; Ewing Sarcoma; Fibrosarcoma; Head and Neck Neoplasms; Kidney Neoplasms; Leiomyosarcoma; Liposarcoma; Neoplasms; Osteosarcoma; Pancreatic Neoplasms; Rhabdomyosarcoma; Sarcoma; Synovial Sarcoma; Wilms Tumor",Australia; Canada; Chile; France; Italy; Mexico; Spain; United States
"A Phase I/II, Open-label Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of SNS-101 (Anti VISTA) as Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid Tumors",I/II,Open,"Regeneron
Sensei Biotherapeutics {Panacea Pharmaceuticals}",Oncology: Bladder; Oncology: Breast; Oncology: Cervical; Oncology: Colorectal; Oncology: Esophageal; Oncology: Gastric; Oncology: Head/Neck; Oncology: Melanoma; Oncology: Ovarian; Oncology: Pancreas; Oncology: Prostate; Oncology: Thyroid; Oncology: Unspecified Solid Tumor,Locally advanced; Metastatic; PD-1 Naive; PD-L1 Naive; Second line; Stage III; Stage IV; Unresectable,Breast Neoplasms; Colorectal Neoplasms; Esophageal Neoplasms; Head and Neck Neoplasms; Melanoma; Ovarian Neoplasms; Pancreatic Neoplasms; Prostatic Neoplasms; Stomach Neoplasms; Thyroid Neoplasms; Urethral Neoplasms; Urinary Bladder Neoplasms; Uterine Cervical Neoplasms,United States
"Phase I, Adaptive-design Trial of Human Chimeric Antigen Receptor Modified T Cells in Patients With Mesothelin Expressing Breast Cancer",I,Open,University of Pennsylvania,Oncology: Breast,Estrogen receptor positive; HER2 negative; HER2 positive; Line of therapy N/A; Progesterone receptor positive; Stage III; Stage IV; Triple receptor negative,Breast Neoplasms,United States
A Window of Opportunity Study of Patritumab Deruxtecan in Patients With Brain Metastases,I,Planned,Daiichi Sankyo {Sankyo Co. Ltd},"Oncology: Bile Duct (Cholangiocarcinoma); Oncology: Bladder; Oncology: Breast; Oncology: Colorectal; Oncology: Gastric; Oncology: Lung, Non-Small Cell; Oncology: Lung, Small Cell; Oncology: Melanoma; Oncology: Metastatic Cancer; Oncology: Neuroendocrine; Oncology: Ovarian; Oncology: Prostate",(N/A); CNS mets; Estrogen receptor positive; HER2 negative; HER2 positive; Neoadjuvant; Progesterone receptor positive; Pulmonary; Triple receptor negative,"Bile Duct Neoplasms; Brain Neoplasms; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Central Nervous System Neoplasms; Cholangiocarcinoma; Colorectal Neoplasms; Melanoma; Neoplasm Metastasis; Neuroendocrine Tumors; Ovarian Neoplasms; Prostatic Neoplasms; Small Cell Lung Carcinoma; Stomach Neoplasms; Urethral Neoplasms; Urinary Bladder Neoplasms",United States
A Single Arm Phase I/II Trial of Abemaciclib + VS-6766 + Fulvestrant in Metastatic HR+/HER2- Breast Cancer,I/II,Open,"Eli Lilly
Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute;
Verastem Oncology {Verastem}",Oncology: Breast,Estrogen receptor positive; HER2 negative; Progesterone receptor positive; Second line; Stage IV,Breast Neoplasms,United States
"Phase I Study of CodaLytic, an Intratumoral Influenza-based Oncolytic Virus, in Patients With Metastatic or Otherwise Inoperable Breast Cancer",I,Planned,Codagenix,Oncology: Breast,Line of therapy N/A; Stage III; Stage IV,Breast Neoplasms; Neoplasm Metastasis; Neoplasms,United States
"A Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of ZN-A-1041 Enteric Capsules as a Single Agent or in Combination in Patients With HER2-Positive Advanced Solid Tumors",I,Open,Zion Pharma/Suzhou Zanrong Pharmaceutical Technology Co.,Oncology: Breast; Oncology: Gastric; Oncology: Metastatic Cancer; Oncology: Unspecified Solid Tumor,CNS mets; HER2 positive; Second line; Stage III; Stage IV,Brain Neoplasms; Breast Neoplasms; Central Nervous System Neoplasms; Neoplasm Metastasis; Neoplasms; Stomach Neoplasms,United States
"A Phase Ia/Ib, Open Label, Multicenter, Dose-escalation Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7502175 as a Single Agent and in Combination With Atezolizumab in Patients With Locally Advanced or Metastatic Solid Tumors",I,Open,Roche;Genentech;,"Oncology: Bladder; Oncology: Breast; Oncology: Cervical; Oncology: Esophageal; Oncology: Gastric; Oncology: Head/Neck; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Renal; Oncology: Unspecified Solid Tumor",HER2 negative; Second line; Stage III; Stage IV; Triple receptor negative,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Esophageal Neoplasms; Head and Neck Neoplasms; Kidney Neoplasms; Liver Neoplasms; Melanoma; Stomach Neoplasms; Urethral Neoplasms; Urinary Bladder Neoplasms; Uterine Cervical Neoplasms; Wilms Tumor",United States
Phase I/II Study of PRO1184 in Patients With Locally Advanced and/or Metastatic Solid Tumors,I/II,Open,ProfoundBio (Suzhou) Co./ProfoundBio US Co.,"Oncology: Breast; Oncology: Endometrial; Oncology: Fallopian Tube; Oncology: Lung, Non-Small Cell; Oncology: Mesothelioma; Oncology: Ovarian; Oncology: Primary Peritoneal",Estrogen receptor positive; HER2 negative; Line of therapy N/A; Progesterone receptor positive; Stage III; Stage IV; Triple receptor negative; Unresectable,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Endometrial Neoplasms; Fallopian Tube Neoplasms; Mesothelioma; Mesothelioma, Malignant; Ovarian Neoplasms; Peritoneal Neoplasms; Triple Negative Breast Neoplasms",China; United States
A Phase Ib Study of TBio-4101 (Autologous Selected and Expanded Tumor-Infiltrating Lymphocytes [TIL]) and Pembrolizumab in Patients With Advanced Solid Tumor Malignancies (STARLING),I,Open,Turnstone Biologics,Oncology: Breast; Oncology: Colorectal; Oncology: Melanoma; Oncology: Unspecified Solid Tumor,Second line; Stage III; Stage IV,Breast Neoplasms; Colorectal Neoplasms; Melanoma,United States
"TACTIVE-U: An Interventional Safety And Efficacy Phase Ib/II, Open label Umbrella Study To Investigate Tolerability, PK and Antitumor Activity Of  ARV-471 (PF-07850327), An Oral Proteolysis Targeting Chimera, In Combination with Other Anticancer treatments In Participants Aged 18 Years And With ER+ Advanced Or Metastatic Breast Cancer, Sub-Study B  (ARV-471 in combination with  Ribociclib)",I/II,Open,"Pfizer;
Arvinas;",Oncology: Breast,Estrogen receptor positive; HER2 negative; Second line; Stage III; Stage IV; Third line,Breast Neoplasms,Canada; United States
"A Modular, Open-Label, Multi-Centre Phase I/II Dose-Finding, Optimisation and Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of EP0062 in Patients With Relapsed Locally Advanced or Metastatic AR+/HER2-/ER+ Breast Cancer",I/II,Open,Ellipses Pharma,Oncology: Breast,Estrogen receptor positive; HER2 negative; Progesterone receptor positive; Second line; Stage III; Stage IV; Third line,Breast Neoplasms,United States
"A Phase 1b/II, Open-Label Umbrella Study To Evaluate Safety And Efficacy Of Elacestrant In Various Combination In Patients With Metastatic Breast Cancer",I/II,Open,Menarini Group/Stemline Therapeutics,Oncology: Breast,Estrogen receptor positive; Second line; Stage III; Stage IV,Breast Neoplasms,United States
"TACTIVE-U: An InterventionalL Safety, And Efficacy Phase  IB/II, Open-label, Umbrella Study To Investigate Tolerability, PK, And Antitumor Activity an ARV-471 (PF-07850327), an Oral Proteolysis Targeting Chimera, in Combination With Other Anticancer Treatments In Participants Aged 18 Years And Over With ER+ Advanced Or Metastatic Breast Cancer, SUB-STUDY A (ARV-471 In Combination With Amebacicilib)",I/II,Open,"Pfizer;
Arvinas;",Oncology: Breast,Estrogen receptor positive; First line; HER2 negative; Second line; Stage III; Stage IV,Breast Neoplasms,Canada; United States
A Clinical Study of AB-201 in HER2-Positive Solid Tumors,I,Planned,Artiva Biotherapeutics,Oncology: Breast; Oncology: Esophageal; Oncology: Gastric; Oncology: Unspecified Solid Tumor,(N/A); HER2 positive; Line of therapy N/A,Breast Neoplasms; Esophageal Neoplasms; Stomach Neoplasms,South Korea; United States
"A First-in-Human, Open-Label, Multi-Center Phase I Study of TST003 in Subjects With Locally Advanced or Metastatic Solid Tumors",I/II,Open,Transcenta Holding,"Oncology: Breast; Oncology: Colorectal; Oncology: Esophageal; Oncology: Gastric; Oncology: Lung, Non-Small Cell; Oncology: Prostate; Oncology: Unspecified Solid Tumor",Second line; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Esophageal Neoplasms; Prostatic Neoplasms; Stomach Neoplasms",China; United States
"A Phase I Open-Label, Multi-Center, Safety and Efficacy Study of PRT3645 in Participants With Select Advanced or Metastatic Solid Tumors",I,Open,Prelude Therapeutics,"Oncology: Breast; Oncology: CNS, Glioblastoma; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Mesothelioma; Oncology: Soft Tissue Sarcoma; Oncology: Unspecified Solid Tumor",(N/A); Advanced; Estrogen receptor positive; HER2 negative; KRAS; Progesterone receptor positive; Second line; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Fibrosarcoma; Glioblastoma; Head and Neck Neoplasms; Leiomyosarcoma; Liposarcoma; Mesothelioma; Mesothelioma, Malignant; Rhabdomyosarcoma; Sarcoma; Squamous Cell Carcinoma of Head and Neck; Synovial Sarcoma",United States
"First-in-human Dose-escalation and Expansion Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of the Anti-CCR8 Antibody BAY 3375968 as Monotherapy and in Combination With Pembrolizumab in Participants With Selected Advanced Solid Tumors",I,Open,Bayer AG,"Oncology: Breast; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Unspecified Solid Tumor",HER2 negative; Second line; Stage III; Stage IV; Triple receptor negative,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Head and Neck Neoplasms; Melanoma; Neoplasms",Canada; Singapore; United States
Phase I/II Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid Tumors,I/II,Open,Moderna {Moderna Therapeutics},"Oncology: Bladder; Oncology: Breast; Oncology: Colorectal; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Skin, Basal Cell Carcinoma",HER2 negative; MSS/pMMR; PD-1 Refractory; PD-L1 Positive; PD-L1 Refractory; Second line; Stage III; Stage IV; Triple receptor negative,"Breast Neoplasms; Carcinoma, Basal Cell; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Head and Neck Neoplasms; Melanoma; Neoplasms; Urethral Neoplasms; Urinary Bladder Neoplasms",Australia; United States
"A Phase 1, First-in-Human, Dose-Finding and Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Activity of XmAb 808 in Combination With Pembrolizumab in Selected Advanced Solid Tumors",I,Open,Xencor,"Oncology: Bladder; Oncology: Breast; Oncology: Colorectal; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Ovarian; Oncology: Prostate; Oncology: Renal; Oncology: Unspecified Solid Tumor",HER2 negative; Hormone refractory; Line of therapy N/A; PD-1 Naive; PD-1 Refractory; Second line; Stage III; Stage IV; Triple receptor negative,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Colorectal Neoplasms; Head and Neck Neoplasms; Kidney Neoplasms; Melanoma; Ovarian Neoplasms; Prostatic Neoplasms; Urethral Neoplasms; Urinary Bladder Neoplasms; Wilms Tumor",United States
"Phase I Dose-Escalation, Dose-Expansion Trial of Intratumoral HER2- and HER3-Primed Dendritic Cells Injections for the Treatment of Early-Stage TNBC and ER Low Positive Breast Cancer (DecipHER)",I,Open,H. Lee Moffitt Cancer Center and Research Institute,Oncology: Breast,HER2 negative; Neoadjuvant; Stage III; Stage IV; Triple receptor negative,Breast Neoplasms; Triple Negative Breast Neoplasms,United States
"A Phase IB/IIA Study of the Safety, Tolerability and Initial Efficacy of Oral AMXT 1501 Dicaprate and Intravenous Difluoromethylornithine (DFMO) in Patients With Cancer",I/II,Open,Aminex Therapeutics,"Oncology: Breast; Oncology: Cervical; Oncology: CNS, Brain Stem Glioma; Oncology: Colorectal; Oncology: Endometrial; Oncology: Esophageal; Oncology: Fallopian Tube; Oncology: Gastric; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Mesothelioma; Oncology: Ovarian; Oncology: Primary Peritoneal; Oncology: Thyroid; Oncology: Unspecified Solid Tumor",(N/A); Advanced; DIPG; Locally advanced; Metastatic; Second line; Stage III; Stage IV; Unresectable,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Diffuse Intrinsic Pontine Glioma; Endometrial Neoplasms; Esophageal Neoplasms; Fallopian Tube Neoplasms; Glioma; Head and Neck Neoplasms; Melanoma; Mesothelioma; Mesothelioma, Malignant; Ovarian Neoplasms; Peritoneal Neoplasms; Stomach Neoplasms; Thyroid Cancer, Papillary; Thyroid Neoplasms; Uterine Cervical Neoplasms",United States
"A Phase 1, Multicenter, Open-Label, Dose Escalation, and Dose Expansion Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of DCBY02 as a Monotherapy in Patients With Advanced or Metastatic Solid Tumors",I,Open,DynamiCure Biotechnology,"Oncology: Breast; Oncology: Cervical; Oncology: CNS, Glioblastoma; Oncology: Colorectal; Oncology: Gastric; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Ovarian; Oncology: Renal; Oncology: Unspecified Solid Tumor",(N/A); Second line; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Colorectal Neoplasms; Glioblastoma; Kidney Neoplasms; Liver Neoplasms; Neoplasms; Ovarian Neoplasms; Stomach Neoplasms; Uterine Cervical Neoplasms; Wilms Tumor",United States
"T Cell Receptor Gene Therapy Targeting KK-LC-1 for Gastric, Breast, Cervical, Lung, and Other KK-LC-1 Positive Cancers",I,Open,"National Institutes of Health/National Cancer Institute;
(Other Hospital/Academic/Medical Center);
T-Cure Bioscience","Oncology: Breast; Oncology: Cervical; Oncology: Gastric; Oncology: Lung, Non-Small Cell",First line; HER2 negative; Second line; Stage IV; Triple receptor negative,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Lung Neoplasms; Stomach Neoplasms; Uterine Cervical Neoplasms",United States
A Phase I trial of RAD202 for HER2-positive breast cancer and Gastric Cancer,I,Planned,Radiopharm Theranostics,Oncology: Breast; Oncology: Gastric,(N/A); HER2 positive; Line of therapy N/A,Breast Neoplasms; Stomach Neoplasms,United States
"A Randomized Window of Opportunity Study of Preoperative Letrozole and Simvastatin Versus Letrozole Alone in Stage I-III Hormone Receptor Positive, HER2 Negative Breast Cancer",I,Open,"National Institutes of Health/National Cancer Institute;
Emory University Hospital - Atlanta",Oncology: Breast,Estrogen receptor positive; First line; HER2 negative; Progesterone receptor positive; Stage I; Stage II; Stage III,Breast Neoplasms; Carcinoma,United States
A Phase Ib/II Basket Study To Assess The Safety And Efficacy Of AsiDNA™ In Combination With Olaparib In Participants With Recurrent Solid Tumors,I/II,Open,Onxeo,Oncology: Breast; Oncology: Fallopian Tube; Oncology: Ovarian; Oncology: Primary Peritoneal; Oncology: Prostate,Estrogen receptor positive; HER2 negative; Hormone refractory; Progesterone receptor positive; Second line; Stage III; Stage IV; Triple receptor negative,Breast Neoplasms; Fallopian Tube Neoplasms; Ovarian Neoplasms; Peritoneal Neoplasms; Prostatic Neoplasms,United States
"A Phase I/IIa, Multicenter, Open-Label, Non-Randomized First in Human Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of DB-1305 in Subjects With Advanced/Metastatic Solid Tumors",I/II,Open,"BioNTech
Duality Biologics","Oncology: Breast; Oncology: Lung, Non-Small Cell; Oncology: Lung, Small Cell; Oncology: Unspecified Solid Tumor",(N/A); HER2 positive; Second line; Stage III; Stage IV; Triple receptor negative,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Small Cell Lung Carcinoma",China; United States
A Phase Ib Trial of ZEN003694 (ZEN-3694) With Pembrolizumab and Nab-Paclitaxel in Patients With Metastatic Triple-Negative Breast Cancer,I,Open,National Institutes of Health/National Cancer Institute;,Oncology: Breast,HER2 negative; PD-1 Naive; PD-1 Refractory; PD-L1 Naive; PD-L1 Refractory; Second line; Stage III; Stage IV; Triple receptor negative,Breast Neoplasms; Carcinoma; Triple Negative Breast Neoplasms,United States
"A Modular Phase I/IIa, Open-label, Multi-centre Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of Ascending Doses of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies (CERTIS1)",I/II,Open,AstraZeneca;,"Oncology: Breast; Oncology: CNS, Glioblastoma; Oncology: Fallopian Tube; Oncology: Ovarian; Oncology: Pancreas; Oncology: Primary Peritoneal; Oncology: Prostate",BRCA; HER2 negative; Hormone refractory; Second line; Stage III; Stage IV,Breast Neoplasms; Fallopian Tube Neoplasms; Glioblastoma; Neoplasms; Ovarian Neoplasms; Pancreatic Neoplasms; Peritoneal Neoplasms; Prostatic Neoplasms,Australia; Germany; South Korea; Spain; Sweden; United Kingdom; United States
"A Phase I/II, First-in-Human, Open-Label, Dose Escalation and Expansion Study of STAR0602, a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule, in Subjects With Unresectable, Locally Advanced, or Metastatic Solid Tumors That Are Antigen-rich (START-001)",I/II,Open,Marengo Therapeutics,"Oncology: Breast; Oncology: Colorectal; Oncology: Lung, Non-Small Cell; Oncology: Metastatic Cancer; Oncology: Ovarian; Oncology: Prostate; Oncology: Unspecified Solid Tumor",(N/A); CNS mets; HER2 negative; Hormone refractory; KRAS; MSI-H/dMMR; MSI-L; MSS/pMMR; PD-1 Naive; PD-1 Refractory; PD-L1 Naive; PD-L1 Refractory; Second line; Stage III; Stage IV; Triple receptor negative,"Brain Neoplasms; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Central Nervous System Neoplasms; Colorectal Neoplasms; Neoplasm Metastasis; Neoplasms, Unknown Primary; Ovarian Neoplasms; Prostatic Neoplasms",United States
"A Phase I/IIa, Multi-Center, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Evidence of Antitumor Activity of JAB-2485 in Adult Patients With Advanced Solid Tumors",I/II,Open,Beijing Jacobio Pharmaceuticals Co.,"Oncology: Breast; Oncology: Lung, Small Cell; Oncology: Neuroendocrine",(N/A); HER2 negative; Line of therapy N/A; Pulmonary; Second line; Stage III; Stage IV; Triple receptor negative,Breast Neoplasms; Neoplasms; Neuroendocrine Tumors; Small Cell Lung Carcinoma,China; United States
"Phase I Dose-escalation Trial of OMTX705, an Anti-fibroblast Activation Protein Antibody-drug Conjugate, as Single Agent and in Combination With Pembrolizumab in Patients With Advanced Solid Tumors",I,Open,Oncomatryx,"Oncology: Breast; Oncology: Gastric; Oncology: Lung, Non-Small Cell; Oncology: Lung, Small Cell; Oncology: Neuroendocrine; Oncology: Ovarian; Oncology: Pancreas; Oncology: Unspecified Solid Tumor",(N/A); Line of therapy N/A; Pulmonary; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Neoplasms, Unknown Primary; Neuroendocrine Tumors; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Small Cell Lung Carcinoma; Stomach Carcinoma; Stomach Neoplasms",Spain; United States
"An Open-label Multicenter Phase Ib-II Study of Elacestrant in Combination With Abemaciclib in Women and Men With Brain Metastasis From Estrogen Receptor Positive, HER-2 Negative Breast Cancer",I/II,Open,Menarini Group/Stemline Therapeutics,Oncology: Breast; Oncology: Metastatic Cancer,CNS mets; Estrogen receptor positive; First line; HER2 negative; Progesterone receptor positive; Second line; Stage IV; Third line,Brain Diseases; Brain Neoplasms; Breast Diseases; Breast Neoplasms; Central Nervous System Diseases; Central Nervous System Neoplasms; Neoplasm Metastasis; Neoplasms; Neoplasms by Site; Nervous System Diseases; Nervous System Neoplasms,France; Germany; Italy; South Korea; Spain; United Kingdom; United States
"A Phase I/II, Open Label, Dose Escalation and Expansion Study of TAC-001 in Patients With Select Advanced or Metastatic Solid Tumors",I/II,Open,Tallac Therapeutics,"Oncology: Bile Duct (Cholangiocarcinoma); Oncology: Bladder; Oncology: Breast; Oncology: Cervical; Oncology: Colorectal; Oncology: Endometrial; Oncology: Esophageal; Oncology: Head/Neck; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Neuroendocrine; Oncology: Ovarian; Oncology: Renal; Oncology: Unspecified Solid Tumor",Line of therapy N/A; Merkel; Metastatic; PD-1 Refractory; PD-L1 Refractory; Second line; Squamous Cell; Stage III; Stage IV,"Bile Duct Neoplasms; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Cholangiocarcinoma; Colorectal Neoplasms; Endometrial Neoplasms; Esophageal Neoplasms; Head and Neck Neoplasms; Kidney Neoplasms; Liver Neoplasms; Melanoma; Neoplasms, Unknown Primary; Neuroendocrine Tumors; Ovarian Neoplasms; Urethral Neoplasms; Urinary Bladder Neoplasms; Uterine Cervical Neoplasms; Wilms Tumor",Australia; United States
"A Phase Ib/IIa, Open-Label, Multi-Center Study of CyPep-1 in Combination With Pembrolizumab to Evaluate the Efficacy and Safety of CyPep-1 in Patients With Advanced or Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC), Melanoma, or Triple-Negative Breast Cancer (TNBC) (CATALYST)",I/II,Open,"Merck & Co./Merck Sharp & Dohme (MSD)
Cytovation",Oncology: Breast; Oncology: Head/Neck; Oncology: Melanoma,HER2 negative; PD-1 Refractory; PD-L1 Refractory; Second line; Stage III; Stage IV; Triple receptor negative,"Breast Neoplasms; Carcinoma; Carcinoma, Squamous Cell; Head and Neck Neoplasms; Melanoma; Squamous Cell Carcinoma of Head and Neck",France; Italy; Netherlands; Spain; United Kingdom; United States
REVERT- Breast Cancer: Phase 1b/2 Study of the Addition of STAT3 Inhibitor TTI-101 to Reverse Resistance on First- Line Palbociclib Plus Aromatase Inhibitor Therapy for Metastatic Hormone Receptor-Positive and HER2-Negative Breast Cancer,I/II,Open,Tvardi Therapeutics,Oncology: Breast,Estrogen receptor positive; First line; HER2 negative; Progesterone receptor positive; Second line; Stage III; Stage IV,Breast Neoplasms,United States
Phase I Study of Adoptive T Cell Therapy Following HER2-Pulsed Dendritic Cell Vaccine and Pepinemab / Trastuzumab in Patients With Metastatic HER2-Positive Breast Cancer,I,Open,"H. Lee Moffitt Cancer Center and Research Institute
Vaccinex",Oncology: Breast,Estrogen receptor positive; Fourth line or greater; HER2 positive; Maintenance/Consolidation; Progesterone receptor positive; Second line; Stage IV; Third line,Breast Neoplasms,United States
Phase I Trial of DS-8201a (Trastuzumab Deruxtecan) in Combination With Neratinib in Solid Tumors With HER2 Alterations,I/II,Open,National Institutes of Health/National Cancer Institute;,Oncology: Breast; Oncology: Gastric; Oncology: Unspecified Solid Tumor,HER2 positive; Second line; Stage IV,"Breast Neoplasms; Neoplasms; Neoplasms, Unknown Primary; Stomach Carcinoma; Stomach Neoplasms",United States
"A Phase Ib/II, Multicenter, Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors With FGFR2b Overexpression (FORTITUDE-301)",I/II,Open,Amgen,"Oncology: Bile Duct (Cholangiocarcinoma); Oncology: Breast; Oncology: Cervical; Oncology: Colorectal; Oncology: Endometrial; Oncology: Esophageal; Oncology: Fallopian Tube; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Ovarian; Oncology: Pancreas; Oncology: Primary Peritoneal; Oncology: Unspecified Solid Tumor",Adenocarcinoma; FGFR; Fourth line or greater; HER2 negative; Intrahepatic; PD-1 Refractory; PD-L1 Refractory; Second line; Stage III; Stage IV; Third line; Triple receptor negative; Unresectable,"Bile Duct Neoplasms; Breast Neoplasms; Carcinoma, Endometrioid; Carcinoma, Non-Small-Cell Lung; Cholangiocarcinoma; Colorectal Neoplasms; Endometrial Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Fallopian Tube Neoplasms; Head and Neck Neoplasms; Neoplasms; Neoplasms, Unknown Primary; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Peritoneal Neoplasms; Uterine Cervical Neoplasms",Argentina; Australia; Austria; Belgium; Brazil; Bulgaria; Canada; Czech Republic; Denmark; Finland; France; Greece; Hungary; Israel; Italy; Japan; Mexico; Netherlands; Poland; Portugal; Romania; Russia; South Korea; Spain; Switzerland; Turkey; United Kingdom; United States
A Phase I/II Study Evaluating the Safety and Efficacy of Ivermectin in Combination With Balstilimab in Patients With Metastatic Triple Negative Breast Cancer With Expansion Cohort in PD-L1 Negative TNBC,I/II,Planned,"National Institutes of Health/National Cancer Institute;
City of Hope Comprehensive Cancer Center",Oncology: Breast,HER2 negative; PD-1 Naive; PD-L1 Naive; Second line; Stage III; Stage IV; Third line; Triple receptor negative,Breast Neoplasms; Triple Negative Breast Neoplasms,United States
"A Phase IB Trial Evaluating the Safety of Ribociclib, Tucatinib, and Trastuzumab in Patients With Metastatic, HER2+ Breast Cancer and a Multicenter, Randomized, Open-Label, Phase II Study of Preoperative Treatment With Ribociclib,Ttrastuzumab, Tucatinib, and Fulvestrant Versus Docetaxel, Carboplatin,Ttrastuzumab, and Pertuzumab in HR+/HER2+ Breast Cancer and Ribociclib, Trastuzumab, and Tucatinib Versus Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab in Patients With HR-/HER2+ Breast Cancer",I/II,Open,"Novartis;
Jonsson Comprehensive Cancer Center; UCLA
Seagen",Oncology: Breast,Estrogen receptor positive; HER2 positive; Neoadjuvant; Progesterone receptor positive; Stage I; Stage II; Stage III; Stage IV,Breast Neoplasms; Carcinoma,United States
A Clinical Study to Evaluate JS105 in Patients with Advanced Malignant Solid Tumors including Breast Cancer,I,Planned,Shanghai Junshi Biosciences Co.,Oncology: Breast; Oncology: Unspecified Solid Tumor,Estrogen receptor positive; HER2 negative; Line of therapy N/A; Progesterone receptor positive; Stage III; Stage IV,"Breast Neoplasms; Neoplasms, Unknown Primary",China; United States
A Phase I/II Trial of ATI-2231 With Phase Ia in Advanced Solid Tumor Malignancies Followed by Phase Ib/II in Combination With Capecitabine in Patients With Hormone Receptor-positive and HER2 Negative Metastatic Breast Cancer,I/II,Planned,"Washington University School of Medicine
US Department of Defense
Aclaris Therapeutics",Oncology: Breast; Oncology: Unspecified Solid Tumor,Estrogen receptor positive; HER2 negative; Progesterone receptor positive; Second line; Stage III; Stage IV; Triple receptor negative,Breast Neoplasms; Neoplasms,United States
A Study of LOXO-783 Administered as Monotherapy and in Combination With Anticancer Therapies for Patients With Advanced Breast Cancer and Other Solid Tumors With a PIK3CA H1047R Mutation,I,Open,Eli Lilly/Loxo Oncology,Oncology: Breast; Oncology: Unspecified Solid Tumor,Estrogen receptor positive; HER2 negative; Stage III; Stage IV; Third line,"Breast Neoplasms; Neoplasms, Unknown Primary",Australia; Canada; China; France; Japan; Singapore; South Korea; Spain; United States
"A First-in-Human, Open-label, Multicenter, Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of PYX-106 in Subjects With Advanced Solid Tumors",I,Open,Pyxis Oncology,"Oncology: Bile Duct (Cholangiocarcinoma); Oncology: Bladder; Oncology: Breast; Oncology: Colorectal; Oncology: Endometrial; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Renal; Oncology: Thyroid",(N/A); Second line; Stage III; Stage IV,"Bile Duct Neoplasms; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Cholangiocarcinoma; Colorectal Neoplasms; Endometrial Neoplasms; Head and Neck Neoplasms; Kidney Neoplasms; Neoplasms, Unknown Primary; Thyroid Neoplasms; Urethral Neoplasms; Urinary Bladder Neoplasms; Wilms Tumor",United States
A Phase I First-in-human Study of BMS-986406 as Monotherapy and Combination Therapies in Participants With Advanced Malignant Tumors,I,Open,Bristol-Myers Squibb,"Oncology: Bladder; Oncology: Breast; Oncology: Esophageal; Oncology: Gastric; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Mesothelioma; Oncology: Ovarian; Oncology: Pancreas; Oncology: Prostate; Oncology: Renal; Oncology: Soft Tissue Sarcoma",HER2 negative; Hormone refractory; Locally advanced; Metastatic; PD-1 Refractory; PD-L1 Refractory; Second line; Stage III; Stage IV; Triple receptor negative; Unresectable,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Esophageal Cancer; Esophageal Neoplasms; Fibrosarcoma; Head and Neck Neoplasms; Kidney Neoplasms; Leiomyosarcoma; Liposarcoma; Melanoma; Mesothelioma; Neoplasms, Mesothelial; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Prostatic Neoplasms; Renal Cancer; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Stomach Carcinoma; Stomach Neoplasms; Synovial Sarcoma; Unspecified; Urethral Neoplasms; Urinary Bladder Neoplasms; Wilms Tumor",Argentina; Belgium; Japan; South Korea; Spain; United States
"A Phase 1 Dose Escalation Trial to Determine the Safety, Tolerance, Maximum Tolerated Dose, and Preliminary Antineoplastic Activity of IKS014, a HER2-Targeting Antibody Drug Conjugate (ADC), in Participants With Advanced HER2+ Solid Tumors",I,Planned,Iksuda Therapeutics,Oncology: Breast; Oncology: Gastric; Oncology: Unspecified Solid Tumor,Estrogen receptor positive; First line; HER2 negative; HER2 positive; Line of therapy N/A; Progesterone receptor positive; Second line; Stage III; Stage IV,Breast Neoplasms; Stomach Carcinoma; Stomach Neoplasms,Australia; United States
"A Phase I Open-Label Dose Escalation and Expansion Study to Determine the Safety, Tolerability, Dosimetry, and Preliminary Efficacy of ²¹²Pb-DOTAM-GRPR1 in Adult Subjects With Recurrent or Metastatic GRPR-expressing Tumors",I,Open,Orano Med {Areva Med},"Oncology: Breast; Oncology: Cervical; Oncology: Colorectal; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Prostate",Estrogen receptor positive; HER2 negative; Hormone refractory; Progesterone receptor positive; Stage IV; Third line,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Melanoma; Prostatic Neoplasms; Uterine Cervical Neoplasms",United States
A Phase I Pilot Study of Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab in Advanced Solid Tumors (PNeoVCA),I,Open,Mayo Clinic;,"Oncology: Bladder; Oncology: Breast; Oncology: Cervical; Oncology: Endometrial; Oncology: Esophageal; Oncology: Gastric; Oncology: Head/Neck; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Lung, Small Cell; Oncology: Melanoma; Oncology: Neuroendocrine; Oncology: Renal; Oncology: Skin, Squamous Cell Carcinoma (cSCC); Oncology: Unspecified Solid Tumor",ALK; BRAF; EGFR; Fourth line or greater; HER2 negative; KRAS; Merkel; MSI-H/dMMR; Pulmonary; Second line; Stage III; Stage IV; Third line; Triple receptor negative,"Adenocarcinoma; Breast Neoplasms; Carcinoma; Carcinoma, Endometrioid; Carcinoma, Hepatocellular; Carcinoma, Merkel Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Carcinoma, Small Cell; Carcinoma, Squamous Cell; Carcinoma, Transitional Cell; Endometrial Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Head and Neck Neoplasms; Kidney Neoplasms; Liver Cancer; Liver Neoplasms; Lung Neoplasms; Melanoma; Neoplasms; Neoplasms, Unknown Primary; Neuroendocrine Tumors; Renal Cancer; Skin Neoplasms; Small Cell Lung Carcinoma; Squamous Cell Carcinoma of Head and Neck; Stomach Carcinoma; Stomach Neoplasms; Urethral Neoplasms; Urinary Bladder Neoplasms; Uterine Cervical Neoplasms; Wilms Tumor",United States
A Dose-escalation Study of the Safety and Pharmacology of DAN-222 in Subjects with Metastatic Breast Cancer,I,Open,Dantari,Oncology: Breast,BRCA; Estrogen receptor positive; HER2 negative; Progesterone receptor positive; Stage IV; Third line,Breast Neoplasms,United States
"A Phase 1 Open-label, Multicenter Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Anti-tumor Activity of CLN-418 in Subjects With Advanced Solid Tumors",I,Open,"Harbour BioMed Therapeutics
Cullinan Oncology","Oncology: Bile Duct (Cholangiocarcinoma); Oncology: Bladder; Oncology: Breast; Oncology: Cervical; Oncology: Endometrial; Oncology: Esophageal; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Ovarian; Oncology: Unspecified Solid Tumor",HER2 negative; Second line; Squamous Cell; Stage III; Stage IV; Triple receptor negative,"Bile Duct Neoplasms; Breast Neoplasms; Carcinoma, Endometrioid; Carcinoma, Non-Small-Cell Lung; Cholangiocarcinoma; Endometrial Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Head and Neck Neoplasms; Neoplasms; Neoplasms, Unknown Primary; Ovarian Cancer; Ovarian Neoplasms; Urethral Neoplasms; Urinary Bladder Neoplasms; Uterine Cervical Neoplasms",Australia; United States
RAGE Inhibition to Decrease Cancer Therapy Related Cardio Toxicity in Women With Early Breast Cancer,I/II,Open,Georgetown University,Oncology: Breast,Estrogen receptor positive; First line; HER2 negative; HER2 positive; Progesterone receptor positive; Stage I; Stage II; Stage III,Breast Neoplasms; Cognitive Dysfunction,United States
"A Phase I/II, Multicenter Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of APS03118 in Adult Patients with Unresectable Locally Advanced or Metastatic Solid Tumors Harboring RET Mutations or Fusions (LASER)",I/II,Planned,Applied Pharmaceutical Science,"Oncology: Breast; Oncology: Colorectal; Oncology: Lung, Non-Small Cell; Oncology: Neuroendocrine; Oncology: Thyroid; Oncology: Unspecified Solid Tumor",Line of therapy N/A; Medullary; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Neoplasms, Unknown Primary; Neuroendocrine Tumors; Thyroid Neoplasms",Australia; China; United States
"A Phase I, Open-Label, Multicenter Study of INCB123667 as Monotherapy in Participants With Selected Advanced Solid Tumors",I,Open,Incyte Corporation,Oncology: Breast; Oncology: Endometrial; Oncology: Esophageal; Oncology: Fallopian Tube; Oncology: Gastric; Oncology: Ovarian; Oncology: Primary Peritoneal; Oncology: Soft Tissue Sarcoma; Oncology: Unspecified Solid Tumor,Estrogen receptor positive; HER2 negative; Progesterone receptor positive; Second line; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Endometrioid; Endometrial Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Fallopian Tube Neoplasms; Fibrosarcoma; Leiomyosarcoma; Liposarcoma; Neoplasms; Neoplasms, Unknown Primary; Ovarian Cancer; Ovarian Neoplasms; Peritoneal Neoplasms; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Stomach Carcinoma; Stomach Neoplasms; Synovial Sarcoma",France; Italy; Japan; Netherlands; Switzerland; United Kingdom; United States
"This is a Multicenter, Single Arm, Open-label, run-in Phase Ib / Roll-over Phase II Study of Tucatinib in Combination With Alpelisib in Subjects With PIK3CA-mutant HER2-positive Locally Advanced Unresectable or Metastatic Breast Cancer.",I/II,Open,"Novartis;
Seagen {Seattle Genetics}",Oncology: Breast,Estrogen receptor positive; HER2 positive; Progesterone receptor positive; Second line; Stage III; Stage IV,Breast Neoplasms,United States
A Phase I Study of SGN-PDL1V in Advanced Solid Tumors,I,Open,Seagen,"Oncology: Breast; Oncology: Esophageal; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Ovarian; Oncology: Unspecified Solid Tumor",HER2 negative; PD-L1 Positive; Second line; Stage III; Stage IV; Triple receptor negative,"Breast Neoplasms; Carcinoma; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Esophageal Cancer; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Head and Neck Neoplasms; Melanoma; Neoplasms, Unknown Primary; Ovarian Cancer; Ovarian Neoplasms; Squamous Cell Carcinoma of Head and Neck",Canada; France; Germany; Italy; Netherlands; Spain; United States
A Phase I Study of SGN-B7H4V in Advanced Solid Tumors,I,Open,Seagen,"Oncology: Bile Duct (Cholangiocarcinoma); Oncology: Breast; Oncology: Endometrial; Oncology: Fallopian Tube; Oncology: Gallbladder; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Ovarian; Oncology: Primary Peritoneal",Adenocarcinoma; Estrogen receptor positive; HER2 negative; Progesterone receptor positive; Second line; Squamous Cell; Stage III; Stage IV; Triple receptor negative,"Bile Duct Neoplasms; Breast Neoplasms; Carcinoma; Carcinoma, Endometrioid; Carcinoma, Non-Small-Cell Lung; Cholangiocarcinoma; Cholangiocarcinoma; Endometrial Neoplasms; Fallopian Tube Neoplasms; Gallbladder Neoplasms; Head and Neck Neoplasms; Neoplasms; Neoplasms, Unknown Primary; Ovarian Cancer; Ovarian Neoplasms; Peritoneal Neoplasms; Triple Negative Breast Neoplasms",Canada; Germany; Spain; United Kingdom; United States
"A Phase I/II Study of GI-101 in Combination with Imfinzi (Durvalumab) and Chemotherapy for the Treatment of Small Cell Lung Cancer, Gastric/Gastroesophageal Junction Cancer, Biliary Tract Cancer and Triple-Negative Breast Cancer",I/II,Planned,"AstraZeneca;
GI Innovation","Oncology: Bile Duct (Cholangiocarcinoma); Oncology: Breast; Oncology: Esophageal; Oncology: Gastric; Oncology: Lung, Small Cell; Oncology: Neuroendocrine",(N/A); HER2 negative; Line of therapy N/A; Pulmonary; Stage III; Stage IV; Triple receptor negative,"Bile Duct Neoplasms; Breast Neoplasms; Carcinoma, Small Cell; Cholangiocarcinoma; Esophageal Cancer; Esophageal Neoplasms; Neuroendocrine Tumors; Small Cell Lung Carcinoma; Stomach Carcinoma; Stomach Neoplasms",Australia; South Korea; United States
"A Phase I Study to Assess the Safety and Efficacy of LYL797, ROR1-Targeting CAR T Cells, in Adults With Relapsed and/or Refractory Solid-Tumor Malignancies",I,Open,Lyell Immunopharma,"Oncology: Breast; Oncology: Lung, Non-Small Cell",Fourth line or greater; HER2 negative; PD-1 Refractory; PD-L1 Refractory; Stage III; Stage IV; Third line; Triple receptor negative,"Breast Neoplasms; Carcinoma; Carcinoma, Non-Small-Cell Lung; Lung Neoplasms; Recurrence; Triple Negative Breast Neoplasms",United States
"A Phase I/IIa, Multicenter, Open-Label, Non-Randomized First in Human Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of DB-1303 in Patients With Advanced/Metastatic Solid Tumors",I/II,Open,"BioNTech
Duality Biologics","Oncology: Breast; Oncology: Colorectal; Oncology: Endometrial; Oncology: Esophageal; Oncology: Gastric; Oncology: Lung, Non-Small Cell; Oncology: Ovarian; Oncology: Unspecified Solid Tumor; Oncology: Vaginal",HER2 negative; HER2 positive; Second line; Stage II; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Endometrial Neoplasms; Esophageal Neoplasms; Neoplasms; Neoplasms, Unknown Primary; Ovarian Neoplasms; Stomach Neoplasms; Vaginal Neoplasms",Australia; China; United States
Phase I Trial of Alpelisib Plus Sacituzumab Govitecan In Patients With Metastatic or Locally Recurrent HER2-Negative Breast Cancer,I,Open,"Novartis;
University of Kansas
Gilead Sciences;",Oncology: Breast,Estrogen receptor positive; Fourth line or greater; HER2 negative; PD-1 Refractory; PD-L1 Refractory; Progesterone receptor positive; Second line; Stage III; Stage IV; Third line; Triple receptor negative,Breast Neoplasms,United States
A Phase I Dose Escalation and Dose Expansion Study of AND019 in Patients With Estrogen Receptor Positive Human Epidermal Growth Factor Receptor 2 Negative Advanced or Metastatic Breast Cancer,I,Open,Kind Pharmaceuticals,Oncology: Breast,Estrogen receptor positive; HER2 negative; Second line; Stage III; Stage IV,Breast Neoplasms,China; United States
A Clinical Study of TRS004 in Patients with Recurrent and Metastatic Breast Cancer,I,Planned,Zhejiang Teruisi Pharmaceutical Co.,Oncology: Breast,Line of therapy N/A; Stage IV,Breast Neoplasms,China; United States
A Dose-confirming Study of CFI-402257 as a Single Agent in Advanced Solid Tumors and in Combination With Fulvestrant in Patients With ER+/HER2- Advanced Breast Cancer After Disease Progression on Prior CDK4/6 and Endocrine Therapy.,I/II,Open,Treadwell Therapeutics,Oncology: Breast; Oncology: Unspecified Solid Tumor,Estrogen receptor positive; HER2 negative; Progesterone receptor positive; Second line; Stage III; Stage IV; Third line,"Breast Neoplasms; Neoplasms, Unknown Primary",United States
"A Phase Ib Dose-escalation And Imaging Study Of Ifabotuzumab In Non-CNS Solid Tumors Such As Breast, Colorectal, Lung, And Pancreatic cancer",I,Planned,Humanigen,"Oncology: Breast; Oncology: Colorectal; Oncology: Lung, Non-Small Cell; Oncology: Lung, Small Cell; Oncology: Neuroendocrine; Oncology: Pancreas",(N/A); Line of therapy N/A; Pulmonary,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Colorectal Neoplasms; Neuroendocrine Tumors; Pancreatic Cancer; Pancreatic Neoplasms; Small Cell Lung Carcinoma",United States
"A Phase I/IIa Multi-center, Open-label Master Protocol to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Antitumor Activity of AZD8205 in Participants With Advanced or Metastatic Solid Malignancies",I/II,Open,AstraZeneca;,Oncology: Bile Duct (Cholangiocarcinoma); Oncology: Breast; Oncology: Endometrial; Oncology: Fallopian Tube; Oncology: Ovarian; Oncology: Primary Peritoneal; Oncology: Unspecified Solid Tumor,HER2 negative; Second line; Stage III; Stage IV; Triple receptor negative,"Bile Duct Neoplasms; Breast Neoplasms; Carcinoma, Endometrioid; Cholangiocarcinoma; Cholangiocarcinoma; Endometrial Neoplasms; Fallopian Tube Neoplasms; Neoplasms, Unknown Primary; Ovarian Cancer; Ovarian Neoplasms; Peritoneal Neoplasms","Australia; Belgium; Canada; China; Japan; Netherlands; Poland; South Korea; Spain; Taiwan, China; Thailand; United Kingdom; United States"
"A Phase I, Open-Label, First in Human, Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ZX-4081 in Patients With Advanced Solid Tumors",I,Open,Nanjing Zenshine Pharmaceuticals Co.,"Oncology: Bladder; Oncology: Breast; Oncology: Colorectal; Oncology: Head/Neck; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Ovarian; Oncology: Renal",Second line; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Colorectal Neoplasms; Head and Neck Neoplasms; Kidney Neoplasms; Liver Cancer; Liver Neoplasms; Melanoma; Neoplasms; Ovarian Cancer; Ovarian Neoplasms; Renal Cancer; Urethral Neoplasms; Urinary Bladder Neoplasms; Wilms Tumor",United States
A Phase I Study of ZEN003694 in Combination With Binimetinib in Solid Tumors With RAS Pathway Alterations and Triple Negative Breast Cancer,I,Open,National Institutes of Health/National Cancer Institute;,Oncology: Breast; Oncology: Unspecified Solid Tumor,BRAF; HER2 negative; HRAS; KRAS; NRAS; Second line; Stage III; Stage IV; Triple receptor negative,"Breast Neoplasms; Neoplasms; Neoplasms, Unknown Primary; Triple Negative Breast Neoplasms",United States
"A Phase I, Open-Label Study of the Safety, Tolerability and Preliminary Clinical Activity of Allogeneic Invariant Natural Killer T (iNKT) Cells (agenT-797) as a Single Agent and in Combination With Approved Immune Checkpoint Inhibitors in Patients With Relapsed/ Refractory Solid Tumors",I,Open,Agenus/MiNK Therapeutics,"Oncology: Bile Duct (Cholangiocarcinoma); Oncology: Breast; Oncology: Cervical; Oncology: Colorectal; Oncology: Gastric; Oncology: Head/Neck; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Pancreas; Oncology: Renal; Oncology: Skin, Squamous Cell Carcinoma (cSCC); Oncology: Thymus; Oncology: Unspecified Solid Tumor",(N/A); Fourth line or greater; Line of therapy N/A; MSI-H/dMMR; PD-1 Refractory; Second line; Third line,"Bile Duct Neoplasms; Breast Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Carcinoma, Squamous Cell; Cholangiocarcinoma; Colorectal Neoplasms; Head and Neck Neoplasms; Kidney Neoplasms; Liver Cancer; Liver Neoplasms; Melanoma; Multiple Myeloma; Neoplasms; Neoplasms, Unknown Primary; Pancreatic Neoplasms; Stomach Neoplasms; Thymus Neoplasms; Uterine Cervical Neoplasms; Wilms Tumor",United States
"Phase I Multicenter, Open-Label, First-in-Human Study of ORM-5029 in Subjects With HER2-Expressing Advanced Solid Tumors",I,Open,Orum Therapeutics,"Oncology: Bile Duct (Cholangiocarcinoma); Oncology: Bladder; Oncology: Breast; Oncology: Gastric; Oncology: Lung, Non-Small Cell; Oncology: Ovarian; Oncology: Unspecified Solid Tumor",HER2 positive; Second line; Stage III; Stage IV,"Bile Duct Neoplasms; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Cholangiocarcinoma; Neoplasms, Unknown Primary; Ovarian Neoplasms; Stomach Neoplasms; Urethral Neoplasms; Urinary Bladder Neoplasms",United States
"A Phase I, Open-label, Dose Escalation and Dose-Expansion Study to Evaluate the Safety and Tolerability of Modified Salmonella Typhimurium SGN1 Administered Via Intratumoral Injection in Patients With Advanced Solid Tumors",I,Open,Guangzhou Sinogen Pharmaceutical Co.,"Oncology: Breast; Oncology: Cervical; Oncology: Head/Neck; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Lung, Small Cell; Oncology: Lymphoma, Hodgkin's; Oncology: Lymphoma, Non-Hodgkin's; Oncology: Melanoma; Oncology: Neuroendocrine; Oncology: Ovarian; Oncology: Soft Tissue Sarcoma; Oncology: Unspecified Solid Tumor",(N/A); Adenocarcinoma; Aggressive; Classical; Indolent; Metastatic; Nodular lymphocyte-predominant; Pulmonary; Second line; Squamous Cell; Stage III; Stage IV; Unresectable,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Fibrosarcoma; Head and Neck Neoplasms; Hodgkin Disease; Hodgkin Lymphoma; Leiomyosarcoma; Liposarcoma; Liver Neoplasms; Lymphoma, Large-Cell, Anaplastic; Lymphoma, Non-Hodgkin; Melanoma; Neoplasms; Neoplasms, Unknown Primary; Neuroendocrine Tumors; Osteosarcoma; Ovarian Neoplasms; Rhabdomyosarcoma; Sarcoma; Small Cell Lung Carcinoma; Synovial Sarcoma; Uterine Cervical Neoplasms","Taiwan, China; United States"
A Phase I Study of TSN084 for the Treatment of Solid Tumours Including NSCLC and TNBC,I,Open,Tyligand Bioscience (Shanghai),"Oncology: Breast; Oncology: Lung, Non-Small Cell; Oncology: Unspecified Solid Tumor",HER2 negative; Line of therapy N/A; Triple receptor negative,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Neoplasms, Unknown Primary",United States
PNV21-001: A Phase I Study of a Personalized Multi-Peptide Neo-Antigen Vaccine in Breast Cancer and PD1/PD-L1 Inhibitor-Refractory Melanoma,I,Open,Fred Hutchinson Cancer Research Center,Oncology: Breast; Oncology: Melanoma,BRAF; Estrogen receptor positive; HER2 negative; PD-1 Refractory; PD-L1 Refractory; Progesterone receptor positive; Second line; Stage III; Stage IV,Breast Neoplasms; Carcinoma; Melanoma; Skin Neoplasms,United States
A Phase 1/1b Dose Escalation/Dose Expansion Study of PRGN-3007 UltraCAR-T Cells in Patients With Advanced Hematologic and Solid Tumor Malignancies,I,Open,"H. Lee Moffitt Cancer Center and Research Institute
Precigen; Inc. {Intrexon}/Precigen","Oncology: Breast; Oncology: Leukemia, Acute Lymphocytic; Oncology: Leukemia, Chronic Lymphocytic; Oncology: Lymphoma, Non-Hodgkin's",Aggressive; Diffuse large B-cell lymphoma (DLBCL); HER2 negative; Mantle cell lymphoma (MCL); Second line; Stage III; Stage IV; Triple receptor negative,"Breast Neoplasms; Chronic Lymphocytic Leukemia; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Large-Cell, Anaplastic; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Precursor Cell Lymphoblastic Leukemia-Lymphoma",United States
"A Multicenter, Phase IB/II Study of Abemaciclib in Combination With Bicalutamide for Androgen Receptor-positive, HER2-negative Metastatic Breast Cancer",I/II,Open,Icahn School of Medicine at Mount Sinai {Mount Sinai School of Medicine},Oncology: Breast,Estrogen receptor positive; HER2 negative; Progesterone receptor positive; Second line; Stage III; Stage IV; Triple receptor negative,Breast Neoplasms,United States
"Phase I Study of Tumor Treating Fields (TTF) in Combination With Cabozantinib, or With Atezolizumab and Nab-Paclitaxel in Patients With Advanced Solid Tumors Involving the Abdomen or Thorax",I,Open,MD Anderson Cancer Center University of Texas;,Oncology: Breast; Oncology: Endometrial; Oncology: Fallopian Tube; Oncology: Liver; Oncology: Ovarian; Oncology: Primary Peritoneal; Oncology: Renal,Line of therapy N/A; Stage III; Stage IV,"Abdominal Neoplasms; Breast Neoplasms; Carcinoma; Carcinoma, Endometrioid; Carcinoma, Hepatocellular; Carcinoma, Ovarian Epithelial; Carcinoma, Renal Cell; Endometrial Neoplasms; Fallopian Tube Neoplasms; Genital Neoplasms, Female; Kidney Neoplasms; Liver Cancer; Liver Neoplasms; Neoplasms; Ovarian Cancer; Ovarian Neoplasms; Peritoneal Neoplasms; Renal Cancer; Thoracic Neoplasms; Wilms Tumor",United States
"A Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Anti-tumor Activity of IPG7236 Administered Orally as a Single Agent in Patients With Advanced Solid Tumors",I,Open,Nanjing Immunophage Biotech Co.,Oncology: Breast; Oncology: Head/Neck; Oncology: Melanoma; Oncology: Renal; Oncology: Unspecified Solid Tumor,HER2 negative; Second line; Stage III; Stage IV; Triple receptor negative,"Breast Neoplasms; Carcinoma, Renal Cell; Head and Neck Neoplasms; Kidney Neoplasms; Melanoma; Neoplasms, Unknown Primary; Renal Cancer; Unspecified; Wilms Tumor",China; United States
"A Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Anti-Tumor Activity of AC682 in Patients With Estrogen Receptor Positive/Human Epidermal Growth Factor Receptor 2 Negative (ER+/HER2-) Locally Advanced or Metastatic Breast Cancer",I,Open,Accutar Biotechnology,Oncology: Breast,Estrogen receptor positive; HER2 negative; Line of therapy N/A; Stage III; Stage IV,Breast Neoplasms,United States
A Phase I/II Single Arm Open-Label Clinical Trial of TC-510 In Patients With Advanced Mesothelin-Expressing Cancer,I/II,Open,TCR2 Therapeutics,Oncology: Breast; Oncology: Colorectal; Oncology: Mesothelioma; Oncology: Ovarian; Oncology: Pancreas; Oncology: Primary Peritoneal,(N/A); HER2 negative; Line of therapy N/A; Triple receptor negative,Breast Neoplasms; Colorectal Neoplasms; Mesothelioma; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Peritoneal Neoplasms,United States
"A Phase I, Open-Label, Multicenter, Dose Escalation Study Evaluating the Safety, Tolerability, and Preliminary Efficacy of IMM2902 in Patients With HER2-Expressing Advanced Solid Tumors",I,Open,ImmuneOnco Biopharmaceuticals (Shanghai) Co.,Oncology: Breast; Oncology: Gastric; Oncology: Unspecified Solid Tumor,Second line; Stage III; Stage IV,"Breast Neoplasms; Neoplasms; Neoplasms, Unknown Primary; Stomach Carcinoma; Stomach Neoplasms",United States
Pharmacokinetics and Safety of Epidiferphane and Taxanes in Breast Cancer Patients,I/II,Open,University of Florida - Gainesville,Oncology: Breast,Line of therapy N/A; Stage 0; Stage I; Stage II; Stage III; Stage IV,Breast Neoplasms,United States
"A First-in-Human Study of Mutant-selective PI3Ka Inhibitor, RLY-2608, as a Single Agent in Advanced Solid Tumor Patients and in Combination With Fulvestrant in Patients With Advanced Breast Cancer",I,Open,Relay Therapeutics,"Oncology: Breast; Oncology: Cervical; Oncology: Head/Neck; Oncology: Ovarian; Oncology: Skin, Squamous Cell Carcinoma (cSCC); Oncology: Unspecified Solid Tumor",Estrogen receptor positive; HER2 negative; Progesterone receptor positive; Second line; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Squamous Cell; Head and Neck Neoplasms; Neoplasms; Neoplasms, Unknown Primary; Ovarian Cancer; Ovarian Neoplasms; Uterine Cervical Neoplasms",United States
"An Open-label, Dose Escalation and Expansion, Phase Ia/Ib Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of TAK-500, a Novel Stimulator of Interferon Genes Agonist, as a Single Agent and in Combination With Pembrolizumab in Adult Patients With Select Locally Advanced or Metastatic Solid Tumors.",I,Open,Takeda,"Oncology: Breast; Oncology: Esophageal; Oncology: Gastric; Oncology: Head/Neck; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Mesothelioma; Oncology: Pancreas; Oncology: Unspecified Solid Tumor",Adenocarcinoma; HER2 negative; Large Cell; Second line; Stage III; Stage IV; Triple receptor negative,"Breast Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Esophageal Cancer; Esophageal Neoplasms; Head and Neck Neoplasms; Liver Cancer; Liver Neoplasms; Mesothelioma; Neoplasms, Mesothelial; Neoplasms, Squamous Cell; Neoplasms, Unknown Primary; Pancreatic Cancer; Pancreatic Neoplasms; Stomach Carcinoma; Stomach Neoplasms",United States
"First-in-human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety of GEN1047 in Subjects With Malignant Solid Tumors",I/II,Open,Genmab,"Oncology: Bile Duct (Cholangiocarcinoma); Oncology: Bladder; Oncology: Breast; Oncology: Cervical; Oncology: Endometrial; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Ovarian; Oncology: Renal",Fourth line or greater; Stage III; Stage IV,"Bile Duct Neoplasms; Breast Neoplasms; Carcinoma, Endometrioid; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Cholangiocarcinoma; Cholangiocarcinoma; Endometrial Neoplasms; Head and Neck Neoplasms; Kidney Neoplasms; Nasopharyngeal Carcinoma; Ovarian Cancer; Ovarian Neoplasms; Renal Cancer; Squamous Cell Carcinoma of Head and Neck; Urethral Neoplasms; Urinary Bladder Neoplasms; Uterine Cervical Neoplasms; Uterine Neoplasms; Wilms Tumor",Denmark; France; Spain; United States
"A PHASE I DOSE ESCALATION AND EXPANSION STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETIC, PHARMACODYNAMIC, AND ANTITUMOR ACTIVITY OF PF-07260437 IN ADVANCED OR METASTATIC SOLID TUMORS",I,Open,Pfizer;,Oncology: Breast; Oncology: Endometrial; Oncology: Ovarian,Estrogen receptor positive; HER2 negative; Progesterone receptor positive; Second line; Stage III; Stage IV; Third line; Triple receptor negative,"Breast Neoplasms; Carcinoma, Endometrioid; Endometrial Neoplasms; Neoplasms; Ovarian Cancer; Ovarian Neoplasms",Puerto Rico; United States
"Phase I/II, Multicenter, Open-label, Clinical and Pharmacokinetic Study of PM14 in Combination with Irinotecan in Pretreated Patients with Selected Advanced Solid Tumors",I/II,Open,PharmaMar,"Oncology: Bile Duct (Cholangiocarcinoma); Oncology: Bladder; Oncology: Breast; Oncology: Cervical; Oncology: Endometrial; Oncology: Esophageal; Oncology: Fallopian Tube; Oncology: Gastric; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Lung, Small Cell; Oncology: Mesothelioma; Oncology: Neuroendocrine; Oncology: Ovarian; Oncology: Pancreas; Oncology: Primary Peritoneal; Oncology: Prostate; Oncology: Renal; Oncology: Soft Tissue Sarcoma; Oncology: Unspecified Solid Tumor",Adenocarcinoma; Gastrointestinal; High-grade; Hormone refractory; Pancreas; Pulmonary; Second line; Stage III; Stage IV,"Bile Duct Neoplasms; Breast Neoplasms; Carcinoma, Endometrioid; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Carcinoma, Small Cell; Cholangiocarcinoma; Endometrial Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Fallopian Tube Neoplasms; Fibrosarcoma; Kidney Neoplasms; Leiomyosarcoma; Liposarcoma; Liver Cancer; Liver Neoplasms; Mesothelioma; Neoplasms, Mesothelial; Neoplasms, Unknown Primary; Neuroendocrine Tumors; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Peritoneal Neoplasms; Prostatic Neoplasms; Renal Cancer; Rhabdomyosarcoma; Sarcoma; Small Cell Lung Carcinoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Stomach Carcinoma; Stomach Neoplasms; Synovial Sarcoma; Urethral Neoplasms; Urinary Bladder Neoplasms; Uterine Cervical Neoplasms; Wilms Tumor",Spain; United States
"Phase I, Open-label Study to Evaluate Safety, Tolerability and Preliminary Efficacy of Modified Salmonella
 Typhimurium SGN1 in Patients With Advanced Solid Tumor",I,Open,Guangzhou Sinogen Pharmaceutical Co.,"Oncology: Breast; Oncology: Cervical; Oncology: Head/Neck; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Lymphoma, Hodgkin's; Oncology: Lymphoma, Non-Hodgkin's; Oncology: Melanoma; Oncology: Neuroendocrine; Oncology: Ovarian; Oncology: Soft Tissue Sarcoma; Oncology: Unspecified Solid Tumor",Adenocarcinoma; Aggressive; Classical; Indolent; Metastatic; Nodular lymphocyte-predominant; Pulmonary; Second line; Squamous Cell; Stage III; Stage IV; Unresectable,"Breast Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Fibrosarcoma; Head and Neck Neoplasms; Hodgkin Disease; Hodgkin Lymphoma; Leiomyosarcoma; Liposarcoma; Liver Cancer; Liver Neoplasms; Lymphoma, Large-Cell, Anaplastic; Lymphoma, Non-Hodgkin; Melanoma; Neoplasms; Neoplasms, Unknown Primary; Neuroendocrine Tumors; Ovarian Cancer; Ovarian Neoplasms; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Synovial Sarcoma; Uterine Cervical Neoplasms","Taiwan, China; United States"
"A Phase I First in Human Study Evaluating Safety, Pharmacokinetics and Efficacy of ABBV-400 in Adult Subjects With Advanced Solid Tumors",I,Open,AbbVie;,"Oncology: Bile Duct (Cholangiocarcinoma); Oncology: Bladder; Oncology: Breast; Oncology: Colorectal; Oncology: Esophageal; Oncology: Gastric; Oncology: Lung, Non-Small Cell; Oncology: Unspecified Solid Tumor",Adenocarcinoma; EGFR; Fourth line or greater; Large Cell; MET Amplification/Alteration; PD-1 Refractory; PD-L1 Refractory; Second line; Stage III; Stage IV; Third line,"Adenocarcinoma; Bile Duct Neoplasms; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Cholangiocarcinoma; Colorectal Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Neoplasms, Unknown Primary; Stomach Carcinoma; Stomach Neoplasms; Urethral Neoplasms; Urinary Bladder Neoplasms",Japan; Puerto Rico; Spain; United States
Phase I Pilot Study With Dose Expansion of Chemotherapy in Combination With CD40 Agonist and Flt3 Ligand in Metastatic Triple Negative Breast Cancer,I,Open,"(Other Cooperative Group);
Celldex Therapeutics {AVANT Immunotherapeutics}
University of Texas Southwest Medical Center",Oncology: Breast,First line; HER2 negative; PD-1 Naive; PD-L1 Naive; Second line; Stage III; Stage IV; Third line; Triple receptor negative,Breast Neoplasms; Triple Negative Breast Neoplasms,United States
NP-G2-044 as Monotherapy and Combination Therapy in Patients With Advanced or Metastatic Solid Tumor Malignancies,I/II,Open,Novita Healthcare {Avexa},Oncology: Breast; Oncology: Cervical; Oncology: Endometrial; Oncology: Fallopian Tube; Oncology: Ovarian; Oncology: Unspecified Solid Tumor; Oncology: Vaginal; Oncology: Vulvar,HER2 negative; PD-1 Refractory; Second line; Stage III; Stage IV; Triple receptor negative,"Breast Neoplasms; Endometrial Neoplasms; Fallopian Tube Neoplasms; Neoplasms; Neoplasms, Unknown Primary; Ovarian Neoplasms; Uterine Cervical Neoplasms; Vaginal Neoplasms; Vulvar Neoplasms",United States
A Phase I/Ib Dose Escalation/Expansion Study of NGM831 as Monotherapy and in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumors,I,Open,"Merck & Co./Merck Sharp & Dohme (MSD)
NGM Biopharmaceuticals","Oncology: Bile Duct (Cholangiocarcinoma); Oncology: Bladder; Oncology: Breast; Oncology: Cervical; Oncology: Colorectal; Oncology: Esophageal; Oncology: Gastric; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Mesothelioma; Oncology: Ovarian; Oncology: Pancreas; Oncology: Prostate; Oncology: Renal",Second line; Stage III; Stage IV,"Bile Duct Neoplasms; Breast Neoplasms; Carcinoma; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Cholangiocarcinoma; Cholangiocarcinoma; Colorectal Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Head and Neck Neoplasms; Kidney Neoplasms; Melanoma; Mesothelioma; Neoplasms, Mesothelial; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Prostatic Neoplasms; Renal Cancer; Squamous Cell Carcinoma of Head and Neck; Stomach Carcinoma; Stomach Neoplasms; Urethral Neoplasms; Urinary Bladder Neoplasms; Uterine Cervical Neoplasms; Wilms Tumor",United States
"A Phase I/Ib Open-label, First-in-human, Single Agent, Dose Escalation and Expansion Study for the Evaluation of Safety, Pharmacokinetics, Pharmacodynamics, and Anti-tumor Activity of SAR443216 in Participants with Relapsed/Refractory HER2 Expressing Solid Tumors.",I,Open,Sanofi;,"Oncology: Breast; Oncology: Gastric; Oncology: Lung, Non-Small Cell; Oncology: Unspecified Solid Tumor",HER2 positive; Second line; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Neoplasms; Neoplasms, Unknown Primary; Stomach Carcinoma; Stomach Neoplasms","South Korea; Spain; Taiwan, China; United States"
"A Phase Ia/b Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of GS-9716 as Monotherapy and in Combination With Anticancer Therapies in Subjects With Solid Malignancies",I,Open,Gilead Sciences;,"Oncology: Bladder; Oncology: Breast; Oncology: Cervical; Oncology: Colorectal; Oncology: Endometrial; Oncology: Esophageal; Oncology: Gastric; Oncology: Head/Neck; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Lung, Small Cell; Oncology: Neuroendocrine; Oncology: Ovarian; Oncology: Prostate; Oncology: Renal; Oncology: Soft Tissue Sarcoma; Oncology: Thyroid",Adenocarcinoma; Follicular; HER2 negative; Hormone refractory; Large Cell; Locally advanced; Metastatic; PD-1 Refractory; PD-L1 Refractory; Pulmonary; Second line; Stage III; Stage IV; Triple receptor negative; Unresectable,"Breast Neoplasms; Carcinoma, Endometrioid; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Carcinoma, Small Cell; Colorectal Neoplasms; Endometrial Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Fibrosarcoma; Head and Neck Neoplasms; Kidney Neoplasms; Leiomyosarcoma; Liposarcoma; Liver Cancer; Liver Neoplasms; Neoplasms; Neuroendocrine Tumors; Ovarian Cancer; Ovarian Neoplasms; Prostatic Neoplasms; Renal Cancer; Rhabdomyosarcoma; Sarcoma; Small Cell Lung Carcinoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Stomach Carcinoma; Stomach Neoplasms; Synovial Sarcoma; Thyroid Neoplasms; Urethral Neoplasms; Urinary Bladder Neoplasms; Uterine Cervical Neoplasms; Wilms Tumor",United States
"A Phase Ib, Open-label, Dose-escalation and Dose-expansion Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of Inavolisib in Combination with Paclitaxel in Patients with Locally Advanced or Metastatic Solid Tumors",I,Open,Roche;Genentech;,Oncology: Breast; Oncology: Fallopian Tube; Oncology: Head/Neck; Oncology: Ovarian; Oncology: Primary Peritoneal; Oncology: Unspecified Solid Tumor,Estrogen receptor positive; HER2 negative; HER2 positive; Progesterone receptor positive; Second line; Stage III; Stage IV; Triple receptor negative,"Breast Neoplasms; Fallopian Tube Neoplasms; Head and Neck Neoplasms; Neoplasms, Unknown Primary; Ovarian Neoplasms; Peritoneal Neoplasms",Canada; Denmark; France; South Korea; Spain; United States
Atezolizumab Plus Tivozanib in Immunologically Cold Tumor Types,I/II,Open,"University of Florida - Gainesville
LG Chem/AVEO Oncology
Roche;Genentech;",Oncology: Bile Duct (Cholangiocarcinoma); Oncology: Breast; Oncology: Fallopian Tube; Oncology: Gallbladder; Oncology: Neuroendocrine; Oncology: Ovarian; Oncology: Pancreas; Oncology: Primary Peritoneal; Oncology: Prostate; Oncology: Soft Tissue Sarcoma; Oncology: Vulvar,Fourth line or greater; HER2 positive; High-grade; Hormone refractory; Intermediate-grade; Low-grade; Metastatic; MSS/pMMR; Second line; Stage III; Stage IV; Third line; Unresectable,Adenocarcinoma; Bile Duct Neoplasms; Breast Neoplasms; Cholangiocarcinoma; Cholangiocarcinoma; Fallopian Tube Neoplasms; Fibrosarcoma; Gallbladder Neoplasms; Leiomyosarcoma; Liposarcoma; Neuroendocrine Tumors; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Peritoneal Neoplasms; Prostatic Neoplasms; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Synovial Sarcoma; Vulvar Neoplasms,United States
A Phase l Study of TAS2940 in Patients With Locally Advanced or Metastatic Solid Tumors With EGFR and / or HER2 Aberrations,I,Open,Otsuka Holdings/Taiho Pharmaceutical,"Oncology: Breast; Oncology: CNS, Glioblastoma; Oncology: Lung, Non-Small Cell; Oncology: Unspecified Solid Tumor",EGFR; HER2 positive; Second line; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Glioblastoma; Neoplasms, Unknown Primary",France; United States
"A Phase I/II Study To Evaluate The Safety, Pharmacokinetics, And Efficacy Of BLU-222 As A Single Agent And In Combination Therapy For Patients With Advanced Solid Tumors.",I/II,Open,Blueprint Medicines,Oncology: Breast; Oncology: Endometrial; Oncology: Esophageal; Oncology: Gastric; Oncology: Ovarian; Oncology: Unspecified Solid Tumor,Estrogen receptor positive; HER2 negative; Progesterone receptor positive; Second line; Stage III; Stage IV; Third line,"Breast Neoplasms; Carcinoma, Endometrioid; Carcinosarcoma; Endometrial Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Mixed Tumor, Mullerian; Neoplasms, Unknown Primary; Ovarian Cancer; Ovarian Neoplasms; Stomach Carcinoma; Stomach Neoplasms",United States
A Phase  I/II  Open-label Trial of KVA12123 Alone and in Combination With Pembrolizumab in Patients With Advanced Solid Tumors,I/II,Open,Kineta,"Oncology: Breast; Oncology: Colorectal; Oncology: Esophageal; Oncology: Gastric; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Ovarian; Oncology: Pancreas; Oncology: Prostate; Oncology: Renal; Oncology: Thyroid; Oncology: Unspecified Solid Tumor",Locally advanced; Metastatic; Second line; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Colorectal Neoplasms; Esophageal Neoplasms; Head and Neck Neoplasms; Kidney Neoplasms; Melanoma; Neoplasms, Unknown Primary; Ovarian Neoplasms; Pancreatic Neoplasms; Prostatic Neoplasms; Stomach Neoplasms; Thyroid Neoplasms; Wilms Tumor",United States
"A Phase I, Open-Label, Dose-Escalation and Dose-Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of ADCT-901 as Monotherapy in Patients With Selected Advanced Solid Tumors",I,Open,ADC Therapeutics {Auven Therapeutics/ADC Therapeutics},Oncology: Bile Duct (Cholangiocarcinoma); Oncology: Breast; Oncology: Fallopian Tube; Oncology: Neuroendocrine; Oncology: Ovarian; Oncology: Prostate; Oncology: Renal; Oncology: Unspecified Solid Tumor,HER2 negative; Other; Second line; Stage III; Stage IV; Triple receptor negative,"Bile Duct Neoplasms; Breast Neoplasms; Carcinoma, Renal Cell; Cholangiocarcinoma; Fallopian Tube Neoplasms; Kidney Neoplasms; Neoplasms; Neoplasms, Unknown Primary; Neuroendocrine Tumors; Ovarian Cancer; Ovarian Neoplasms; Prostatic Neoplasms; Renal Cancer; Wilms Tumor",Spain; United States
A Clinical Study of ATG-101 for the Treatment of Advanced/ Metastatic Solid Tumors and B-cell Non-Hodgkin Lymphoma (B-NHL),I,Open,Antengene Corporation Limited/Antengene Corporation Co.,"Oncology: Breast; Oncology: Cervical; Oncology: CNS, Glioblastoma; Oncology: Esophageal; Oncology: Gastric; Oncology: Head/Neck; Oncology: Lymphoma, Non-Hodgkin's; Oncology: Unspecified Solid Tumor",(N/A); Aggressive; Diffuse large B-cell lymphoma (DLBCL); Extranodal marginal zone B-cell lymphoma (MALT); Follicular lymphoma (FL); HER2 negative; Indolent; Lymphoblastic lymphoma (LBL); Mantle cell lymphoma (MCL); Other subtype; Second line; Small lymphocytic lymphoma (SLL); Stage III; Stage IV; Third line; Triple receptor negative; Waldenstrom's macroglobulinemia (WM),"Breast Neoplasms; Esophageal Neoplasms; Glioblastoma; Head and Neck Neoplasms; Lymphoma, B-Cell, Marginal Zone; Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Large-Cell, Anaplastic; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Neoplasms, Unknown Primary; Stomach Neoplasms; Uterine Cervical Neoplasms; Waldenstrom Macroglobulinemia",China; United States
A Phase I/Ib Dose Escalation/Expansion Study of NGM438 as Monotherapy and in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumors,I,Open,NGM Biopharmaceuticals,"Oncology: Bile Duct (Cholangiocarcinoma); Oncology: Bladder; Oncology: Breast; Oncology: Cervical; Oncology: Colorectal; Oncology: Esophageal; Oncology: Gastric; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Mesothelioma; Oncology: Ovarian; Oncology: Pancreas; Oncology: Prostate; Oncology: Renal; Oncology: Unspecified Solid Tumor",Second line; Stage III; Stage IV,"Bile Duct Neoplasms; Breast Neoplasms; Carcinoma; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Cholangiocarcinoma; Cholangiocarcinoma; Colorectal Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Head and Neck Neoplasms; Kidney Neoplasms; Melanoma; Mesothelioma; Neoplasms, Mesothelial; Neoplasms, Unknown Primary; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Prostatic Neoplasms; Renal Cancer; Squamous Cell Carcinoma of Head and Neck; Stomach Carcinoma; Stomach Neoplasms; Urethral Neoplasms; Urinary Bladder Neoplasms; Uterine Cervical Neoplasms; Wilms Tumor",United States
"A Phase I Dose-Escalation Study to Investigate the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamic Activity of CLN-619 (Anti-MICA/MICB Antibody) Alone and in Combination With Pembrolizumab in Patients With Advanced Solid Tumors",I,Open,Cullinan Oncology,"Oncology: Breast; Oncology: Cervical; Oncology: Colorectal; Oncology: Endometrial; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Mesothelioma; Oncology: Ovarian; Oncology: Pancreas; Oncology: Prostate; Oncology: Renal; Oncology: Thyroid; Oncology: Unspecified Solid Tumor",(N/A); Fourth line or greater; Line of therapy N/A; PD-1 Refractory; PD-L1 Refractory; Second line; Stage III; Stage IV; Third line,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Colorectal Neoplasms; Endometrial Neoplasms; Head and Neck Neoplasms; Kidney Neoplasms; Melanoma; Mesothelioma; Neoplasms; Neoplasms, Unknown Primary; Ovarian Neoplasms; Pancreatic Neoplasms; Prostatic Neoplasms; Thyroid Neoplasms; Uterine Cervical Neoplasms; Wilms Tumor",Australia; Poland; Spain; United States
"A Phase Ib/II Study to Investigate the Safety, Tolerability, of APG-2575 as a Single Agent or in Combination With Systemic Anti-cancer Agents in Patients With ER Positive Breast Cancer or Advanced Solid Tumors.",I/II,Open,Ascentage Pharma Group,Oncology: Breast; Oncology: Unspecified Solid Tumor,Estrogen receptor positive; HER2 negative; Second line; Stage III; Stage IV,"Breast Neoplasms; Neoplasms, Unknown Primary",China; United States
Phase I/II Study of Stereotactic Radiation and Abemaciclib in the Management of Hormone Receptor Positive HER2 Negative Breast Cancer Brain Metastases,I/II,Open,"Eli Lilly
H. Lee Moffitt Cancer Center and Research Institute",Oncology: Breast; Oncology: Metastatic Cancer,CNS mets; Estrogen receptor positive; HER2 negative; Line of therapy N/A; Progesterone receptor positive; Stage IV,Brain Neoplasms; Breast Neoplasms; Central Nervous System Neoplasms; Neoplasm Metastasis,United States
A Phase I/II Dose Escalation/Expansion Study of NGM707 as Monotherapy and in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies,I/II,Open,"Merck & Co./Merck Sharp & Dohme (MSD)
NGM Biopharmaceuticals","Oncology: Breast; Oncology: Cervical; Oncology: CNS, Glioblastoma; Oncology: Colorectal; Oncology: Esophageal; Oncology: Gastric; Oncology: Head/Neck; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Mesothelioma; Oncology: Ovarian; Oncology: Pancreas; Oncology: Renal",Adenocarcinoma; Fourth line or greater; Second line; Squamous Cell; Stage III; Stage IV; Third line,"Breast Neoplasms; Carcinoma; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Cholangiocarcinoma; Colorectal Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Glioblastoma; Head and Neck Neoplasms; Kidney Neoplasms; Liver Cancer; Liver Neoplasms; Melanoma; Mesothelioma; Neoplasms, Mesothelial; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Renal Cancer; Squamous Cell Carcinoma of Head and Neck; Stomach Carcinoma; Stomach Neoplasms; Uterine Cervical Neoplasms; Wilms Tumor","South Korea; Taiwan, China; United States"
"A Phase Ib/II, Multicenter, Open-label Study of S-531011 as Monotherapy and in Combination With an Immune Checkpoint Inhibitor in Participants With Locally Advanced or Metastatic Solid Tumors",I/II,Open,Shionogi,"Oncology: Bladder; Oncology: Breast; Oncology: Esophageal; Oncology: Gastric; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Renal; Oncology: Unspecified Solid Tumor",HER2 negative; Second line; Stage III; Stage IV; Triple receptor negative,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Esophageal Cancer; Esophageal Neoplasms; Head and Neck Neoplasms; Kidney Neoplasms; Melanoma; Neoplasms; Neoplasms, Unknown Primary; Renal Cancer; Stomach Carcinoma; Stomach Neoplasms; Urethral Neoplasms; Urinary Bladder Neoplasms; Wilms Tumor",Japan; United States
"Phase Ib Study of Neoadjuvant DPX-Survivac, Aromatase Inhibition, and With/Without Radiotherapy or Cyclophosphamide in HR+HER2- Breast Cancer",I,Open,"(Other Cooperative Group);
IMV Inc. {IImmunovaccine {ImmunoVaccine Technologies}}",Oncology: Breast,Adjuvant; Estrogen receptor positive; HER2 negative; Neoadjuvant; Progesterone receptor positive; Stage I; Stage II; Stage III; Triple receptor negative,Breast Neoplasms,United States
A First-in-Human Phase I Trial of ATG-101 in Patients With Metastatic/Advanced Solid Tumors and Mature B-cell Non-Hodgkin Lymphomas,I,Open,Antengene Corporation Limited/Antengene Corporation Co.,"Oncology: Breast; Oncology: Cervical; Oncology: CNS, Glioblastoma; Oncology: Esophageal; Oncology: Gastric; Oncology: Head/Neck; Oncology: Lymphoma, Non-Hodgkin's; Oncology: Unspecified Solid Tumor",(N/A); Aggressive; Diffuse large B-cell lymphoma (DLBCL); Extranodal marginal zone B-cell lymphoma (MALT); Follicular lymphoma (FL); HER2 negative; Indolent; Lymphoblastic lymphoma (LBL); Mantle cell lymphoma (MCL); Other subtype; Second line; Small lymphocytic lymphoma (SLL); Stage II; Stage III; Stage IV; Triple receptor negative; Waldenstrom's macroglobulinemia (WM),"Breast Neoplasms; Esophageal Neoplasms; Glioblastoma; Head and Neck Neoplasms; Hematologic Neoplasms; Lymphoma; Lymphoma, B-Cell; Lymphoma, B-Cell, Marginal Zone; Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Large-Cell, Anaplastic; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Neoplasms; Neoplasms, Unknown Primary; Stomach Neoplasms; Uterine Cervical Neoplasms; Waldenstrom Macroglobulinemia",Australia; United States
"An Open-label, Two-part Dose escalation and Expansion Study to Evaluate Safety, Pharmacokinetics, and Preliminary Activity of JBI-778 in Solid Tumors Patients with Stable Brain Metastasis",I/II,Planned,Jubilant Life Sciences,"Oncology: Breast; Oncology: CNS, Glioblastoma; Oncology: Lung, Non-Small Cell; Oncology: Metastatic Cancer; Oncology: Myelodysplastic Syndrome; Oncology: Unspecified Solid Tumor",(N/A); CNS mets; HER2 negative; Line of therapy N/A; RA/RARS; RCMD; Second line; Triple receptor negative,"Acute Myelocytic Leukemia; Brain Neoplasms; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Central Nervous System Neoplasms; Glioblastoma; Leukemia, Myeloid, Acute; Lymphoma, Non-Hodgkin; Myelodysplastic Syndromes; Neoplasm Metastasis",United States
"An Open Label, Phase I Dose Escalation Trial, With Dose Confirmation and Expansion, of BI 1810631 as Monotherapy in Patients With Advanced or Metastatic Solid Tumors With HER2 Aberrations",I,Open,Boehringer Ingelheim,"Oncology: Bladder; Oncology: Breast; Oncology: Cervical; Oncology: Colorectal; Oncology: Endometrial; Oncology: Esophageal; Oncology: Lung, Non-Small Cell; Oncology: Renal; Oncology: Small Intestine; Oncology: Unspecified Solid Tumor",(N/A); ALK; BRAF; EGFR; Fourth line or greater; HER2 positive; Line of therapy N/A; Second line; Stage III; Stage IV; Third line,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Colorectal Neoplasms; Endometrial Neoplasms; Esophageal Neoplasms; Intestinal Neoplasms; Kidney Neoplasms; Neoplasm Metastasis; Neoplasms, Unknown Primary; Urethral Neoplasms; Urinary Bladder Neoplasms; Uterine Cervical Neoplasms; Wilms Tumor","Australia; Austria; Belgium; China; France; Germany; Hong Kong, S.A.R., China; Israel; Italy; Japan; Netherlands; Portugal; Singapore; South Korea; Spain; Sweden; United Kingdom; United States"
"A Phase I-II Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents in Subjects With Advanced Malignancies",I/II,Open,OncoResponse,"Oncology: Breast; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Soft Tissue Sarcoma; Oncology: Unspecified Cancer; Oncology: Unspecified Solid Tumor",ALK; EGFR; First line; PD-1 Refractory; PD-L1 Refractory; Second line; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Fibrosarcoma; Head and Neck Neoplasms; Leiomyosarcoma; Liposarcoma; Melanoma; Neoplasms; Neoplasms, Unknown Primary; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Squamous Cell Carcinoma of Head and Neck; Synovial Sarcoma; Triple Negative Breast Neoplasms",United States
"To Evaluate TROP2-TRACTr in an Initial Proof of Concept Clinical Trial in Triple Receptor Negative Breast Cancer, Urothelial Cancer and Non Small Cell Lung Cancer Patients",I,Planned,Janux Therapeutics,"Oncology: Bladder; Oncology: Breast; Oncology: Lung, Non-Small Cell; Oncology: Renal",(N/A); HER2 negative; Line of therapy N/A; Triple receptor negative,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Kidney Neoplasms; Renal Cancer; Urethral Neoplasms; Urinary Bladder Neoplasms; Wilms Tumor",United States
"An Open-label, Phase I, Dose-escalation Study to Evaluate the Safety and Preliminary Antitumor Activity of TAK-676 With Pembrolizumab Following Radiation Therapy in the Treatment of Non-small-cell Lung Cancer, Triple-negative Breast Cancer, or Squamous-cell Carcinoma of the Head and Neck That Has Progressed on Checkpoint Inhibitors.",I,Open,Takeda,"Oncology: Breast; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell",HER2 negative; PD-1 Refractory; PD-L1 Refractory; Second line; Stage III; Stage IV; Triple receptor negative,"Breast Neoplasms; Carcinoma; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Head and Neck Neoplasms; Squamous Cell Carcinoma of Head and Neck; Triple Negative Breast Neoplasms",United States
"A Phase I/II a, First-in-Human (FIH), Open-Label, Dose-Escalation and Dose Expansion Study of the Monoclonal Antibody IMT-009 in Patients With Advanced Solid Tumors or Lymphomas",I/II,Open,Immunitas Therapeutics,"Oncology: Breast; Oncology: Colorectal; Oncology: Esophageal; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Lymphoma, Hodgkin's; Oncology: Lymphoma, Non-Hodgkin's; Oncology: Skin, Squamous Cell Carcinoma (cSCC); Oncology: Small Intestine; Oncology: Unspecified Solid Tumor",Aggressive; BRAF; BRCA; Classical; Cutaneous T-cell lymphoma (CTCL); Diffuse large B-cell lymphoma (DLBCL); Estrogen receptor positive; Fourth line or greater; HER2 negative; Indolent; Line of therapy N/A; MSI-H/dMMR; MSS/pMMR; Nodular lymphocyte-predominant; Other subtype; PD-1 Refractory; PD-L1 Refractory; Peripheral T-cell lymphoma (PTCL); Progesterone receptor positive; Second line; Squamous Cell; Stage III; Stage IV; Third line; Triple receptor negative,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Colorectal Neoplasms; Esophageal Neoplasms; Head and Neck Neoplasms; Hodgkin Disease; Intestinal Neoplasms; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Large-Cell, Anaplastic; Lymphoma, Non-Hodgkin; Lymphoma, T-Cell, Cutaneous; Lymphoma, T-Cell, Peripheral; Neoplasms",United States
"A Phase I, Dose-Escalation and Dose-Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Antitumor Activities of CS5001, an Anti-ROR1 Antibody Drug Conjugate, in Patients With Advanced Solid Tumors and Lymphomas",I,Open,"CStone Pharmaceuticals
United Biotechnology (Zhuhai Hengqin) Co.","Oncology: Breast; Oncology: Lymphoma, Hodgkin's; Oncology: Lymphoma, Non-Hodgkin's; Oncology: Unspecified Solid Tumor",Aggressive; Classical; Diffuse large B-cell lymphoma (DLBCL); Extranodal marginal zone B-cell lymphoma (MALT); Follicular lymphoma (FL); HER2 negative; Indolent; Lymphoblastic lymphoma (LBL); Mantle cell lymphoma (MCL); Nodular lymphocyte-predominant; Other subtype; Second line; Small lymphocytic lymphoma (SLL); Stage III; Stage IV; Third line; Triple receptor negative; Waldenstrom's macroglobulinemia (WM),"Breast Neoplasms; Hodgkin Disease; Hodgkin Lymphoma; Lymphoma; Lymphoma, B-Cell, Marginal Zone; Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Large-Cell, Anaplastic; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Neoplasms, Unknown Primary; Waldenstrom Macroglobulinemia",Australia; China; United States
"Dose Escalation and Expansion Clinical Study to Evaluate the Safety and Efficacy of ELU001 in Subjects Who Have Advanced, Recurrent or Refractory FRa Overexpressing Tumors",I/II,Open,Elucida Oncology,"Oncology: Bile Duct (Cholangiocarcinoma); Oncology: Breast; Oncology: Colorectal; Oncology: Endometrial; Oncology: Esophageal; Oncology: Fallopian Tube; Oncology: Gastric; Oncology: Lung, Non-Small Cell; Oncology: Ovarian; Oncology: Primary Peritoneal; Oncology: Unspecified Cancer",Distal; Fourth line or greater; HER2 negative; Hilar; Intrahepatic; Second line; Stage III; Stage IV; Triple receptor negative,"Adenocarcinoma; Adenocarcinoma, Clear Cell; Bile Duct Neoplasms; Breast Neoplasms; Carcinoma; Carcinoma, Endometrioid; Carcinoma, Non-Small-Cell Lung; Carcinoma, Ovarian Epithelial; Carcinosarcoma; Cholangiocarcinoma; Cholangiocarcinoma; Colonic Neoplasms; Colorectal Neoplasms; Cystadenocarcinoma, Serous; Endometrial Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Fallopian Tube Neoplasms; Klatskin Tumor; Neoplasm Metastasis; Neoplasms; Ovarian Cancer; Ovarian Diseases; Ovarian Neoplasms; Peritoneal Neoplasms; Rectal Neoplasms; Stomach Carcinoma; Stomach Neoplasms; Triple Negative Breast Neoplasms; Uterine Diseases",United States
"A Phase I/IIa, Open-label, Multi-centre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of the DNA Polymerase Theta Inhibitor ART4215 Administered Orally as Monotherapy and in Combination to Patients With Advanced or Metastatic Solid Tumors",I/II,Open,Artios Pharma,Oncology: Breast; Oncology: Ovarian; Oncology: Prostate; Oncology: Unspecified Solid Tumor,Fourth line or greater; HER2 negative; Second line; Stage III; Stage IV; Third line,"Breast Neoplasms; Neoplasm Metastasis; Neoplasms, Unknown Primary; Ovarian Cancer; Ovarian Neoplasms; Prostatic Neoplasms",United States
"A Multicentre, Open-label, Non-randomized, Phase Ia/Ib Study of NG-641, a Tumour-selective and Transgene-expressing Adenoviral Vector, in Combination With Nivolumab in Patients With Metastatic or Advanced Epithelial Tumours (NEBULA)",I,Open,"Bristol-Myers Squibb
Akamis Bio {PsiOxus Therapeutics}","Oncology: Bile Duct (Cholangiocarcinoma); Oncology: Bladder; Oncology: Breast; Oncology: Cervical; Oncology: Endometrial; Oncology: Esophageal; Oncology: Gastric; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Renal; Oncology: Skin, Squamous Cell Carcinoma (cSCC); Oncology: Unspecified Cancer; Oncology: Unspecified Solid Tumor",(N/A); Distal; HER2 negative; Hilar; Intrahepatic; Line of therapy N/A; MSI-H/dMMR; PD-1 Refractory; PD-L1 Refractory; Second line; Stage III; Stage IV; Triple receptor negative,"Bile Duct Neoplasms; Breast Neoplasms; Carcinoma, Endometrioid; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Carcinoma, Squamous Cell; Cholangiocarcinoma; Endometrial Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Kidney Neoplasms; Liver Cancer; Liver Neoplasms; Neoplasm Metastasis; Neoplasms; Neoplasms, Glandular and Epithelial; Renal Cancer; Stomach Carcinoma; Stomach Neoplasms; Urethral Neoplasms; Urinary Bladder Neoplasms; Uterine Cervical Neoplasms; Wilms Tumor",Spain; United Kingdom; United States
"A Multicenter, Open-label, Phase Ia Study of HC-5404-FU in Subjects With Selected, Advanced Solid Tumors",I,Open,HiberCell {Biothera Pharmaceuticals},"Oncology: Breast; Oncology: Colorectal; Oncology: Gastric; Oncology: Lung, Non-Small Cell; Oncology: Lung, Small Cell; Oncology: Neuroendocrine; Oncology: Renal",Fourth line or greater; HER2 positive; Pulmonary; Stage IV; Third line,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Carcinoma, Small Cell; Colorectal Neoplasms; Kidney Neoplasms; Neuroendocrine Tumors; Renal Cancer; Small Cell Lung Carcinoma; Stomach Carcinoma; Stomach Neoplasms; Wilms Tumor",United States
"A Phase Ib/II, Open-Label, Multicenter, Randomized Umbrella Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Breast Cancer (MORPHEUS- BREAST CANCER)",I/II,Open,Roche; {F. Hoffmann-La Roche;},Oncology: Breast,Estrogen receptor positive; HER2 negative; HER2 positive; Second line; Stage III; Stage IV; Third line,Breast Neoplasms,Australia; Israel; South Korea; Spain; United States
Neratinib and Capmatinib Combination (Phase Ib/II) in Metastatic Breast Cancer and Inflammatory Breast Cancer Patients With Abnormal HER-family and c-Met Pathway Activity as Measured by the CELsignia Signaling Analysis Test,I/II,Open,"Novartis;
MD Anderson Cancer Center University of Texas;
Puma Biotechnology
Celcuity",Oncology: Breast,Estrogen receptor positive; Fourth line or greater; HER2 negative; HER2 positive; Progesterone receptor positive; Second line; Stage III; Stage IV; Third line,Breast Neoplasms; Inflammatory Breast Neoplasms,United States
"A Phase I/II, Open-Label, Dose-Escalation, Safety and Tolerability Study of NC762 in Subjects With Advanced or Metastatic Solid Tumors",I/II,Open,NextCure,"Oncology: Breast; Oncology: Colorectal; Oncology: Endometrial; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Ovarian; Oncology: Pancreas; Oncology: Primary Peritoneal; Oncology: Prostate; Oncology: Unspecified Solid Tumor",Second line; Squamous Cell; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Endometrial Neoplasms; Liver Neoplasms; Neoplasms, Unknown Primary; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Neoplasms; Peritoneal Neoplasms; Prostatic Neoplasms",United States
Focused Ultrasound With Low-Dose Gemcitabine to Augment Immune Control of Early Stage Breast Cancer,I,Open,University of Virginia,Oncology: Breast,Estrogen receptor positive; First line; HER2 negative; HER2 positive; Progesterone receptor positive; Stage 0; Stage I; Stage II; Stage III; Triple receptor negative,Breast Neoplasms,United States
Multicenter Open Label Phase Ib/II Trial of Abemaciclib and Elacestrant in Patients With Brain Metastasis Due to HR+/Her2- Breast Cancer,I/II,Open,(Other Industry Sponsor),Oncology: Breast; Oncology: Metastatic Cancer,CNS mets; Estrogen receptor positive; Fourth line or greater; HER2 negative; Progesterone receptor positive; Second line; Stage IV; Third line,Brain Neoplasms; Breast Neoplasms; Central Nervous System Neoplasms; Neoplasm Metastasis,United States
"A Phase Ia Open-Label, Dose-Escalation, and a Phase II Study to Investigate the Safety, PK, PD, and Clinical Activity of ST-067 Administered Subcutaneously as Monotherapy in Patients with Relapsed or Refractory Solid Tumors",I/II,Open,"Merck & Co./Merck Sharp & Dohme (MSD)
Simcha IL-18","Oncology: Bladder; Oncology: Breast; Oncology: Cervical; Oncology: Endometrial; Oncology: Esophageal; Oncology: Gastric; Oncology: Head/Neck; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Lung, Small Cell; Oncology: Melanoma; Oncology: Neuroendocrine; Oncology: Ovarian; Oncology: Renal; Oncology: Unspecified Solid Tumor",HER2 negative; Merkel; MSI-H/dMMR; Pulmonary; Second line; Stage III; Stage IV; Triple receptor negative,"Breast Neoplasms; Carcinoma; Carcinoma, Endometrioid; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Carcinoma, Small Cell; Endometrial Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Head and Neck Neoplasms; Kidney Neoplasms; Liver Cancer; Liver Neoplasms; Melanoma; Neoplasms, Unknown Primary; Neuroendocrine Tumors; Ovarian Cancer; Ovarian Neoplasms; Renal Cancer; Small Cell Lung Carcinoma; Squamous Cell Carcinoma of Head and Neck; Stomach Carcinoma; Stomach Neoplasms; Triple Negative Breast Neoplasms; Urethral Neoplasms; Urinary Bladder Neoplasms; Uterine Cervical Neoplasms; Wilms Tumor",United States
"A Phase I, First-in-Human, Open-Label, Dose-Escalation and Expansion Study of IMGN151 (Anti-FRα Antibody-drug Conjugate) in Adult Patients With Recurrent Endometrial Cancer and Recurrent, High-Grade Serous Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers",I,Open,ImmunoGen,"Oncology: Breast; Oncology: Endometrial; Oncology: Fallopian Tube; Oncology: Lung, Non-Small Cell; Oncology: Ovarian; Oncology: Primary Peritoneal",(N/A); Fourth line or greater; HER2 negative; Line of therapy N/A; Second line; Stage III; Stage IV; Third line; Triple receptor negative,"Breast Neoplasms; Carcinoma, Endometrioid; Carcinoma, Non-Small-Cell Lung; Endometrial Neoplasms; Fallopian Tube Neoplasms; Ovarian Cancer; Ovarian Neoplasms; Peritoneal Neoplasms",United States
"A Phase IB, Open-Label, Dose-Escalation Study of the Safety of and Antigen-specific Immune Responses Elicited by VB10.NEO in Combination With Atezolizumab in Patients With Locally Advanced and Metastatic Tumors",I,Open,"Roche;Genentech;
Nykode Therapeutics {Vaccibody}","Oncology: Anal; Oncology: Bladder; Oncology: Breast; Oncology: Cervical; Oncology: Esophageal; Oncology: Gastric; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Renal; Oncology: Unspecified Solid Tumor",HER2 negative; Maintenance/Consolidation; MSI-H/dMMR; Stage III; Stage IV; Triple receptor negative,"Anus Neoplasms; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Esophageal Cancer; Esophageal Neoplasms; Head and Neck Neoplasms; Kidney Neoplasms; Melanoma; Neoplasms; Neoplasms, Unknown Primary; Renal Cancer; Stomach Carcinoma; Stomach Neoplasms; Urethral Neoplasms; Urinary Bladder Neoplasms; Uterine Cervical Neoplasms; Wilms Tumor",Germany; Spain; United States
"A Phase Ia, Dose Escalation, Safety and Tolerability Study of NX-1607, a Casitas B-lineage Lymphoma Proto-oncogene (CBL-B) Inhibitor, in Adults With Advanced Malignancies, With Phase Ib Expansion in Select Tumor Types",I,Open,Nurix Therapeutics,"Oncology: Bladder; Oncology: Breast; Oncology: Cervical; Oncology: Colorectal; Oncology: Esophageal; Oncology: Fallopian Tube; Oncology: Gastric; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Lymphoma, Non-Hodgkin's; Oncology: Melanoma; Oncology: Mesothelioma; Oncology: Ovarian; Oncology: Primary Peritoneal; Oncology: Prostate; Oncology: Renal; Oncology: Unspecified Solid Tumor",Adenocarcinoma; Aggressive; Diffuse large B-cell lymphoma (DLBCL); HER2 negative; Hormone refractory; MSS/pMMR; Second line; Stage III; Stage IV; Third line; Triple receptor negative; Unresectable,"Breast Neoplasms; Carcinoma; Carcinoma, Non-Small-Cell Lung; Carcinoma, Ovarian Epithelial; Carcinoma, Renal Cell; Chronic Lymphocytic Leukemia; Colorectal Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Fallopian Tube Neoplasms; Head and Neck Neoplasms; Kidney Neoplasms; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Large-Cell, Anaplastic; Lymphoma, Non-Hodgkin; Melanoma; Mesothelioma; Mesothelioma, Malignant; Neoplasms; Neoplasms, Mesothelial; Neoplasms, Unknown Primary; Ovarian Cancer; Ovarian Neoplasms; Peritoneal Neoplasms; Prostatic Neoplasms; Renal Cancer; Squamous Cell Carcinoma of Head and Neck; Stomach Carcinoma; Stomach Neoplasms; Triple Negative Breast Neoplasms; Urethral Neoplasms; Urinary Bladder Neoplasms; Uterine Cervical Neoplasms; Wilms Tumor",United Kingdom; United States
"A Phase I/II, Open-label, Multicenter Study to Investigate the Safety, Pharmacokinetics, and Efficacy of CYC140, an Oral PLK1 Inhibitor, in Subjects With Advanced Solid Tumors and Lymphoma",I/II,Open,Cyclacel,"Oncology: Bile Duct (Cholangiocarcinoma); Oncology: Bladder; Oncology: Breast; Oncology: Colorectal; Oncology: Esophageal; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Lung, Small Cell; Oncology: Lymphoma, Non-Hodgkin's; Oncology: Neuroendocrine; Oncology: Ovarian; Oncology: Pancreas; Oncology: Prostate",Aggressive; Cutaneous T-cell lymphoma (CTCL); Diffuse large B-cell lymphoma (DLBCL); Extranodal marginal zone B-cell lymphoma (MALT); Follicular lymphoma (FL); HER2 negative; Indolent; KRAS; Mantle cell lymphoma (MCL); Peripheral T-cell lymphoma (PTCL); Pulmonary; Second line; Small lymphocytic lymphoma (SLL); Stage III; Stage IV; Triple receptor negative; Waldenstrom's macroglobulinemia (WM),"Acute Myelocytic Leukemia; Bile Duct Neoplasms; Breast Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Cholangiocarcinoma; Chronic Lymphocytic Leukemia; Colorectal Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Leukemia, Myeloid, Acute; Liver Cancer; Liver Neoplasms; Lymphoma, B-Cell, Marginal Zone; Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Large-Cell, Anaplastic; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Lymphoma, T-Cell, Cutaneous; Lymphoma, T-Cell, Peripheral; Myelodysplastic Syndromes; Neoplasms, Unknown Primary; Neuroendocrine Tumors; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Prostatic Neoplasms; Small Cell Lung Carcinoma; Urethral Neoplasms; Urinary Bladder Neoplasms; Waldenstrom Macroglobulinemia",United States
"Phase I Study to Assess the Safety, Tolerability, and Pharmacokinetics of ON 123300 Capsules Administered Orally as Escalating Daily Doses in Patients With Advanced Cancer Relapsed or Refractory to at Least One (1) Prior Line of Therapy",I,Open,Onconova Therapeutics,Oncology: Breast; Oncology: Unspecified Cancer,Estrogen receptor positive; HER2 negative; Progesterone receptor positive; Second line; Stage III; Stage IV,Breast Neoplasms; Neoplasms; Unspecified,United States
"A Phase I, First-in-human, Dose Escalation and Expansion, Multicenter Study of XMT-1660 in Participants With Solid Tumors",I,Open,Mersana Therapeutics,Oncology: Breast; Oncology: Endometrial; Oncology: Fallopian Tube; Oncology: Ovarian; Oncology: Primary Peritoneal,Estrogen receptor positive; HER2 negative; Progesterone receptor positive; Second line; Stage III; Stage IV; Triple receptor negative,"Breast Neoplasms; Carcinoma, Endometrioid; Endometrial Neoplasms; Fallopian Tube Neoplasms; Ovarian Cancer; Ovarian Neoplasms; Peritoneal Neoplasms; Triple Negative Breast Neoplasms",United States
A Phase I/II Study Investigating Safety and Efficacy of Autologous TAC T Cells Targeting HER2 in Relapsed or Refractory Solid Tumors.,I/II,Open,"Merck & Co.
Triumvira Immunologics","Oncology: Breast; Oncology: Colorectal; Oncology: Esophageal; Oncology: Gallbladder; Oncology: Gastric; Oncology: Lung, Non-Small Cell; Oncology: Ovarian; Oncology: Pancreas; Oncology: Unspecified Solid Tumor",HER2 positive; Stage III; Stage IV; Third line,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Esophageal Neoplasms; Gallbladder Neoplasms; Neoplasms; Neoplasms, Unknown Primary; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Stomach Carcinoma; Stomach Neoplasms",Canada; United States
"A Phase I/Ib, Open-Label, Multicenter, Dose-Escalation Study of RMC 5552 Monotherapy in Adult Subjects With Relapsed/Refractory Solid Tumors",I,Open,Revolution Medicines,"Oncology: Breast; Oncology: Colorectal; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Ovarian; Oncology: Pancreas; Oncology: Unspecified Solid Tumor",Estrogen receptor positive; Fourth line or greater; HER2 negative; HER2 positive; Progesterone receptor positive; Second line; Stage III; Stage IV; Third line; Triple receptor negative,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Head and Neck Neoplasms; Neoplasms; Neoplasms, Unknown Primary; Ovarian Neoplasms; Pancreatic Neoplasms",United States
A Phase I Safety and Window-of-opportunity Study of Preoperative Intratumoral Injection of OX40-ligand Expressing Oncolytic Adenovirus (DNX-2440) in Patients With Resectable Liver Metastasis,I,Open,"H. Lee Moffitt Cancer Center and Research Institute
DNAtrix {VectorLogics}","Oncology: Breast; Oncology: Colorectal; Oncology: Gastric; Oncology: GIST; Oncology: Liver; Oncology: Melanoma; Oncology: Metastatic Cancer; Oncology: Osteosarcoma; Oncology: Pancreas; Oncology: Renal; Oncology: Skin, Squamous Cell Carcinoma (cSCC); Oncology: Soft Tissue Sarcoma",Liver mets; Neoadjuvant; Resectable; Stage IV,"Breast Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Renal Cell; Carcinoma, Squamous Cell; Colorectal Neoplasms; Ewing Sarcoma; Fibrosarcoma; Gastrointestinal Stromal Tumors; Kidney Neoplasms; Leiomyosarcoma; Liposarcoma; Liver Cancer; Liver Neoplasms; Melanoma; Neoplasm Metastasis; Neoplasms, Second Primary; Osteosarcoma; Pancreatic Cancer; Pancreatic Neoplasms; Renal Cancer; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Stomach Carcinoma; Stomach Neoplasms; Synovial Sarcoma; Wilms Tumor",United States
Phase I/II Study of Stereotactic Radiosurgery With Concurrent Administration of DNA Damage Response (DDR) Inhibitor (OLAparib) Followed by Adjuvant Combination of DuRvalumab (MEDI4736) and Physician's Choice Systemic Therapy in Subjects With BreAst Cancer Brain Metastases,I/II,Open,"AstraZeneca;
University of North Carolina",Oncology: Breast; Oncology: Metastatic Cancer,Adjuvant; BRCA; CNS mets; HER2 negative; PD-1 Naive; PD-L1 Naive; Stage IV; Triple receptor negative,Brain Neoplasms; Breast Neoplasms; Central Nervous System Neoplasms; Neoplasm Metastasis,United States
Phase I/I B Study of DS-8201a in Combination With ATR Inhibition (AZD6738) in Advanced Solid Tumors With HER2 Expression (DASH Trial),I,Open,National Institutes of Health/National Cancer Institute;,Oncology: Breast; Oncology: Colorectal; Oncology: Endometrial; Oncology: Esophageal; Oncology: Gastric; Oncology: Head/Neck; Oncology: Liver; Oncology: Unspecified Solid Tumor,HER2 positive; Second line; Stage III; Stage IV,"Adenocarcinoma; Breast Neoplasms; Carcinoma; Carcinoma, Endometrioid; Carcinoma, Hepatocellular; Colonic Neoplasms; Colorectal Neoplasms; Endometrial Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Head and Neck Neoplasms; Liver Cancer; Liver Neoplasms; Neoplasm Metastasis; Neoplasms; Neoplasms, Unknown Primary; Salivary Gland Neoplasms; Stomach Carcinoma; Stomach Neoplasms",United States
"A Phase I Dose-Escalation Trial of Talazoparib in Combination With Belinostat for Metastatic Breast Cancer, Metastatic Castration Resistant Prostate Cancer, and Metastatic Ovarian Cancer",I,Open,"Pfizer;
University of Michigan Comprehensive Cancer Center
Aurobindo Pharma/Acrotech Biopharma",Oncology: Breast; Oncology: Ovarian; Oncology: Prostate,Estrogen receptor positive; HER2 negative; Hormone refractory; Progesterone receptor positive; Second line; Stage III; Stage IV,Breast Neoplasms; Neoplasm Metastasis; Ovarian Cancer; Ovarian Neoplasms; Prostatic Neoplasms,United States
Neratinib and Tepotinib Combination in Advanced Breast Cancer and Inflammatory Breast Cancer Patients With Abnormal Her2 and C-met Pathway Activity as Measured by the Celsignia Signaling Pathway Activity Test,I/II,Planned,"MD Anderson Cancer Center University of Texas;
City of Hope Comprehensive Cancer Center
Ohio State University",Oncology: Breast,Estrogen receptor positive; Fourth line or greater; HER2 negative; HER2 positive; Progesterone receptor positive; Second line; Stage III; Stage IV; Third line,Breast Neoplasms,United States
Phase I/II Safety and Efficacy Study of NUV-868 as Monotherapy and in Combination With Olaparib or Enzalutamide in Adult Patients With Advanced Solid Tumors,I/II,Open,Nuvation Bio,Oncology: Breast; Oncology: Fallopian Tube; Oncology: Ovarian; Oncology: Pancreas; Oncology: Primary Peritoneal; Oncology: Prostate; Oncology: Unspecified Solid Tumor,BRCA; HER2 negative; Hormone refractory; Second line; Stage III; Stage IV; Triple receptor negative,"Acute Myelocytic Leukemia; Breast Neoplasms; Fallopian Tube Neoplasms; Leukemia, Myeloid, Acute; Neoplasms; Neoplasms, Unknown Primary; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Peritoneal Neoplasms; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Triple Negative Breast Neoplasms",United States
A Phase I Dose Escalation and Expanded Cohort Study of P-MUC1C-ALLO1 in Adult Subjects With Advanced or Metastatic Solid Tumors,I,Open,Poseida Therapeutics,"Oncology: Breast; Oncology: Colorectal; Oncology: Gastric; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Lung, Small Cell; Oncology: Neuroendocrine; Oncology: Ovarian; Oncology: Pancreas; Oncology: Renal; Oncology: Unspecified Solid Tumor",(N/A); Pulmonary; Second line; Stage III; Stage IV,"Breast Neoplasms; Carcinoma; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Carcinoma, Small Cell; Colorectal Neoplasms; Head and Neck Neoplasms; Kidney Neoplasms; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms; Neoplasms, Unknown Primary; Neuroendocrine Tumors; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Renal Cancer; Small Cell Lung Carcinoma; Squamous Cell Carcinoma of Head and Neck; Stomach Carcinoma; Stomach Neoplasms; Wilms Tumor",United States
"A Phase 1b Trial of ARV-471 in Combination With Everolimus in Patients With ER+, HER2- Advanced or Metastatic Breast Cancer",I,Open,"Pfizer;
Arvinas;",Oncology: Breast,Estrogen receptor positive; HER2 negative; Second line; Stage IV; Third line,Breast Neoplasms,Spain; United States
Phase I Trial of Adjuvant Therapy With an Alpha-lactalbumin Vaccine in Patients With Non-Metastatic Triple-Negative Breast Cancer at High Risk of Recurrence,I,Open,(Other Hospital/Academic/Medical Center);,Oncology: Breast,Adjuvant; HER2 negative; Stage I; Stage II; Stage III; Triple receptor negative,Breast Neoplasms; Triple Negative Breast Neoplasms,United States
"Phase IB Trial of Niraparib and TSR-042 in Patients With BRCA-Mutated Breast, Pancreas or Ovary Cancer",I,Open,"GlaxoSmithKline
University of Washington",Oncology: Breast; Oncology: Fallopian Tube; Oncology: Ovarian; Oncology: Pancreas; Oncology: Primary Peritoneal,BRCA; Estrogen receptor positive; HER2 positive; Progesterone receptor positive; Second line; Stage III; Stage IV,"Breast Neoplasms; Carcinoma; Carcinoma, Ovarian Epithelial; Fallopian Tube Neoplasms; Neoplasms; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Peritoneal Neoplasms",United States
"A Phase I, First in Human, Study to Evaluate the Safety and Tolerability of AdAPT-001 in Subjects With Refractory Solid Tumors",I,Open,EpicentRx {RadioRx},Oncology: Breast; Oncology: Colorectal; Oncology: Fallopian Tube; Oncology: Gastric; Oncology: Head/Neck; Oncology: Melanoma; Oncology: Soft Tissue Sarcoma; Oncology: Unspecified Solid Tumor,Second line; Stage III; Stage IV,"Breast Neoplasms; Colorectal Neoplasms; Fallopian Tube Neoplasms; Fibrosarcoma; Head and Neck Neoplasms; Leiomyosarcoma; Liposarcoma; Melanoma; Neoplasms; Neoplasms, Unknown Primary; Rhabdomyosarcoma; Sarcoma; Stomach Neoplasms; Synovial Sarcoma",United States
A Phase I Study of SGN-STNV in Advanced Solid Tumors,I,Open,Seagen,"Oncology: Breast; Oncology: Cervical; Oncology: Colorectal; Oncology: Endometrial; Oncology: Esophageal; Oncology: Gastric; Oncology: Lung, Non-Small Cell; Oncology: Ovarian; Oncology: Pancreas",HER2 negative; Second line; Stage III; Stage IV,"Adenocarcinoma; Breast Neoplasms; Carcinoma; Carcinoma, Endometrioid; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Endometrial Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Neoplasms; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Pseudomyxoma Peritonei; Stomach Carcinoma; Stomach Neoplasms; Uterine Cervical Neoplasms",Canada; France; Italy; Spain; United Kingdom; United States
A Dose Escalation and Expansion Study of the Safety and Pharmacokinetics of XL102 as Single-Agent and Combination Therapy in Subjects With Inoperable Locally Advanced or Metastatic Solid Tumors,I,Open,Exelixis,Oncology: Breast; Oncology: Ovarian; Oncology: Prostate; Oncology: Unspecified Solid Tumor,Estrogen receptor positive; HER2 negative; Hormone refractory; Progesterone receptor positive; Second line; Stage III; Stage IV; Triple receptor negative,"Breast Neoplasms; Carcinoma, Ovarian Epithelial; Neoplasms; Neoplasms, Unknown Primary; Ovarian Cancer; Ovarian Neoplasms; Prostatic Neoplasms; Triple Negative Breast Neoplasms",Belgium; Italy; Spain; United States
Evaluation of Variations pharmacokinEtics and phArmacogeNOmics of Ribociclib in rAce-based Cohorts: The LEANORA Study,I,Open,"(Other Hospital/Academic/Medical Center);
Breast Cancer Research Foundation",Oncology: Breast,Estrogen receptor positive; HER2 negative; Line of therapy N/A; Progesterone receptor positive; Stage III; Stage IV,Breast Neoplasms,United States
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 as Single-Agent and Combination Therapy in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors,I,Open,Exelixis,"Oncology: Bladder; Oncology: Breast; Oncology: Cervical; Oncology: Esophageal; Oncology: Fallopian Tube; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Ovarian; Oncology: Pancreas; Oncology: Primary Peritoneal; Oncology: Prostate; Oncology: Renal; Oncology: Unspecified Solid Tumor",Estrogen receptor positive; HER2 negative; Progesterone receptor positive; Second line; Stage III; Stage IV; Triple receptor negative,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Esophageal Cancer; Esophageal Neoplasms; Fallopian Tube Neoplasms; Head and Neck Neoplasms; Kidney Neoplasms; Neoplasms, Unknown Primary; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Peritoneal Neoplasms; Prostatic Neoplasms; Renal Cancer; Triple Negative Breast Neoplasms; Urethral Neoplasms; Urinary Bladder Neoplasms; Uterine Cervical Neoplasms; Wilms Tumor",United States
"A Phase Ib/II, 2-part Open-label Study to Assess the Safety and Antitumor Activity of Zanidatamab in Combination With ALX148 in Advanced HER2-expressing Cancer",I/II,Open,Zymeworks,Oncology: Breast; Oncology: Unspecified Solid Tumor,HER2 positive; Stage III; Stage IV; Third line,"Breast Neoplasms; Neoplasms, Unknown Primary; Unspecified",United States
Phase Ib Expansion Study of CX-5461 in Patients With Solid Tumours and BRCA2 and/or PALB2 Mutation,I,Open,Senhwa Biosciences,Oncology: Breast; Oncology: Fallopian Tube; Oncology: Ovarian; Oncology: Pancreas; Oncology: Primary Peritoneal; Oncology: Prostate; Oncology: Unspecified Solid Tumor,BRCA; Second line; Stage II; Stage III; Stage IV,"Breast Neoplasms; Fallopian Tube Neoplasms; Neoplasms; Neoplasms, Unknown Primary; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Peritoneal Neoplasms; Prostatic Neoplasms",Canada; United States
"A Modular Phase I/IIa, Open-label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of Ascending Doses of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies",I/II,Open,AstraZeneca;,"Oncology: Bile Duct (Cholangiocarcinoma); Oncology: Bladder; Oncology: Breast; Oncology: Cervical; Oncology: Colorectal; Oncology: Endometrial; Oncology: Gastric; Oncology: Lung, Non-Small Cell; Oncology: Lung, Small Cell; Oncology: Neuroendocrine; Oncology: Ovarian; Oncology: Pancreas; Oncology: Prostate",BRCA; Fourth line or greater; HER2 negative; Hormone refractory; Pulmonary; Second line; Stage III; Stage IV; Triple receptor negative,"Bile Duct Neoplasms; Breast Neoplasms; Carcinoma, Endometrioid; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Cholangiocarcinoma; Colorectal Neoplasms; Endometrial Neoplasms; Lung Neoplasms; Neuroendocrine Tumors; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Prostatic Neoplasms; Small Cell Lung Carcinoma; Stomach Carcinoma; Stomach Neoplasms; Urethral Neoplasms; Urinary Bladder Neoplasms; Uterine Cervical Neoplasms",Australia; Canada; China; Czech Republic; Hungary; Italy; Japan; Poland; Russia; South Korea; Spain; United Kingdom; United States
"A Phase 1b Open-Label Multicenter Study of OP-1250 in Combination With the CDK4/6 Inhibitor Ribociclib or With the PI3K Inhibitor Alpelisib in Adult Subjects With Advanced and/or Metastatic HR Positive, HER2 Negative Breast Cancer",I,Open,"Novartis;
Olema Oncology",Oncology: Breast,Estrogen receptor positive; HER2 negative; Progesterone receptor positive; Second line; Stage III; Stage IV; Third line,Breast Neoplasms,Australia; United States
A Phase I Study in High-Risk Women with Early Stage Triple Receptor Negative (TNBC) Breast Cancer who are Receiving Standard of Care,I,Open,"US Department of Defense
(Other Hospital/Academic/Medical Center);
Anixa Biosciences",Oncology: Breast,HER2 negative; Line of therapy N/A; Stage I; Stage II; Stage III; Triple receptor negative,Breast Neoplasms,United States
"A Phase I/II Trial of EMB-02, a Bi-specific Antibody Against PD-1 and LAG-3, in Patients With Advanced Solid Tumors",I/II,Open,EpimAb Biotherapeutics,"Oncology: Anal; Oncology: Breast; Oncology: Gastric; Oncology: Head/Neck; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Lung, Small Cell; Oncology: Melanoma; Oncology: Mesothelioma; Oncology: Neuroendocrine; Oncology: Unspecified Solid Tumor",BRAF; HER2 negative; PD-1 Refractory; PD-L1 Refractory; Pulmonary; Second line; Stage III; Stage IV; Triple receptor negative,"Anus Neoplasms; Breast Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Head and Neck Neoplasms; Liver Cancer; Liver Neoplasms; Melanoma; Mesothelioma; Neoplasms; Neoplasms, Mesothelial; Neoplasms, Unknown Primary; Neuroendocrine Tumors; Small Cell Lung Carcinoma; Stomach Carcinoma; Stomach Neoplasms",Australia; China; United States
"A Phase I Study of In Situ Immunomodulation With CDX-301, Radiotherapy, CDX-1140, and Poly-ICLC in Patients With Unresectable and Metastatic Solid Tumors With Injectable Palpable Disease",I,Open,Roswell Park Cancer Institute,Oncology: Breast; Oncology: Melanoma,HER2 negative; Second line; Stage III; Stage IV,Breast Neoplasms; Carcinoma; Melanoma,United States
"A Phase I/II, Open-Label, Single-Arm, Dose-Escalation and Dose-Expansion Study of the Safety, Tolerability, Pharmacokinetic, and Antitumor Activity of E-602 as a Single Agent and in Combination With Cemiplimab in Patients With Advanced Cancers",I/II,Open,Palleon Pharmaceuticals,"Oncology: Bladder; Oncology: Breast; Oncology: Colorectal; Oncology: Esophageal; Oncology: Gastric; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Ovarian; Oncology: Pancreas; Oncology: Renal; Oncology: Unspecified Solid Tumor",MSI-H/dMMR; Second line; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Colorectal Neoplasms; Esophageal Neoplasms; Head and Neck Neoplasms; Kidney Neoplasms; Melanoma; Neoplasms, Unknown Primary; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Stomach Neoplasms; Unspecified; Urethral Neoplasms; Urinary Bladder Neoplasms; Wilms Tumor",United States
"A Phase I, First in Human, Open-label, Dose Escalation and Dose Expansion Study of TST005 in Patients With Locally Advanced or Metastatic Solid Tumors",I,Open,Transcenta Holding {Mabspace Biosciences Co.},"Oncology: Anal; Oncology: Bile Duct (Cholangiocarcinoma); Oncology: Bladder; Oncology: Breast; Oncology: Cervical; Oncology: Colorectal; Oncology: Endometrial; Oncology: Esophageal; Oncology: Gastric; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Lung, Small Cell; Oncology: Neuroendocrine; Oncology: Pancreas; Oncology: Penile; Oncology: Prostate; Oncology: Renal; Oncology: Unspecified Solid Tumor; Oncology: Vaginal; Oncology: Vulvar",PD-1 Refractory; PD-L1 Refractory; Pulmonary; Second line; Stage III; Stage IV; Third line,"Anus Neoplasms; Bile Duct Neoplasms; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Carcinoma, Small Cell; Cholangiocarcinoma; Colorectal Neoplasms; Endometrial Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Head and Neck Neoplasms; Kidney Neoplasms; Neoplasms; Neoplasms, Unknown Primary; Neuroendocrine Tumors; Pancreatic Cancer; Pancreatic Neoplasms; Penile Neoplasms; Prostatic Neoplasms; Small Cell Lung Carcinoma; Stomach Carcinoma; Stomach Neoplasms; Urethral Neoplasms; Urinary Bladder Neoplasms; Uterine Cervical Neoplasms; Vaginal Neoplasms; Vulvar Neoplasms; Wilms Tumor",China; United States
"An Open-label, Multicenter, Dose Escalation Phase 1b Study to Assess the Safety and Pharmacokinetics of Subcutaneous Delivery of Amivantamab, a Human Bispecific EGFR and cMet Antibody for the Treatment of Advanced Solid Malignancies.",I,Open,Johnson & Johnson/Janssen R&D {Johnson & Johnson/J&JPRD {Johnson & Johnson/Janssen-Cilag/Janssen Research Foundation}},"Oncology: Breast; Oncology: Colorectal; Oncology: Esophageal; Oncology: Gastric; Oncology: Head/Neck; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Mesothelioma; Oncology: Ovarian; Oncology: Renal; Oncology: Thyroid",EGFR; Fourth line or greater; Medullary; Metastatic; Second line; Stage III; Stage IV; Third line; Unresectable,"Breast Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Colorectal Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Head and Neck Neoplasms; Kidney Neoplasms; Liver Cancer; Liver Neoplasms; Mesothelioma; Neoplasms; Neoplasms, Mesothelial; Ovarian Cancer; Ovarian Neoplasms; Renal Cancer; Stomach Carcinoma; Stomach Neoplasms; Thyroid Neoplasms; Wilms Tumor",Canada; South Korea; United Kingdom; United States
"A Phase I Dose Escalation and Expansion Study to Evaluate Safety, Tolerability, Pharmacokinetic, Pharmacodynamic, and Anti-tumor Activity of PF-07248144 in Participants With Advanced or Metastatic Solid Tumors.",I,Open,Pfizer;,"Oncology: Breast; Oncology: Lung, Non-Small Cell; Oncology: Prostate",Estrogen receptor positive; Fourth line or greater; HER2 negative; Hormone refractory; Second line; Stage III; Stage IV; Third line,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Prostatic Neoplasms",China; Japan; South Korea; United States
Phase I/II Study of Radiation Therapy Followed by Intrathecal Trastuzumab/Pertuzumab in the Management of HER2+ Breast Leptomeningeal Disease,I/II,Open,"H. Lee Moffitt Cancer Center and Research Institute
Roche;Genentech;",Oncology: Breast; Oncology: Metastatic Cancer,CNS mets; Fourth line or greater; HER2 positive; Second line; Stage IV; Third line,Brain Neoplasms; Breast Neoplasms; Central Nervous System Neoplasms; Meningeal Neoplasms; Neoplasm Metastasis,United States
"Open Label, Phase Ib Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Clinical Activity of CYH33, an Oral a-specific PI3K Inhibitor in Combination With Olaparib, an Oral PARP Inhibitor in Patients With Advanced Solid Tumors.",I,Open,"Haihe Biopharma Co.
Haihe Biopharma Co./Shanghai Haihe Pharmaceutical Research and Development Co.",Oncology: Breast; Oncology: Endometrial; Oncology: Ovarian; Oncology: Primary Peritoneal; Oncology: Prostate; Oncology: Unspecified Solid Tumor,BRCA; Second line; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Endometrioid; Endometrial Neoplasms; Neoplasms, Unknown Primary; Ovarian Cancer; Ovarian Neoplasms; Peritoneal Neoplasms; Prostatic Neoplasms",Australia; China; United States
A Phase I Study of TAS0612 in Patients With Locally Advanced or Metastatic Solid Tumors,I,Open,Otsuka Holdings/Taiho Pharmaceutical,Oncology: Breast; Oncology: Unspecified Solid Tumor,Estrogen receptor positive; HER2 negative; KRAS; Progesterone receptor positive; Second line; Stage III; Stage IV,"Breast Neoplasms; Neoplasms; Neoplasms, Unknown Primary",France; Spain; United States
"An Open-Label, Phase Ib/2 Study to Evaluate the Safety and Efficacy of Fruquintinib in Combination With Tislelizumab in Patients With Advanced Solid Tumors",I/II,Open,"Hutchmed {Hutchison MediPharma}
BeiGene",Oncology: Breast; Oncology: Colorectal; Oncology: Endometrial; Oncology: Unspecified Solid Tumor,HER2 negative; Progesterone receptor positive; Second line; Stage III; Stage IV; Triple receptor negative,"Breast Neoplasms; Carcinoma, Endometrioid; Colorectal Neoplasms; Endometrial Neoplasms; Triple Negative Breast Neoplasms",United States
"A Safety, Tolerability, and Pharmacokinetics Phase I Clinical Trial Of ON 123300 in Relapsed/Refractory, Advanced Cancer Including Patients with HR+ HER 2- Metastatic Breast Cancer with Resistance to Approved Second-Generation CDK4/6 Inhibitors and Non-Hodgkin’s Lymphoma with a special interest in Mantle Cell Lymphoma",I,Planned,"Onconova Therapeutics
Hanx Biopharmaceutical Co.","Oncology: Breast; Oncology: Lymphoma, Non-Hodgkin's",Aggressive; Estrogen receptor positive; HER2 negative; Mantle cell lymphoma (MCL); Progesterone receptor positive; Second line; Stage III; Stage IV,"Breast Neoplasms; Lymphoma, Large-Cell, Anaplastic; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin",United States
"A Phase I, Multicenter, Single Agent Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Evidence of Antitumor Activity of CPO-100 in Adult Patients With Advanced Solid Tumors",I,Open,CSPC Pharmaceutical Group Co./Conjupro Biotherapeutics,"Oncology: Breast; Oncology: Gastric; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Ovarian; Oncology: Prostate; Oncology: Unspecified Solid Tumor",First line; Second line; Stage III; Stage IV; Third line,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Head and Neck Neoplasms; Neoplasms; Neoplasms, Unknown Primary; Ovarian Cancer; Ovarian Neoplasms; Prostatic Neoplasms; Stomach Carcinoma; Stomach Neoplasms",United States
"A Phase I/IIa Study Evaluating The Safety, Tolerability, Pharamcokinetics, Pharmacodynamics, And Anti-Tumor Activity Of PF-07220060 As A Single Agent And as Part of Combination Therapy In Participants With Advanced Solid Tumors",I,Open,Pfizer;,"Oncology: Breast; Oncology: Colorectal; Oncology: Lung, Non-Small Cell; Oncology: Prostate; Oncology: Soft Tissue Sarcoma; Oncology: Unspecified Solid Tumor",Adenocarcinoma; Estrogen receptor positive; First line; Fourth line or greater; HER2 negative; HER2 positive; Progesterone receptor positive; Second line; Stage III; Stage IV; Third line; Untreated,"Adenocarcinoma of Lung; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Fibrosarcoma; Leiomyosarcoma; Liposarcoma; Neoplasms, Unknown Primary; Prostatic Neoplasms; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Synovial Sarcoma",United States
"Phase I/IIa Dose Escalation, Finding and Expansion Study Evaluating Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Anti Tumor Activity of PF-07104091 as a Single Agent and in Combination Therapy",I/II,Open,Pfizer;,"Oncology: Breast; Oncology: Fallopian Tube; Oncology: Lung, Non-Small Cell; Oncology: Lung, Small Cell; Oncology: Neuroendocrine; Oncology: Ovarian; Oncology: Primary Peritoneal",(N/A); Estrogen receptor positive; Fourth line or greater; HER2 negative; Progesterone receptor positive; Pulmonary; Second line; Stage III; Stage IV; Third line; Triple receptor negative,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Fallopian Tube Neoplasms; Lung Neoplasms; Neuroendocrine Tumors; Ovarian Cancer; Ovarian Neoplasms; Peritoneal Neoplasms; Small Cell Lung Carcinoma; Triple Negative Breast Neoplasms",Argentina; Bulgaria; China; Japan; Mexico; Ukraine; United States
"Phase I/II Study of the Safety, Pharmacokinetics, and Preliminary Clinical Activity of BT8009 in Patients with Nectin-4 Expressing Advanced Malignancies",I/II,Open,Bicycle Therapeutics,"Oncology: Bladder; Oncology: Breast; Oncology: Esophageal; Oncology: Gastric; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Ovarian; Oncology: Pancreas; Oncology: Renal; Oncology: Unspecified Solid Tumor",First line; Fourth line or greater; HER2 negative; Second line; Stage III; Stage IV; Third line; Triple receptor negative,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Esophageal Cancer; Esophageal Neoplasms; Head and Neck Neoplasms; Kidney Neoplasms; Neoplasms; Neoplasms, Unknown Primary; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Renal Cancer; Stomach Carcinoma; Stomach Neoplasms; Triple Negative Breast Neoplasms; Urethral Neoplasms; Urinary Bladder Neoplasms; Wilms Tumor","Belgium; Canada; France; Germany; Hong Kong, S.A.R., China; Italy; Netherlands; South Korea; Spain; United Kingdom; United States"
"A Phase Ib Dose-escalation Study of the Safety and Pharmacokinetics of Fixed-dose PCS6422 With Escalating Doses of Capecitabine Administered Orally to Patients With Advanced, Refractory Gastrointestinal Tract Tumors",I,Open,Processa Pharmaceuticals,Oncology: Bile Duct (Cholangiocarcinoma); Oncology: Breast; Oncology: Colorectal; Oncology: Esophageal; Oncology: Gallbladder; Oncology: Gastric; Oncology: Liver; Oncology: Pancreas,Second line; Stage III; Stage IV; Unresectable,"Bile Duct Neoplasms; Breast Neoplasms; Carcinoma, Hepatocellular; Cholangiocarcinoma; Colorectal Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Gallbladder Neoplasms; Liver Cancer; Liver Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Stomach Carcinoma; Stomach Neoplasms",United States
"A First-in-human Study of Highly Selective FGFR2 Inhibitor, RLY-4008, in Patients With Intrahepatic Cholangiocarcinoma (ICC) and Other Advanced Solid Tumors.",I/II,Open,Relay Therapeutics,Oncology: Bile Duct (Cholangiocarcinoma); Oncology: Breast; Oncology: Endometrial; Oncology: Gastric; Oncology: Liver; Oncology: Unspecified Solid Tumor,FGFR; First line; Fourth line or greater; Intrahepatic; Second line; Stage III; Stage IV; Third line; Unresectable,"Bile Duct Neoplasms; Breast Neoplasms; Carcinoma, Endometrioid; Carcinoma, Hepatocellular; Cholangiocarcinoma; Cholangiocarcinoma; Endometrial Neoplasms; Liver Cancer; Liver Neoplasms; Neoplasms, Unknown Primary; Stomach Carcinoma; Stomach Neoplasms","Australia; Canada; France; Germany; Hong Kong, S.A.R., China; Italy; Netherlands; Singapore; South Korea; Spain; Sweden; Taiwan, China; United Kingdom; United States"
Phase I Trial of Intratumoral Administration of a Measles Virus Derivative Expressing the Helicobacter Pylori Neutrophil-Activating Protein (NAP) (MV-s-NAP) in Patients With Metastatic Breast Cancer,I,Open,Mayo Clinic;,Oncology: Breast,Estrogen receptor positive; HER2 negative; HER2 positive; Progesterone receptor positive; Second line; Stage III; Stage IV; Triple receptor negative,Breast Neoplasms; Carcinoma,United States
Clinical and Immunologic Activity of Nemvaleukin Alfa With Less Frequent IV Dosing Schedule as Monotherapy and in Combination With Pembrolizumab and Impact on Tumor Microenvironment in Solid Tumor Patients - ARTISTRY-3,I/II,Open,Alkermes,"Oncology: Bile Duct (Cholangiocarcinoma); Oncology: Breast; Oncology: Cervical; Oncology: Colorectal; Oncology: Esophageal; Oncology: Fallopian Tube; Oncology: Gastric; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Lung, Small Cell; Oncology: Melanoma; Oncology: Neuroendocrine; Oncology: Ovarian; Oncology: Renal; Oncology: Unspecified Solid Tumor",(N/A); Fourth line or greater; HER2 negative; Intrahepatic; MSI-H/dMMR; MSS/pMMR; Pulmonary; Second line; Stage III; Stage IV; Third line; Triple receptor negative,"Bile Duct Neoplasms; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Cholangiocarcinoma; Colorectal Neoplasms; Esophageal Neoplasms; Fallopian Tube Neoplasms; Head and Neck Neoplasms; Kidney Neoplasms; Melanoma; Neoplasms; Neoplasms, Unknown Primary; Neuroendocrine Tumors; Ovarian Cancer; Ovarian Neoplasms; Renal Cancer; Small Cell Lung Carcinoma; Stomach Neoplasms; Uterine Cervical Neoplasms; Wilms Tumor",Spain; United States
"A Phase I First-Time-in-Human, Open-Label Study of GSK4381562 Administered as Monotherapy and in Combination With Anticancer Agents in Participants With Selected Advanced Solid Tumors",I,Open,"GlaxoSmithKline
Surface Oncology","Oncology: Breast; Oncology: Colorectal; Oncology: Endometrial; Oncology: Gastric; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Ovarian; Oncology: Renal; Oncology: Unspecified Solid Tumor",Second line; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Endometrioid; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Colorectal Neoplasms; Endometrial Neoplasms; Head and Neck Neoplasms; Kidney Neoplasms; Neoplasms, Unknown Primary; Ovarian Cancer; Ovarian Neoplasms; Renal Cancer; Stomach Carcinoma; Stomach Neoplasms; Unspecified; Wilms Tumor",Canada; Japan; Spain; United States
Pilot Trial of Nivolumab Plus Cabozantinib for Advanced Solid Tumors in Patients With HIV Infection,I,Open,National Institutes of Health/National Cancer Institute;,"Infectious Disease: HIV; Oncology: Bladder; Oncology: Breast; Oncology: Head/Neck; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Lung, Small Cell; Oncology: Melanoma; Oncology: Neuroendocrine; Oncology: Ovarian; Oncology: Prostate; Oncology: Renal; Oncology: Thyroid; Oncology: Unspecified Solid Tumor",Extensive; First line; Follicular; HER2 negative; HIV-related cancer; Hormone refractory; Limited; Locally advanced; Medullary; Metastatic; Papillary; PD-1 Naive; PD-L1 Naive; Pulmonary; Recurrent; Second line; Stage III; Stage IV; Triple receptor negative; Untreated,"Acquired Immunodeficiency Syndrome; Breast Neoplasms; Carcinoma; Carcinoma, Hepatocellular; Carcinoma, Medullary; Carcinoma, Neuroendocrine; Carcinoma, Non-Small-Cell Lung; Carcinoma, Ovarian Epithelial; Carcinoma, Renal Cell; Carcinoma, Small Cell; Carcinoma, Transitional Cell; Head and Neck Neoplasms; HIV Infections; HIV Seropositivity; Infections; Kaposi Sarcoma; Kidney Neoplasms; Liver Cancer; Liver Neoplasms; Lung Neoplasms; Melanoma; Neoplasms; Neuroendocrine Tumors; Ovarian Cancer; Ovarian Neoplasms; Prostatic Neoplasms; Renal Cancer; Sarcoma; Sarcoma, Kaposi; Skin Neoplasms; Small Cell Lung Carcinoma; Thyroid Diseases; Thyroid Neoplasms; Urethral Neoplasms; Urinary Bladder Neoplasms; Wilms Tumor",United States
"A Phase I/II, Open Label, Multi-center, Non-randomized Dose Escalation and Dose Expansion Study of AMXI-5001 in Patients With Advanced Malignancies",I/II,Open,AtlasMedx,Oncology: Breast; Oncology: Ovarian,Second line; Stage III; Stage IV,Breast Neoplasms; Neoplasms; Ovarian Cancer; Ovarian Neoplasms,United States
"Phase 1/2a Study of the Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Clinical Activity of RP-3500 Alone or in Combination With Talazoparib or Gemcitabine in Advanced Solid Tumors With ATR Inhibitor Sensitizing Mutations (TRESR Study)",I/II,Open,"Roche;
Repare Therapeutics",Oncology: Breast; Oncology: Head/Neck; Oncology: Melanoma; Oncology: Ovarian; Oncology: Pancreas; Oncology: Prostate; Oncology: Unspecified Solid Tumor,BRCA; Fourth line or greater; Second line; Stage III; Stage IV,"Breast Neoplasms; Head and Neck Neoplasms; Melanoma; Neoplasms; Neoplasms, Unknown Primary; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Prostatic Neoplasms",Canada; Denmark; United Kingdom; United States
"A Phase I Dose Escalation and Dose Expansion and Phase II Monotherapy Open-label, First-in-Human, Multicenter Study of OP-1250 in Adult Subjects With Advanced and/or Metastatic Hormone Receptor (HR)-Positive, HER2-negative Breast Cancer",I/II,Open,Olema Oncology,Oncology: Breast,Estrogen receptor positive; HER2 negative; Progesterone receptor positive; Second line; Stage III; Stage IV,Breast Neoplasms,Australia; United States
A Phase I Trial of the ATR Inhibitor BAY 1895344 in Combination With Cisplatin and With Cisplatin Plus Gemcitabine in Advanced Solid Tumors With an Emphasis on Urothelial Carcinoma,I,Open,National Institutes of Health/National Cancer Institute;,"Oncology: Bile Duct (Cholangiocarcinoma); Oncology: Bladder; Oncology: Breast; Oncology: Cervical; Oncology: Endometrial; Oncology: Esophageal; Oncology: Gastric; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Lung, Small Cell; Oncology: Mesothelioma; Oncology: Neuroendocrine; Oncology: Ovarian; Oncology: Penile; Oncology: Renal",Advanced; HER2 negative; Pulmonary; Second line; Stage III; Stage IV; Triple receptor negative,"Bile Duct Neoplasms; Breast Neoplasms; Carcinoma; Carcinoma, Endometrioid; Carcinoma, Non-Small-Cell Lung; Carcinoma, Ovarian Epithelial; Carcinoma, Renal Cell; Carcinoma, Small Cell; Carcinoma, Transitional Cell; Cholangiocarcinoma; Cholangiocarcinoma; Endometrial Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Head and Neck Neoplasms; Kidney Neoplasms; Lung Neoplasms; Mesothelioma; Mesothelioma, Malignant; Neoplasms, Mesothelial; Neuroendocrine Tumors; Ovarian Cancer; Ovarian Neoplasms; Penile Neoplasms; Renal Cancer; Small Cell Lung Carcinoma; Stomach Carcinoma; Stomach Neoplasms; Urethral Neoplasms; Urinary Bladder Neoplasms; Uterine Cervical Neoplasms; Wilms Tumor",United States
"A Phase I/II, FIH, Two-part, Open-label Clinical Trial of Intravenous (IV) Administration of CTL-002 Given as Monotherapy and/or in Combination With an Anti-PD-1 Checkpoint Inhibitor in Subjects With Advanced-stage, Relapsed/Refractory Solid Tumors (The “GDFATHER“-Trial: GDF-15 Antibody-mediaTed Human Effector Cell Relocation)",I/II,Open,CatalYm,"Oncology: Bladder; Oncology: Breast; Oncology: Cervical; Oncology: Colorectal; Oncology: Head/Neck; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Mesothelioma; Oncology: Unspecified Solid Tumor",Fourth line or greater; MSS/pMMR; Neoadjuvant; PD-1 Refractory; PD-L1 Refractory; Second line; Stage III; Stage IV; Third line,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Head and Neck Neoplasms; Liver Neoplasms; Melanoma; Mesothelioma; Neoplasms, Mesothelial; Neoplasms, Unknown Primary; Unspecified; Urethral Neoplasms; Urinary Bladder Neoplasms; Uterine Cervical Neoplasms",Germany; Spain; Switzerland; United States
"A Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of ZN-A-1041 Enteric Capsules as a Single Agent or in Combination in Patients With HER2-Positive Advanced Solid Tumors",I,Open,"Zion Pharma/Suzhou Zanrong Pharmaceutical Technology Co.
Zion Pharma",Oncology: Breast; Oncology: Metastatic Cancer; Oncology: Unspecified Solid Tumor,CNS mets; HER2 positive; Second line; Stage III; Stage IV; Third line,"Brain Neoplasms; Breast Neoplasms; Central Nervous System Neoplasms; Neoplasm Metastasis; Neoplasms; Neoplasms, Unknown Primary",China; United States
"A Phase I/II, Dose Escalation and Expansion Study of the Safety, Tolerability, and Anti-tumor Activity of BND-22 Administered Alone and in Combination With Pembrolizumab or With Cetuximab in Patients With Advanced Solid Tumors",I/II,Open,Biond Biologics,"Oncology: Bile Duct (Cholangiocarcinoma); Oncology: Bladder; Oncology: Breast; Oncology: Cervical; Oncology: Colorectal; Oncology: Esophageal; Oncology: Gallbladder; Oncology: Gastric; Oncology: Head/Neck; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Renal; Oncology: Unspecified Solid Tumor",Second line; Stage III; Stage IV; Unresectable,"Bile Duct Neoplasms; Breast Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Cholangiocarcinoma; Colorectal Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Gallbladder Neoplasms; Head and Neck Neoplasms; Kidney Neoplasms; Liver Cancer; Liver Neoplasms; Melanoma; Neoplasms, Unknown Primary; Renal Cancer; Stomach Carcinoma; Stomach Neoplasms; Unspecified; Urethral Neoplasms; Urinary Bladder Neoplasms; Uterine Cervical Neoplasms; Wilms Tumor",Israel; United States
"This Study is a Phase I/II Clinical Evaluation of a New Investigational Agent, Lutetium-177-PEG-αvβ3-IAC (HurlutinTM Lu-177) to Treat Patients With Unresectable Angiogenic Breast Cancer.",I/II,Planned,"Department of Veterans Affairs
(Other Hospital/Academic/Medical Center);
All India Institute of Medical Sciences (AIIMS)
University of Witwatersrand; South Africa
PositronPharma
Advanced Imaging Projects",Oncology: Breast; Oncology: Unspecified Solid Tumor,Second line; Stage III; Stage IV,"Breast Neoplasms; Neoplasms, Unknown Primary",Chile; India; Italy; South Africa; Switzerland; United States
"A Multi-Center Open Label Dose Escalation and Dose Expansion Study to Evaluate Safety, Tolerability, Dosimetry, and Preliminary Efficacy of the HER2 Directed Radioligand CAM-H2 in Patients With Advanced/Metastatic HER2-Positive Breast, Gastric, and GEJ Cancer",I/II,Open,Precirix {Camel-IDS},Oncology: Breast; Oncology: Esophageal; Oncology: Gastric; Oncology: Metastatic Cancer,CNS mets; Fourth line or greater; HER2 positive; Second line; Stage III; Stage IV; Third line,Brain Neoplasms; Breast Neoplasms; Central Nervous System Neoplasms; Disease Progression; Esophageal Cancer; Esophageal Neoplasms; Neoplasm Metastasis; Stomach Carcinoma; Stomach Neoplasms,Canada; United States
"Phase I/II, First-in-human, Open-label Dose Escalation and Cohort Expansion Study of KB-0742 in Patients with Relapsed or Refractory Solid Tumors or Non-Hodgkin Lymphoma",I/II,Open,Kronos Bio,"Oncology: Breast; Oncology: Lung, Non-Small Cell; Oncology: Lung, Small Cell; Oncology: Lymphoma, Non-Hodgkin's; Oncology: Neuroendocrine; Oncology: Ovarian; Oncology: Soft Tissue Sarcoma; Oncology: Unspecified Solid Tumor",(N/A); Aggressive; HER2 negative; Indolent; Pulmonary; Second line; Stage III; Stage IV; Triple receptor negative,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Fibrosarcoma; Leiomyosarcoma; Liposarcoma; Lymphoma; Lymphoma, Large-Cell, Anaplastic; Lymphoma, Non-Hodgkin; Neoplasms; Neoplasms, Unknown Primary; Neuroendocrine Tumors; Ovarian Neoplasms; Rhabdomyosarcoma; Sarcoma; Small Cell Lung Carcinoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Synovial Sarcoma",United States
Preoperative Use of Radiation Boost to Enhance Effectiveness of Immune Checkpoint Blockade Therapy in Operable Breast Cancer,I/II,Open,University of Pennsylvania,Oncology: Breast,Adjuvant; Estrogen receptor positive; HER2 negative; HER2 positive; Neoadjuvant; Progesterone receptor positive; Stage II; Triple receptor negative,Breast Neoplasms,United States
"A Phase Ia/Ib Dose-Escalation and Dose-Expansion Study Evaluating the Safety, Pharmacokinetics, and Activity of GDC-6036 as a Single Agent and in Combination With Other Anti-cancer Therapies in Patients With Advanced or Metastatic Solid Tumors With a KRAS G12C Mutation",I,Open,Roche;Genentech;,"Oncology: Bile Duct (Cholangiocarcinoma); Oncology: Breast; Oncology: Colorectal; Oncology: Endometrial; Oncology: Esophageal; Oncology: Gastric; Oncology: Lung, Non-Small Cell; Oncology: Neuroendocrine; Oncology: Pancreas; Oncology: Unspecified Solid Tumor",Fourth line or greater; KRAS; Second line; Stage III; Stage IV; Third line,"Bile Duct Neoplasms; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Cholangiocarcinoma; Colorectal Neoplasms; Endometrial Neoplasms; Esophageal Neoplasms; Neoplasms, Unknown Primary; Neuroendocrine Tumors; Pancreatic Neoplasms; Stomach Neoplasms",Australia; Belgium; Brazil; Canada; France; Germany; Hungary; Israel; Italy; Kenya; Netherlands; New Zealand; Norway; Poland; Russia; South Korea; Spain; Switzerland; United Kingdom; United States
A Phase I/II Study of REGN7075 (EGFRxCD28 Costimulatory Bispecific Antibody) in Combination With Cemiplimab in Patients With Advanced Solid Tumors,I/II,Open,Regeneron,"Oncology: Breast; Oncology: Colorectal; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Skin, Squamous Cell Carcinoma (cSCC); Oncology: Unspecified Solid Tumor",BRAF; HER2 negative; Line of therapy N/A; MSS/pMMR; PD-1 Naive; PD-L1 Naive; Stage III; Stage IV; Triple receptor negative,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Colorectal Neoplasms; Head and Neck Neoplasms; Neoplasms; Neoplasms, Unknown Primary",Japan; United States
"A Phase I Multi-Country, Multi-Center, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of SHR-A1811 in HER2 Expressing or Mutated Advanced Malignant Solid Tumor Subjects",I,Open,"Jiangsu Hengrui Pharmaceuticals Co. {Jiangsu Hengrui Medicine}/Shanghai Hengrui Pharmaceutical {Shanghai Hengrui Pharmaceutical (Jiangsu Hengrui Medicine; HKG Science & Tech. JV)}
Jiangsu Hengrui Pharmaceuticals Co. {Jiangsu Hengrui Medicine Co.}/Atridia
Jiangsu Hengrui Pharmaceuticals Co. {Jiangsu Hengrui Medicine Co.}/Suzhou Suncadia Biopharmaceuticals Co.","Oncology: Bile Duct (Cholangiocarcinoma); Oncology: Bladder; Oncology: Breast; Oncology: Colorectal; Oncology: Endometrial; Oncology: Gastric; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Renal; Oncology: Unspecified Solid Tumor",Fourth line or greater; HER2 positive; Second line; Stage III; Stage IV,"Bile Duct Neoplasms; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Cholangiocarcinoma; Colorectal Neoplasms; Endometrial Neoplasms; Head and Neck Neoplasms; Kidney Neoplasms; Neoplasms; Neoplasms, Unknown Primary; Stomach Carcinoma; Stomach Neoplasms; Urethral Neoplasms; Urinary Bladder Neoplasms; Wilms Tumor","Australia; China; South Korea; Taiwan, China; United States"
A Phase I/II Open-Label Study to Evaluate Safety and Efficacy of SEL120 in Patients with Relapsed/refractory Metastatic or Advanced Solid Tumors,I/II,Open,Ryvu Therapeutics {Selvita},Oncology: Breast; Oncology: Unspecified Solid Tumor,HER2 negative; Second line; Stage III; Stage IV; Triple receptor negative,"Breast Neoplasms; Neoplasms, Unknown Primary; Recurrence",Australia; China; Czech Republic; France; Netherlands; Poland; Russia; Spain; United States
"Phase I/II Study of the Safety, Pharmacokinetics, and Preliminary Clinical Activity of BT7480 in Patients With Nectin-4 Associated Advanced Malignancies",I/II,Open,Bicycle Therapeutics,"Oncology: Breast; Oncology: Esophageal; Oncology: Gastric; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Ovarian; Oncology: Renal; Oncology: Unspecified Solid Tumor",Estrogen receptor positive; HER2 negative; HER2 positive; Progesterone receptor positive; Second line; Stage III; Stage IV; Triple receptor negative,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Esophageal Cancer; Esophageal Neoplasms; Head and Neck Neoplasms; Kidney Neoplasms; Neoplasms; Neoplasms, Unknown Primary; Ovarian Cancer; Ovarian Neoplasms; Renal Cancer; Stomach Carcinoma; Stomach Neoplasms; Wilms Tumor",United States
"A Phase I/II Multicenter, Open-label, Dose-escalation, Safety, Pharmacodynamic, and Pharmacokinetic Study of Q901 Administered Via Intravenous Infusion in Adult Patients With Selected Advanced Solid Tumors With a Cohort Expansion at the Recommended Phase II Dose",I/II,Open,Qurient,"Oncology: Breast; Oncology: Colorectal; Oncology: Endometrial; Oncology: Lung, Small Cell; Oncology: Neuroendocrine; Oncology: Ovarian; Oncology: Pancreas; Oncology: Prostate; Oncology: Unspecified Solid Tumor",(N/A); Estrogen receptor positive; HER2 negative; Hormone refractory; Progesterone receptor positive; Pulmonary; Second line; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Endometrioid; Carcinoma, Small Cell; Colorectal Neoplasms; Endometrial Neoplasms; Neoplasms, Unknown Primary; Neuroendocrine Tumors; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Prostatic Neoplasms; Small Cell Lung Carcinoma",United States
BRE-03: Window of Opportunity Trial of Preoperative Lenvatinib Plus Pembrolizumab in Early-Stage Triple-Negative Breast Cancer (TNBC),I,Open,University of Illinois at Chicago Health Sciences Center,Oncology: Breast,Estrogen receptor positive; First line; HER2 negative; Stage I; Stage II; Triple receptor negative,Breast Neoplasms; Triple Negative Breast Neoplasms,United States
"First-in-Human, Phase I/Ib, Open-label, Multicenter Study of Bifunctional EGFR/TGFß Fusion Protein BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-Driven Advanced Solid Tumors",I,Open,"Merck & Co./Merck Sharp & Dohme (MSD)
Biocon/Bicara Therapeutics","Oncology: Anal; Oncology: Breast; Oncology: CNS, Glioblastoma; Oncology: Colorectal; Oncology: Head/Neck; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Ovarian; Oncology: Pancreas; Oncology: Skin, Squamous Cell Carcinoma (cSCC); Oncology: Thyroid; Oncology: Unspecified Solid Tumor",Anaplastic; EGFR; First line; Fourth line or greater; HER2 negative; KRAS; PD-1 Refractory; PD-L1 High; PD-L1 Positive; PD-L1 Refractory; Second line; Squamous Cell; Stage III; Stage IV; Third line; Triple receptor negative,"Anus Neoplasms; Breast Neoplasms; Carcinoma; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Ovarian Epithelial; Carcinoma, Squamous Cell; Colorectal Neoplasms; Glioblastoma; Head and Neck Neoplasms; Liver Cancer; Liver Neoplasms; Lung Neoplasms; Melanoma; Neoplasms, Unknown Primary; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Squamous Cell Carcinoma of Head and Neck; Thyroid Neoplasms",Canada; United States
A Phase Ib Clinical Study of DPV-001 with BMS-986178 and Nivolumab in Patients with Advanced Triple Negative Breast Cancer,I,Open,"Bristol-Myers Squibb
UbiVac",Oncology: Breast,First line; HER2 negative; Second line; Stage III; Stage IV; Triple receptor negative,Breast Neoplasms,Poland; United States
"A Phase I/II, First-In-Human, Multi-Part, Open-Label, Multiple-Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, Biological, and Clinical Activity of DF6002 as a Monotherapy and in Combination With Nivolumab in Patients With Locally Advanced or Metastatic Solid Tumors, and Expansion in Selected Indications",I/II,Open,Dragonfly Therapeutics,"Oncology: Bladder; Oncology: Breast; Oncology: Cervical; Oncology: Endometrial; Oncology: Esophageal; Oncology: Gastric; Oncology: Head/Neck; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Lung, Small Cell; Oncology: Melanoma; Oncology: Neuroendocrine; Oncology: Ovarian; Oncology: Prostate; Oncology: Renal; Oncology: Skin, Squamous Cell Carcinoma (cSCC)",BRAF; Extensive; Fourth line or greater; HER2 negative; Merkel; Metastatic; PD-1 Naive; PD-1 Refractory; PD-L1 Naive; PD-L1 Refractory; Pulmonary; Second line; Stage III; Stage IV; Third line; Triple receptor negative,"Breast Neoplasms; Carcinoma, Endometrioid; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Carcinoma, Small Cell; Carcinoma, Squamous Cell; Colorectal Neoplasms; Endometrial Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Head and Neck Neoplasms; Hodgkin Disease; Hodgkin Lymphoma; Kidney Neoplasms; Liver Cancer; Liver Neoplasms; Lymphoma, Non-Hodgkin; Melanoma; Neoplasms; Neuroendocrine Tumors; Ovarian Cancer; Ovarian Neoplasms; Prostatic Neoplasms; Renal Cancer; Small Cell Lung Carcinoma; Stomach Carcinoma; Stomach Neoplasms; Urethral Neoplasms; Urinary Bladder Neoplasms; Uterine Cervical Neoplasms; Wilms Tumor",Australia; France; Spain; United States
"A First-In-Human, Phase I/II Study Of CFI-402411, a Hematopoietic Progenitor Kinase-1 (HPK1) Inhibitor, as a Single Agent and in Combination With Pembrolizumab in Subjects With Advanced Solid Malignancies.",I/II,Open,"Treadwell Therapeutics
TIO Discovery","Oncology: Bladder; Oncology: Breast; Oncology: Cervical; Oncology: Endometrial; Oncology: Esophageal; Oncology: Gastric; Oncology: Head/Neck; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Lung, Small Cell; Oncology: Melanoma; Oncology: Neuroendocrine; Oncology: Renal; Oncology: Unspecified Solid Tumor",HER2 negative; Metastatic; MSI-H/dMMR; Pulmonary; Second line; Stage III; Stage IV; Triple receptor negative,"Breast Neoplasms; Carcinoma, Endometrioid; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Carcinoma, Small Cell; Endometrial Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Head and Neck Neoplasms; Kidney Neoplasms; Liver Cancer; Liver Neoplasms; Melanoma; Neoplasms; Neoplasms, Unknown Primary; Neuroendocrine Tumors; Renal Cancer; Small Cell Lung Carcinoma; Stomach Carcinoma; Stomach Neoplasms; Urethral Neoplasms; Urinary Bladder Neoplasms; Uterine Cervical Neoplasms; Wilms Tumor","Canada; Hong Kong, S.A.R., China; Singapore; United States"
"A Phase I, First-In-Human, Multicenter, Open-Label, Study of GQ1001, a HER2 Targeted Antibody-Drug Conjugate, Administered Intravenously, in Adult Patients With HER2-Positive Advanced Solid Tumors",I,Open,"GeneQuantum Healthcare (Suzhou) Co.
Conjugate Light (Australia)",Oncology: Bile Duct (Cholangiocarcinoma); Oncology: Bladder; Oncology: Breast; Oncology: Esophageal; Oncology: Gastric; Oncology: Unspecified Solid Tumor,Fourth line or greater; HER2 positive; Second line; Stage III; Stage IV; Third line,"Bile Duct Neoplasms; Breast Neoplasms; Cholangiocarcinoma; Esophageal Cancer; Esophageal Neoplasms; Neoplasms; Neoplasms, Unknown Primary; Stomach Carcinoma; Stomach Neoplasms; Urethral Neoplasms; Urinary Bladder Neoplasms",Australia; China; United States
"Phase I Study of X-PACT (X-ray Psoralen Activated Cancer Therapy) for Intra-tumoral Injection of Superficial Tumors in Patients With Advanced Head and Neck Cancer, Breast Cancer, Soft Tissue Sarcoma or Melanoma",I,Open,Immunolight,Oncology: Breast; Oncology: Head/Neck; Oncology: Melanoma; Oncology: Soft Tissue Sarcoma; Oncology: Unspecified Solid Tumor,PD-1 Refractory; PD-L1 Refractory; Second line; Stage III; Stage IV,Breast Neoplasms; Fibrosarcoma; Head and Neck Neoplasms; Leiomyosarcoma; Liposarcoma; Melanoma; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Synovial Sarcoma,United States
A Phase I/II Study of CBX-12 in Subjects with Advanced or Metastatic Refractory Solid Tumors,I/II,Open,"Exelixis
Cybrexa Therapeutics","Oncology: Bladder; Oncology: Breast; Oncology: Colorectal; Oncology: Esophageal; Oncology: Gastric; Oncology: Lung, Non-Small Cell; Oncology: Lung, Small Cell; Oncology: Neuroendocrine; Oncology: Ovarian; Oncology: Pancreas; Oncology: Renal; Oncology: Unspecified Solid Tumor",Pulmonary; Second line; Stage III; Stage IV,"Appendiceal Neoplasms; Breast Neoplasms; Carcinoma; Carcinoma, Non-Small-Cell Lung; Carcinoma, Ovarian Epithelial; Carcinoma, Renal Cell; Carcinoma, Small Cell; Colorectal Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Kidney Neoplasms; Neoplasms, Unknown Primary; Neuroendocrine Tumors; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Renal Cancer; Sarcoma; Small Cell Lung Carcinoma; Stomach Carcinoma; Stomach Neoplasms; Urethral Neoplasms; Urinary Bladder Neoplasms; Wilms Tumor",United States
A Phase I Study of SGN-B6A in Advanced Solid Tumors,I,Open,Seagen {Seattle Genetics},"Oncology: Bladder; Oncology: Breast; Oncology: Cervical; Oncology: Esophageal; Oncology: Gastric; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Ovarian; Oncology: Pancreas; Oncology: Skin, Squamous Cell Carcinoma (cSCC)",Adenocarcinoma; HER2 negative; Second line; Squamous Cell; Stage III; Stage IV,"Breast Neoplasms; Carcinoma; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Esophageal Cancer; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Head and Neck Neoplasms; Neoplasms; Neoplasms, Squamous Cell; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Squamous Cell Carcinoma of Head and Neck; Stomach Carcinoma; Stomach Neoplasms; Urethral Neoplasms; Urinary Bladder Neoplasms; Uterine Cervical Neoplasms",France; Spain; Switzerland; United Kingdom; United States
"Phase I/Ib, Open-label, Multiple Ascending Dose, First-in-Human Study, to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of INT-1B3 in Patients With Advanced Solid Tumors",I,Open,InteRNA Technologies,Oncology: Breast; Oncology: Liver; Oncology: Unspecified Solid Tumor,HER2 negative; PD-1 Refractory; PD-L1 Refractory; Second line; Stage III; Stage IV; Triple receptor negative,"Breast Neoplasms; Carcinoma, Hepatocellular; Liver Cancer; Liver Neoplasms; Neoplasms; Neoplasms, Unknown Primary",Belgium; Netherlands; United States
Clinical Onboard Utilization of Image Guided Radiation Therapy With Magnetic Resonance (CONFIRM): A Master Protocol,I/II,Open,Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute;,"Oncology: Bladder; Oncology: Breast; Oncology: Gastric; Oncology: Head/Neck; Oncology: Lymphoma, Non-Hodgkin's",(N/A); Aggressive; Line of therapy N/A; Mantle cell lymphoma (MCL),"Breast Carcinoma In Situ; Breast Neoplasms; Head and Neck Neoplasms; Laryngeal Neoplasms; Lymphoma, Large-Cell, Anaplastic; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Stomach Carcinoma; Stomach Neoplasms; Urethral Neoplasms; Urinary Bladder Neoplasms",United States
Phase Ib Study of INO-5401 Alone or INO-5401 in Combination With INO-9012 Followed by Electroporation in Adult Cancer and Non-Cancer Patients With BRCA1 or BRCA2 Mutations,I,Open,"University of Pennsylvania
Inovio Pharmaceuticals {Inovio Biomedical}",Oncology: Breast; Oncology: Ovarian; Oncology: Pancreas; Oncology: Prostate,(N/A); BRCA; Line of therapy N/A,Breast Neoplasms; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Prostatic Neoplasms; Unspecified,United States
"A Phase I Trial of T Cell Receptor Gene Therapy Targeting KK-LC-1 for Gastric, Breast, Cervical, Lung and Other KK-LC-1 Positive Epithelial Cancers",I,Open,"National Institutes of Health/National Cancer Institute;
(Other Hospital/Academic/Medical Center);
T-Cure Bioscience","Oncology: Breast; Oncology: Cervical; Oncology: Gastric; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Unspecified Cancer",HER2 negative; Second line; Stage IV; Triple receptor negative,"Breast Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Liver Cancer; Liver Neoplasms; Neoplasms; Stomach Carcinoma; Stomach Neoplasms; Unspecified; Uterine Cervical Neoplasms",United States
A Phase I/II Trial Evaluating the Safety and Efficacy of Eribulin in Combination With Copanlisib in Patients With Metastatic Triple Negative Breast Cancer,I/II,Open,National Institutes of Health/National Cancer Institute;,Oncology: Breast,Fourth line or greater; HER2 negative; Second line; Stage III; Stage IV; Third line; Triple receptor negative,Breast Neoplasms; Carcinoma; Triple Negative Breast Neoplasms,United States
"Phase I/IIa, First-in-human, Open-label, Dose Escalation Trial With Expansion Cohorts to Evaluate Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of BNT151 as a Monotherapy and in Combination With Other Anti-cancer Agents in Patients With Solid Tumors",I/II,Open,BioNTech,"Oncology: Breast; Oncology: Head/Neck; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Renal; Oncology: Unspecified Solid Tumor",HER2 negative; Second line; Stage IV; Triple receptor negative,"Breast Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Head and Neck Neoplasms; Kidney Neoplasms; Liver Cancer; Liver Neoplasms; Neoplasms; Neoplasms, Unknown Primary; Renal Cancer; Wilms Tumor",Spain; United Kingdom; United States
"A Phase I, Open Label, Dose Escalation Study of ACE1702 Cell Immunotherapy in Subjects With Advanced or Metastatic HER2-expressing Solid Tumors",I,Open,Acepodia,Oncology: Breast; Oncology: Gastric; Oncology: Unspecified Solid Tumor,HER2 positive; Line of therapy N/A; Stage III; Stage IV,"Breast Neoplasms; Neoplasm Metastasis; Neoplasms; Neoplasms, Unknown Primary; Stomach Carcinoma; Stomach Neoplasms","Taiwan, China; United States"
"A Phase I/II Open-Label, Multicenter Study to Assess the Safety, Pharmacokinetics, and Antitumor Activity of UCB6114 Administered Intravenously to Participants With Advanced Solid Tumors.",I/II,Open,UCB,"Oncology: Bladder; Oncology: Breast; Oncology: Colorectal; Oncology: Esophageal; Oncology: Gastric; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Pancreas; Oncology: Prostate",Line of therapy N/A; Stage I; Stage II; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Head and Neck Neoplasms; Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Prostatic Neoplasms; Stomach Carcinoma; Stomach Neoplasms; Urethral Neoplasms; Urinary Bladder Neoplasms",United Kingdom; United States
A Phase I/Ib Trial of the CDK4/6 Antagonist Ribociclib And The HDAC Inhibitor Belinostat In Patients With Metastatic Triple Negative Breast Cancer And Recurrent Ovarian Cancer With Response Prediction By Genomics (CHARGE).,I,Open,"Novartis;
University of Utah
Aurobindo Pharma/Acrotech Biopharma",Oncology: Breast; Oncology: Ovarian,HER2 negative; Line of therapy N/A; Stage III; Stage IV; Triple receptor negative,Breast Neoplasms; Ovarian Cancer; Ovarian Neoplasms,United States
"A Phase I, Multicenter, Open-label Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of hSTC810 Monotherapy in Subjects With Advanced Solid Tumors",I,Open,STCube,"Oncology: Anal; Oncology: Bile Duct (Cholangiocarcinoma); Oncology: Bladder; Oncology: Breast; Oncology: Colorectal; Oncology: Esophageal; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Lung, Small Cell; Oncology: Melanoma; Oncology: Mesothelioma; Oncology: Ovarian; Oncology: Pancreas; Oncology: Soft Tissue Sarcoma; Oncology: Thymus; Oncology: Unspecified Solid Tumor",Advanced; First line; Line of therapy N/A; MSI-H/dMMR; Stage III; Stage IV,"Anus Neoplasms; Bile Duct Neoplasms; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Cholangiocarcinoma; Colorectal Neoplasms; Esophageal Neoplasms; Fibrosarcoma; Head and Neck Neoplasms; Leiomyosarcoma; Liposarcoma; Melanoma; Mesothelioma; Neoplasms; Neoplasms, Unknown Primary; Ovarian Neoplasms; Pancreatic Neoplasms; Rhabdomyosarcoma; Sarcoma; Small Cell Lung Carcinoma; Synovial Sarcoma; Thymus Neoplasms; Urethral Neoplasms; Urinary Bladder Neoplasms",South Korea; United States
"A Phase I/II Study to Evaluate Safety, Efficacy of Bria-OTS in Patients with Advanced Breast Cancer",I/II,Planned,BriaCell,Oncology: Breast,Line of therapy N/A; Stage III; Stage IV,Breast Neoplasms,United States
"A First-in-Human, Multicenter, Phase I/II, Open-Label Study of XTX101 in Patients With Advanced Solid Tumors",I/II,Open,Xilio Therapeutics,"Oncology: Bladder; Oncology: Breast; Oncology: Cervical; Oncology: Colorectal; Oncology: Endometrial; Oncology: Esophageal; Oncology: Fallopian Tube; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Neuroendocrine; Oncology: Pancreas; Oncology: Prostate; Oncology: Renal; Oncology: Skin, Squamous Cell Carcinoma (cSCC); Oncology: Soft Tissue Sarcoma; Oncology: Unspecified Solid Tumor",Fourth line or greater; MSI-H/dMMR; PD-1 Refractory; PD-L1 Refractory; Second line; Stage III; Stage IV; Third line,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Carcinoma, Squamous Cell; Colorectal Neoplasms; Endometrial Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Fallopian Tube Neoplasms; Fibrosarcoma; Head and Neck Neoplasms; Kidney Neoplasms; Leiomyosarcoma; Liposarcoma; Melanoma; Neoplasms; Neoplasms, Unknown Primary; Neuroendocrine Tumors; Pancreatic Neoplasms; Prostatic Neoplasms; Renal Cancer; Rhabdomyosarcoma; Sarcoma; Synovial Sarcoma; Urethral Neoplasms; Urinary Bladder Neoplasms; Uterine Cervical Neoplasms; Wilms Tumor",United States
Pilot Study of DS-8201a Pharmacodynamics in Patients With HER2-Expressing Advanced Solid Tumors,I,Open,National Institutes of Health/National Cancer Institute;,Oncology: Breast; Oncology: Unspecified Solid Tumor,HER2 positive; Second line; Stage III; Stage IV,"Breast Neoplasms; Neoplasms; Neoplasms, Unknown Primary",United States
"Phase l, First in Human, Multi-centre, Open-label, Clinical Trial of MPT0B640 in Subject With Locally Advanced or Metastatic Solid Malignancies.",I,Planned,J Ints Bio {Joseah Bio},"Oncology: Breast; Oncology: Colorectal; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Pancreas; Oncology: Prostate; Oncology: Unspecified Solid Tumor",HER2 negative; Second line; Stage III; Stage IV; Triple receptor negative,"Breast Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Liver Cancer; Liver Neoplasms; Neoplasms; Neoplasms, Unknown Primary; Pancreatic Cancer; Pancreatic Neoplasms; Prostatic Neoplasms",South Korea; United States
A Phase I Study of Cancer Peptides Plus GM-CSF and Adjuvant Following Completion of Prescribed Systemic Therapy of Estrogen Receptor Positive Breast Cancer,I,Open,Duke University Medical Center,Oncology: Breast,Adjuvant; Estrogen receptor positive; Stage II; Stage III,Breast Neoplasms,United States
Pilot Clinical Trial of Treatment With Bortezomib to Inhibit Homologous Recombination (HR) Followed by Pembrolizumab and Cisplatin in Patients With Chemotherapy-Pretreated Metastatic Triple Negative Breast Cancer,I,Open,Baylor Research Institute,Oncology: Breast; Oncology: Metastatic Cancer,HER2 negative; Liver mets; Other mets; Second line; Stage IV; Triple receptor negative,Breast Neoplasms; Liver Neoplasms; Neoplasm Metastasis,United States
DNA Damage Repair (DDR) Inhibitor-Based Basket of Baskets Phase I/II Trial in Patients With Advanced Solid Tumors Harboring Aberrations in DDR Genes (D-BoB),I/II,Open,"MD Anderson Cancer Center University of Texas;
National Institutes of Health/National Cancer Institute;",Oncology: Breast; Oncology: Colorectal; Oncology: Prostate; Oncology: Unspecified Solid Tumor,(N/A); BRCA; Hormone refractory; Line of therapy N/A; PD-1 Refractory; PD-L1 Refractory; Second line; Stage III; Stage IV,"Breast Neoplasms; Colorectal Neoplasms; Neoplasms; Neoplasms, Unknown Primary; Prostatic Neoplasms",United States
Phase I/II Study of IMC-F106C in Advance PRAME-Positive Cancers,I/II,Open,Immunocore,"Oncology: Bladder; Oncology: Breast; Oncology: Endometrial; Oncology: Fallopian Tube; Oncology: Lung, Non-Small Cell; Oncology: Lung, Small Cell; Oncology: Melanoma; Oncology: Neuroendocrine; Oncology: Osteosarcoma; Oncology: Ovarian; Oncology: Primary Peritoneal; Oncology: Renal; Oncology: Unspecified Solid Tumor",Adjuvant; HER2 negative; Pulmonary; Second line; Stage III; Stage IV; Triple receptor negative,"Breast Neoplasms; Carcinoma, Endometrioid; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Carcinoma, Small Cell; Endometrial Neoplasms; Ewing Sarcoma; Fallopian Tube Neoplasms; Kidney Neoplasms; Melanoma; Neoplasms, Unknown Primary; Neuroendocrine Tumors; Osteosarcoma; Ovarian Cancer; Ovarian Neoplasms; Peritoneal Neoplasms; Renal Cancer; Small Cell Lung Carcinoma; Unspecified; Urethral Neoplasms; Urinary Bladder Neoplasms; Wilms Tumor",United Kingdom; United States
"A Phase I Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of GS-1811, an Afucosylated Anti-CCR8 Monoclonal Antibody, as Monotherapy and in Combination With an Anti-PD-1 Monoclonal Antibody in Adults With Advanced Solid Tumors",I,Open,Gilead Sciences;,"Oncology: Breast; Oncology: Colorectal; Oncology: Esophageal; Oncology: Gastric; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Unspecified Solid Tumor",Adenocarcinoma; Estrogen receptor positive; First line; HER2 negative; HER2 positive; Large Cell; MSS/pMMR; PD-1 Naive; PD-1 Refractory; PD-L1 Naive; PD-L1 Positive; PD-L1 Refractory; Progesterone receptor positive; Second line; Squamous Cell; Stage II; Stage III; Stage IV; Third line; Triple receptor negative,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Esophageal Neoplasms; Head and Neck Neoplasms; Neoplasms; Neoplasms, Unknown Primary; Stomach Neoplasms","Australia; Taiwan, China; United States"
A Phase I Study of SEA-TGT (SGN-TGT) in Subjects With Advanced Malignancies.,I,Open,Seagen {Seattle Genetics},"Oncology: Bladder; Oncology: Breast; Oncology: Cervical; Oncology: Esophageal; Oncology: Gastric; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Lymphoma, Hodgkin's; Oncology: Lymphoma, Non-Hodgkin's; Oncology: Melanoma; Oncology: Ovarian; Oncology: Unspecified Solid Tumor",(N/A); Aggressive; Classical; Diffuse large B-cell lymphoma (DLBCL); Fourth line or greater; HER2 negative; PD-1 Naive; PD-L1 Naive; Peripheral T-cell lymphoma (PTCL); Second line; Squamous Cell; Stage III; Stage IV; Third line; Triple receptor negative,"Breast Neoplasms; Carcinoma; Carcinoma, Non-Small-Cell Lung; Esophageal Cancer; Esophageal Neoplasms; Head and Neck Neoplasms; Hodgkin Disease; Hodgkin Lymphoma; Lymphoma; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Large-Cell, Anaplastic; Lymphoma, Non-Hodgkin; Lymphoma, T-Cell, Peripheral; Melanoma; Ovarian Cancer; Ovarian Neoplasms; Squamous Cell Carcinoma of Head and Neck; Stomach Carcinoma; Stomach Neoplasms; Triple Negative Breast Neoplasms; Urethral Neoplasms; Urinary Bladder Neoplasms; Uterine Cervical Neoplasms",France; Italy; Spain; United Kingdom; United States
A Phase I Study of GNX102 in Patients With Advanced Solid Tumors,I,Open,GlycoNex,"Oncology: Bladder; Oncology: Breast; Oncology: Cervical; Oncology: Colorectal; Oncology: Endometrial; Oncology: Esophageal; Oncology: Gastric; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Ovarian; Oncology: Pancreas; Oncology: Prostate",Second line; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Endometrioid; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Endometrial Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Liver Cancer; Liver Neoplasms; Melanoma; Neoplasm Metastasis; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Prostatic Neoplasms; Stomach Carcinoma; Stomach Neoplasms; Urethral Neoplasms; Urinary Bladder Neoplasms; Uterine Cervical Neoplasms",United States
"A Phase I Open-Label Study to Evaluate the Safety and Antitumor Activity of FS120, an OX40/CD137 Bispecific Antibody, Alone and in Combination With Pembrolizumab, in Subjects With Advanced Malignancies",I,Open,Sino Biopharmaceutical/invoX Pharma/F-star Therapeutics,"Oncology: Bladder; Oncology: Breast; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Unspecified Solid Tumor",Estrogen receptor positive; HER2 negative; HER2 positive; Progesterone receptor positive; Second line; Stage III; Stage IV; Triple receptor negative,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Head and Neck Neoplasms; Neoplasm Metastasis; Neoplasms, Unknown Primary; Urethral Neoplasms; Urinary Bladder Neoplasms",Spain; United States
Phase I Trial of Intravenous Administration of TAEK-VAC-HerBy Vaccine Alone and in Combination With HER2 Antibodies in Patients With Advanced Cancer,I/II,Open,Bavarian Nordic,"Oncology: Breast; Oncology: Colorectal; Oncology: Endometrial; Oncology: Esophageal; Oncology: Gastric; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Lung, Small Cell; Oncology: Neuroendocrine; Oncology: Ovarian; Oncology: Pancreas; Oncology: Prostate",Fourth line or greater; HER2 positive; Merkel; Pulmonary; Second line; Stage III; Stage IV; Third line,"Breast Neoplasms; Carcinoma, Endometrioid; Carcinoma, Hepatocellular; Carcinoma, Merkel Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Chordoma; Colorectal Neoplasms; Endometrial Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Liver Cancer; Liver Neoplasms; Neuroendocrine Tumors; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Prostatic Neoplasms; Small Cell Lung Carcinoma; Stomach Carcinoma; Stomach Neoplasms",United States
A Phase I Study of CAR T-cell therapy as Monotherapy and in Combination with OncoSec's TAVO (IL-12) in Patients with Triple-negative Breast Cancer (TNBC),I,Planned,"Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute;
OncoSec Medical",Oncology: Breast; Oncology: Unspecified Solid Tumor,(N/A); HER2 negative; Line of therapy N/A; Triple receptor negative,"Breast Neoplasms; Neoplasms, Unknown Primary",United States
A Phase Ib/II Study of SDX-7320 in Combination with Alpelisib and Fulvestrant to Assess Safety in Patients with Metastatic Breast Cancer with the PIK3CA Mutation,I/II,Open,SynDevRx,Oncology: Breast,Estrogen receptor positive; HER2 negative; Progesterone receptor positive; Second line; Stage III; Stage IV,Breast Neoplasms,United States
"First-in-Human Phase I Trial to Investigate the Safety, Tolerability, Pharmacokinetics, Biological and Clinical Activity of Metarrestin (ML-246) in Subjects With Metastatic Solid Tumors.",I,Open,National Institutes of Health/National Cancer Institute;,Oncology: Breast; Oncology: Pancreas; Oncology: Unspecified Solid Tumor,Second line; Stage III; Stage IV,"Breast Neoplasms; Colorectal Neoplasms; Neoplasms; Neoplasms, Unknown Primary; Nerve Sheath Neoplasms; Neurofibrosarcoma; Pancreatic Cancer; Pancreatic Neoplasms",United States
A Phase Ib/II Study of the Safety and Pharmacology of Nilotinib to Prevent Paclitaxel-Induced Peripheral Neuropathy in Patients With Breast Cancer,I/II,Open,"National Institutes of Health/National Cancer Institute;
Ohio State University",Oncology: Breast; Oncology: Supportive Care,Line of therapy N/A; Neurotoxicity; Stage I; Stage II; Stage III,Breast Neoplasms; Palliative Care; Peripheral Nervous System Diseases,United States
"A Phase I, Open-Label, Dose Escalation and Expansion Study of TH1902 in Patients With Advanced Solid Tumors",I,Open,"Theratechnologies
Windtree Therapeutics","Oncology: Breast; Oncology: Colorectal; Oncology: Endometrial; Oncology: Lung, Small Cell; Oncology: Melanoma; Oncology: Neuroendocrine; Oncology: Ovarian; Oncology: Pancreas; Oncology: Prostate; Oncology: Thyroid; Oncology: Unspecified Solid Tumor",(N/A); Estrogen receptor positive; HER2 negative; Locally advanced; Metastatic; Progesterone receptor positive; Pulmonary; Second line; Stage III; Stage IV; Triple receptor negative,"Breast Neoplasms; Carcinoma, Endometrioid; Carcinoma, Ovarian Epithelial; Colorectal Neoplasms; Endometrial Neoplasms; Melanoma; Neuroendocrine Tumors; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Prostatic Neoplasms; Small Cell Lung Carcinoma; Thyroid Neoplasms; Triple Negative Breast Neoplasms",United States
An Open-label Phase Ib/IIa Study of NT-I7 (Efineptakin Alfa) in Combination With Pembrolizumab in Subjects With Relapsed/Refractory Advanced Solid Tumors,I/II,Open,Genexine/NeoImmuneTech,"Oncology: Breast; Oncology: Colorectal; Oncology: Lung, Non-Small Cell; Oncology: Lung, Small Cell; Oncology: Melanoma; Oncology: Neuroendocrine; Oncology: Ovarian; Oncology: Pancreas; Oncology: Unspecified Solid Tumor",ALK; BRAF; BRCA; EGFR; First line; Fourth line or greater; HER2 negative; MSS/pMMR; PD-1 Naive; PD-1 Refractory; PD-L1 Naive; PD-L1 Refractory; Pulmonary; Second line; Stage III; Stage IV; Third line; Triple receptor negative; Untreated,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Colorectal Neoplasms; Lung Neoplasms; Melanoma; Neoplasms, Unknown Primary; Neuroendocrine Tumors; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Small Cell Lung Carcinoma; Triple Negative Breast Neoplasms",United States
A Phase I/Ib Study of BP1001-A (a Liposomal Grb2 Antisense Oligonucleotide) in Patients With Advanced or Recurrent Solid Tumors,I,Open,Bio-Path Holdings,Oncology: Breast; Oncology: Endometrial; Oncology: Fallopian Tube; Oncology: Ovarian; Oncology: Pancreas; Oncology: Primary Peritoneal; Oncology: Unspecified Solid Tumor,HER2 negative; Second line; Stage III; Stage IV; Triple receptor negative,"Breast Neoplasms; Carcinoma, Endometrioid; Carcinoma, Ovarian Epithelial; Endometrial Neoplasms; Fallopian Tube Neoplasms; Neoplasms; Neoplasms, Unknown Primary; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Neoplasms; Peritoneal Neoplasms",United States
"Open-Label, Phase I Study to Evaluate Duration of Severe Neutropenia After Same-Day Dosing of Eflapegrastim in Patients With Breast-Cancer",I,Open,Spectrum Pharmaceuticals,Oncology: Breast; Oncology: Supportive Care,First line; Neutropenia; Stage I; Stage II; Stage III,Breast Neoplasms; Neutropenia; Palliative Care,United States
A Phase I Dose Escalation Study of NMS-03305293 in Adult Patients With Selected Advanced/Metastatic Solid Tumors,I,Open,Nerviano Medical Sciences,Oncology: Breast; Oncology: Ovarian; Oncology: Pancreas; Oncology: Prostate,BRCA; Estrogen receptor positive; Fourth line or greater; HER2 negative; Hormone refractory; Progesterone receptor positive; Second line; Stage III; Stage IV; Third line,Breast Neoplasms; Neoplasms; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Prostatic Neoplasms,China; Italy; United States
Phase I/II Study of BDC-1001 as a Single Agent and in Combination With Nivolumab in Patients With Advanced HER2-Expressing Solid Tumors,I/II,Open,"Bristol-Myers Squibb
Bolt Biotherapeutics","Oncology: Bladder; Oncology: Breast; Oncology: Cervical; Oncology: Colorectal; Oncology: Endometrial; Oncology: Esophageal; Oncology: Gastric; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Ovarian; Oncology: Pancreas; Oncology: Renal; Oncology: Unspecified Solid Tumor",Fourth line or greater; HER2 positive; Second line; Stage III; Stage IV; Third line,"Breast Neoplasms; Carcinoma, Endometrioid; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Colorectal Neoplasms; Endometrial Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Kidney Neoplasms; Liver Cancer; Liver Neoplasms; Neoplasms; Neoplasms, Unknown Primary; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Renal Cancer; Stomach Carcinoma; Stomach Neoplasms; Urethral Neoplasms; Urinary Bladder Neoplasms; Uterine Cervical Neoplasms; Wilms Tumor",South Korea; Spain; United States
A Pilot Study of FES Imaging to Optimize Tamoxifen Dose for Metastatic Breast Cancer Patients With ESR1 Mutations,I,Open,University of Wisconsin,Oncology: Breast; Oncology: Metastatic Cancer,CNS mets; Estrogen receptor positive; HER2 negative; Second line; Stage IV,Brain Neoplasms; Breast Neoplasms; Central Nervous System Neoplasms; Neoplasm Metastasis,United States
"Phase I/II Study of the Safety, Pharmacokinetics, and Preliminary Clinical Activity of BT5528 in Patients With Advanced Malignancies Associated With EphA2 Expression.",I/II,Open,Bicycle Therapeutics,"Oncology: Bladder; Oncology: Breast; Oncology: Esophageal; Oncology: Gastric; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Ovarian; Oncology: Pancreas; Oncology: Renal; Oncology: Unspecified Solid Tumor",HER2 negative; PD-1 Refractory; Second line; Stage III; Stage IV; Triple receptor negative,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Esophageal Cancer; Esophageal Neoplasms; Gastrointestinal Neoplasms; Head and Neck Neoplasms; Kidney Neoplasms; Neoplasms, Unknown Primary; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Renal Cancer; Stomach Carcinoma; Stomach Neoplasms; Triple Negative Breast Neoplasms; Urethral Neoplasms; Urinary Bladder Neoplasms; Wilms Tumor",Belgium; South Korea; Spain; United Kingdom; United States
"A Phase I, First-in-Human Study of Intratumoral Administration of CF33-hNIS-antiPDL1, A Novel Chimeric Oncolytic Poxvirus Encoding Human Sodium Iodide Symporter (HNIS) in Patients With Metastatic Triple Negative Breast Cancer",I,Open,"National Institutes of Health/National Cancer Institute;
City of Hope Comprehensive Cancer Center
Imugene {Biolife Science}",Oncology: Breast,Fourth line or greater; HER2 negative; Stage III; Stage IV; Third line; Triple receptor negative,Breast Neoplasms; Triple Negative Breast Neoplasms,United States
Phase Ia/Ib Open Label Dose-escalation and Expansion Study of TPST-1495 as a Single Agent and in Combination With Pembrolizumab in Subjects With Solid Tumors,I,Open,Tempest Therapeutics,"Oncology: Anal; Oncology: Bladder; Oncology: Breast; Oncology: Cervical; Oncology: Colorectal; Oncology: Endometrial; Oncology: Esophageal; Oncology: Gastric; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Pancreas; Oncology: Renal; Oncology: Unspecified Solid Tumor",Adenocarcinoma; Fourth line or greater; HER2 negative; MSS/pMMR; Second line; Squamous Cell; Stage III; Stage IV; Third line; Triple receptor negative,"Adenocarcinoma; Anus Neoplasms; Breast Neoplasms; Carcinoma; Carcinoma, Endometrioid; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Colorectal Neoplasms; Endometrial Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Head and Neck Neoplasms; Kidney Neoplasms; Neoplasms; Neoplasms, Unknown Primary; Pancreatic Neoplasms; Squamous Cell Carcinoma of Head and Neck; Stomach Carcinoma; Stomach Neoplasms; Urethral Neoplasms; Urinary Bladder Neoplasms; Uterine Cervical Neoplasms; Wilms Tumor",United States
"A Phase Ib Dose Escalation and Expansion Trial to Investigate the Safety, Tolerability, Pharmacokinetics, and Biological Activity of ATRC-101 as Monotherapy and in Combination With Other Anticancer Agents in Adults With Advanced Solid Malignancies",I,Open,Atreca,"Oncology: Bladder; Oncology: Breast; Oncology: Colorectal; Oncology: Esophageal; Oncology: Fallopian Tube; Oncology: Head/Neck; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Ovarian; Oncology: Primary Peritoneal",BRAF; Fourth line or greater; HER2 negative; MSI-H/dMMR; PD-1 Refractory; PD-L1 Refractory; Second line; Stage III; Stage IV; Third line; Triple receptor negative,"Breast Neoplasms; Carcinoma; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Ovarian Epithelial; Carcinoma, Squamous Cell; Colorectal Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Fallopian Tube Neoplasms; Head and Neck Neoplasms; Liver Cancer; Liver Neoplasms; Melanoma; Ovarian Cancer; Ovarian Neoplasms; Peritoneal Neoplasms; Squamous Cell Carcinoma of Head and Neck; Urethral Neoplasms; Urinary Bladder Neoplasms",United States
"An Open-Label, Dose-Escalation Phase Ib/II Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of Modakafusp Alfa (TAK-573) as a Single Agent and in Combination With Pembrolizumab in Adult Patients With Advanced or Metastatic Solid Tumors",I/II,Open,Takeda,"Oncology: Breast; Oncology: Colorectal; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Pancreas; Oncology: Prostate; Oncology: Unspecified Solid Tumor",BRAF; HER2 negative; MSI-H/dMMR; MSS/pMMR; PD-1 Naive; PD-1 Refractory; Second line; Stage III; Stage IV; Third line; Triple receptor negative,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Head and Neck Neoplasms; Melanoma; Neoplasms, Unknown Primary; Pancreatic Cancer; Pancreatic Neoplasms; Prostatic Neoplasms",Australia; United States
A Phase I Study of ZN-c3 as a Single Agent in Subjects With Solid Tumors,I,Open,"Zentalis/Zeno Pharmaceuticals
Zentalis/K-Group Beta","Oncology: Bladder; Oncology: Breast; Oncology: Colorectal; Oncology: Endometrial; Oncology: Fallopian Tube; Oncology: Lung, Non-Small Cell; Oncology: Lung, Small Cell; Oncology: Melanoma; Oncology: Neuroendocrine; Oncology: Ovarian; Oncology: Renal; Oncology: Unspecified Solid Tumor",Extensive; Fourth line or greater; HER2 negative; Limited; Pulmonary; Second line; Stage III; Stage IV; Third line; Triple receptor negative,"Breast Neoplasms; Carcinoma, Endometrioid; Carcinoma, Non-Small-Cell Lung; Carcinoma, Ovarian Epithelial; Carcinoma, Renal Cell; Carcinoma, Small Cell; Colorectal Neoplasms; Endometrial Neoplasms; Fallopian Tube Neoplasms; Kidney Neoplasms; Lung Neoplasms; Melanoma; Neoplasms, Unknown Primary; Neuroendocrine Tumors; Ovarian Cancer; Ovarian Neoplasms; Renal Cancer; Small Cell Lung Carcinoma; Triple Negative Breast Neoplasms; Urethral Neoplasms; Urinary Bladder Neoplasms; Wilms Tumor",United States
"A Phase Ib/II, Multicenter, Open-Label Study of TT-00420 Tablet, as Monotherapy or in Combination Regimens, in Patients With Advanced Solid Tumors",I/II,Open,TransThera Biosciences Co.,"Oncology: Bile Duct (Cholangiocarcinoma); Oncology: Bladder; Oncology: Breast; Oncology: Gallbladder; Oncology: Gastric; Oncology: Liver; Oncology: Lung, Small Cell; Oncology: Neuroendocrine; Oncology: Prostate; Oncology: Soft Tissue Sarcoma; Oncology: Thyroid; Oncology: Unspecified Solid Tumor",Estrogen receptor positive; HER2 negative; Line of therapy N/A; Metastatic; Progesterone receptor positive; Pulmonary; Stage III; Stage IV; Triple receptor negative,"Bile Duct Neoplasms; Breast Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Small Cell; Cholangiocarcinoma; Cholangiocarcinoma; Fibrosarcoma; Gallbladder Neoplasms; Leiomyosarcoma; Liposarcoma; Liver Cancer; Liver Neoplasms; Neoplasms, Unknown Primary; Neuroendocrine Tumors; Prostatic Neoplasms; Rhabdomyosarcoma; Sarcoma; Small Cell Lung Carcinoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Stomach Carcinoma; Stomach Neoplasms; Synovial Sarcoma; Thyroid Neoplasms; Triple Negative Breast Neoplasms; Urethral Neoplasms; Urinary Bladder Neoplasms",United States
"A Phase I-II, First-in-Human Study of SKB264 in Patients With Locally Advanced/Unresectable/Metastatic Solid Tumors Who Are Refractory to Available Standard Therapies.",I/II,Open,"Sichuan Kelun Pharmaceutical Co./Klus Pharma
Sichuan Kelun Pharmaceutical Co./Sichuan Kelun Botai Biopharmaceutical Co.","Oncology: Bladder; Oncology: Breast; Oncology: Endometrial; Oncology: Esophageal; Oncology: Gastric; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Lung, Small Cell; Oncology: Neuroendocrine; Oncology: Ovarian; Oncology: Pancreas; Oncology: Renal",Extensive; HER2 negative; MSI-H/dMMR; MSS/pMMR; PD-1 Refractory; PD-L1 Refractory; Pulmonary; Second line; Stage III; Stage IV; Triple receptor negative,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Ovarian Epithelial; Carcinoma, Renal Cell; Carcinoma, Small Cell; Endometrial Neoplasms; Esophageal Neoplasms; Head and Neck Neoplasms; Kidney Neoplasms; Lung Neoplasms; Neuroendocrine Tumors; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Small Cell Lung Carcinoma; Stomach Carcinoma; Stomach Neoplasms; Urethral Neoplasms; Urinary Bladder Neoplasms; Wilms Tumor",China; United States
SHARON: Study of Metastatic Cancers in Patients With a Defect in a Homologous Recombination Gene Using Autologous Stems Cells and Potentiated Redox Cycling to Overcome Drug Resistance to Nitrogen Mustard Derivatives,I,Open,"Myriad Genetics
General Oncology; Inc.",Oncology: Breast; Oncology: Pancreas,BRCA; HER2 negative; Line of therapy N/A; Stage IV,"Adenocarcinoma; Breast Neoplasms; Carcinoma, Acinar Cell; Pancreatic Cancer; Pancreatic Neoplasms",United States
"A Phase Ib/IIa, Randomized, Placebo-Controlled Trial of the Synthetic Cannabinoid ART27.13 in Patients with Cancer Anorexia and Weight Loss",I/II,Open,Artelo Biosciences,Oncology: Breast; Oncology: Colorectal; Oncology: Prostate; Oncology: Supportive Care; Oncology: Unspecified Cancer,(N/A); Cachexia; Line of therapy N/A,Breast Neoplasms; Cachexia; Colorectal Neoplasms; Neoplasms; Palliative Care; Prostatic Neoplasms,Australia; Canada; Ireland; Norway; United Kingdom; United States
"A Phase I/II, First-In-Human, Multi-Part, Open-Label, Multiple-Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, Biological, and Clinical Activity of DF1001 in Patients With Locally Advanced or Metastatic Solid Tumors, and Expansion in Selected Indications",I/II,Open,Dragonfly Therapeutics,"Oncology: Bladder; Oncology: Breast; Oncology: Esophageal; Oncology: Gastric; Oncology: Lung, Non-Small Cell; Oncology: Renal; Oncology: Unspecified Solid Tumor",HER2 positive; PD-1 Refractory; PD-L1 Refractory; Second line; Stage III; Stage IV; Third line,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Esophageal Neoplasms; Kidney Neoplasms; Neoplasms; Neoplasms, Unknown Primary; Renal Cancer; Stomach Neoplasms; Urethral Neoplasms; Urinary Bladder Neoplasms; Wilms Tumor",Belgium; Denmark; France; Netherlands; United States
"Safety, Pharmacokinetics (PK), and Efficacy of ONC-392 as a Single Agent and in Combination With Pembrolizumab in Advanced Solid Tumors and NSCLC: An Open Label Phase IA/IB Study. Preserve CTLA4 Checkpoint Function (PRESERVE-001)",I/II,Open,"National Institutes of Health/National Cancer Institute;
OncoC4","Oncology: Breast; Oncology: Cervical; Oncology: Colorectal; Oncology: Esophageal; Oncology: Fallopian Tube; Oncology: Gastric; Oncology: Head/Neck; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Lung, Small Cell; Oncology: Melanoma; Oncology: Neuroendocrine; Oncology: Osteosarcoma; Oncology: Ovarian; Oncology: Pancreas; Oncology: Primary Peritoneal; Oncology: Prostate; Oncology: Renal; Oncology: Skin, Squamous Cell Carcinoma (cSCC); Oncology: Soft Tissue Sarcoma; Oncology: Unspecified Solid Tumor",(N/A); ALK; EGFR; First line; Fourth line or greater; HER2 negative; Merkel; PD-1 Naive; PD-1 Refractory; PD-L1 Naive; PD-L1 Positive; PD-L1 Refractory; Pulmonary; Second line; Stage III; Stage IV; Third line; Triple receptor negative; Untreated,"Breast Neoplasms; Carcinoma; Carcinoma, Hepatocellular; Carcinoma, Merkel Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Carcinoma, Small Cell; Carcinoma, Squamous Cell; Colorectal Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Ewing Sarcoma; Fallopian Tube Neoplasms; Fibrosarcoma; Head and Neck Neoplasms; Kidney Neoplasms; Leiomyosarcoma; Liposarcoma; Liver Cancer; Liver Neoplasms; Lung Neoplasms; Melanoma; Neoplasms, Unknown Primary; Neuroendocrine Tumors; Osteosarcoma; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Peritoneal Neoplasms; Prostatic Neoplasms; Renal Cancer; Rhabdomyosarcoma; Sarcoma; Small Cell Lung Carcinoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Stomach Carcinoma; Stomach Neoplasms; Synovial Sarcoma; Uterine Cervical Neoplasms; Wilms Tumor",Australia; United States
A Phase I Study of ASTX727 Plus Talazoparib in Patients With Triple Negative or Hormone Resistant/ Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Metastatic Breast Cancer,I,Open,"Otsuka Holdings/Otsuka Pharmaceutical/Astex Pharmaceuticals {SuperGen}
Pfizer;
Van Andel Research Institute",Oncology: Breast,Estrogen receptor positive; HER2 negative; Progesterone receptor positive; Second line; Stage IV; Triple receptor negative,Breast Neoplasms; Triple Negative Breast Neoplasms,United States
A Phase I/II Clinical Trial of FlowVax(TM) Peptide Vaccine in Breast Cancer Patients.,I/II,Planned,Flow Pharma,Oncology: Breast; Oncology: Cervical,(N/A); Line of therapy N/A,Breast Neoplasms; Uterine Cervical Neoplasms,China; United States
A Phase I Dose Escalation Trial of Alpha-Tocopheryloxyacetic Acid (a-TEA) in Patients With Treatment Refractory HER2+ Metastatic Breast Cancer,I,Open,"University of Washington
Veana Therapeutics",Oncology: Breast,Estrogen receptor positive; HER2 positive; Progesterone receptor positive; Second line; Stage IV,Breast Neoplasms; Carcinoma,United States
"Phase I/IIa, Non-Randomised, Open-Label Dose Escalation and Expansion Trial With Isunakinra Alone and in Combination With a PD-1/PD-L1 Inhibitor in Patients With Metastatic or Unresectable, Locally Advanced Malignant Solid Tumors.",I/II,Open,"Baylor Research Institute
Buzzard Pharmaceuticals",Oncology: Bile Duct (Cholangiocarcinoma); Oncology: Breast; Oncology: Colorectal; Oncology: Prostate; Oncology: Unspecified Solid Tumor,Fourth line or greater; PD-1 Naive; PD-1 Refractory; PD-L1 Naive; PD-L1 Refractory; Second line; Stage III; Stage IV; Third line,"Bile Duct Neoplasms; Breast Neoplasms; Cholangiocarcinoma; Colorectal Neoplasms; Neoplasms; Neoplasms, Unknown Primary; Prostatic Neoplasms",United States
Phase Ib/II Trial of Copanlisib in Combination With Trastuzumab and Pertuzumab After Induction Treatment of HER2 Positive (HER2+) Metastatic Breast Cancer (MBC) With PIK3CA Mutation or PTEN Mutation,I/II,Open,National Institutes of Health/National Cancer Institute;,Oncology: Breast,Estrogen receptor positive; HER2 positive; Progesterone receptor positive; Second line; Stage III; Stage IV,Breast Neoplasms; Carcinoma,United States
"A Multicenter Phase I, Open-Label Study of SQ3370 in Patients With Advanced Solid Tumors.",I,Open,Shasqi,Oncology: Breast; Oncology: Head/Neck; Oncology: Neuroendocrine; Oncology: Ovarian; Oncology: Soft Tissue Sarcoma; Oncology: Unspecified Solid Tumor,First line; Fourth line or greater; HER2 negative; Locally advanced; Merkel; Second line; Stage III; Stage IV; Third line; Triple receptor negative,"Breast Neoplasms; Fibrosarcoma; Head and Neck Neoplasms; Leiomyosarcoma; Liposarcoma; Neoplasms, Unknown Primary; Neuroendocrine Tumors; Ovarian Neoplasms; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Synovial Sarcoma; Unspecified",Australia; United States
A Phase 1-2 Dose-Escalation and Cohort-Expansion Study of Intravenous Zotatifin (eFT226) in Subjects With Selected Advanced Solid Tumor Malignancies,I/II,Open,eFFECTOR Therapeutics,"Oncology: Bile Duct (Cholangiocarcinoma); Oncology: Breast; Oncology: Colorectal; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Pancreas; Oncology: Unspecified Solid Tumor",Estrogen receptor positive; FGFR; Fourth line or greater; HER2 negative; HER2 positive; KRAS; PD-1 Refractory; PD-L1 Refractory; Second line; Stage III; Stage IV; Third line,"Bile Duct Neoplasms; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Cholangiocarcinoma; Colorectal Neoplasms; Melanoma; Neoplasms; Neoplasms, Unknown Primary; Pancreatic Cancer; Pancreatic Neoplasms; Stomach Carcinoma; Stomach Neoplasms",United States
"A Phase I/II Safety, Tolerability and Efficacy Study of ST101 In Adult Patients with Unresectable and Metastatic, Advanced HR Positive Breast Cancer, Glioblastoma, Melanoma and Castration-Resistant Prostate Cancer.",I/II,Open,Sapience Therapeutics,"Oncology: Breast; Oncology: CNS, Glioblastoma; Oncology: Esophageal; Oncology: Liver; Oncology: Melanoma; Oncology: Prostate; Oncology: Small Intestine; Oncology: Soft Tissue Sarcoma; Oncology: Unspecified Solid Tumor",(N/A); BRAF; Estrogen receptor positive; Fourth line or greater; HER2 positive; Hormone refractory; Line of therapy N/A; Metastatic; PD-1 Refractory; PD-L1 Refractory; Progesterone receptor positive; Second line; Stage III; Stage IV; Third line,"Breast Neoplasms; Esophageal Neoplasms; Fibrosarcoma; Glioblastoma; Intestinal Neoplasms; Leiomyosarcoma; Liposarcoma; Liver Neoplasms; Melanoma; Neoplasms, Unknown Primary; Prostatic Neoplasms; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Synovial Sarcoma",United Kingdom; United States
"An Open-label, Phase I, First-in-human, Dose Escalation and Expansion Study to Evaluate the Safety, Tolerability, Maximum Tolerated or Administered Dose, Pharmacokinetics, Pharmacodynamics and Tumor Response Profile of the Aryl Hydrocarbon Receptor Inhibitor (AhRi) BAY 2416964 in Participants With Advanced Solid Tumors",I,Open,"MD Anderson Cancer Center University of Texas;
Royal Marsden NHS Trust
Bayer AG
Prisma Health","Oncology: Bladder; Oncology: Breast; Oncology: Colorectal; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Pancreas; Oncology: Renal; Oncology: Unspecified Solid Tumor",Fourth line or greater; MSS/pMMR; Second line; Stage III; Stage IV; Third line,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Colorectal Neoplasms; Head and Neck Neoplasms; Kidney Neoplasms; Neoplasms; Neoplasms, Unknown Primary; Pancreatic Neoplasms; Renal Cancer; Urethral Neoplasms; Urinary Bladder Neoplasms; Wilms Tumor",Canada; China; Germany; Spain; United Kingdom; United States
"A First-in-human, Two-part Clinical Study to Assess the Safety, Tolerability and Activity of IV Doses of ICT01 as Monotherapy and in Combination With a Checkpoint Inhibitor, in Patients With Advanced-stage, Relapsed/Refractory Cancer.

EValuation of ICT01 in Immuno-ONcology (EVICTION).",I/II,Open,ImCheck Therapeutics,"Oncology: Bladder; Oncology: Breast; Oncology: Cervical; Oncology: Colorectal; Oncology: Gastric; Oncology: Head/Neck; Oncology: Leukemia, Acute Lymphocytic; Oncology: Leukemia, Acute Myelogenous; Oncology: Lung, Non-Small Cell; Oncology: Lymphoma, Non-Hodgkin's; Oncology: Melanoma; Oncology: Ovarian; Oncology: Pancreas; Oncology: Prostate; Oncology: Unspecified Hematological Cancer; Oncology: Unspecified Solid Tumor",Aggressive; Diffuse large B-cell lymphoma (DLBCL); Follicular lymphoma (FL); Indolent; PD-1 Refractory; PD-L1 Refractory; Second line; Stage III; Stage IV,"Acute Myelocytic Leukemia; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Head and Neck Neoplasms; Hematologic Neoplasms; Leukemia, Myeloid, Acute; Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Large-Cell, Anaplastic; Lymphoma, Non-Hodgkin; Melanoma; Neoplasms, Unknown Primary; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prostatic Neoplasms; Stomach Carcinoma; Stomach Neoplasms; Unspecified; Urethral Neoplasms; Urinary Bladder Neoplasms; Uterine Cervical Neoplasms",Belgium; France; Germany; Spain; United Kingdom; United States
"A Phase I, Open-label, Dose Finding Study to Assess the Safety, Tolerability, PK, and Preliminary Efficacy of OBT076, a CD205-directed ADC, in Recurrent and/or Metastatic CD205+ Solid Tumors and CD205+ HER2-negative Metastatic Breast Cancer",I,Open,Oxford BioTherapeutics,"Oncology: Bladder; Oncology: Breast; Oncology: Gastric; Oncology: Lung, Non-Small Cell; Oncology: Ovarian; Oncology: Renal; Oncology: Thymus; Oncology: Thyroid; Oncology: Unspecified Solid Tumor",Estrogen receptor positive; HER2 negative; Locally advanced; Metastatic; PD-L1 Positive; Progesterone receptor positive; Second line; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Kidney Neoplasms; Neoplasms; Neoplasms, Unknown Primary; Ovarian Neoplasms; Stomach Carcinoma; Stomach Neoplasms; Thymus Neoplasms; Thyroid Neoplasms; Urethral Neoplasms; Urinary Bladder Neoplasms; Wilms Tumor",Belgium; France; Greece; United States
"A Phase 1-2 Multicenter, Open-Label, Dose-Escalation Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of ABN401 in Patients With Advanced Solid Tumors and Dose-Expansion in Patients With Non-Small Cell Lung Cancer Harboring c-MET Dysregulation",I/II,Open,Abion,"Oncology: Breast; Oncology: Colorectal; Oncology: Endometrial; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Pancreas; Oncology: Prostate; Oncology: Soft Tissue Sarcoma; Oncology: Unspecified Solid Tumor",Locally advanced; MET Amplification/Alteration; Metastatic; Second line; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Endometrial Neoplasms; Fibrosarcoma; Leiomyosarcoma; Liposarcoma; Melanoma; Neoplasms, Unknown Primary; Pancreatic Neoplasms; Prostatic Neoplasms; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Synovial Sarcoma",Australia; South Korea; United States
"A Phase I, First-in-human Study of the Safety, Single- and Multiple-Dose Pharmacokinetics, and Preliminary Activity of Escalating Doses of RBN-2397, an Oral PARP7 Inhibitor, in Patients With Solid Tumors",I,Open,Ribon Therapeutics,"Oncology: Breast; Oncology: Colorectal; Oncology: Endometrial; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Lung, Small Cell; Oncology: Lymphoma, Non-Hodgkin's; Oncology: Neuroendocrine; Oncology: Pancreas; Oncology: Unspecified Solid Tumor",(N/A); Aggressive; Estrogen receptor positive; HER2 negative; Mantle cell lymphoma (MCL); PD-1 Refractory; PD-L1 Refractory; Progesterone receptor positive; Pulmonary; Second line; Squamous Cell; Stage III; Stage IV; Third line,"Breast Neoplasms; Carcinoma, Endometrioid; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Colorectal Neoplasms; Endometrial Neoplasms; Head and Neck Neoplasms; Lymphoma, Large-Cell, Anaplastic; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Neoplasms; Neoplasms, Unknown Primary; Neuroendocrine Tumors; Pancreatic Cancer; Pancreatic Neoplasms; Small Cell Lung Carcinoma",Spain; United States
A Phase I Study of StemVacs-V in Patients with Metastatic Breast Cancer,I,Planned,Therapeutic Solutions International,Oncology: Breast,Line of therapy N/A; Stage IV,Breast Neoplasms,United States
"A Phase I Study of FF-10850 Topotecan Liposome Injection in Advanced Solid Tumors Including Ovarian and Cervical Carcinoma, Sarcomas, and Neuroendocrine Tumors Including Small Cell Lung Cancer and Merkel Cell Carcinoma",I,Open,Fujifilm Corporation/Fujifilm Pharmaceuticals U.S.A.,"Oncology: Breast; Oncology: Cervical; Oncology: Endometrial; Oncology: Lung, Small Cell; Oncology: Neuroendocrine; Oncology: Osteosarcoma; Oncology: Ovarian; Oncology: Pancreas; Oncology: Prostate; Oncology: Soft Tissue Sarcoma; Oncology: Unspecified Solid Tumor",Merkel; Metastatic; Pulmonary; Second line; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Small Cell; Endometrial Neoplasms; Ewing Sarcoma; Fibrosarcoma; Leiomyosarcoma; Liposarcoma; Neoplasms; Neoplasms, Unknown Primary; Neuroendocrine Tumors; Osteosarcoma; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Neoplasms; Prostatic Neoplasms; Rhabdomyosarcoma; Sarcoma; Small Cell Lung Carcinoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Synovial Sarcoma; Uterine Cervical Neoplasms",United States
Phase I/II Study to Evaluate Antibody-Drug Conjugate Sacituzumab Govitecan in Combination With PARP Inhibitor Talazoparib in Patients With Metastatic Breast Cancer,I/II,Open,"Pfizer;
Massachusetts General Hospital",Oncology: Breast,Fourth line or greater; HER2 negative; Second line; Stage IV; Third line; Triple receptor negative,Breast Neoplasms,United States
A Phase Ib/II Study of Onvansertib in Combination With Paclitaxel in Triple-negative Metastatic Breast Cancer Patients,I/II,Open,"Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute;
Cardiff Oncology {Trovagene}",Oncology: Breast,First line; HER2 negative; Second line; Stage III; Stage IV; Triple receptor negative,Breast Neoplasms,United States
"A Phase I, Multi-Center, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Evidence of Antitumor Activity of JAB-3312 in Adult Patients With Advanced Solid Tumors",I,Open,Beijing Jacobio Pharmaceuticals Co.,"Oncology: Breast; Oncology: Colorectal; Oncology: Esophageal; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Pancreas",BRAF; BRCA; First line; KRAS; Second line; Stage III; Stage IV,"Breast Neoplasms; Carcinoma; Carcinoma, Ductal; Carcinoma, Non-Small-Cell Lung; Carcinoma, Pancreatic Ductal; Carcinoma, Squamous Cell; Colorectal Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Head and Neck Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Squamous Cell Carcinoma of Head and Neck",United States
"A Phase I, Dose Escalation Safety and Tolerability Study of VAXINIA (CF33- hNIS), Administered Intratumorally or Intravenously as a Monotherapy or in Combination with Pembrolizumab in Adult Patients with Metastatic or Advanced Solid Tumours (MAST)",I,Open,Imugene {Biolife Science},"Oncology: Bladder; Oncology: Breast; Oncology: Colorectal; Oncology: Gastric; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Renal; Oncology: Unspecified Solid Tumor",HER2 negative; PD-1 Refractory; PD-L1 Refractory; Stage III; Stage IV; Third line; Triple receptor negative,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Colorectal Neoplasms; Head and Neck Neoplasms; Kidney Neoplasms; Melanoma; Neoplasms; Neoplasms, Unknown Primary; Renal Cancer; Stomach Carcinoma; Stomach Neoplasms; Urethral Neoplasms; Urinary Bladder Neoplasms; Wilms Tumor",Australia; United States
A Multicenter Open-label Phase I/Ib Study to Evaluate the Safety and Preliminary Efficacy of SO-C101 as Monotherapy and in Combination With Pembrolizumab in Patients With Selected Advanced/Metastatic Solid Tumors,I,Open,Sotio,"Oncology: Anal; Oncology: Bladder; Oncology: Breast; Oncology: Cervical; Oncology: Colorectal; Oncology: Gastric; Oncology: Head/Neck; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Lung, Small Cell; Oncology: Melanoma; Oncology: Mesothelioma; Oncology: Neuroendocrine; Oncology: Ovarian; Oncology: Renal; Oncology: Skin, Squamous Cell Carcinoma (cSCC); Oncology: Thymus; Oncology: Thyroid; Oncology: Unspecified Solid Tumor",Fourth line or greater; HER2 negative; Merkel; PD-1 Naive; PD-1 Refractory; PD-L1 Naive; PD-L1 Refractory; Pulmonary; Second line; Stage III; Stage IV; Third line; Triple receptor negative,"Anus Neoplasms; Biliary Tract Neoplasms; Breast Neoplasms; Carcinoma; Carcinoma, Hepatocellular; Carcinoma, Merkel Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Carcinoma, Small Cell; Carcinoma, Squamous Cell; Colorectal Neoplasms; Head and Neck Neoplasms; Kidney Neoplasms; Liver Cancer; Liver Neoplasms; Lung Neoplasms; Melanoma; Mesothelioma; Mesothelioma, Malignant; Microsatellite Instability; Neoplasms, Mesothelial; Neoplasms, Unknown Primary; Neuroendocrine Tumors; Ovarian Cancer; Ovarian Neoplasms; Renal Cancer; Small Cell Lung Carcinoma; Squamous Cell Carcinoma of Head and Neck; Stomach Carcinoma; Stomach Neoplasms; Thymus Neoplasms; Thyroid Neoplasms; Triple Negative Breast Neoplasms; Urethral Neoplasms; Urinary Bladder Neoplasms; Uterine Cervical Neoplasms; Wilms Tumor",Czech Republic; France; Spain; United States
Phase I/IIA Safety and Efficacy Study of IMSA101 in Patients With Advanced Treatment-Refractory Malignancies,I/II,Open,ImmuneSensor Therapeutics,"Oncology: Breast; Oncology: Esophageal; Oncology: Gastric; Oncology: Head/Neck; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Renal",HER2 negative; PD-1 Refractory; PD-L1 Refractory; Second line; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Esophageal Cancer; Esophageal Neoplasms; Head and Neck Neoplasms; Kidney Neoplasms; Liver Cancer; Liver Neoplasms; Melanoma; Neoplasms; Renal Cancer; Stomach Carcinoma; Stomach Neoplasms; Wilms Tumor",United States
"An Open-Label, Multicenter Phase 1/2 Dose Escalation and Expansion Study of THOR-707 as a Single Agent and as a Combination Therapy in Adult Subjects With Advanced or Metastatic Solid Tumors.",I/II,Open,Sanofi;/Synthorx,"Oncology: Bladder; Oncology: Breast; Oncology: Colorectal; Oncology: Esophageal; Oncology: Gastric; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Pancreas; Oncology: Prostate; Oncology: Renal; Oncology: Unspecified Solid Tumor",Adenocarcinoma; Estrogen receptor positive; Fourth line or greater; HER2 negative; HER2 positive; Large Cell; PD-1 Naive; PD-1 Refractory; Second line; Squamous Cell; Stage III; Stage IV; Third line; Triple receptor negative,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Colorectal Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Head and Neck Neoplasms; Kidney Neoplasms; Melanoma; Neoplasm Metastasis; Neoplasms, Unknown Primary; Pancreatic Cancer; Pancreatic Neoplasms; Prostatic Neoplasms; Renal Cancer; Stomach Carcinoma; Stomach Neoplasms; Urethral Neoplasms; Urinary Bladder Neoplasms; Wilms Tumor",Australia; Austria; Singapore; Spain; United Kingdom; United States
"A Phase I, Open Label, Dose-Escalation and Expansion Study to Evaluate the Safety, Pharmacokinetics and Initial Therapeutic Activity of AVA6000, a Novel FAP-activated Doxorubicin Prodrug Administered Intravenously in Patients With Locally Advanced or Metastatic Selected Solid Tumours",I,Open,Avacta,"Oncology: Bile Duct (Cholangiocarcinoma); Oncology: Bladder; Oncology: Breast; Oncology: Colorectal; Oncology: Esophageal; Oncology: Gastric; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Ovarian; Oncology: Pancreas; Oncology: Prostate; Oncology: Soft Tissue Sarcoma; Oncology: Unspecified Solid Tumor",Metastatic; Second line; Stage III; Stage IV; Unresectable,"Bile Duct Neoplasms; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Cholangiocarcinoma; Colorectal Neoplasms; Esophageal Neoplasms; Fibrosarcoma; Head and Neck Neoplasms; Leiomyosarcoma; Liposarcoma; Neoplasms, Unknown Primary; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Prostatic Neoplasms; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Stomach Carcinoma; Stomach Neoplasms; Synovial Sarcoma; Urethral Neoplasms; Urinary Bladder Neoplasms",United Kingdom; United States
"A Phase I/II, Open-Label, Dose-Escalation Study of CRX100 in Patients With Advanced Solid Tumors",I/II,Open,BioEclipse Therapeutics,Oncology: Breast; Oncology: Colorectal; Oncology: Gastric; Oncology: Liver; Oncology: Osteosarcoma; Oncology: Ovarian; Oncology: Unspecified Solid Tumor,(N/A); HER2 negative; Second line; Stage III; Stage IV; Triple receptor negative,"Breast Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Ovarian Epithelial; Colorectal Neoplasms; Ewing Sarcoma; Liver Cancer; Liver Neoplasms; Neoplasms, Unknown Primary; Osteosarcoma; Ovarian Cancer; Ovarian Neoplasms; Stomach Carcinoma; Stomach Neoplasms; Triple Negative Breast Neoplasms",United States
"A First-in-human, Open-label Dose Escalation Followed by Dose Expansion Phase I/IIa Trial to Evaluate the Safety, Preliminary Efficacy and Pharmacokinetics of Intratumoral CyPep-1 Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Solid Cancers.",I/II,Open,"Merck & Co.
Cytovation",Oncology: Breast; Oncology: Head/Neck; Oncology: Melanoma,HER2 negative; PD-1 Refractory; PD-L1 Refractory; Second line; Stage III; Stage IV; Triple receptor negative,Breast Neoplasms; Head and Neck Neoplasms; Melanoma; Neoplasms,France; Germany; Netherlands; Spain; United Kingdom; United States
"Adoptive Immunotherapy for Advanced MUC1* Positive Breast Cancer With Autologous T Cells Engineered to Express a Chimeric Antigen Receptor, huMNC2-CAR44 Specific for a Cleaved Form of MUC1 (MUC1*)",I/II,Open,"Fred Hutchinson Cancer Research Center
City of Hope Comprehensive Cancer Center
Minerva Biotechnologies",Oncology: Breast,Estrogen receptor positive; Fourth line or greater; HER2 negative; HER2 positive; Progesterone receptor positive; Stage IV; Third line; Triple receptor negative,Breast Neoplasms,United States
"First-in-human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety of GEN1046 in Subjects With Malignant Solid Tumors",I/II,Open,"Genmab
BioNTech","Oncology: Bladder; Oncology: Breast; Oncology: Cervical; Oncology: Colorectal; Oncology: Endometrial; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Ovarian; Oncology: Pancreas; Oncology: Renal; Oncology: Unspecified Solid Tumor",Fourth line or greater; HER2 negative; PD-L1 Positive; Second line; Stage III; Stage IV; Third line; Triple receptor negative,"Breast Neoplasms; Carcinoma; Carcinoma, Endometrioid; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Colorectal Neoplasms; Endometrial Neoplasms; Head and Neck Neoplasms; Kidney Neoplasms; Neoplasms, Unknown Primary; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Renal Cancer; Squamous Cell Carcinoma of Head and Neck; Triple Negative Breast Neoplasms; Urethral Neoplasms; Urinary Bladder Neoplasms; Uterine Cervical Neoplasms; Wilms Tumor",Belgium; Czech Republic; Germany; Hungary; Israel; Italy; Japan; Poland; Spain; United States
Expanded Access for the Treatment of Cancers With Rearranged During Transfection (RET) Activation,I/II,Open,Eli Lilly/Loxo Oncology,"Oncology: Breast; Oncology: Colorectal; Oncology: Lung, Non-Small Cell; Oncology: Neuroendocrine; Oncology: Pancreas; Oncology: Renal; Oncology: Thyroid; Oncology: Unspecified Solid Tumor",(N/A); Fourth line or greater; Medullary; Papillary; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Colorectal Neoplasms; Kidney Neoplasms; Neoplasms, Unknown Primary; Neuroendocrine Tumors; Pancreatic Cancer; Pancreatic Neoplasms; Renal Cancer; Thyroid Cancer, Papillary; Thyroid Diseases; Thyroid Neoplasms; Wilms Tumor","Australia; France; Germany; Hong Kong, S.A.R., China; Israel; Italy; Japan; Netherlands; New Zealand; Poland; Singapore; South Korea; Spain; Switzerland; United States"
"A Phase I, Open-Label Study of ABSK021 to Assess Safety, Tolerability, and Pharmacokinetics in Patients With Advanced Solid Tumor",I,Open,Abbisko Therapeutics Co.,"Oncology: Breast; Oncology: Colorectal; Oncology: Esophageal; Oncology: Lung, Non-Small Cell; Oncology: Lung, Small Cell; Oncology: Neuroendocrine; Oncology: Pancreas; Oncology: Soft Tissue Sarcoma; Oncology: Tenosynovial Giant Cell Tumor; Oncology: Thymus; Oncology: Unspecified Solid Tumor",Diffuse; Extensive; HER2 negative; Localized; Pulmonary; Second line; Stage III; Stage IV; Thymoma; Triple receptor negative,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Esophageal Neoplasms; Fibrosarcoma; Giant Cell Tumor of Tendon Sheath; Leiomyosarcoma; Liposarcoma; Neoplasms, Unknown Primary; Neuroendocrine Tumors; Pancreatic Cancer; Pancreatic Neoplasms; Rhabdomyosarcoma; Sarcoma; Small Cell Lung Carcinoma; Synovial Sarcoma; Synovitis, Pigmented Villonodular; Thymoma; Thymus Neoplasms; Unspecified",Australia; China; United States
"A Phase I/II Open Label, Dose Escalation and Expansion Study of MDNA11, IL-2 Superkine, Administered Alone or in Combination With Immune Checkpoint Inhibitor in Patients With Advanced Solid Tumors

The ABILITY (A Beta-only IL-2 ImmunoTherapY) study",I/II,Open,Medicenna Therapeutics,"Oncology: Bile Duct (Cholangiocarcinoma); Oncology: Bladder; Oncology: Breast; Oncology: Cervical; Oncology: Colorectal; Oncology: Endometrial; Oncology: Esophageal; Oncology: Gallbladder; Oncology: Gastric; Oncology: Head/Neck; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Mesothelioma; Oncology: Neuroendocrine; Oncology: Pancreas; Oncology: Renal; Oncology: Skin, Basal Cell Carcinoma; Oncology: Skin, Squamous Cell Carcinoma (cSCC); Oncology: Soft Tissue Sarcoma; Oncology: Unspecified Solid Tumor",(N/A); Adenocarcinoma; Fourth line or greater; HER2 negative; Large Cell; Line of therapy N/A; Merkel; Metastatic; Second line; Squamous Cell; Stage III; Stage IV; Third line; Triple receptor negative; Unresectable,"Bile Duct Neoplasms; Biliary Tract Neoplasms; Breast Neoplasms; Carcinoma; Carcinoma, Basal Cell; Carcinoma, Merkel Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Carcinoma, Squamous Cell; Cholangiocarcinoma; Cholangiocarcinoma; Colorectal Neoplasms; Endometrial Neoplasms; Esophageal Neoplasms; Fibrosarcoma; Gallbladder Neoplasms; Head and Neck Neoplasms; Kidney Neoplasms; Leiomyosarcoma; Liposarcoma; Liver Neoplasms; Lung Neoplasms; Melanoma; Mesothelioma; Neoplasms; Neoplasms, Basal Cell; Neoplasms, Unknown Primary; Neuroendocrine Tumors; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Neoplasms; Renal Cancer; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Squamous Cell Carcinoma of Head and Neck; Stomach Carcinoma; Stomach Neoplasms; Synovial Sarcoma; Triple Negative Breast Neoplasms; Urethral Neoplasms; Urinary Bladder Neoplasms; Uterine Cervical Neoplasms; Uterine Neoplasms; Wilms Tumor",Australia; Canada; United Kingdom; United States
"Open Label, Multicenter, Phase I Study to Evaluate the Maximum Tolerated Dose of Orally Administered CB-03-10 With Dose Expansion Phase, in Subjects With Advanced Solid Tumors",I,Open,Cosmo Pharmaceuticals,Oncology: Breast; Oncology: Colorectal; Oncology: Pancreas; Oncology: Prostate; Oncology: Unspecified Solid Tumor,HER2 negative; Hormone refractory; Second line; Stage III; Stage IV; Triple receptor negative,"Breast Neoplasms; Colorectal Neoplasms; Neoplasms; Neoplasms, Unknown Primary; Pancreatic Cancer; Pancreatic Neoplasms; Prostatic Neoplasms",United States
"A Phase I/IIa Open-label, Multi-center Study to Evaluate the Safety, Tolerability, Whole-body Distribution, Radiation Dosimetry and Anti-tumor Activity of [177Lu]-NeoB Administered in Patients With Advanced Solid Tumors Known to Overexpress Gastrin-releasing Peptide Receptor (GRPR)",I/II,Open,Novartis;/Advanced Accelerator Applications,"Oncology: Breast; Oncology: CNS, Glioblastoma; Oncology: GIST; Oncology: Lung, Non-Small Cell; Oncology: Prostate; Oncology: Unspecified Solid Tumor",Second line; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Gastrointestinal Stromal Tumors; Glioblastoma; Neoplasms, Unknown Primary; Prostatic Neoplasms; Unspecified",Austria; Germany; Netherlands; Spain; United Kingdom; United States
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XL092 as Single-Agent and Combination Therapy in Subjects With Inoperable Locally Advanced or Metastatic Solid Tumors,I,Open,Exelixis,"Oncology: Bladder; Oncology: Breast; Oncology: Colorectal; Oncology: Lung, Non-Small Cell; Oncology: Prostate; Oncology: Renal",Estrogen receptor positive; HER2 negative; HER2 positive; PD-1 Naive; PD-1 Refractory; PD-L1 Naive; PD-L1 Refractory; Progesterone receptor positive; Second line; Stage III; Stage IV,"Breast Neoplasms; Carcinoma; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Colorectal Neoplasms; Kidney Neoplasms; Neoplasms; Prostatic Neoplasms; Renal Cancer; Urethral Neoplasms; Urinary Bladder Neoplasms; Wilms Tumor",Australia; Czech Republic; France; Spain; United Kingdom; United States
Assessing the Immunogenicity of pING-hHER3FL in Patients With Resected Malignancies,I,Open,Duke University Medical Center,"Oncology: Bladder; Oncology: Breast; Oncology: Cervical; Oncology: Colorectal; Oncology: Endometrial; Oncology: Esophageal; Oncology: Gastric; Oncology: Head/Neck; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Neuroendocrine; Oncology: Ovarian; Oncology: Pancreas; Oncology: Prostate",Pulmonary; Second line; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Endometrioid; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Endometrial Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Head and Neck Neoplasms; Liver Cancer; Liver Neoplasms; Neoplasms; Neuroendocrine Tumors; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Prostatic Neoplasms; Stomach Carcinoma; Stomach Neoplasms; Urethral Neoplasms; Urinary Bladder Neoplasms; Uterine Cervical Neoplasms",United States
"A Phase I First-in Human, Multi-Center, Open Label Dose-Escalation Study to Determine the Safety, Tolerability, Pharmacokinetics and RP2D of ABBV-151 as a Single Agent and in Combination With ABBV-181 in Subjects With Locally Advanced or Metastatic Solid Tumors",I,Open,AbbVie;,"Oncology: Bladder; Oncology: Breast; Oncology: Colorectal; Oncology: Head/Neck; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Pancreas; Oncology: Renal; Oncology: Unspecified Solid Tumor",Fourth line or greater; HER2 negative; MSS/pMMR; PD-1 Naive; PD-1 Refractory; PD-L1 Naive; PD-L1 Refractory; Second line; Stage III; Stage IV; Third line; Triple receptor negative,"Breast Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Colorectal Neoplasms; Head and Neck Neoplasms; Kidney Neoplasms; Liver Cancer; Liver Neoplasms; Neoplasms; Neoplasms, Unknown Primary; Pancreatic Cancer; Pancreatic Neoplasms; Renal Cancer; Urethral Neoplasms; Urinary Bladder Neoplasms; Wilms Tumor","Australia; Belgium; Canada; France; Israel; Japan; Puerto Rico; South Korea; Spain; Taiwan, China; United States"
"A Phase I/IIa Open Label, Multicenter Study to Access the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of AFM24 in Patients With Advanced Solid Tumors",I/II,Open,Affimed {Affimed Therapeutics AG},"Oncology: Bladder; Oncology: Breast; Oncology: Cervical; Oncology: CNS, Glioblastoma; Oncology: Colorectal; Oncology: Esophageal; Oncology: Gastric; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Ovarian; Oncology: Pancreas; Oncology: Renal",BRAF; EGFR; Fourth line or greater; KRAS; MSS/pMMR; NRAS; PD-1 Refractory; PD-L1 Refractory; Second line; Stage III; Stage IV; Third line,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Colorectal Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Glioblastoma; Head and Neck Neoplasms; Kidney Neoplasms; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Renal Cancer; Stomach Carcinoma; Stomach Neoplasms; Unspecified; Urethral Neoplasms; Urinary Bladder Neoplasms; Uterine Cervical Neoplasms; Wilms Tumor",Germany; South Korea; Spain; United Kingdom; United States
A Phase Ia/Ib Dose-escalation Study of Intravenously Administered SB 11285 Alone and in Combination With Atezolizumab in Patients With Advanced Solid Tumors,I/II,Open,"Roche;
Sino Biopharmaceutical/invoX Pharma/F-star Therapeutics {Spring Bank Pharmaceuticals}","Oncology: Bladder; Oncology: Breast; Oncology: Cervical; Oncology: Colorectal; Oncology: Endometrial; Oncology: Gastric; Oncology: Head/Neck; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Neuroendocrine; Oncology: Ovarian; Oncology: Pancreas; Oncology: Prostate; Oncology: Renal; Oncology: Thyroid; Oncology: Unspecified Solid Tumor",BRAF; HER2 negative; Merkel; PD-1 Naive; PD-1 Refractory; PD-L1 Naive; PD-L1 Refractory; Second line; Stage III; Stage IV; Triple receptor negative,"Breast Neoplasms; Carcinoma, Endometrioid; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Colorectal Neoplasms; Endometrial Neoplasms; Head and Neck Neoplasms; Kidney Neoplasms; Liver Cancer; Liver Neoplasms; Melanoma; Neoplasms, Unknown Primary; Neuroendocrine Tumors; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Prostatic Neoplasms; Renal Cancer; Squamous Cell Carcinoma of Head and Neck; Stomach Carcinoma; Stomach Neoplasms; Thyroid Neoplasms; Urethral Neoplasms; Urinary Bladder Neoplasms; Uterine Cervical Neoplasms; Wilms Tumor",United States
"An Open-Label, Multicenter, Phase I Study of RP3 as a Single Agent and in Combination With PD-1 Blockade in Patients With Solid Tumors.",I,Open,"Bristol-Myers Squibb
Replimune","Oncology: Breast; Oncology: Colorectal; Oncology: Esophageal; Oncology: Gastric; Oncology: Head/Neck; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Metastatic Cancer; Oncology: Pancreas; Oncology: Unspecified Solid Tumor",Liver mets; Second line; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Head and Neck Neoplasms; Liver Cancer; Liver Neoplasms; Melanoma; Neoplasm Metastasis; Neoplasms; Neoplasms, Unknown Primary; Pancreatic Cancer; Pancreatic Neoplasms; Stomach Carcinoma; Stomach Neoplasms",France; Spain; United Kingdom; United States
tGLI1 as a Therapeutic Target in Brain Metastases: A Window of Opportunity Study in Breast Cancer Brain Metastases and Primary Gliomas,I,Open,"National Institutes of Health/National Cancer Institute;
(Other Hospital/Academic/Medical Center);","Oncology: Breast; Oncology: CNS, Glioblastoma; Oncology: CNS, Other; Oncology: Metastatic Cancer",CNS mets; Estrogen receptor positive; HER2 negative; HER2 positive; Neoadjuvant; Progesterone receptor positive; Stage IV; Triple receptor negative,Astrocytoma; Brain Neoplasms; Breast Neoplasms; Carcinoma; Central Nervous System Neoplasms; Glioblastoma; Glioma; Neoplasm Metastasis; Oligodendroglioma,United States
A Phase IB Trial of Neoadjuvant Multi-Epitope HER2 Peptide Vaccine in Patients With HER2-Expressing DCIS,I/II,Open,"National Institutes of Health/National Cancer Institute;
Mayo Clinic;",Oncology: Breast,HER2 positive; Neoadjuvant; Stage 0,"Breast Neoplasms; Carcinoma; Carcinoma in Situ; Carcinoma, Ductal; Carcinoma, Ductal, Breast; Carcinoma, Intraductal, Noninfiltrating; Unspecified",United States
An Open-Label Multicenter Phase Ib Study of AN0025 in Combination With Pembrolizumab in Patients With Advanced Solid Tumors,I,Open,"Merck & Co./Merck Sharp & Dohme (MSD)
Adlai Nortye Biopharma Co.","Oncology: Bladder; Oncology: Breast; Oncology: Cervical; Oncology: Colorectal; Oncology: Lung, Non-Small Cell; Oncology: Unspecified Solid Tumor",Adenocarcinoma; Fourth line or greater; HER2 negative; Large Cell; MSS/pMMR; Other subtype; PD-1 Naive; PD-1 Refractory; PD-L1 Naive; PD-L1 Positive; PD-L1 Refractory; Second line; Squamous Cell; Stage III; Stage IV; Third line; Triple receptor negative,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Neoplasms, Unknown Primary; Triple Negative Breast Neoplasms; Urethral Neoplasms; Urinary Bladder Neoplasms; Uterine Cervical Neoplasms",France; United States
"In Situ Vaccination With Flt3L, Radiation, and Poly-ICLC Combined With Pembrolizumab in Patients With Non-Hodgkin's Lymphoma, Metastatic Breast Cancer, and Head and Neck Squamous Cell Carcinoma",I/II,Open,"Icahn School of Medicine at Mount Sinai {Mount Sinai School of Medicine}
Celldex Therapeutics {AVANT Immunotherapeutics {Medarex/Celldex Therapeutics {Alteris Therapeutics}}}
Merck & Co./Merck Sharp & Dohme (MSD)","Oncology: Breast; Oncology: Head/Neck; Oncology: Leukemia, Chronic Lymphocytic; Oncology: Lymphoma, Non-Hodgkin's",Aggressive; Cutaneous T-cell lymphoma (CTCL); Extranodal marginal zone B-cell lymphoma (MALT); First line; Follicular lymphoma (FL); Indolent; Mantle cell lymphoma (MCL); Other subtype; Second line; Small lymphocytic lymphoma (SLL); Stage IV; Waldenstrom's macroglobulinemia (WM),"Breast Neoplasms; Carcinoma; Carcinoma, Squamous Cell; Chronic Lymphocytic Leukemia; Head and Neck Neoplasms; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma; Lymphoma, B-Cell, Marginal Zone; Lymphoma, Follicular; Lymphoma, Large-Cell, Anaplastic; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Lymphoma, T-Cell, Cutaneous; Squamous Cell Carcinoma of Head and Neck; Waldenstrom Macroglobulinemia",United States
"A Phase I/IIa, Multicenter, Open-Label Study to Assess the Safety, Tolerability, Pharmacokinetics of ICP-192 in Patients With Advanced Solid Malignancies",I/II,Open,Beijing InnoCare Pharma Tech Co.,Oncology: Bile Duct (Cholangiocarcinoma); Oncology: Bladder; Oncology: Breast; Oncology: Head/Neck; Oncology: Ovarian; Oncology: Unspecified Solid Tumor,FGFR; First line; Second line; Stage III; Stage IV; Unresectable,"Bile Duct Neoplasms; Breast Neoplasms; Cholangiocarcinoma; Head and Neck Neoplasms; Neoplasms, Unknown Primary; Ovarian Cancer; Ovarian Neoplasms; Unspecified; Urethral Neoplasms; Urinary Bladder Neoplasms",China; United States
A First in Human Phase I Trial of Binary Oncolytic Adenovirus in Combination With HER2-Specific Autologous CAR T Cells in Patients With Advanced HER2 Positive Solid Tumors,I,Open,"Baylor College of Medicine
(Other Hospital/Academic/Medical Center);
Tessa Therapeutics {FF CanVac}","Oncology: Bladder; Oncology: Breast; Oncology: Colorectal; Oncology: Esophageal; Oncology: Gastric; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Pancreas; Oncology: Unspecified Solid Tumor",HER2 positive; Second line; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Colorectal Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Head and Neck Neoplasms; Neoplasms, Unknown Primary; Pancreatic Cancer; Pancreatic Neoplasms; Salivary Gland Neoplasms; Squamous Cell Carcinoma of Head and Neck; Stomach Carcinoma; Stomach Neoplasms; Urethral Neoplasms; Urinary Bladder Neoplasms",United States
"A Phase IB/II, 2-stage, Open-label, Multicenter Study to Determine the Efficacy and Safety of Durvalumab (MEDI4736) + Paclitaxel and Durvalumab (MEDI4736) in Combination With Novel Oncology Therapies With or Without Paclitaxel for First-line Metastatic Triple Negative Breast Cancer",I/II,Open,AstraZeneca;,Oncology: Breast,First line; HER2 negative; PD-L1 Positive; Stage III; Stage IV; Triple receptor negative,Breast Neoplasms; Neoplasms; Triple Negative Breast Neoplasms,"Canada; Poland; South Korea; Taiwan, China; United Kingdom; United States"
Multicenter Phase I/Ib Trial of Olaparib in Combination With Vorinostat in Patients With Relapsed/Refractory and/or Metastatic Breast Cancer,I,Open,"AstraZeneca;
(Other Hospital/Academic/Medical Center);",Oncology: Breast,HER2 positive; Second line; Stage IV,Breast Neoplasms,United States
"A Phase I/II, First-in-Human, Open-Label, Dose-Escalation and Expansion Study of IMGC936 (Anti-ADAM9 Antibody Drug Conjugate) in Patients With Advanced Solid Tumors",I/II,Open,"ImmunoGen
MacroGenics","Oncology: Breast; Oncology: Colorectal; Oncology: Esophageal; Oncology: Gastric; Oncology: Lung, Non-Small Cell; Oncology: Pancreas; Oncology: Unspecified Solid Tumor",Adenocarcinoma; HER2 negative; Large Cell; Second line; Stage III; Stage IV; Triple receptor negative,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Neoplasms; Neoplasms, Unknown Primary; Pancreatic Cancer; Pancreatic Neoplasms; Stomach Carcinoma; Stomach Neoplasms",Italy; Spain; United States
"Phase I/II, Two-Part, Multicenter First-in-Human Study of DS-7300a in Subjects With Advanced Solid Malignant Tumors.",I/II,Open,Daiichi Sankyo,"Oncology: Bladder; Oncology: Breast; Oncology: Endometrial; Oncology: Esophageal; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Lung, Small Cell; Oncology: Melanoma; Oncology: Neuroendocrine; Oncology: Osteosarcoma; Oncology: Prostate; Oncology: Soft Tissue Sarcoma; Oncology: Unspecified Solid Tumor",(N/A); Adenocarcinoma; Hormone refractory; Metastatic; Pulmonary; Second line; Squamous Cell; Stage III; Stage IV; Unresectable,"Breast Neoplasms; Carcinoma, Endometrioid; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Endometrial Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Ewing Sarcoma; Fibrosarcoma; Head and Neck Neoplasms; Leiomyosarcoma; Liposarcoma; Melanoma; Neoplasms; Neoplasms, Unknown Primary; Neuroendocrine Tumors; Osteosarcoma; Prostatic Neoplasms; Rhabdomyosarcoma; Sarcoma; Small Cell Lung Carcinoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Synovial Sarcoma; Urethral Neoplasms; Urinary Bladder Neoplasms",Japan; United States
"A Phase I, Multi-center, Open-label, and Dose-finding Study to Assess the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of ATG 037 Monotherapy and Combination Therapy With Pembrolizumab in Patients With Locally Advanced or Metastatic Solid Tumors",I,Open,"Calithera Biosciences
Antengene Corporation Limited","Oncology: Breast; Oncology: Colorectal; Oncology: Gastric; Oncology: Lung, Non-Small Cell; Oncology: Pancreas; Oncology: Unspecified Hematological Cancer; Oncology: Unspecified Solid Tumor",Fourth line or greater; HER2 negative; Second line; Stage III; Stage IV; Third line; Triple receptor negative,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Hematologic Neoplasms; Neoplasms, Unknown Primary; Pancreatic Cancer; Pancreatic Neoplasms; Stomach Carcinoma; Stomach Neoplasms; Unspecified",Australia; China; United States
"An Open-Label, Multicenter, First-in-Human, Phase I Dose-Escalation and Multicohort Expansion Study of INBRX-109 in Subjects with Locally Advanced or Metastatic Solid Tumors Including Sarcomas",I,Open,Inhibrx,Oncology: Breast; Oncology: Colorectal; Oncology: Gastric; Oncology: Mesothelioma; Oncology: Osteosarcoma; Oncology: Pancreas; Oncology: Soft Tissue Sarcoma; Oncology: Unspecified Solid Tumor,Estrogen receptor positive; First line; Fourth line or greater; HER2 negative; HER2 positive; Locally advanced; Metastatic; Progesterone receptor positive; Second line; Stage III; Stage IV; Third line; Triple receptor negative,"Adenocarcinoma; Breast Neoplasms; Chondrosarcoma; Colorectal Neoplasms; Ewing Sarcoma; Fibrosarcoma; Leiomyosarcoma; Liposarcoma; Mesothelioma; Mesothelioma, Malignant; Neoplasms, Mesothelial; Neoplasms, Unknown Primary; Osteosarcoma; Pancreatic Cancer; Pancreatic Neoplasms; Rhabdomyosarcoma; Sarcoma; Sarcoma, Ewing; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Stomach Carcinoma; Stomach Neoplasms; Synovial Sarcoma",United States
"A Phase I/IIa Study of Intra-tumoral BT-001 (TG6030) Administered Alone and in Combination With Pembrolizumab in Patients With Cutaneous or, Subcutaneous Lesions or Easily Injectable Lymph Nodes of Metastatic/Advanced Solid Tumors.",I/II,Open,"Transgene
Merck & Co./Merck Sharp & Dohme (MSD)
BioInvent","Oncology: Breast; Oncology: Lung, Non-Small Cell; Oncology: Lymphoma, Non-Hodgkin's; Oncology: Melanoma; Oncology: Neuroendocrine; Oncology: Osteosarcoma; Oncology: Soft Tissue Sarcoma; Oncology: Unspecified Solid Tumor",Aggressive; HER2 negative; Indolent; Locally advanced; Merkel; Metastatic; PD-1 Naive; PD-1 Refractory; PD-L1 Naive; PD-L1 Refractory; Second line; Stage III; Stage IV; Triple receptor negative,"Breast Neoplasms; Carcinoma, Merkel Cell; Carcinoma, Non-Small-Cell Lung; Ewing Sarcoma; Fibrosarcoma; Leiomyosarcoma; Liposarcoma; Lymphoma, Large-Cell, Anaplastic; Lymphoma, Non-Hodgkin; Melanoma; Neoplasm Metastasis; Neoplasms, Unknown Primary; Neuroendocrine Tumors; Osteosarcoma; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Synovial Sarcoma; Triple Negative Breast Neoplasms",Belgium; France; United States
"Phase I/IIa Open-label Clinical Study of BI-1607, an Fc-Engineered Monoclonal Antibody to CD32b (FcγRIIB), in Combination with Trastuzumab in Subjects with HER2-positive Advanced Solid Tumors",I/II,Open,BioInvent,Oncology: Breast; Oncology: Esophageal; Oncology: Gastric; Oncology: Unspecified Solid Tumor,HER2 positive; Second line; Stage III; Stage IV; Third line,"Breast Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Neoplasms, Unknown Primary; Stomach Carcinoma; Stomach Neoplasms",Germany; Spain; United Kingdom; United States
A Phase I/II Trial of Leflunomide in Women With Previously Treated Metastatic Triple Negative Cancers,I/II,Open,Icahn School of Medicine at Mount Sinai {Mount Sinai School of Medicine},Oncology: Breast,HER2 negative; Second line; Stage IV; Triple receptor negative,Breast Diseases; Breast Neoplasms; Triple Negative Breast Neoplasms,United States
A Phase I Cellular Immunotherapy Study of Intraventricularly Administered Autologous HER2-Targeted Chimeric Antigen Receptor (HER2-CAR) T Cells in Patients With Brain and/or Leptomeningeal Metastases From HER2 Positive Cancers,I,Open,"National Institutes of Health/National Cancer Institute;
City of Hope Comprehensive Cancer Center
California Institute for Regenerative Medicine (CIRM)",Oncology: Breast; Oncology: Metastatic Cancer,CNS mets; HER2 positive; Line of therapy N/A; Stage IV,"Brain Neoplasms; Breast Neoplasms; Central Nervous System Neoplasms; Neoplasm Metastasis; Neoplasms; Neoplasms, Second Primary",United States
"Harnessing Olaparib, Palbociclib and Endocrine Therapy: A Phase I/II Trial of Olaparib, Palbociclib and Fulvestrant in Patients With BRCA Mutation-associated, Hormone Receptor-positive, Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Metastatic Breast Cancer (HOPE).",I/II,Open,Abramson Cancer Center at University of Pennsylvania Medical Center;;,Oncology: Breast,BRCA; Estrogen receptor positive; First line; HER2 negative; Progesterone receptor positive; Second line; Stage III; Stage IV; Third line,Breast Neoplasms,United States
"A Phase Ib, Multicenter, Two-Part, Open-Label Study of Trastuzumab Deruxtecan (DS-8201a), An Anti-Human Epidermal Growth Factor Receptor-2 (HER2)-Antibody Drug Conjugate (ADC), In Combination With Pembrolizumab, An Anti-PD-1 Antibody, For Subjects With Locally Advanced/Metastatic Breast Or Non-Small Cell Lung Cancer (NSCLC).",I,Open,"AstraZeneca;
Merck & Co./Merck Sharp & Dohme (MSD)
Daiichi Sankyo","Oncology: Breast; Oncology: Lung, Non-Small Cell",ALK; BRAF; EGFR; Estrogen receptor positive; First line; HER2 positive; PD-1 Naive; PD-L1 Naive; Progesterone receptor positive; Second line; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Lung Neoplasms",France; Spain; United Kingdom; United States
"A Phase I/II, Open Label, Dose Escalation, and Cohort Expansion Clinical Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ARV-471 Alone and in Combination with Palbociclib (IBRANCE) in Patients with Estrogen Receptor Positive/Human Epidermal Growth Factor Receptor 2 Negative (ER+/HER2-) Locally Advanced or Metastatic Breast Cancer, who Have Received Prior Hormonal Therapy and Chemotherapy in the Locally Advanced/Metastatic Setting",I/II,Open,"Pfizer;
Arvinas;",Oncology: Breast,Estrogen receptor positive; Fourth line or greater; HER2 negative; Second line; Stage III; Stage IV; Third line,Breast Neoplasms,United States
"A Phase Ib Clinical Trial Evaluating DCVax-Direct, Autologous Activated Dendritic Cells for Intratumoral Injection, in Patients With Unresectable Brain Metastases From Breast- or Non-Small Cell Lung Cancer",I,Planned,"Northwest Biotherapeutics
Mayo Clinic;","Oncology: Breast; Oncology: Lung, Non-Small Cell; Oncology: Metastatic Cancer",CNS mets; Estrogen receptor positive; First line; HER2 negative; HER2 positive; Progesterone receptor positive; Stage IV; Triple receptor negative,"Brain Neoplasms; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Central Nervous System Neoplasms; Lung Neoplasms; Neoplasm Metastasis; Neoplasms; Neoplasms, Second Primary",United States
Phase I Study of Autologous T Lymphocytes Expressing GD2-specific Chimeric Antigen and Constitutively Active IL-7 Receptors for the Treatment of Patients With Relapsed or Refractory Neuroblastoma and Other GD2 Positive Solid Cancers(GAIL-N),I,Open,"Baylor College of Medicine
(Other Hospital/Academic/Medical Center);",Oncology: Breast; Oncology: Melanoma; Oncology: Neuroblastoma; Oncology: Osteosarcoma; Oncology: Soft Tissue Sarcoma; Oncology: Unspecified Solid Tumor,Fourth line or greater; HER2 positive; Pediatric or Adolescent; Second line; Stage IV; Third line,"Breast Neoplasms; Ewing Sarcoma; Fibrosarcoma; Leiomyosarcoma; Liposarcoma; Melanoma; Neoplasms, Unknown Primary; Neuroblastoma; Osteosarcoma; Rhabdomyosarcoma; Sarcoma; Sarcoma, Ewing; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Synovial Sarcoma",United States
"A Phase I Dose Escalation and Expansion Study of AZD9833 Alone or in Combination in Women With ER-positive, HER2-negative Advanced Breast Cancer (SERENA-1)",I,Open,AstraZeneca;,Oncology: Breast,Estrogen receptor positive; Fourth line or greater; HER2 negative; Second line; Stage III; Stage IV; Third line,Breast Neoplasms,Spain; United Kingdom; United States
A Safety Lead-In/Randomized Phase II Study of BMX-001 as a Therapeutic Agent for Treatment of Cancer Patients With Multiple Brain Metastases Undergoing Whole-Brain Radiotherapy,I/II,Open,"National Institutes of Health/National Cancer Institute;
Duke Comprehensive Cancer Center
BioMimetix JV","Oncology: Breast; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Metastatic Cancer; Oncology: Renal",CNS mets; Line of therapy N/A; Stage IV,"Brain Neoplasms; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Central Nervous System Neoplasms; Kidney Neoplasms; Melanoma; Neoplasm Metastasis; Renal Cancer; Wilms Tumor",United States
A Pilot Trial of Topical Calcipotriene Treatment for Breast Cancer Immunoprevention,I,Open,Massachusetts General Hospital,Oncology: Breast,Adjuvant; Estrogen receptor positive; HER2 negative; HER2 positive; Progesterone receptor positive; Stage 0; Stage I; Stage II; Triple receptor negative,Breast Neoplasms,United States
"A Phase I/II, Open-label, Multi-Center Study of the Safety and Efficacy of KY1044 as Single Agent and in Combination With Anti-PD-L1 (Atezolizumab) in Adult Patients With Selected Advanced Malignancies",I/II,Open,Sanofi;/Kymab,"Oncology: Breast; Oncology: Cervical; Oncology: Esophageal; Oncology: Gastric; Oncology: Head/Neck; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Pancreas; Oncology: Renal; Oncology: Unspecified Solid Tumor",Adenocarcinoma; First line; Fourth line or greater; HER2 negative; Large Cell; PD-1 Naive; PD-1 Refractory; PD-L1 Naive; PD-L1 Refractory; Second line; Squamous Cell; Stage III; Stage IV; Third line; Triple receptor negative,"Breast Neoplasms; Carcinoma; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Esophageal Cancer; Esophageal Neoplasms; Head and Neck Neoplasms; Kidney Neoplasms; Liver Cancer; Liver Neoplasms; Melanoma; Neoplasms, Unknown Primary; Pancreatic Cancer; Pancreatic Neoplasms; Renal Cancer; Squamous Cell Carcinoma of Head and Neck; Stomach Carcinoma; Stomach Neoplasms; Triple Negative Breast Neoplasms; Uterine Cervical Neoplasms; Wilms Tumor","Germany; Hungary; Italy; Poland; Spain; Taiwan, China; United Kingdom; United States"
"A Phase I Open Label, Multi-Arm, Multicenter Study of MK-4830 as Monotherapy and in Combination With Pembrolizumab for Participants With Advanced Solid Tumors",I,Open,Merck & Co./Merck Sharp & Dohme (MSD),"Oncology: Breast; Oncology: CNS, Glioblastoma; Oncology: Esophageal; Oncology: Fallopian Tube; Oncology: Gastric; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Mesothelioma; Oncology: Ovarian; Oncology: Pancreas; Oncology: Primary Peritoneal; Oncology: Renal; Oncology: Unspecified Solid Tumor",Adenocarcinoma; First line; Fourth line or greater; HER2 negative; Large Cell; PD-1 Naive; PD-1 Refractory; PD-L1 Naive; PD-L1 Positive; PD-L1 Refractory; Second line; Stage III; Stage IV; Third line; Triple receptor negative,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Esophageal Cancer; Esophageal Neoplasms; Fallopian Tube Neoplasms; Glioblastoma; Head and Neck Neoplasms; Kidney Neoplasms; Mesothelioma; Neoplasms, Mesothelial; Neoplasms, Unknown Primary; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Peritoneal Neoplasms; Renal Cancer; Stomach Carcinoma; Stomach Neoplasms; Unspecified; Wilms Tumor",Australia; Canada; Greece; Israel; Poland; South Africa; South Korea; Spain; United States
Examining Oncolytic Poliovirus Bioactivity in Tumor Tissue After Intratumoral Administration of PVSRIPO in Women With Invasive Breast Cancer,I,Open,"Duke University Medical Center
US Department of Defense
Istari Oncology",Oncology: Breast,Estrogen receptor positive; HER2 negative; HER2 positive; Neoadjuvant; Progesterone receptor positive; Stage II; Stage III; Stage IV; Triple receptor negative,Breast Neoplasms,United States
A Pilot Trial of Atorvastatin in p53-Mutant and p53 Wild-Type Malignancies,I,Open,University of Kansas,"Oncology: Bladder; Oncology: Breast; Oncology: CNS, Glioblastoma; Oncology: Endometrial; Oncology: Esophageal; Oncology: Gastric; Oncology: Leukemia, Acute Myelogenous; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Myelodysplastic Syndrome; Oncology: Ovarian; Oncology: Unspecified Cancer; Oncology: Unspecified Hematological Cancer; Oncology: Unspecified Solid Tumor",(N/A); First line; Neoadjuvant; Second line; Untreated,"Acute Myelocytic Leukemia; Breast Neoplasms; Carcinoma, Endometrioid; Carcinoma, Non-Small-Cell Lung; Endometrial Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Glioblastoma; Hematologic Neoplasms; Leukemia, Myeloid, Acute; Melanoma; Myelodysplastic Syndromes; Neoplasms; Neoplasms, Unknown Primary; Ovarian Cancer; Ovarian Neoplasms; Stomach Carcinoma; Stomach Neoplasms; Urethral Neoplasms; Urinary Bladder Neoplasms",United States
"An Open-Label, Multiple-Dose, Dose-Escalation Study to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics of VMD-928 in Subjects With Solid Tumors or Lymphoma",I,Open,VM Oncology,"Oncology: Bile Duct (Cholangiocarcinoma); Oncology: Breast; Oncology: Cervical; Oncology: Esophageal; Oncology: Gastric; Oncology: Head/Neck; Oncology: Leukemia, Acute Myelogenous; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Lymphoma, Hodgkin's; Oncology: Lymphoma, Non-Hodgkin's; Oncology: Melanoma; Oncology: Mesothelioma; Oncology: Ovarian; Oncology: Pancreas; Oncology: Prostate; Oncology: Skin, Squamous Cell Carcinoma (cSCC); Oncology: Thymus; Oncology: Unspecified Solid Tumor",Aggressive; Classical; HER2 negative; Indolent; Nodular lymphocyte-predominant; Second line; Squamous Cell; Stage III; Stage IV; Thymic carcinoma; Thymoma; Triple receptor negative,"Acute Myelocytic Leukemia; Bile Duct Neoplasms; Breast Neoplasms; Carcinoma; Carcinoma, Adenoid Cystic; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cholangiocarcinoma; Esophageal Cancer; Esophageal Neoplasms; Head and Neck Neoplasms; Hodgkin Disease; Hodgkin Lymphoma; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Liver Cancer; Liver Neoplasms; Lung Neoplasms; Lymphoma; Lymphoma, Large-Cell, Anaplastic; Lymphoma, Non-Hodgkin; Melanoma; Mesothelioma; Mesothelioma, Malignant; Neoplasms, Mesothelial; Neoplasms, Unknown Primary; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Prostatic Neoplasms; Squamous Cell Carcinoma of Head and Neck; Stomach Carcinoma; Stomach Neoplasms; Thymoma; Thymus Neoplasms; Uterine Cervical Neoplasms",United States
A Phase 1a/1b Study Exploring the Safety and Tolerability of INCB081776 in Participants With Advanced Malignancies,I,Open,Incyte Corporation,"Oncology: Bladder; Oncology: Breast; Oncology: Esophageal; Oncology: Gastric; Oncology: Head/Neck; Oncology: Leukemia, Acute Myelogenous; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Renal; Oncology: Soft Tissue Sarcoma; Oncology: Unspecified Solid Tumor",(N/A); HER2 negative; Metastatic; MSI-H/dMMR; PD-1 Naive; PD-1 Refractory; PD-L1 Naive; PD-L1 Refractory; Second line; Stage III; Stage IV; Triple receptor negative,"Acute Myelocytic Leukemia; Breast Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Esophageal Cancer; Esophageal Neoplasms; Fibrosarcoma; Head and Neck Neoplasms; Kidney Neoplasms; Leiomyosarcoma; Leukemia, Myeloid, Acute; Liposarcoma; Liver Cancer; Liver Neoplasms; Melanoma; Neoplasms; Neoplasms, Unknown Primary; Renal Cancer; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Stomach Carcinoma; Stomach Neoplasms; Synovial Sarcoma; Urethral Neoplasms; Urinary Bladder Neoplasms; Wilms Tumor",United States
"A Phase I/II Safety and Efficacy Dose Escalation / Dose Expansion Study of a CAB-ROR2-ADC, Alone and in Combination With a PD-1 Inhibitor, in Patients With Advanced Solid Tumors (Ph1) and Melanoma and NSCLC Patients (Ph2)",I/II,Open,BioAtla,"Oncology: Breast; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Soft Tissue Sarcoma; Oncology: Unspecified Solid Tumor",HER2 negative; Locally advanced; Metastatic; PD-1 Refractory; PD-L1 Refractory; Second line; Stage III; Stage IV; Triple receptor negative; Unresectable,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Fibrosarcoma; Head and Neck Neoplasms; Leiomyosarcoma; Liposarcoma; Melanoma; Neoplasms, Unknown Primary; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Synovial Sarcoma; Triple Negative Breast Neoplasms","France; Germany; Greece; Hong Kong, S.A.R., China; Italy; Poland; Spain; Taiwan, China; United States"
A Phase I/II Study of CPI-0209 in Patients With Advanced Solid Tumors and Lymphomas,I/II,Open,MorphoSys/Constellation Pharmaceuticals,"Oncology: Bile Duct (Cholangiocarcinoma); Oncology: Bladder; Oncology: Breast; Oncology: Colorectal; Oncology: Endometrial; Oncology: Gastric; Oncology: Lung, Small Cell; Oncology: Lymphoma, Hodgkin's; Oncology: Lymphoma, Non-Hodgkin's; Oncology: Melanoma; Oncology: Mesothelioma; Oncology: Neuroendocrine; Oncology: Ovarian; Oncology: Pancreas; Oncology: Prostate; Oncology: Renal; Oncology: Soft Tissue Sarcoma; Oncology: Unspecified Hematological Cancer; Oncology: Unspecified Solid Tumor",Aggressive; Classical; Diffuse large B-cell lymphoma (DLBCL); Fourth line or greater; Hormone refractory; Indolent; Metastatic; MSI-H/dMMR; Nodular lymphocyte-predominant; PD-1 Refractory; Peripheral T-cell lymphoma (PTCL); Pulmonary; Second line; Stage III; Stage IV; Third line,"Bile Duct Neoplasms; Breast Neoplasms; Carcinoma, Endometrioid; Carcinoma, Renal Cell; Carcinoma, Small Cell; Cholangiocarcinoma; Colorectal Neoplasms; Endometrial Neoplasms; Fibrosarcoma; Hematologic Neoplasms; Hodgkin Disease; Hodgkin Lymphoma; Kidney Neoplasms; Leiomyosarcoma; Liposarcoma; Lymphoma; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Large-Cell, Anaplastic; Lymphoma, Non-Hodgkin; Lymphoma, T-Cell; Lymphoma, T-Cell, Peripheral; Melanoma; Mesothelioma; Mesothelioma, Malignant; Neoplasms; Neoplasms, Mesothelial; Neoplasms, Unknown Primary; Neuroendocrine Tumors; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Renal Cancer; Rhabdomyosarcoma; Sarcoma; Small Cell Lung Carcinoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Stomach Carcinoma; Stomach Neoplasms; Synovial Sarcoma; Urethral Neoplasms; Urinary Bladder Neoplasms; Wilms Tumor",France; Italy; Poland; Spain; United Kingdom; United States
Pembrolizumab And Stereotactic Radiosurgery (Srs) Of Selected Brain Metastases In Breast Cancer Patients.,I/II,Open,"Weill Medical College of Cornell University
Merck & Co./Merck Sharp & Dohme (MSD)",Oncology: Breast; Oncology: Metastatic Cancer,Adjuvant; CNS mets; Neoadjuvant; Stage IV,Brain Neoplasms; Breast Neoplasms; Central Nervous System Neoplasms; Neoplasm Metastasis,United States
"A Phase Ia/Ib, Open Label, Multicenter, Dose-escalation Study of BI 907828 in Patients With Advanced or Metastatic Solid Tumors",I,Open,Boehringer Ingelheim,"Oncology: Bladder; Oncology: Breast; Oncology: CNS, Glioblastoma; Oncology: GIST; Oncology: Lung, Non-Small Cell; Oncology: Metastatic Cancer; Oncology: Osteosarcoma; Oncology: Pancreas; Oncology: Soft Tissue Sarcoma; Oncology: Unspecified Solid Tumor",Adenocarcinoma; CNS mets; Estrogen receptor positive; First line; Fourth line or greater; HER2 negative; HER2 positive; Large Cell; Progesterone receptor positive; Second line; Stage III; Stage IV; Third line; Triple receptor negative,"Brain Neoplasms; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Central Nervous System Neoplasms; Ewing Sarcoma; Fibrosarcoma; Gastrointestinal Stromal Tumors; Glioblastoma; Leiomyosarcoma; Liposarcoma; Neoplasm Metastasis; Neoplasms, Unknown Primary; Osteosarcoma; Pancreatic Cancer; Pancreatic Neoplasms; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Synovial Sarcoma; Unspecified; Urethral Neoplasms; Urinary Bladder Neoplasms",Belgium; Canada; Germany; Japan; Poland; Spain; Sweden; United States
"A Phase Ia/Ib, Open-Label, Dose-Escalation Study of the Safety and Pharmacokinetics of Runimotamab Administered Intravenously as a Single Agent and in Combination With Trastuzumab in Patients With Locally Advanced or Metastatic HER2-Expressing Cancers",I,Open,Roche;Genentech; {Genentech;},Oncology: Breast; Oncology: Esophageal; Oncology: Gastric; Oncology: Unspecified Solid Tumor,HER2 negative; HER2 positive; Second line; Stage III; Stage IV,"Breast Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Neoplasms, Unknown Primary; Stomach Carcinoma; Stomach Neoplasms; Unspecified","Australia; Belgium; Canada; Denmark; France; Italy; Japan; Netherlands; Singapore; South Korea; Spain; Taiwan, China; United Kingdom; United States"
A Phase Ib Investigation of Pembrolizumab in Combination With Intratumoral Injection of Clostridium Novyi-NT in Patients With Treatment-Refractory Solid Tumors,I,Open,"MD Anderson Cancer Center University of Texas;
Merck & Co./Merck Sharp & Dohme (MSD)
BioMed Valley Discoveries","Oncology: Anal; Oncology: Bladder; Oncology: Breast; Oncology: Cervical; Oncology: CNS, Glioblastoma; Oncology: CNS, Medulloblastoma; Oncology: CNS, Other; Oncology: Colorectal; Oncology: Endometrial; Oncology: Esophageal; Oncology: Gastric; Oncology: GIST; Oncology: Head/Neck; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Mesothelioma; Oncology: Ovarian; Oncology: Pancreas; Oncology: Prostate; Oncology: Renal; Oncology: Soft Tissue Sarcoma; Oncology: Testicular; Oncology: Thyroid",Advanced; Metastatic; Second line; Stage III; Stage IV,"Anus Neoplasms; Breast Neoplasms; Carcinoma, Endometrioid; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Central Nervous System Neoplasms; Colorectal Neoplasms; Endometrial Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Eye Neoplasms; Fibrosarcoma; Gastrointestinal Stromal Tumors; Genital Neoplasms, Female; Genital Neoplasms, Male; Glioblastoma; Head and Neck Neoplasms; Kidney Neoplasms; Leiomyosarcoma; Lip Neoplasms; Liposarcoma; Liver Cancer; Liver Neoplasms; Medulloblastoma; Mesothelioma; Neoplasms; Neoplasms, Mesothelial; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Prostatic Neoplasms; Renal Cancer; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Stomach Carcinoma; Stomach Neoplasms; Synovial Sarcoma; Testicular Cancer; Testicular Neoplasms; Thyroid Neoplasms; Urethral Neoplasms; Urinary Bladder Neoplasms; Urologic Neoplasms; Uterine Cervical Neoplasms; Wilms Tumor",United States
"A Phase I/IIa Study in 3 Parts (Phase Ia and Phase Ib - Dose Escalations and Phase IIa Expansion Cohorts) to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of MIV-818 in Patients with Liver Cancer Manifestations",I/II,Open,Medivir,"Oncology: Bile Duct (Cholangiocarcinoma); Oncology: Breast; Oncology: Colorectal; Oncology: Gastric; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Metastatic Cancer; Oncology: Pancreas; Oncology: Renal; Oncology: Unspecified Solid Tumor",Fourth line or greater; Intrahepatic; Liver mets; Second line; Stage III; Stage IV; Third line,"Bile Duct Neoplasms; Breast Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Cholangiocarcinoma; Cholangiocarcinoma; Colorectal Neoplasms; Kidney Neoplasms; Liver Cancer; Liver Neoplasms; Melanoma; Neoplasm Metastasis; Neoplasms, Unknown Primary; Pancreatic Cancer; Pancreatic Neoplasms; Renal Cancer; Stomach Carcinoma; Stomach Neoplasms; Wilms Tumor",Belgium; South Korea; Spain; United Kingdom; United States
A Phase I/II Study of OBI-3424 in Subjects With Advanced Solid Tumors,I/II,Open,OBI Pharma,"Oncology: Breast; Oncology: Colorectal; Oncology: Leukemia, Acute Lymphocytic; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Ovarian; Oncology: Pancreas; Oncology: Prostate; Oncology: Unspecified Solid Tumor",(N/A); Fourth line or greater; Hormone refractory; Second line; Stage III; Stage IV; T-cell; Third line,"Adenocarcinoma; Breast Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Liver Cancer; Liver Neoplasms; Melanoma; Neoplasms, Unknown Primary; Ovarian Neoplasms; Pancreatic Neoplasms; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prostatic Neoplasms",United States
A Phase I/II Study Using the Administration of Autologous T-Cells Engineered Using the Sleeping Beauty Transposon/Transposase System to Express T-Cell Receptors Reactive Against Mutated Neoantigens in Patients With Metastatic Cancer,I/II,Open,National Institutes of Health/National Cancer Institute;,"Oncology: Bladder; Oncology: Breast; Oncology: CNS, Glioblastoma; Oncology: Colorectal; Oncology: GIST; Oncology: Lung, Non-Small Cell; Oncology: Ovarian; Oncology: Unspecified Solid Tumor",Adenocarcinoma; Large Cell; Second line; Squamous Cell; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Gastrointestinal Stromal Tumors; Glioblastoma; Neoplasms, Unknown Primary; Ovarian Cancer; Ovarian Neoplasms; Urethral Neoplasms; Urinary Bladder Neoplasms; Urogenital Neoplasms",United States
"A Multicenter, Open-Label Phase I/II Trial Evaluating the Safety, Tolerability, and Efficacy of MORAb-202, a Folate Receptor Alpha (FRa)-Targeting Antibody-drug Conjugate (ADC) in Subjects With Selected Tumor Types",I/II,Open,"Bristol-Myers Squibb
Eisai/Morphotek","Oncology: Breast; Oncology: Endometrial; Oncology: Fallopian Tube; Oncology: Lung, Non-Small Cell; Oncology: Ovarian; Oncology: Primary Peritoneal",Adenocarcinoma; Fourth line or greater; HER2 negative; PD-1 Naive; PD-1 Refractory; PD-L1 Naive; PD-L1 Refractory; Second line; Stage III; Stage IV; Triple receptor negative,"Breast Neoplasms; Carcinoma, Endometrioid; Carcinoma, Non-Small-Cell Lung; Endometrial Neoplasms; Fallopian Tube Neoplasms; Ovarian Cancer; Ovarian Neoplasms; Peritoneal Neoplasms; Unspecified",United Kingdom; United States
A Phase I Clinical Study To Test The Safety And Efficacy of CARMA in Patients With Recurrent Ovarian Cancer And in Patients With HER2-overexpressing Malignancies Through A Basket Trial Approach.,I,Open,"MD Anderson Cancer Center University of Texas;
Sarah Cannon Research Institute {Sarah Cannon-Minnie Pearl Cancer Center}
Abramson Cancer Center at University of Pennsylvania Medical Center;;
University of North Carolina
Carisma Therapeutics {CARMA Therapeutics}","Oncology: Bile Duct (Cholangiocarcinoma); Oncology: Bladder; Oncology: Breast; Oncology: Cervical; Oncology: Colorectal; Oncology: Endometrial; Oncology: Esophageal; Oncology: Gallbladder; Oncology: Gastric; Oncology: Head/Neck; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Lung, Small Cell; Oncology: Neuroendocrine; Oncology: Ovarian; Oncology: Pancreas; Oncology: Prostate; Oncology: Testicular; Oncology: Unspecified Solid Tumor",Adenocarcinoma; EGFR; Fourth line or greater; HER2 positive; Pulmonary; Second line; Squamous Cell; Stage IV; Third line,"Bile Duct Neoplasms; Biliary Tract Neoplasms; Breast Neoplasms; Carcinoma; Carcinoma, Ductal; Carcinoma, Endometrioid; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Ovarian Epithelial; Carcinoma, Small Cell; Carcinoma, Squamous Cell; Carcinoma, Transitional Cell; Cholangiocarcinoma; Colorectal Neoplasms; Endometrial Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Gallbladder Neoplasms; Head and Neck Neoplasms; Inflammatory Breast Neoplasms; Liver Cancer; Liver Neoplasms; Lung Neoplasms; Neoplasms; Neoplasms, Unknown Primary; Neuroendocrine Tumors; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Prostatic Neoplasms; Small Cell Lung Carcinoma; Stomach Carcinoma; Stomach Neoplasms; Testicular Cancer; Testicular Neoplasms; Urethral Neoplasms; Urinary Bladder Neoplasms; Uterine Cervical Neoplasms",United States
Phase I/II Dose-Escalation and Expansion Study of FLX475 Alone and in Combination with Pembrolizumab in Advanced Cancer,I/II,Open,"Merck & Co./Merck Sharp & Dohme (MSD)
RAPT Therapeutics {FLX Bio {Flexus Biosciences}}","Oncology: Bladder; Oncology: Breast; Oncology: Cervical; Oncology: Colorectal; Oncology: Esophageal; Oncology: Gastric; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Lymphoma, Hodgkin's; Oncology: Lymphoma, Non-Hodgkin's; Oncology: Melanoma; Oncology: Ovarian; Oncology: Renal",Adenocarcinoma; Aggressive; Classical; Fourth line or greater; HER2 negative; Other subtype; PD-L1 High; PD-L1 Positive; Second line; Stage III; Stage IV; Third line; Triple receptor negative,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Colorectal Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Head and Neck Neoplasms; Hodgkin Disease; Hodgkin Lymphoma; Kidney Neoplasms; Lymphoma, Large-Cell, Anaplastic; Lymphoma, Non-Hodgkin; Melanoma; Neoplasms; Ovarian Cancer; Ovarian Neoplasms; Renal Cancer; Stomach Carcinoma; Stomach Neoplasms; Urethral Neoplasms; Urinary Bladder Neoplasms; Uterine Cervical Neoplasms; Wilms Tumor","Australia; Georgia; Hong Kong, S.A.R., China; South Korea; Taiwan, China; Thailand; United States"
"A Phase Ib/IIa, Open-Label, Dose-Escalation/Dose-Expansion Safety, Tolerability and Pharmacokinetic Study of IMX-110 in Patients with Advanced Solid Tumors",I/II,Open,Immix Biopharma,Oncology: Breast; Oncology: Colorectal; Oncology: Esophageal; Oncology: Ovarian; Oncology: Pancreas; Oncology: Soft Tissue Sarcoma; Oncology: Unspecified Solid Tumor,Second line; Stage III; Stage IV,"Breast Neoplasms; Colorectal Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Fibrosarcoma; Leiomyosarcoma; Liposarcoma; Neoplasms; Neoplasms, Unknown Primary; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Synovial Sarcoma",Australia; United States
"Phase I, Two-part, Multicenter, Open-label, Multiple Dose, First-in-human Study of DS-1062a in Subjects With Advanced Solid Tumors (TROPION-PanTumor01)",I,Open,"AstraZeneca;
Daiichi Sankyo","Oncology: Bladder; Oncology: Breast; Oncology: Cervical; Oncology: Colorectal; Oncology: Endometrial; Oncology: Esophageal; Oncology: Fallopian Tube; Oncology: Gastric; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Lung, Small Cell; Oncology: Neuroendocrine; Oncology: Ovarian; Oncology: Pancreas; Oncology: Primary Peritoneal; Oncology: Prostate; Oncology: Renal",Adenocarcinoma; ALK; EGFR; Estrogen receptor positive; Extensive; Fourth line or greater; HER2 negative; Hormone refractory; Large Cell; PD-1 Refractory; PD-L1 Refractory; Progesterone receptor positive; Pulmonary; Second line; Squamous Cell; Stage III; Stage IV; Third line; Triple receptor negative,"Breast Neoplasms; Carcinoma, Endometrioid; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Carcinoma, Small Cell; Colorectal Neoplasms; Endometrial Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Fallopian Tube Neoplasms; Head and Neck Neoplasms; Kidney Neoplasms; Neuroendocrine Tumors; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Peritoneal Neoplasms; Prostatic Neoplasms; Renal Cancer; Small Cell Lung Carcinoma; Stomach Carcinoma; Stomach Neoplasms; Triple Negative Breast Neoplasms; Urethral Neoplasms; Urinary Bladder Neoplasms; Uterine Cervical Neoplasms; Wilms Tumor",Japan; United States
"An Open-Label, Multicenter, Phase I/II Study of RP1 as a Single Agent and in Combination with PD1 Blockade in Patients with Solid Tumors.",I/II,Open,"Bristol-Myers Squibb
Replimune","Oncology: Breast; Oncology: Colorectal; Oncology: Head/Neck; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Neuroendocrine; Oncology: Pancreas; Oncology: Skin, Basal Cell Carcinoma; Oncology: Skin, Squamous Cell Carcinoma (cSCC); Oncology: Soft Tissue Sarcoma; Oncology: Unspecified Solid Tumor",BRAF; First line; Locally advanced; Merkel; Metastatic; MSI-H/dMMR; PD-1 Naive; PD-1 Refractory; PD-L1 Naive; PD-L1 Positive; PD-L1 Refractory; Second line; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Basal Cell; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Colorectal Neoplasms; Fibrosarcoma; Head and Neck Neoplasms; Leiomyosarcoma; Liposarcoma; Liver Cancer; Liver Neoplasms; Lymphoma, Non-Hodgkin; Melanoma; Microsatellite Instability; Neoplasms, Basal Cell; Neoplasms, Unknown Primary; Neuroendocrine Tumors; Pancreatic Cancer; Pancreatic Neoplasms; Rhabdomyosarcoma; Sarcoma; Skin Neoplasms; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Synovial Sarcoma",Australia; France; Germany; Spain; United Kingdom; United States
A Phase Ib/II Study of the PARP Inhibitor Niraparib in Combination With Trastuzumab in Patients With Metastatic HER2+ Breast Cancer,I/II,Open,"(Other Cooperative Group);
University of Alabama; Birmingham
Susan G. Komen {Susan G. Komen Breast Cancer Research Foundation}
(Other Hospital/Academic/Medical Center);
GlaxoSmithKline/Tesaro",Oncology: Breast,Estrogen receptor positive; HER2 positive; Progesterone receptor positive; Second line; Stage III; Stage IV,Breast Neoplasms,United States
Phase I Trial of 5-aza-4'-Thio-2'-Deoxycytidine (Aza-TdC) in Patients With Advanced Solid Tumors,I,Open,National Institutes of Health/National Cancer Institute;,Oncology: Breast; Oncology: Colorectal; Oncology: Ovarian; Oncology: Soft Tissue Sarcoma; Oncology: Unspecified Solid Tumor,Second line; Stage III; Stage IV,"Breast Neoplasms; Colorectal Neoplasms; Fibrosarcoma; Leiomyosarcoma; Liposarcoma; Neoplasms; Neoplasms, Unknown Primary; Ovarian Cancer; Ovarian Neoplasms; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Synovial Sarcoma",United States
"An Open-label Phase I/IIa Study to Evaluate the Safety and Efficacy of CCS1477 as Monotherapy and in Combination, in Patients With Advanced Solid/Metastatic Tumours.",I/II,Open,CellCentric,"Oncology: Breast; Oncology: Lung, Non-Small Cell; Oncology: Prostate; Oncology: Unspecified Solid Tumor",Hormone refractory; Second line; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Neoplasms, Unknown Primary; Prostatic Neoplasms",France; Germany; Netherlands; Spain; Sweden; United Kingdom; United States
"A Phase I, Open-Label, Dose-Escalation, Safety, Tolerability, and Preliminary Efficacy Study of MCLA-145 in Participants With Advanced or Metastatic Malignancies",I,Open,"Merus
Incyte Corporation","Oncology: Bladder; Oncology: Breast; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Lymphoma, Non-Hodgkin's; Oncology: Melanoma; Oncology: Unspecified Solid Tumor",Aggressive; Diffuse large B-cell lymphoma (DLBCL); Extranodal marginal zone B-cell lymphoma (MALT); Follicular lymphoma (FL); HER2 negative; Indolent; Mantle cell lymphoma (MCL); MSI-H/dMMR; PD-1 Refractory; Second line; Stage III; Stage IV; Triple receptor negative,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Head and Neck Neoplasms; Lymphoma, B-Cell, Marginal Zone; Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Large-Cell, Anaplastic; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Melanoma; Neoplasms; Neoplasms, Unknown Primary; Urethral Neoplasms; Urinary Bladder Neoplasms",Belgium; Netherlands; Spain; United States
A Phase I/II Study of the SV-BR-1-GM Regimen in Metastatic or Locally Recurrent Breast Cancer Patients in Combination With Retifanlimab,I/II,Open,"Incyte Corporation
BriaCell",Oncology: Breast,Estrogen receptor positive; Fourth line or greater; HER2 negative; HER2 positive; Progesterone receptor positive; Second line; Stage III; Stage IV; Third line; Triple receptor negative,Breast Neoplasms,United States
"An Open Label, Multicenter, Dose-Finding Clinical Phase I Study of ASN004 to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy in Patients With Advanced Malignant Solid Tumors",I,Open,Asana BioSciences,"Oncology: Breast; Oncology: Colorectal; Oncology: Lung, Non-Small Cell; Oncology: Ovarian; Oncology: Unspecified Solid Tumor",Second line; Stage III; Stage IV,"Adenocarcinoma; Breast Neoplasms; Carcinoma; Carcinoma, Non-Small-Cell Lung; Carcinoma, Ovarian Epithelial; Colonic Neoplasms; Colorectal Neoplasms; Lung Neoplasms; Neoplasms; Neoplasms, Unknown Primary; Ovarian Cancer; Ovarian Neoplasms",United States
"A Phase I/II, Open-label, Multicenter Study to Investigate the Safety, Pharmacokinetics, and Efficacy of Fadraciclib (CYC065), an Oral CDK 2/9 Inhibitor, in Subjects with Advanced Solid Tumors and Lymphoma",I/II,Open,Cyclacel,"Oncology: Bile Duct (Cholangiocarcinoma); Oncology: Breast; Oncology: Colorectal; Oncology: Endometrial; Oncology: Liver; Oncology: Lymphoma, Hodgkin's; Oncology: Lymphoma, Non-Hodgkin's; Oncology: Ovarian; Oncology: Pancreas; Oncology: Unspecified Solid Tumor",(N/A); Aggressive; Classical; Cutaneous T-cell lymphoma (CTCL); HER2 negative; Indolent; KRAS; Line of therapy N/A; Nodular lymphocyte-predominant; Peripheral T-cell lymphoma (PTCL); Second line; Stage III; Stage IV; Triple receptor negative,"Bile Duct Neoplasms; Breast Neoplasms; Carcinoma, Endometrioid; Carcinoma, Hepatocellular; Cholangiocarcinoma; Colorectal Neoplasms; Endometrial Neoplasms; Hodgkin Disease; Hodgkin Lymphoma; Liver Cancer; Liver Neoplasms; Lymphoma; Lymphoma, Large-Cell, Anaplastic; Lymphoma, Non-Hodgkin; Lymphoma, T-Cell, Cutaneous; Lymphoma, T-Cell, Peripheral; Neoplasms, Unknown Primary; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Neoplasms",South Korea; Spain; United States
A Phase I Dose Escalation / Dose Expansion Study of NBTXR3 Activated by Radiotherapy for Patients With Advanced Cancers Treated With An Anti-PD-1 Therapy,I,Open,Nanobiotix,"Oncology: Bladder; Oncology: Breast; Oncology: Cervical; Oncology: Colorectal; Oncology: Gastric; Oncology: Head/Neck; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Lung, Small Cell; Oncology: Melanoma; Oncology: Metastatic Cancer; Oncology: Neuroendocrine; Oncology: Renal; Oncology: Thyroid; Oncology: Unspecified Cancer",(N/A); Anaplastic; Fourth line or greater; HER2 negative; Liver mets; Merkel; MSI-H/dMMR; Other mets; PD-1 Naive; PD-1 Refractory; Pulmonary; Second line; Stage III; Stage IV; Third line; Triple receptor negative,"Breast Neoplasms; Carcinoma; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Carcinoma, Small Cell; Colorectal Neoplasms; Disease; Head and Neck Neoplasms; Kidney Neoplasms; Liver Cancer; Liver Neoplasms; Melanoma; Microsatellite Instability; Neoplasm Metastasis; Neoplasms; Neoplasms, Second Primary; Neuroendocrine Tumors; Small Cell Lung Carcinoma; Squamous Cell Carcinoma of Head and Neck; Stomach Carcinoma; Stomach Neoplasms; Thyroid Neoplasms; Urethral Neoplasms; Urinary Bladder Neoplasms; Uterine Cervical Neoplasms; Wilms Tumor",United States
"Phase I, Open-label, Dose-escalating, Clinical and Pharmacokinetic Study of PM14 Administered Intravenously to Patients With Advanced Solid Tumors",I,Open,PharmaMar,Oncology: Breast; Oncology: Colorectal; Oncology: Fallopian Tube; Oncology: Gastric; Oncology: Ovarian; Oncology: Pancreas; Oncology: Primary Peritoneal; Oncology: Prostate; Oncology: Soft Tissue Sarcoma; Oncology: Unspecified Solid Tumor,BRCA; Fourth line or greater; Second line; Stage III; Stage IV; Third line,"Breast Neoplasms; Colorectal Neoplasms; Fallopian Tube Neoplasms; Fibrosarcoma; Leiomyosarcoma; Liposarcoma; Neoplasms; Neoplasms, Unknown Primary; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Peritoneal Neoplasms; Prostatic Neoplasms; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Stomach Carcinoma; Stomach Neoplasms; Synovial Sarcoma",France; Spain; United States
A Phase I/II Study of Anti-CD3 x Anti-HER2/Neu (HER2Bi) Armed Activated T Cells (ATC) and Pembrolizumab Combination Therapy in Women With Metastatic Breast Cancer,I/II,Open,"University of Virginia
Merck & Co./Merck Sharp & Dohme (MSD)",Oncology: Breast,Estrogen receptor positive; HER2 negative; HER2 positive; Progesterone receptor positive; Second line; Stage IV; Triple receptor negative,Breast Neoplasms,United States
Niraparib Plus Carboplatin in Patients With Homologous Recombination Deficient Advanced Solid Tumor Malignancies,I,Open,"Oregon Health and Science University
Georgetown University Medical Center
GlaxoSmithKline/Tesaro","Oncology: Bladder; Oncology: Breast; Oncology: Cervical; Oncology: Colorectal; Oncology: Endometrial; Oncology: Esophageal; Oncology: Gastric; Oncology: GIST; Oncology: Head/Neck; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Neuroendocrine; Oncology: Ovarian; Oncology: Pancreas; Oncology: Prostate; Oncology: Renal; Oncology: Thyroid; Oncology: Unspecified Solid Tumor",Second line; Stage III; Stage IV; Unspecified,"Breast Neoplasms; Carcinoma, Endometrioid; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Colorectal Neoplasms; Endometrial Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Gastrointestinal Stromal Tumors; Head and Neck Neoplasms; Kidney Neoplasms; Liver Cancer; Liver Neoplasms; Melanoma; Neoplasms; Neoplasms, Unknown Primary; Neuroendocrine Tumors; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Prostatic Neoplasms; Renal Cancer; Stomach Carcinoma; Stomach Neoplasms; Thyroid Neoplasms; Urethral Neoplasms; Urinary Bladder Neoplasms; Uterine Cervical Neoplasms; Wilms Tumor",United States
"A Phase I, Open-Label, Multicenter, Dose Escalation Study of mRNA-2752, a Lipid Nanoparticle Encapsulating mRNAs Encoding Human OX40L, IL-23, and IL-36, for Intratumoral Injection Alone and in Combination With Immune Checkpoint Blockade",I,Open,"AstraZeneca;
Moderna {Moderna Therapeutics}","Oncology: Bladder; Oncology: Breast; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Lymphoma, Hodgkin's; Oncology: Lymphoma, Non-Hodgkin's; Oncology: Melanoma; Oncology: Unspecified Solid Tumor",Aggressive; Classical; Diffuse large B-cell lymphoma (DLBCL); Fourth line or greater; HER2 negative; Indolent; Nodular lymphocyte-predominant; PD-1 Naive; PD-1 Refractory; PD-L1 Naive; PD-L1 Positive; PD-L1 Refractory; Second line; Stage III; Stage IV; Third line; Triple receptor negative,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Head and Neck Neoplasms; Hodgkin Disease; Hodgkin Lymphoma; Lymphoma; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Large-Cell, Anaplastic; Lymphoma, Non-Hodgkin; Melanoma; Neoplasms; Neoplasms, Unknown Primary; Triple Negative Breast Neoplasms; Urethral Neoplasms; Urinary Bladder Neoplasms",Australia; Israel; Italy; United States
"An Open-label, First-in-human, Dose-escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Maximum Tolerated Dose and / or Recommended Phase II Dose of the ATR Inhibitor BAY1895344 in Patients With Advanced Solid Tumors and Lymphomas",I/II,Open,Bayer AG/Bayer Pharmaceuticals,"Oncology: Breast; Oncology: Cervical; Oncology: Colorectal; Oncology: Endometrial; Oncology: Fallopian Tube; Oncology: Lung, Non-Small Cell; Oncology: Lung, Small Cell; Oncology: Lymphoma, Non-Hodgkin's; Oncology: Neuroendocrine; Oncology: Ovarian; Oncology: Primary Peritoneal; Oncology: Prostate",Adenocarcinoma; Aggressive; Diffuse large B-cell lymphoma (DLBCL); Estrogen receptor positive; Fourth line or greater; HER2 negative; Hormone refractory; Indolent; Mantle cell lymphoma (MCL); Progesterone receptor positive; Pulmonary; Second line; Squamous Cell; Stage III; Stage IV; Triple receptor negative,"Breast Neoplasms; Carcinoma, Endometrioid; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Colorectal Neoplasms; Endometrial Neoplasms; Fallopian Tube Neoplasms; Lymphoma; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Large-Cell, Anaplastic; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Neuroendocrine Tumors; Ovarian Cancer; Ovarian Neoplasms; Peritoneal Neoplasms; Prostatic Neoplasms; Small Cell Lung Carcinoma; Uterine Cervical Neoplasms",Canada; China; France; Germany; Japan; Singapore; Switzerland; United Kingdom; United States
"A Phase I, Multicenter, Open-label, Dose-Escalation, Safety, Pharmacokinetic and Pharmacodynamic Study of Minnelide Capsules Given Daily for 21 Days Followed by 7 Days Off Schedule in Patients With Advanced Solid Tumors",I,Open,Minneamrita Therapeutics,Oncology: Breast; Oncology: Colorectal; Oncology: Gastric; Oncology: Pancreas; Oncology: Prostate; Oncology: Unspecified Cancer; Oncology: Unspecified Solid Tumor,Second line; Stage III; Stage IV,"Breast Neoplasms; Carcinoma; Colorectal Neoplasms; Neoplasms; Neoplasms, Unknown Primary; Pancreatic Cancer; Pancreatic Neoplasms; Prostatic Neoplasms; Stomach Carcinoma; Stomach Neoplasms",United States
"A Phase I Study of HMBD-002-V4C26 (HMBD-002), a Monoclonal Antibody Targeting VISTA, as Monotherapy and Combined With Pembrolizumab, in Patients With Advanced Solid Malignancies.",I/II,Open,Hummingbird Bioscience,"Oncology: Breast; Oncology: Lung, Non-Small Cell; Oncology: Unspecified Solid Tumor",HER2 negative; PD-1 Refractory; PD-L1 Refractory; Second line; Stage III; Stage IV; Triple receptor negative,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Neoplasms; Neoplasms, Unknown Primary; Triple Negative Breast Neoplasms",United States
"A Phase I/II, Single Arm, Non-randomized Study of Ribociclib (LEE011), a CDK 4/6 Inhibitor, in Combination With Bicalutamide, an Androgen Receptor (AR) Inhibitor, in Advanced AR+ Triple-negative Breast Cancer: Big Ten Cancer Research Consortium BRE15-024.",I/II,Open,"Novartis;
(Other Academic Cancer Center)",Oncology: Breast,HER2 negative; Second line; Stage III; Stage IV; Triple receptor negative,Breast Neoplasms; Triple Negative Breast Neoplasms,United States
"A Multicenter Phase I/II, Open-Label Study of DCC-3014 to Assess the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics in Patients With Advanced Tumors and Tenosynovial Giant Cell Tumor",I/II,Open,Deciphera Pharmaceuticals,"Oncology: Breast; Oncology: Gastric; Oncology: Leukemia, Acute Lymphocytic; Oncology: Leukemia, Acute Myelogenous; Oncology: Leukemia, Chronic Lymphocytic; Oncology: Lung, Non-Small Cell; Oncology: Myelodysplastic Syndrome; Oncology: Ovarian; Oncology: Prostate; Oncology: Tenosynovial Giant Cell Tumor",(N/A); Diffuse; Maintenance/Consolidation; Second line; Stage III; Stage IV,"Acute Myelocytic Leukemia; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Chronic Lymphocytic Leukemia; Giant Cell Tumor of Tendon Sheath; Giant Cell Tumors; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Neoplasms; Ovarian Cancer; Ovarian Neoplasms; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prostatic Neoplasms; Stomach Carcinoma; Stomach Neoplasms; Synovitis; Synovitis, Pigmented Villonodular",Australia; Canada; France; Italy; Netherlands; Poland; Spain; United Kingdom; United States
"A Phase I/II Study With Open-Label, Dose Escalation Phase Followed by Single-Arm Expansion at the Maximum Tolerated Dose to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of NT219 Injection Alone and in Combination With ERBITUX (Cetuximab) in Adults with Advanced Solid Tumors and Head and Neck Cancer",I/II,Open,Purple Biotech {Kitov Pharma},Oncology: Breast; Oncology: Colorectal; Oncology: Esophageal; Oncology: Gastric; Oncology: Head/Neck; Oncology: Mesothelioma; Oncology: Pancreas; Oncology: Thyroid; Oncology: Unspecified Solid Tumor,Fourth line or greater; Metastatic; Papillary; PD-1 Refractory; PD-L1 Refractory; Second line; Stage III; Stage IV; Third line,"Breast Neoplasms; Colorectal Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Head and Neck Neoplasms; Mesothelioma; Neoplasms; Neoplasms, Unknown Primary; Pancreatic Cancer; Pancreatic Neoplasms; Squamous Cell Carcinoma of Head and Neck; Stomach Carcinoma; Stomach Neoplasms; Thyroid Neoplasms",Canada; Israel; United States
"A Phase I, Open-Label, Dose-Escalation Study Evaluating the Safety, Tolerability, and Pharmacokinetics of Inavolisib as a Single Agent in Patients With Locally Advanced or Metastatic PIK3CA-Mutant Solid Tumors and in Combination With Endocrine and Targeted Therapies in Patients With Locally Advanced or Metastatic PIK3CA-Mutant Breast Cancer",I,Open,Roche;Genentech;,Oncology: Breast; Oncology: Colorectal; Oncology: Unspecified Solid Tumor,Estrogen receptor positive; Fourth line or greater; HER2 negative; HER2 positive; Progesterone receptor positive; Second line; Stage III; Stage IV; Third line,"Breast Neoplasms; Colorectal Neoplasms; Neoplasms, Unknown Primary",Canada; France; Spain; United Kingdom; United States
Effects of MK-3475 (Pembrolizumab) on the Breast Tumor Microenvironment in Triple Negative Breast Cancer With and Without Intra-operative RT: a Window of Opportunity Study,I,Open,Merck & Co./Merck Sharp & Dohme (MSD),Oncology: Breast,Estrogen receptor positive; HER2 negative; Neoadjuvant; Progesterone receptor positive; Stage I; Stage II; Stage III; Triple receptor negative,Breast Neoplasms; Triple Negative Breast Neoplasms,United States
"A Phase 1 Study of RGX-104, a Small Molecule LXR Agonist, as a Single Agent and as Combination Therapy in Patients With Advanced Solid Malignancies and Expansion in Select Malignancies",I/II,Open,Inspirna {Rgenix},"Oncology: Bile Duct (Cholangiocarcinoma); Oncology: Bladder; Oncology: Breast; Oncology: Colorectal; Oncology: Endometrial; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Lung, Small Cell; Oncology: Lymphoma, Hodgkin's; Oncology: Lymphoma, Non-Hodgkin's; Oncology: Melanoma; Oncology: Neuroendocrine; Oncology: Ovarian; Oncology: Primary Peritoneal; Oncology: Renal; Oncology: Soft Tissue Sarcoma; Oncology: Unspecified Solid Tumor",Adenocarcinoma; Aggressive; Classical; Extensive; First line; Fourth line or greater; HER2 negative; High-grade; Indolent; Large Cell; Limited; Nodular lymphocyte-predominant; PD-L1 Positive; Pulmonary; Second line; Stage III; Stage IV; Third line; Triple receptor negative; Unspecified; Untreated,"Bile Duct Neoplasms; Breast Neoplasms; Carcinoma, Endometrioid; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Carcinoma, Small Cell; Cholangiocarcinoma; Colorectal Neoplasms; Endometrial Neoplasms; Fibrosarcoma; Head and Neck Neoplasms; Hodgkin Disease; Hodgkin Lymphoma; Kidney Neoplasms; Leiomyosarcoma; Liposarcoma; Lymphoma; Lymphoma, Large-Cell, Anaplastic; Lymphoma, Non-Hodgkin; Melanoma; Neoplasms; Neoplasms, Unknown Primary; Neuroendocrine Tumors; Ovarian Cancer; Ovarian Neoplasms; Peritoneal Neoplasms; Renal Cancer; Rhabdomyosarcoma; Sarcoma; Small Cell Lung Carcinoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Synovial Sarcoma; Urethral Neoplasms; Urinary Bladder Neoplasms; Wilms Tumor",United States
"A Phase I Study of OTS167PO, a MELK Inhibitor, to Evaluate Safety, Tolerability and Pharmacokinetics in Patients With Advanced Breast Cancer and Dose-Expansion Study in Patients With Triple Negative Breast Cancer",I,Open,OncoTherapy Science,Oncology: Breast,HER2 negative; Second line; Stage III; Stage IV; Triple receptor negative,Breast Neoplasms; Triple Negative Breast Neoplasms,Japan; United States
Testing the Ability of Pembrolizumab to Alter the Tumor Immune MicroEnvironment (TIME) of High Risk DCIS,I,Open,"(Other Hospital/Academic/Medical Center);
Merck & Co./Merck Sharp & Dohme (MSD)
Moderna {Moderna Therapeutics}",Oncology: Breast,HER2 positive; Neoadjuvant; Stage 0,"Breast Neoplasms; Carcinoma; Carcinoma, Intraductal, Noninfiltrating",United States
Phase I/II Clinical Trial Of TERTiNT (4-1BB-based Adoptive T-Cell Therapy) To Treat  Cancer Patients,I/II,Open,(Other Hospital/Academic/Medical Center);,"Oncology: Breast; Oncology: Lung, Non-Small Cell",(N/A); Second line,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung",United States
A Phase I/II Study Administering Peripheral Blood Lymphocytes Transduced With a CD70-Binding Chimeric Antigen Receptor to Patients With CD70-Expressing Cancers,I/II,Open,"National Institutes of Health/National Cancer Institute;
Center for Cancer Research",Oncology: Breast; Oncology: Melanoma; Oncology: Ovarian; Oncology: Pancreas; Oncology: Renal; Oncology: Unspecified Solid Tumor,Second line; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Renal Cell; Kidney Neoplasms; Melanoma; Neoplasms, Unknown Primary; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Renal Cancer; Wilms Tumor",United States
"A Multi-Center, Randomized, Double Blind, Placebo-Controlled, Phase IIA Study to Evaluate the Safety and Efficacy of BLEX 404 Oral Liquid With Adjuvant Chemotherapy in Patients With Triple Negative Breast Cancer (TNBC) After Surgery",I/II,Planned,BioLite,Oncology: Breast,Adjuvant; HER2 negative; Stage III; Stage IV; Triple receptor negative,Breast Neoplasms; Triple Negative Breast Neoplasms,"Taiwan, China; United States"
"Phase I/II Study of 9-ING-41, a Glycogen Synthase Kinase-3 Beta (GSK-3ß) Inhibitor, as a Single Agent and Combined With Chemotherapy, in Patients With Refractory Hematologic Malignancies or Solid Tumors.",I/II,Open,"(Other Hospital/Academic/Medical Center);
Actuate Therapeutics","Oncology: Bladder; Oncology: Breast; Oncology: CNS, Astrocytoma; Oncology: CNS, Glioblastoma; Oncology: CNS, Oligodendroglioma; Oncology: Colorectal; Oncology: Endometrial; Oncology: Gastric; Oncology: Head/Neck; Oncology: Leukemia, Acute Lymphocytic; Oncology: Leukemia, Acute Myelogenous; Oncology: Leukemia, Chronic Lymphocytic; Oncology: Leukemia, Chronic Myelogenous; Oncology: Lung, Non-Small Cell; Oncology: Lung, Small Cell; Oncology: Lymphoma, Non-Hodgkin's; Oncology: Melanoma; Oncology: Neuroendocrine; Oncology: Osteosarcoma; Oncology: Ovarian; Oncology: Pancreas; Oncology: Primary Peritoneal; Oncology: Renal; Oncology: Soft Tissue Sarcoma; Oncology: Unspecified Hematological Cancer",Advanced; Aggressive; BRAF; EGFR; Fourth line or greater; Grade 2; Grade 3; Indolent; Merkel; Metastatic; PD-1 Refractory; PD-L1 Positive; PD-L1 Refractory; Pulmonary; Second line; Stage III; Stage IV; Third line,"Acute Myelocytic Leukemia; Astrocytoma; Bone Neoplasms; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Carcinoma, Small Cell; Chronic Lymphocytic Leukemia; Chronic Myeloid Leukemia; Colorectal Neoplasms; Endometrial Neoplasms; Ewing Sarcoma; Fibrosarcoma; Glioblastoma; Glioma; Head and Neck Neoplasms; Hematologic Neoplasms; Kidney Neoplasms; Leiomyosarcoma; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Leukemia, T-Cell; Liposarcoma; Lung Neoplasms; Lymphoma; Lymphoma, Large-Cell, Anaplastic; Lymphoma, Non-Hodgkin; Melanoma; Neoplasm Metastasis; Neoplasms; Neuroendocrine Tumors; Osteosarcoma; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Peritoneal Neoplasms; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Renal Cancer; Rhabdomyosarcoma; Sarcoma; Small Cell Lung Carcinoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Stomach Carcinoma; Stomach Neoplasms; Synovial Sarcoma; Urethral Neoplasms; Urinary Bladder Neoplasms; Wilms Tumor",Denmark; France; Germany; Netherlands; Spain; United Kingdom; United States
"A Phase I/II Study of Oral Selpercatinib (LOXO-292) in Patients With Advanced Solid Tumors, Including RET Fusion-Positive Solid Tumors, Medullary Thyroid Cancer, and Other Tumors With RET Activation (LIBRETTO-001)",I/II,Open,"Eli Lilly
Eli Lilly/Loxo Oncology","Oncology: Bile Duct (Cholangiocarcinoma); Oncology: Breast; Oncology: Colorectal; Oncology: Lung, Non-Small Cell; Oncology: Neuroendocrine; Oncology: Ovarian; Oncology: Pancreas; Oncology: Small Intestine; Oncology: Soft Tissue Sarcoma; Oncology: Thyroid; Oncology: Unspecified Solid Tumor",Adenocarcinoma; Anaplastic; First line; Follicular; Fourth line or greater; Large Cell; Medullary; Other; Papillary; Second line; Squamous Cell; Stage I; Stage II; Stage III; Stage IV; Third line,"Bile Duct Neoplasms; Breast Neoplasms; Carcinoma, Neuroendocrine; Carcinoma, Non-Small-Cell Lung; Cholangiocarcinoma; Colonic Neoplasms; Colorectal Neoplasms; Fibrosarcoma; Intestinal Neoplasms; Leiomyosarcoma; Liposarcoma; Lung Neoplasms; Neoplasms, Unknown Primary; Neuroendocrine Tumors; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Synovial Sarcoma; Thyroid Diseases; Thyroid Neoplasms","Australia; Canada; Denmark; France; Germany; Hong Kong, S.A.R., China; Israel; Italy; Japan; Netherlands; Poland; Singapore; South Korea; Spain; Switzerland; Taiwan, China; United Kingdom; United States"
A Phase I Multiple-Dose Study to Evaluate the Safety and Tolerability of XmAb23104 in Subjects With Selected Advanced Solid Tumor,I,Open,Xencor,"Oncology: Bladder; Oncology: Breast; Oncology: Cervical; Oncology: Colorectal; Oncology: Endometrial; Oncology: Esophageal; Oncology: Gastric; Oncology: Head/Neck; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Lung, Small Cell; Oncology: Melanoma; Oncology: Neuroendocrine; Oncology: Pancreas; Oncology: Renal; Oncology: Soft Tissue Sarcoma; Oncology: Unspecified Solid Tumor",(N/A); Adenocarcinoma; HER2 negative; Large Cell; MSI-H/dMMR; MSS/pMMR; PD-1 Refractory; PD-L1 Refractory; Pulmonary; Second line; Stage III; Stage IV; Triple receptor negative,"Breast Neoplasms; Carcinoma; Carcinoma, Endometrioid; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Carcinoma, Small Cell; Colorectal Neoplasms; Endometrial Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Fibrosarcoma; Head and Neck Neoplasms; Histiocytoma, Malignant Fibrous; Kidney Neoplasms; Leiomyosarcoma; Liposarcoma; Liver Cancer; Liver Neoplasms; Lung Neoplasms; Melanoma; Nasopharyngeal Carcinoma; Neoplasms, Unknown Primary; Neuroendocrine Tumors; Pancreatic Cancer; Pancreatic Neoplasms; Renal Cancer; Rhabdomyosarcoma; Sarcoma; Small Cell Lung Carcinoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Squamous Cell Carcinoma of Head and Neck; Stomach Carcinoma; Stomach Neoplasms; Synovial Sarcoma; Urethral Neoplasms; Urinary Bladder Neoplasms; Uterine Cervical Neoplasms; Wilms Tumor",United States
Phase I/II With Expansion Cohorts in a Study of NEO-201 in Adults With Chemo-Resistant Solid Tumors,I/II,Open,"National Institutes of Health/National Cancer Institute;
Precision Biologics {Neogenix}","Oncology: Breast; Oncology: Cervical; Oncology: Colorectal; Oncology: Endometrial; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Metastatic Cancer; Oncology: Pancreas",BRAF; MSI-H/dMMR; MSS/pMMR; Other mets; PD-1 Refractory; PD-L1 Positive; PD-L1 Refractory; Second line; Squamous Cell; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Colorectal Neoplasms; Endometrial Neoplasms; Head and Neck Neoplasms; Neoplasm Metastasis; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Squamous Cell Carcinoma of Head and Neck; Uterine Cervical Neoplasms; Uterine Neoplasms",United States
"An Open-label, Multicenter Phase I Dose Escalation Study to Characterize Safety, Tolerability, Preliminary Anti-tumor Activity, Pharmacokinetics and Maximum Tolerated Dose of VIP152 (BAY 1251152) as Monotherapy or Combination Therapy in Subjects With Advanced Cancer.",I,Open,Bayer AG/Bayer Pharmaceuticals,"Oncology: Breast; Oncology: Colorectal; Oncology: Lymphoma, Non-Hodgkin's; Oncology: Ovarian; Oncology: Pancreas; Oncology: Prostate; Oncology: Unspecified Solid Tumor",Aggressive; Diffuse large B-cell lymphoma (DLBCL); Follicular lymphoma (FL); Fourth line or greater; HER2 negative; Mantle cell lymphoma (MCL); Second line; Stage III; Stage IV; Third line; Triple receptor negative,"Breast Neoplasms; Colorectal Neoplasms; Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Large-Cell, Anaplastic; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Neoplasms, Unknown Primary; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Prostatic Neoplasms; Unspecified",Chile; Spain; United States
A Phase Ib/IIa Three-Part Open-Label Multicenter Study to Evaluate the Safety and Efficacy of LY2880070 as Monotherapy and in Combination With Gemcitabine in Patients With Advanced or Metastatic Cancer,I/II,Open,Esperas Pharma,Oncology: Breast; Oncology: Colorectal; Oncology: Endometrial; Oncology: Ovarian; Oncology: Pancreas; Oncology: Soft Tissue Sarcoma; Oncology: Unspecified Solid Tumor,Fourth line or greater; HER2 negative; Second line; Stage III; Stage IV; Third line; Triple receptor negative,"Breast Neoplasms; Carcinoma, Endometrioid; Colorectal Neoplasms; Endometrial Neoplasms; Fibrosarcoma; Leiomyosarcoma; Liposarcoma; Neoplasm Metastasis; Neoplasms; Neoplasms, Unknown Primary; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Synovial Sarcoma; Triple Negative Breast Neoplasms",Canada; United States
"A Phase I/II Study of the Safety, Pharmacokinetics, and Anti-Tumor Activity of the Oral EGFR/HER2 Inhibitor TAK-788 (AP32788) in Non-Small Cell Lung Cancer.",I/II,Open,Takeda,"Oncology: Bile Duct (Cholangiocarcinoma); Oncology: Bladder; Oncology: Breast; Oncology: Esophageal; Oncology: Gallbladder; Oncology: Gastric; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Metastatic Cancer; Oncology: Unspecified Solid Tumor",CNS mets; EGFR; First line; Fourth line or greater; HER2 positive; Second line; Stage III; Stage IV; Third line,"Bile Duct Neoplasms; Brain Neoplasms; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Central Nervous System Neoplasms; Cholangiocarcinoma; Esophageal Cancer; Esophageal Neoplasms; Gallbladder Neoplasms; Head and Neck Neoplasms; Neoplasm Metastasis; Neoplasms, Unknown Primary; Stomach Carcinoma; Stomach Neoplasms; Urethral Neoplasms; Urinary Bladder Neoplasms","China; France; Germany; Italy; Japan; South Korea; Spain; Taiwan, China; United Kingdom; United States"
Phase I Study of Carfilzomib in Combination With Cyclophosphamide and Etoposide for Children With Relapsed and Refractory Solid Tumors and Leukemias,I,Open,"Amgen {Onyx Pharmaceuticals}
(Other Hospital/Academic/Medical Center);","Oncology: Bladder; Oncology: Breast; Oncology: Colorectal; Oncology: Esophageal; Oncology: Gastric; Oncology: Leukemia, Acute Lymphocytic; Oncology: Leukemia, Acute Myelogenous; Oncology: Leukemia, Chronic Lymphocytic; Oncology: Leukemia, Chronic Myelogenous; Oncology: Lung, Non-Small Cell; Oncology: Lung, Small Cell; Oncology: Lymphoma, Hodgkin's; Oncology: Lymphoma, Non-Hodgkin's; Oncology: Multiple Myeloma; Oncology: Neuroendocrine; Oncology: Prostate; Oncology: Renal; Oncology: Soft Tissue Sarcoma; Oncology: Thyroid; Oncology: Unspecified Solid Tumor",(N/A); Aggressive; Classical; Indolent; Nodular lymphocyte-predominant; Pediatric or Adolescent; Pulmonary; Second line,"Acute Myelocytic Leukemia; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Carcinoma, Small Cell; Chronic Lymphocytic Leukemia; Chronic Myeloid Leukemia; Colorectal Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Fibrosarcoma; Hodgkin Disease; Hodgkin Lymphoma; Kidney Neoplasms; Leiomyosarcoma; Leukemia; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Liposarcoma; Lymphoma, Large-Cell, Anaplastic; Lymphoma, Non-Hodgkin; Multiple Myeloma; Neoplasms; Neoplasms, Unknown Primary; Neuroendocrine Tumors; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prostatic Neoplasms; Renal Cancer; Rhabdomyosarcoma; Sarcoma; Small Cell Lung Carcinoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Stomach Carcinoma; Stomach Neoplasms; Synovial Sarcoma; Thyroid Neoplasms; Urethral Neoplasms; Urinary Bladder Neoplasms; Wilms Tumor",United States
"Phase I/II Study of the Anti-Programmed Death Ligand-1 Antibody Durvalumab (MEDI4736) in Combination With Olaparib and/or Cediranib for Advanced Solid Tumors and Advanced or Recurrent Ovarian, Triple Negative Breast, Lung, Prostate and Colorectal Cancers",I/II,Open,National Institutes of Health/National Cancer Institute;,"Oncology: Breast; Oncology: Cervical; Oncology: Colorectal; Oncology: Endometrial; Oncology: Fallopian Tube; Oncology: Lung, Non-Small Cell; Oncology: Lung, Small Cell; Oncology: Neuroendocrine; Oncology: Ovarian; Oncology: Primary Peritoneal; Oncology: Prostate; Oncology: Soft Tissue Sarcoma; Oncology: Unspecified Solid Tumor",ALK; BRAF; BRCA; EGFR; Fourth line or greater; HER2 negative; Hormone refractory; PD-1 High; PD-1 Naive; PD-L1 Naive; PD-L1 Positive; Pulmonary; Second line; Squamous Cell; Stage III; Stage IV; Third line; Triple receptor negative,"Breast Neoplasms; Carcinoma, Endometrioid; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Colorectal Neoplasms; Endometrial Neoplasms; Fallopian Tube Neoplasms; Fibrosarcoma; Leiomyosarcoma; Liposarcoma; Neoplasms; Neoplasms, Unknown Primary; Neuroendocrine Tumors; Ovarian Cancer; Ovarian Neoplasms; Peritoneal Neoplasms; Prostatic Neoplasms; Rhabdomyosarcoma; Sarcoma; Small Cell Lung Carcinoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Synovial Sarcoma; Uterine Cervical Neoplasms",United States
Phase I Trial of the Combination of Nilotinib and Paclitaxel in Adults and Pediatric Patients With Refractory Solid Tumors,I,Open,National Institutes of Health/National Cancer Institute;,"Oncology: Anal; Oncology: Bile Duct (Cholangiocarcinoma); Oncology: Bladder; Oncology: Breast; Oncology: Colorectal; Oncology: Endometrial; Oncology: Lung, Non-Small Cell; Oncology: Neuroendocrine; Oncology: Osteosarcoma; Oncology: Ovarian; Oncology: Small Intestine; Oncology: Soft Tissue Sarcoma; Oncology: Unspecified Solid Tumor",Metastatic; Second line; Stage III; Stage IV,"Anus Neoplasms; Bile Duct Neoplasms; Breast Neoplasms; Carcinoma, Endometrioid; Carcinoma, Non-Small-Cell Lung; Cholangiocarcinoma; Colorectal Neoplasms; Endometrial Neoplasms; Ewing Sarcoma; Fibrosarcoma; Intestinal Neoplasms; Leiomyosarcoma; Liposarcoma; Neoplasms; Neoplasms, Unknown Primary; Neuroendocrine Tumors; Osteosarcoma; Ovarian Neoplasms; Rhabdomyosarcoma; Sarcoma; Synovial Sarcoma; Urethral Neoplasms; Urinary Bladder Neoplasms",United States
"A Phase I, Open-Label, Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Clinical Activity of OB318 in Patients With Advanced Solid Malignancies",I,Open,Microbio Group/Microbio/Oneness Biotech,"Oncology: Breast; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Prostate; Oncology: Unspecified Solid Tumor",Second line; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Liver Cancer; Liver Neoplasms; Neoplasms; Neoplasms, Unknown Primary; Prostatic Neoplasms","Taiwan, China; United States"
"A Phase I/II Study of MCLA-128, a Full Length IgG1 Bispecific Antibody Targeting HER2 and HER3, in Patients With Solid Tumors (eNRGy)",I/II,Open,"(Other Industry Sponsor)
(Other Hospital/Academic/Medical Center);
Merus","Oncology: Breast; Oncology: Colorectal; Oncology: Endometrial; Oncology: Esophageal; Oncology: Gastric; Oncology: Lung, Non-Small Cell; Oncology: Neuroendocrine; Oncology: Ovarian; Oncology: Pancreas; Oncology: Renal; Oncology: Soft Tissue Sarcoma; Oncology: Unspecified Solid Tumor",Adenocarcinoma; Fourth line or greater; HER2 positive; Large Cell; Second line; Squamous Cell; Stage III; Stage IV; Third line,"Breast Neoplasms; Carcinoma, Endometrioid; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Colorectal Neoplasms; Endometrial Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Fibrosarcoma; Kidney Neoplasms; Leiomyosarcoma; Liposarcoma; Neoplasms, Unknown Primary; Neuroendocrine Tumors; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Renal Cancer; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Stomach Carcinoma; Stomach Neoplasms; Synovial Sarcoma; Wilms Tumor","Austria; Belgium; Canada; Denmark; France; Germany; Israel; Italy; Japan; Netherlands; Norway; Portugal; Singapore; South Korea; Spain; Sweden; Taiwan, China; United Kingdom; United States"
"A Modular Phase I, Open-Label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumour Activity of Ceralasertib in Combination With Cytotoxic Chemotherapy and/or DNA Damage Repair/Novel Anti-cancer Agents in Patients With Advanced Solid Malignancies.",I,Open,AstraZeneca;,"Oncology: Breast; Oncology: Cervical; Oncology: Colorectal; Oncology: Esophageal; Oncology: Gastric; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Lung, Small Cell; Oncology: Mesothelioma; Oncology: Neuroendocrine; Oncology: Ovarian; Oncology: Prostate",Adenocarcinoma; BRCA; HER2 negative; Pulmonary; Second line; Stage III; Stage IV; Third line; Triple receptor negative,"Adenocarcinoma; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Colorectal Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Head and Neck Neoplasms; Mesothelioma; Neoplasms; Neoplasms, Mesothelial; Neuroendocrine Tumors; Ovarian Cancer; Ovarian Neoplasms; Prostatic Neoplasms; Small Cell Lung Carcinoma; Stomach Carcinoma; Stomach Neoplasms; Uterine Cervical Neoplasms",Australia; Canada; France; South Korea; Spain; United Kingdom; United States
A Safety and Efficacy Study of dCellVax in Patients with Advanced Metastatic Breast Cancer,I/II,Planned,Regen BioPharma,Oncology: Breast,Line of therapy N/A; Stage III; Stage IV,Breast Neoplasms,United States
Randomized Phase II Study of Partial Breast Irradiation and Sequential vs. Concurrent Chemotherapy in Women with Early Stage Breast Cancer (PBI 3.0).,I/II,Open,(Other Hospital/Academic/Medical Center);,Oncology: Breast,Adjuvant; Estrogen receptor positive; Stage I; Stage II,Breast Neoplasms,United States
EphA2 Gene Targeting Using Neutral Liposomal Small Interfering RNA Delivery: A Phase I Clinical Trial.,I,Open,"(Other Cooperative Group);
MD Anderson Cancer Center University of Texas;
National Institutes of Health/National Cancer Institute;
(Other Hospital/Academic/Medical Center);",Oncology: Breast; Oncology: Ovarian; Oncology: Prostate; Oncology: Unspecified Solid Tumor,Line of therapy N/A; Stage III; Stage IV,"Breast Neoplasms; Neoplasms; Neoplasms, Unknown Primary; Ovarian Cancer; Ovarian Neoplasms; Prostatic Neoplasms",United States
Phase I Active Immunotherapy Trial with a Combination of Two Chimeric (Trastuzumab-like and Pertuzumab-like) Human Epidermal Growth Factor Receptor 2 (HER-2) B Cell Peptide Vaccine Emulsified in ISA 720 and Nor-MDP Adjuvant in Patients with Advanced Solid Tumors,I/II,Open,"National Institutes of Health/National Cancer Institute;
Ohio State University",Oncology: Breast; Oncology: Cervical; Oncology: Colorectal; Oncology: Endometrial; Oncology: Esophageal; Oncology: GIST; Oncology: Ovarian; Oncology: Pancreas; Oncology: Soft Tissue Sarcoma; Oncology: Unspecified Solid Tumor,EGFR; Fourth line or greater; HER2 positive; Second line; Stage III; Stage IV; Third line,"Breast Neoplasms; Carcinoma, Endometrioid; Colorectal Neoplasms; Endometrial Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Fibrosarcoma; Gastrointestinal Stromal Tumors; Leiomyosarcoma; Liposarcoma; Neoplasms; Neoplasms, Unknown Primary; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Synovial Sarcoma; Uterine Cervical Neoplasms",United States
BettER: Biomarker Driven Early Therapeutic Selection in Patients With HR+ HER2- Metastatic or Unresectable Breast Cancer,II,Planned,"Washington University School of Medicine
BioVica AB",Oncology: Breast,Estrogen receptor positive; HER2 negative; Progesterone receptor positive; Second line; Stage III; Stage IV,Breast Neoplasms,United States
RETENTION: An Open-Label Phase II Trial of InteRlEukin (5) InhibiTion for the prEveNTION of Alpelisib Rash in Metastatic PIK3CA-mutant Hormone-Receptor Positive Breast Cancer,II,Open,"AstraZeneca;
Novartis;
Memorial Sloan-Kettering Cancer Center",Oncology: Breast,Estrogen receptor positive; HER2 negative; Progesterone receptor positive; Second line; Stage IV,Breast Neoplasms,United States
"An Open-label, Interventional, Multicenter, Randomized, Phase II Study of Fulvestrant With or Without Samuraciclib in Participants With Metastatic or Locally Advanced Hormone Receptor (HR) Positive and Human Epidermal Growth Factor Receptor (HER)2-Negative Breast Cancer (BC)",II,Open,"Pfizer;
Carrick Therapeutics",Oncology: Breast,Estrogen receptor positive; HER2 negative; Progesterone receptor positive; Second line; Stage III; Stage IV,Breast Neoplasms,United States
"Phase II, Multi-Center, Randomized, Open-Label Trial of BDC-1001 as a Single Agent and in Combination With Pertuzumab in Subjects With HER2-Positive Metastatic Breast Cancer Previously Treated With Trastuzumab Deruxtecan",II,Planned,"Roche; {F. Hoffmann-La Roche;}
Bolt Biotherapeutics",Oncology: Breast,Fourth line or greater; HER2 positive; Second line; Stage III; Stage IV; Third line,Breast Neoplasms,South Korea; United States
OCTANE: Adjuvant Liposomal Doxorubicin and Carboplatin for Early-stage Triple Negative Breast Cancer,II,Planned,(Other Hospital/Academic/Medical Center);,Oncology: Breast,(N/A); Adjuvant; First line; Triple receptor negative,Breast Neoplasms; Triple Negative Breast Neoplasms,United States
Phase IIA Trial of Acolbifene (20 mg) vs Low Dose Tamoxifen (5 mg) in Pre-Menopausal Women at High Risk for Development of Breast Cancer,II,Planned,National Institutes of Health/National Cancer Institute;,Oncology: Breast; Oncology: Ovarian,(N/A); Line of therapy N/A,"Breast Carcinoma In Situ; Breast Neoplasms; Carcinoma; Carcinoma in Situ; Carcinoma, Ductal; Carcinoma, Ductal, Breast; Carcinoma, Intraductal, Noninfiltrating; Carcinoma, Lobular; Hyperplasia; Ovarian Neoplasms",United States
Genetically-informed Therapy for ER+ Breast Cancer in a Post-CDK4/6 Inhibitor Setting: a Phase II Umbrella Study (GERTRUDE),II,Planned,Dartmouth-Hitchcock Medical Center,Oncology: Breast,Estrogen receptor positive; HER2 negative; Second line; Stage III; Stage IV,Breast Neoplasms,United States
Neoadjuvant Neratinib in Stage I-III HER2-Mutated Lobular Breast Cancers,II,Planned,"National Institutes of Health/National Cancer Institute;
Vanderbilt-Ingram Cancer Center
Puma Biotechnology",Oncology: Breast,Estrogen receptor positive; HER2 negative; Neoadjuvant; Stage I; Stage II; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Lobular",United States
"A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo As Maintenance Therapy After First Line Induction Therapy in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer",III,Open,Roche; {F. Hoffmann-La Roche;},Oncology: Breast,HER2 positive; Maintenance/Consolidation; Second line; Stage III; Stage IV,Breast Neoplasms,Argentina; South Korea; United States
Window of Opportunity Analysis of Pre-Operative Tucatinib for Surgically Resected HER2+ Brain Metastases: Understanding Mechanisms of Resistance,II,Open,"Memorial Sloan-Kettering Cancer Center
Seagen","Oncology: Breast; Oncology: Colorectal; Oncology: Esophageal; Oncology: Gastric; Oncology: Lung, Non-Small Cell; Oncology: Metastatic Cancer",CNS mets; First line; HER2 positive; MET Amplification/Alteration; Neoadjuvant; Second line; Stage IV,"Brain Neoplasms; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Central Nervous System Neoplasms; Colorectal Neoplasms; Esophageal Neoplasms; Neoplasm Metastasis; Stomach Neoplasms",United States
A Study of the Natural History of Ado-trastuzumab Emtansine (T-DM1)-Induced Peripheral Neuropathy in HER2-positive Breast Cancer Patients,IV,Open,Mayo Clinic;,Oncology: Breast,Adjuvant; HER2 positive; Second line; Stage I; Stage II; Stage III; Stage IV,Breast Neoplasms,United States
Evaluating and Monitoring Immune and Clinical Responses in Early-Stage Triple Negative Breast Cancer Undergoing Neoadjuvant Chemo-immunotherapy With Pembrolizumab,IV,Planned,"National Institutes of Health/National Cancer Institute;
(Other Hospital/Academic/Medical Center);",Oncology: Breast,Estrogen receptor positive; HER2 negative; Neoadjuvant; Progesterone receptor positive; Stage I; Stage II; Stage III; Stage IV; Triple receptor negative,Breast Neoplasms,United States
"A Phase II, Multicenter, Randomized, Double-Blind Study of RO7247669 Combined With Nab-Paclitaxel Compared With Pembrolizumab Combined With Nab-Paclitaxel in Participants With Previously Untreated, PD-L1-Positive, Locally-Advanced Unresectable or Metastatic Triple-Negative Breast Cancer",II,Open,Roche; {F. Hoffmann-La Roche;},Oncology: Breast,First line; HER2 negative; PD-L1 Positive; Stage III; Stage IV; Triple receptor negative,Breast Neoplasms; Triple Negative Breast Neoplasms,United States
A Phase II Trial of Carboplatin +/- Tocilizumab as Initial Therapy for Metastatic Triple Negative and ER-low Breast Cancers,II,Planned,"Indiana University Cancer Center
Roche;Genentech;",Oncology: Breast,First line; HER2 negative; Stage III; Stage IV; Triple receptor negative,Breast Neoplasms; Triple Negative Breast Neoplasms,United States
"A Randomized, Open-label, Phase III Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Patients With Hormone Receptor-Positive (HR+)/Human Epidermal Growth Factor Receptor 2 Negative (HER2-) (HER2 IHC0 or HER2-low [IHC 1+, IHC 2+/ISH-]) Inoperable, Locally Advanced, or Metastatic Breast Cancer and Have Received Endocrine Therapy",III,Open,Gilead Sciences;,Oncology: Breast,Estrogen receptor positive; Fourth line or greater; HER2 negative; Progesterone receptor positive; Stage III; Stage IV; Third line,Breast Neoplasms,United States
"NeoTAILOR: A Phase II Biomarker-directed Approach to Guide Neoadjuvant Therapy for Patients With Stage II/III ER-positive, HER2-negative Breast Cancer",II,Planned,Washington University School of Medicine,Oncology: Breast,Estrogen receptor positive; HER2 negative; Neoadjuvant; Stage II; Stage III,Breast Neoplasms,United States
A Pivotal Phase III Monotherapy Clinical Trial Of OP-1250 In Second- And Third Line Setting in Patients with ER+/HER2- Metastatic Breast Cancer,III,Planned,Olema Oncology,Oncology: Breast,Estrogen receptor positive; HER2 negative; Second line; Stage IV; Third line,Breast Neoplasms,Australia; United States
"Levels of Circulating Tumor DNA as a Predictive Marker for Early Switch in Treatment for Patients With Metastatic (Stage IV) Breast Cancer: A Phase II  Randomized, Open-Label Study",II,Open,(Other Hospital/Academic/Medical Center);,Oncology: Breast,Estrogen receptor positive; HER2 negative; Line of therapy N/A; Stage IV,Breast Neoplasms,United States
OptimICE-PCR: De-Escalation of Therapy in Early-Stage TNBC Patients Who Achieve pCR After Neoadjuvant Chemotherapy With Checkpoint Inhibitor Therapy,III,Open,"National Institutes of Health/National Cancer Institute;
Alliance for Clinical Trials in Oncology",Oncology: Breast,Estrogen receptor positive; HER2 negative; Neoadjuvant; Progesterone receptor positive; Stage I; Stage II; Stage III; Triple receptor negative,Breast Neoplasms,United States
Iron Replacement to Reduce Anemia During Neoadjuvant Chemotherapy,II,Open,Fox Chase Cancer Center,Oncology: Bladder; Oncology: Breast; Oncology: Colorectal; Oncology: Gastric; Oncology: Prostate; Oncology: Renal; Oncology: Supportive Care,(N/A); Anemia; Neoadjuvant,"Anemia; Breast Neoplasms; Carcinoma, Renal Cell; Colorectal Neoplasms; Kidney Neoplasms; Palliative Care; Prostatic Neoplasms; Stomach Neoplasms; Urethral Neoplasms; Urinary Bladder Neoplasms; Wilms Tumor",United States
"TRUDI: A Phase II Study of Neoadjuvant Trastuzumab Deruxtecan and Durvalumab for Stage III, HER2-expressing Inflammatory Breast Cancer",II,Open,"AstraZeneca;
Daiichi Sankyo",Oncology: Breast,Estrogen receptor positive; HER2 positive; Neoadjuvant; Progesterone receptor positive; Stage III,Adenocarcinoma; Breast Neoplasms; Inflammatory Breast Neoplasms,United States
"A Phase III, Open-Label, Randomised Study to Assess the Efficacy and Safety of Extended Therapy With Camizestrant Versus Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) in Patients With ER+/HER2- Early Breast Cancer",III,Open,"AstraZeneca;
Thermo Fisher Scientific/Patheon",Oncology: Breast,Estrogen receptor positive; HER2 negative; Second line; Stage I; Stage II; Stage III,Breast Neoplasms,Argentina; Australia; Austria; Belgium; Brazil; Bulgaria; Canada; Chile; China; Colombia; Czech Republic; France; Georgia; Germany; Hungary; India; Israel; Italy; Japan; Malaysia; Mexico; Netherlands; Peru; Philippines; Poland; Portugal; Romania; Serbia; Singapore; South Africa; South Korea; Spain; Thailand; Turkey; United Kingdom; United States; Vietnam
A Randomized Clinical Trial Comparing ctDNA-Directed Therapy Change With Standard of Care in Patients With Metastatic Triple Negative Breast Cancer,II,Planned,"National Institutes of Health/National Cancer Institute;
Vanderbilt-Ingram Cancer Center",Oncology: Breast,Estrogen receptor positive; First line; HER2 negative; Progesterone receptor positive; Stage IV; Triple receptor negative,Breast Neoplasms; Carcinoma,United States
An Early Phase and Phase II Clinical Trial to Evaluate Ganglioside-Monosialic Acid (GM1) for Preventing Paclitaxel-Associated Neuropathy,II,Open,"National Institutes of Health/National Cancer Institute;
Alliance for Clinical Trials in Oncology",CNS: Pain (neuropathic); Oncology: Breast; Oncology: Supportive Care,Cancers-related; Neurotoxicity; Second line; Stage IV,Breast Neoplasms; Cancer pain; Cancer Pain; Neuralgia; Palliative Care; Peripheral Nervous System Diseases,United States
An Evaluation of FACIT-Fatigue in Patients with Locally Advanced or Metastatic Breast Cancer receiving Treatment with Taxane-based Chemotherapy,IV,Open,(Other Hospital/Academic/Medical Center);,Oncology: Breast,Line of therapy N/A; Stage III; Stage IV,Breast Neoplasms,Italy; United States
Impact of Beta-2 Adrenergic Blockade With Checkpoint Inhibition in Checkpoint Inhibitor Refractory Metastatic Triple Negative Breast Cancer,II,Planned,Roswell Park Cancer Institute,Oncology: Breast,First line; HER2 negative; PD-1 Refractory; PD-L1 Refractory; Second line; Stage IV; Triple receptor negative,Breast Neoplasms; Carcinoma; Triple Negative Breast Neoplasms,United States
The STOP-HER2 Trial: A Phase II Study of Stopping Trastuzumab - Outcomes in Patients With HER2+ Metastatic Breast Cancer,II,Open,"(Other Academic Cancer Center)
National Institutes of Health/National Cancer Institute;
Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute;
Johns Hopkins University
Susan G. Komen {Susan G. Komen Breast Cancer Research Foundation}",Oncology: Breast,Estrogen receptor positive; First line; HER2 positive; Stage IV,Breast Neoplasms,United States
Phase II Study of Estradiol Therapy to Target ER-Mutant and ER-Wild-Type ER+ Metastatic or Advanced Breast Cancer,II,Open,Dartmouth-Hitchcock Medical Center,Oncology: Breast,Estrogen receptor positive; Progesterone receptor positive; Second line; Stage III; Stage IV,Breast Neoplasms,United States
A Phase III Randomized Trial of Radiotherapy Optimization for Low-Risk HER2-Positive Breast Cancer (HERO),III,Open,"Eastern Cooperative Oncology Group (ECOG)
Southwest Oncology Group
National Institutes of Health/National Cancer Institute;
Alliance for Clinical Trials in Oncology
NRG Oncology",Oncology: Breast,(N/A); Adjuvant; HER2 positive,Breast Neoplasms,United States
Phase II Trial of the PARP Inhibitor Niraparib and PD-1 Inhibitor Dostarlimab in Patients With Advanced Cancers With Active Progressing Brain Metastases (STARLET),II,Planned,MD Anderson Cancer Center University of Texas;,"Oncology: Breast; Oncology: Lung, Non-Small Cell; Oncology: Lung, Small Cell; Oncology: Metastatic Cancer; Oncology: Neuroendocrine",(N/A); CNS mets; HER2 negative; PD-L1 Positive; Pulmonary; Second line; Stage III; Stage IV; Triple receptor negative,"Brain Neoplasms; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Central Nervous System Neoplasms; Neoplasm Metastasis; Neuroendocrine Tumors; Small Cell Lung Carcinoma",United States
An Observational Study of Women With Breast Cancer Examining the Effect of Endocrine Therapy on Aging,IV,Open,(Other Hospital/Academic/Medical Center);,Oncology: Breast,Line of therapy N/A; Stage I; Stage II; Stage III,Arthralgia; Breast Neoplasms,United States
Integrating Gene Signatures to Guide HR+MBC Therapy in a Diverse Cohort (INSIGHT),II,Open,"Vanderbilt-Ingram Cancer Center
Susan G. Komen {Susan G. Komen Breast Cancer Research Foundation}
Agendia",Oncology: Breast,Estrogen receptor positive; HER2 negative; Progesterone receptor positive; Second line; Stage IV,Breast Neoplasms,United States
"Phase 2, Single Center, Single Arm Study to Evaluate the Decrease in CIPN With the Addition of Hydroxychloroquine to Chemotherapy in Patients With Early Stage (1-3) Breast Cancer and Gynecological Cancers Treated With Curative Intent",II,Planned,University of Arizona,Oncology: Breast; Oncology: Cervical; Oncology: Endometrial; Oncology: Fallopian Tube; Oncology: Ovarian; Oncology: Primary Peritoneal,(N/A); First line; Line of therapy N/A; Stage I; Stage II; Stage III,Breast Neoplasms; Endometrial Neoplasms; Fallopian Tube Neoplasms; Ovarian Neoplasms; Peripheral Nervous System Diseases; Peritoneal Neoplasms; Uterine Cervical Neoplasms,United States
"Definitive Local Consolidative Therapy for Oligometastatic Solid Tumors: Results from the Lead-In Phase of the Randomized Basket Trial EXTEND

EXTernal beam radiation to Eliminate Nominal metastatic disease",II,Open,University of Texas,"Oncology: Bile Duct (Cholangiocarcinoma); Oncology: Breast; Oncology: Cervical; Oncology: Colorectal; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Ovarian; Oncology: Pancreas; Oncology: Prostate; Oncology: Renal; Oncology: Soft Tissue Sarcoma",Line of therapy N/A; Stage IV,"Bile Duct Neoplasms; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Cholangiocarcinoma; Colorectal Neoplasms; Fibrosarcoma; Head and Neck Neoplasms; Kidney Neoplasms; Leiomyosarcoma; Liposarcoma; Melanoma; Ovarian Neoplasms; Pancreatic Neoplasms; Prostatic Neoplasms; Rhabdomyosarcoma; Sarcoma; Synovial Sarcoma; Uterine Cervical Neoplasms; Wilms Tumor",United States
A Phase II Study of Neoadjuvant Sacituzumab Govitecan and Pembrolizumab Therapy for Immunochemotherapy-resistant Early-stage Triple-negative Breast Cancer (TNBC),II,Open,"MD Anderson Cancer Center University of Texas;
Gilead Sciences;",Oncology: Breast,HER2 negative; Neoadjuvant; Stage I; Triple receptor negative,Breast Neoplasms; Triple Negative Breast Neoplasms,United States
A Phase II Study of Tucatinib and Ado-trastuzumab Emtansine (T-DM1) in Patients With HER2-positive Metastatic Solid Tumors and Metastases to Brain (TUCATEMEB),II,Open,"MD Anderson Cancer Center University of Texas;
Roche;Genentech;
Seagen",Oncology: Breast; Oncology: Gastric; Oncology: Metastatic Cancer,CNS mets; HER2 positive; Second line; Stage IV,Brain Neoplasms; Breast Neoplasms; Central Nervous System Neoplasms; Neoplasm Metastasis; Stomach Neoplasms,United States
Phase II Trial of Alpelisib With iNOS Inhibitor and Nab-paclitaxel in Patients With HER2 Negative Metastatic or Locally Advanced Metaplastic Breast Cancer (MpBC),II,Open,"Novartis;
(Other Hospital/Academic/Medical Center);",Oncology: Breast,First line; HER2 negative; Second line; Stage III; Stage IV; Triple receptor negative,Breast Neoplasms; Triple Negative Breast Neoplasms,United States
"A phase III trial comparing ARV-471 (PF-07850327) with fulvestrant in subjects with estrogen receptor-positive, HER2-negative advanced breast cancer who had progressed on prior endocrine-based therapy for advanced disease , randomized, open, multicenter trial (VERITAC-2)",III,Open,"Pfizer;
Arvinas;",Oncology: Breast,Estrogen receptor positive; First line; HER2 negative; Second line; Stage III; Stage IV,Breast Neoplasms,"Australia; Austria; Belgium; Brazil; Bulgaria; Canada; China; Czech Republic; Finland; France; Germany; Greece; Hungary; India; Israel; Italy; Japan; Mexico; Norway; Poland; Puerto Rico; Slovakia; South Africa; South Korea; Spain; Sweden; Switzerland; Taiwan, China; Turkey; United Kingdom; United States"
"A Phase III, Multicenter, Randomized, Open-Label Study Evaluating the Efficacy and Safety of Inavolisib Plus Fulvestrant Versus Alpelisib Plus Fulvestrant in Patients With Hormone Receptor-Positive, HER2-Negative, PIK3CA Mutated, Locally Advanced or Metastatic Breast Cancer Who Progressed During or After CDK4/6 Inhibitor and Endocrine Combination Therapy",III,Open,Roche; {F. Hoffmann-La Roche; {Memory Pharmaceuticals}},Oncology: Breast,Estrogen receptor positive; HER2 negative; Progesterone receptor positive; Second line; Stage III; Stage IV,Breast Neoplasms,"Argentina; Mexico; Taiwan, China; Turkey; United States"
"Open-label, Safety Extension Study for Subjects With HR+, HER2-Negative Breast Cancer Who Have Completed the OVarian Suppression Evaluating Subcutaneous LeuprolIde Acetate in Breast Cancer OVELIA Study",III,Open,Tolmar Pharmaceuticals,Oncology: Breast,(N/A); Estrogen receptor positive; HER2 negative; Line of therapy N/A; Progesterone receptor positive,Breast Neoplasms,United States
Neoadjuvant TIL- and Response-Adapted Chemoimmunotherapy for TNBC,II,Open,University of Kansas,Oncology: Breast,Estrogen receptor positive; HER2 negative; Neoadjuvant; Progesterone receptor positive; Stage II; Stage III; Stage IV; Triple receptor negative,Breast Neoplasms; Triple Negative Breast Neoplasms,United States
"A Randomized, Open-label, Phase 3 Study of Adjuvant Sacituzumab Govitecan and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy",III,Open,"Gilead Sciences;
Alliance for Clinical Trials in Oncology",Oncology: Breast,Adjuvant; Estrogen receptor positive; HER2 negative; Neoadjuvant; Progesterone receptor positive; Stage I; Stage II; Triple receptor negative,Breast Neoplasms; Triple Negative Breast Neoplasms,Japan; United States
"A Phase III Open-label, Randomised Study of Datopotamab Deruxtecan (DatoDXd) With or Without Durvalumab Versus Investigator's Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Who Have Residual Invasive Disease in the Breast and/or Axillary Lymph Nodes at Surgical Resection Following Neoadjuvant Systemic Therapy (TROPION-Breast03)",III,Open,"AstraZeneca;
Southwest Oncology Group
Daiichi Sankyo",Oncology: Breast,HER2 negative; Neoadjuvant; Stage I; Stage II; Stage III; Triple receptor negative,Breast Neoplasms,"Belgium; Brazil; Canada; China; Denmark; France; Germany; Greece; Italy; Japan; Poland; South Korea; Spain; Sweden; Taiwan, China; Turkey; United Kingdom; United States"
A Randomized Phase II Non-inferiority Trial of (Z)-Endoxifen and Exemestane + Goserelin as Neoadjuvant Treatment in Premenopausal Women With ER+/HER2- Breast Cancer,II,Open,"(Other Cooperative Group);
Atossa Therapeutics {Atossa Genetics}",Oncology: Breast,Estrogen receptor positive; HER2 negative; Neoadjuvant; Stage II,Breast Neoplasms,United States
"ELACESTRANT in Women and Men With CDK4/6 Inhibitor-Naive Estrogen Receptor Positive, HER-2 Negative Metastatic Breast Cancer: An Open-Label Multicenter Phase 2 Study (ELCIN)",II,Open,Menarini Group/Stemline Therapeutics,Oncology: Breast,Estrogen receptor positive; HER2 negative; Second line; Stage III; Stage IV,Breast Neoplasms,United States
"A Multi-center, Multi-country Prospective Observational Study of Patients Initiating T-DXd in the First or Second Treatment Line for HER2+ Unresectable and/or Metastatic Breast Cancer",IV,Open,AstraZeneca;,Oncology: Breast,First line; HER2 positive; Second line; Stage III; Stage IV,Breast Neoplasms,Brazil; United States
A ComboMATCH Treatment Trial EAY191-N2: Phase II Trial of Fulvestrant and Binimetinib in Patients With Hormone Receptor-Positive Metastatic Breast Cancer With a Frameshift or Nonsense Mutation or Genomic Deletion in NF1,II,Open,"National Institutes of Health/National Cancer Institute;
NRG Oncology",Oncology: Breast,Estrogen receptor positive; Progesterone receptor positive; Second line; Stage IV,Breast Neoplasms; Carcinoma,United States
Tranexamic Acid Usage in Bilateral Mastectomy to Reduce Post-surgical Drainage,II,Open,"Northwestern University
NorthWestern Memorial Hospital
(Other Hospital/Academic/Medical Center);",Cardiovascular: Hemostasis/Hemophilia; Oncology: Breast,(N/A); Line of therapy N/A; Surgical patients (other),Blood Coagulation Disorders; Breast Neoplasms; Hemostatic Disorders,United States
"An Open-label, Randomized, Non-comparative Phase II Study of ARV-471 or Anastrozole in Post-menopausal Women With ER+/HER2- Breast Cancer in the Neoadjuvant Setting",II,Open,"Pfizer;
Arvinas;",Oncology: Breast,Estrogen receptor positive; HER2 negative; Neoadjuvant; Stage I; Stage II; Stage III,Breast Neoplasms,Georgia; Germany; Spain; United States
A Phase I/II Study of Intratumorally Injected Autologous Dendritic Cells (DCs) in PD-L1-Negative Treatment Naïve and in Refractory Metastatic Triple Negative Breast Cancer Patients,II,Planned,Roswell Park Cancer Institute,Oncology: Breast,First line; HER2 negative; PD-L1 Naive; PD-L1 Positive; Stage III; Stage IV; Triple receptor negative,Breast Neoplasms; Carcinoma; Triple Negative Breast Neoplasms,United States
"Phase II, Open-Labeled, Single-Armed Combination Treatment With Anastrozole, Fulvestrant and Abemaciclib for Hormone Receptor Positive, HER2(-) Metastatic Breast Cancer",II,Open,University of California Medical Center; Irvine,Oncology: Breast,Estrogen receptor positive; First line; HER2 negative; Maintenance/Consolidation; Progesterone receptor positive; Second line; Stage III; Stage IV,Breast Neoplasms,United States
"An Open Label, Randomized, Multicenter Study Comparing the Efficacy and Safety of the Combination of Lasofoxifene and Abemaciclib to the Combination of Fulvestrant and Abemaciclib for the Treatment of Pre- and Postmenopausal Women and Men With Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation",III,Open,Sermonix Pharmaceuticals,Oncology: Breast,Estrogen receptor positive; HER2 negative; Line of therapy N/A; Stage III; Stage IV,Breast Neoplasms,Israel; Japan; United States
"EMBER-4: A Randomized, Open-Label, Phase 3 Study of Adjuvant Imlunestrant vs Standard Adjuvant Endocrine Therapy in Patients Who Have Previously Received 2 to 5 Years of Adjuvant Endocrine Therapy for ER+, HER2- Early Breast Cancer With an Increased Risk of Recurrence",III,Open,Eli Lilly,Oncology: Breast,Adjuvant; Estrogen receptor positive; HER2 negative; Second line; Stage I; Stage II; Stage III,Breast Neoplasms,"Argentina; Australia; Austria; Belgium; Brazil; Canada; China; Czech Republic; Finland; France; Germany; Greece; Hong Kong, S.A.R., China; Hungary; India; Ireland; Israel; Italy; Japan; Mexico; Netherlands; Poland; Portugal; Romania; Singapore; Slovakia; South Korea; Spain; Taiwan, China; Turkey; United Kingdom; United States"
ETHAN: A Phase II Study Comparing Different Endocrine Therapies for male Breast cancer,II,Planned,"Eli Lilly
(Other Cooperative Group);
Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute;",Oncology: Breast,Estrogen receptor positive; HER2 negative; Neoadjuvant; Progesterone receptor positive; Stage I; Stage II; Stage III,"Breast Neoplasms; Breast Neoplasms, Male",United States
"A Phase II, Multicentre, Open-Label Study to Assess the Efficacy and Safety of Olaparib Monotherapy and Olaparib Plus Durvalumab Combination as Neoadjuvant Therapy in Patients With BRCA Mutations and Early Stage HER2-Negative Breast Cancer",II,Open,AstraZeneca;,Oncology: Breast,HER2 negative; Neoadjuvant; Stage III,Breast Neoplasms,Australia; Austria; Belgium; France; Germany; Israel; Italy; Spain; United Kingdom; United States
Comparison of Adjuvant Monotherapy With Endocrine Therapy or Accelerated Partial Breast Irradiation Following Lumpectomy for Low Risk Breast Cancer Patients Over 65 (CAMERAN),II,Open,UNC Lineberger Comprehensive Cancer Center,Oncology: Breast,Adjuvant; Estrogen receptor positive; HER2 negative; Progesterone receptor positive; Stage I,Breast Neoplasms,United States
"A Phase II Study of Ribociclib And Endocrine Treatment of Physician's Choice for Locoregional Recurrent, Resected Hormone Receptor Positive HER2 Negative Breast Cancer",II,Open,"Novartis;
Hoosier Cancer Research Network {Hoosier Oncology Group}",Oncology: Breast,(N/A); Estrogen receptor positive; HER2 negative; Progesterone receptor positive; Second line,Breast Neoplasms; Recurrence,United States
"A Phase II Study of the Safety, Tolerability and Antitumor Activity of Tucatinib in Combination With Eribulin and Trastuzumab in Patients With Pretreated Unresectable Locally Advanced or Metastatic HER2+ Breast Cancer",II,Open,(Other Cooperative Group);,Oncology: Breast,HER2 positive; Second line; Stage III; Stage IV,Breast Neoplasms,United States
"A Phase II Trial of The Immunogenicity of a DNA Plasmid Based Vaccine (STEMVAC) Encoding Th1 Selective Epitopes From Five Antigens Associated With Breast Cancer Stem Cells (MDM2, YB1, SOX2, CDC25B, CD105) in Participants With Early Stage Triple Negative Breast Cancer",II,Open,"National Institutes of Health/National Cancer Institute;
University of Washington
University of Wisconsin",Oncology: Breast,HER2 negative; Line of therapy N/A; Stage I; Stage II; Stage III; Triple receptor negative,Breast Neoplasms; Triple Negative Breast Neoplasms,United States
"A Phase II, Multicenter, Open-Label Basket Study of Navicixizumab Monotherapy or in Combination With Paclitaxel or Irinotecan in Patients With Select Advanced Solid Tumors",II,Open,OncXerna Therapeutics {Oncologie},Oncology: Breast; Oncology: Colorectal; Oncology: Esophageal; Oncology: Fallopian Tube; Oncology: Gastric; Oncology: Ovarian; Oncology: Primary Peritoneal; Oncology: Unspecified Solid Tumor,Fourth line or greater; HER2 negative; PD-1 Refractory; PD-L1 Positive; PD-L1 Refractory; Second line; Stage III; Stage IV; Third line; Triple receptor negative,Breast Neoplasms; Colorectal Neoplasms; Esophageal Neoplasms; Fallopian Tube Neoplasms; Ovarian Neoplasms; Peritoneal Neoplasms; Stomach Neoplasms; Triple Negative Breast Neoplasms,United States
Comprehensive Single-Cell Transcriptional Analysis of Aromatase Inhibitor-Resistant Breast Cancer,II,Open,Mayo Clinic;,Oncology: Breast,Estrogen receptor positive; First line; HER2 negative; Progesterone receptor positive; Stage I; Stage II,Breast Neoplasms; Carcinoma,United States
Pilot Study to Evaluate 64Cu-DOTA-Trastuzumab Imaging in Patients With HER2+ Breast Cancer With Brain Metastatsis Treated With Fam-Trastuzumab Deruxtecan,IV,Open,"National Institutes of Health/National Cancer Institute;
City of Hope Comprehensive Cancer Center",Oncology: Breast; Oncology: Metastatic Cancer,CNS mets; HER2 positive; Second line; Stage IV,Brain Neoplasms; Breast Neoplasms; Central Nervous System Neoplasms; Neoplasm Metastasis; Neoplasms,United States
"A Randomized, Open-label, Phase III Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Patients With Previously Untreated, Locally Advanced, Inoperable or Metastatic Triple-Negative Breast Cancer Whose Tumors Do Not Express PD-L1 or in Patients Previously Treated With Anti-PD-(L)1 Agents in the Early Setting Whose Tumors Do Express PD-L1",III,Open,Gilead Sciences;,Oncology: Breast,First line; HER2 negative; PD-L1 Positive; PD-L1 Refractory; Stage III; Stage IV; Triple receptor negative,Breast Neoplasms; Triple Negative Breast Neoplasms,Argentina; Australia; Austria; Belgium; Brazil; Canada; Chile; Czech Republic; France; Germany; Hungary; Israel; Italy; Japan; Mexico; Netherlands; Peru; Poland; Puerto Rico; Romania; Russia; Slovakia; South Africa; Spain; Switzerland; Turkey; Ukraine; United Kingdom; United States
"An Open-Labeled, Single Arm Phase II Efficacy and Safety Study of REM-001 Photodynamic Therapy (PDT) for Treatment of Cutaneous Metastatic Breast Cancer (CMBC) That is Refractory or Not Eligible for Radiotherapy or Surgery",II,Planned,Kintara Therapeutics,Oncology: Breast,Estrogen receptor positive; HER2 positive; Progesterone receptor positive; Second line; Stage IV,Breast Neoplasms,United States
"Phase II Trial of the Combination of the BET Inhibitor, ZEN003694 (ZEN-3694), and the PARP Inhibitor Talazoparib, in Patients With Molecularly-Selected Solid Tumors (ComBET)",II,Open,National Institutes of Health/National Cancer Institute;,Oncology: Breast; Oncology: Ovarian; Oncology: Pancreas; Oncology: Prostate; Oncology: Unspecified Solid Tumor,(N/A); BRCA; First line; KRAS; Line of therapy N/A; Second line; Stage III; Stage IV,"Breast Neoplasms; Carcinoma; Carcinoma, Ovarian Epithelial; Neoplasms; Neoplasms, Unknown Primary; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Neoplasms; Prostatic Neoplasms",United States
"A Phase II Study of Human Epidermal Growth Factor Receptor 2 (HER-2) Directed Dendritic Cell (DC1) Vaccine Plus Weekly Paclitaxel, Trastuzumab and Pertuzumab in Patients With HER-2 Positive Breast Cancer",II,Open,"H. Lee Moffitt Cancer Center and Research Institute
ImmunoRestoration",Oncology: Breast,Estrogen receptor positive; HER2 positive; Neoadjuvant; Progesterone receptor positive; Stage I; Stage II; Stage III,Breast Neoplasms,United States
Secondary Brain Metastases Prevention After Isolated Intracranial Progression on Trastuzumab/Pertuzumab or T-DM1 In Patients With Advanced Human Epidermal Growth Factor Receptor 2+ Breast Cancer with The Addition of Tucatinib,II,Open,Seagen,Oncology: Breast,Adjuvant; First line; HER2 positive; Second line; Stage III; Stage IV,"Brain Neoplasms; Breast Neoplasms; Neoplasm Metastasis; Neoplasms, Second Primary",United States
"Phase II Trial of Fulvestrant Plus Abemaciclib With or Without Run-in of Fulvestrant in Er-Positive, Her2-Negative Metastatic Breast Cancer After Failure of a CDK4/6 Inhibitor In Combination With an Aromatase Inhibitor",II,Open,"Eli Lilly
(Other Hospital/Academic/Medical Center);",Oncology: Breast,HER2 negative; Second line; Stage IV,Breast Neoplasms,United States
"A Phase III, Randomized, Open-Label, Multicenter Study Evaluating the Efficacy and Safety of Giredestrant Plus Everolimus Compared With The Physician's Choice of Endocrine Therapy Plus Everolimus in Patients With Estrogen Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer",III,Open,Roche;Genentech;,Oncology: Breast,Adjuvant; Estrogen receptor positive; HER2 negative; Second line; Stage II; Stage III; Stage IV,Breast Neoplasms,Japan; Spain; United Kingdom; United States
A Phase IIa Study Assessing QBS72S For Treating Brain Metastases of Triple Negative Breast Cancer,II,Open,(Other Hospital/Academic/Medical Center);,Oncology: Breast; Oncology: Metastatic Cancer,CNS mets; HER2 negative; Second line; Stage I; Stage II; Triple receptor negative,Brain Neoplasms; Breast Neoplasms; Central Nervous System Neoplasms; Neoplasm Metastasis; Triple Negative Breast Neoplasms,United States
"A Phase III, Randomized, Open-Label Study Evaluating the Efficacy and Safety of Giredestrant in Combination With Phesgo Versus Phesgo After Induction Therapy With Phesgo + Taxane in Patients With Previously Untreated HER2-Positive, Estrogen Receptor-Positive Locally-Advanced or Metastatic Breast Cancer",III,Open,Roche; {F. Hoffmann-La Roche;},Oncology: Breast,Estrogen receptor positive; First line; HER2 positive; Maintenance/Consolidation; Stage III; Stage IV,Breast Neoplasms,"Argentina; Belgium; Brazil; China; Colombia; Germany; Hungary; India; Italy; Kenya; Mexico; Poland; Portugal; Russia; South Korea; Spain; Taiwan, China; Thailand; Turkey; Uganda; Ukraine; United Kingdom; United States"
A Study of Adjuvant Chemoradiation and Biomarkers of Response in High-risk Breast Cancer,II/III,Open,University of Virginia,Oncology: Breast,Adjuvant; HER2 negative; HER2 positive; Stage I; Stage II; Stage III,Breast Neoplasms,United States
"A Phase II study of THIO and a Checkpoint Inhibitor in Patients with Colorectal, Hepatocellular, Small Cell Lung Cancer",II,Planned,MAIA Biotechnology,"Oncology: Breast; Oncology: Colorectal; Oncology: Gastric; Oncology: Liver; Oncology: Lung, Small Cell; Oncology: Neuroendocrine; Oncology: Ovarian; Oncology: Prostate; Oncology: Unspecified Solid Tumor",(N/A); Line of therapy N/A; Pulmonary,Breast Neoplasms; Colorectal Neoplasms; Liver Neoplasms; Neuroendocrine Tumors; Ovarian Neoplasms; Prostatic Neoplasms; Small Cell Lung Carcinoma; Stomach Neoplasms,United States
A Registration Study of  Bria-IMT™ in Combination with retifanlimab in Patients with Third line Advanced Breast Cancer,III,Planned,BriaCell,Oncology: Breast,Stage III; Stage IV; Third line,Breast Neoplasms; Neoplasms,United States
"A phase I B/2, open-label, multicenter, dose escalation and dose expansion study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and antitumor activity of PF-07220060 in combination with PF-07104091 plus endocrine therapy in participants with advanced solid tumors",II,Open,Pfizer;,Oncology: Breast; Oncology: Unspecified Solid Tumor,Estrogen receptor positive; HER2 negative; HER2 positive; Progesterone receptor positive; Second line; Stage III; Stage IV,"Breast Neoplasms; Neoplasms, Unknown Primary",Argentina; Brazil; Bulgaria; China; Czech Republic; Mexico; South Africa; Spain; United States
Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) Trial: Adaptive Clinical Treatment (ACT),II,Planned,"Oregon Health and Science University
Roche;Genentech;",Oncology: Breast; Oncology: Ovarian; Oncology: Unspecified Solid Tumor,Second line; Stage III; Stage IV,"Breast Neoplasms; Carcinoma; Carcinoma, Ovarian Epithelial; Neoplasms; Neoplasms, Unknown Primary; Ovarian Cancer; Ovarian Neoplasms",United States
Correlation of Molecular Markers With Response to Therapy and Breast Cancer Behavior,Other,Open,"National Institutes of Health/National Cancer Institute;
UNC Lineberger Comprehensive Cancer Center",Oncology: Breast,Adjuvant; First line; Neoadjuvant; Stage II; Stage III; Stage IV,Breast Neoplasms,United States
"AIPAC-003 (Active Immunotherapy and PAClitaxel): A Randomized, Double-blind, Placebo-controlled Phase III Trial Testing Eftilagimod Alpha (Soluble LAG-3) in HER2-neg/Low Metastatic Breast Cancer Patients Receiving Paclitaxel, Following an Open-label Dose Optimization",II/III,Open,Immutep {Prima Biomed/Immutep},Oncology: Breast,Estrogen receptor positive; HER2 negative; Progesterone receptor positive; Second line; Stage IV,Breast Neoplasms,Belgium; Bulgaria; Czech Republic; Germany; Italy; Netherlands; Poland; Romania; Spain; United States
Phase II of Neoadjuvant Olaparib in Combination With Pembrolizumab in Patients With Triple Negative Breast Cancer (TNBC) or Hormone Receptor-positive HER2-negative Breast Cancer and Germline Mutations in DNA Damage Repair Genes,II,Open,"Memorial Sloan-Kettering Cancer Center
Merck & Co./Merck Sharp & Dohme (MSD)",Oncology: Breast,Estrogen receptor positive; HER2 negative; Neoadjuvant; Progesterone receptor positive; Stage II; Stage III; Triple receptor negative,Breast Neoplasms; Triple Negative Breast Neoplasms,United States
Phase IV Single-arm Pharmacokinetic Study of Skeletal Muscle Area-based Paclitaxel Infusion in Patients With Breast Cancer,IV,Open,University of Michigan Comprehensive Cancer Center,Oncology: Breast,Line of therapy N/A; Stage I; Stage II; Stage III,Breast Neoplasms,United States
Human Pilot Studies To Evaluate Fulvestrant For the Treatment of HR+/HER- Advanced Breast Cancer,II,Planned,Eagle Pharmaceuticals,Oncology: Breast,Estrogen receptor positive; HER2 negative; Line of therapy N/A; Progesterone receptor positive; Stage III; Stage IV,Breast Neoplasms,United States
Enhancing Immunotherapy by Targeting the EGFR Pathway in Inflammatory Breast Cancer: A Phase II Study of Panitumumab (PmAb) and Pembrolizumab (Pembro) in Combination With Neoadjuvant Chemotherapy (NAC) in Patients With Newly Diagnosed Triple Negative Inflammatory Breast Cancer (TN-IBC),II,Open,"MD Anderson Cancer Center University of Texas;
National Institutes of Health/National Cancer Institute;",Oncology: Breast,HER2 negative; Neoadjuvant; Stage III; Stage IV; Triple receptor negative,Breast Neoplasms; Carcinoma; Inflammatory Breast Neoplasms,United States
"A Phase III, Open-label, Randomised Study of Datopotamab Deruxtecan (Dato-DXd) Versus Investigator's Choice of Chemotherapy in Patients Who Are Not Candidates for PD-1/PD-L1 Inhibitor Therapy in First-line Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION Breast02)",III,Open,"AstraZeneca;
Daiichi Sankyo",Oncology: Breast,First line; HER2 negative; PD-L1 Positive; Stage IV; Triple receptor negative,Breast Neoplasms; Triple Negative Breast Neoplasms,"Argentina; Belgium; Brazil; Canada; China; France; Germany; Hungary; India; Italy; Japan; Mexico; Philippines; Poland; Russia; Singapore; South Africa; South Korea; Spain; Taiwan, China; Thailand; Turkey; United Kingdom; United States"
"postMONARCH: A Randomized, Double Blind, Placebo-Controlled, Phase lll Study to Compare the Efficacy of Abemaciclib Plus Fulvestrant to Placebo Plus Fulvestrant in Participants With HR+, HER2-, Advanced or Metastatic Breast Cancer Following Progression on a CDK4 & 6 Inhibitor and Endocrine Therapy",III,Open,Eli Lilly,Oncology: Breast,Estrogen receptor positive; HER2 negative; HER2 positive; Progesterone receptor positive; Second line; Stage III; Stage IV,Breast Neoplasms; Neoplasm Metastasis; Neoplasms,"Argentina; Australia; Belgium; China; Czech Republic; Denmark; France; Greece; Hungary; Israel; Italy; Mexico; Poland; Russia; South Korea; Spain; Sweden; Taiwan, China; Turkey; United States"
A Post-trial Access Roll-over Study to Allow Access to Ribociclib (LEE011) for Patients Who Are on Ribociclib Treatment in Novartis;-sponsored Study,IV,Open,Novartis;,Oncology: Breast,HER2 negative; Line of therapy N/A; Stage IV,Breast Neoplasms,"Australia; Brazil; Colombia; France; Germany; Greece; Hong Kong, S.A.R., China; Italy; Japan; Mexico; Poland; Portugal; Singapore; South Africa; South Korea; Spain; Taiwan, China; Thailand; Turkey; United States; Vietnam"
"Phase II Study of Neoadjuvant Endocrine Therapy in ER-positive, HER2-negative Early Stage Breast Cancer",II,Open,University of Kentucky,Oncology: Breast,Estrogen receptor positive; HER2 negative; Neoadjuvant; Stage I; Stage II,Breast Neoplasms,United States
Phase II Trial of Autologous Rapamycin-Resistant Th1/Tc1 (RAPA-201) Cell Therapy of PD-(L)1 Resistant Solid Tumors,II,Open,Rapa Therapeutics,"Oncology: Bladder; Oncology: Breast; Oncology: Esophageal; Oncology: Gastric; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Lung, Small Cell; Oncology: Melanoma; Oncology: Neuroendocrine; Oncology: Unspecified Cancer; Oncology: Unspecified Solid Tumor",ALK; BRAF; BRCA; EGFR; HER2 negative; Pulmonary; Second line; Third line; Triple receptor negative,"Adenocarcinoma; Breast Neoplasms; Carcinoma; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Carcinoma, Squamous Cell; Esophageal Cancer; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Head and Neck Neoplasms; Melanoma; Nasopharyngeal Carcinoma; Neoplasms; Neoplasms, Unknown Primary; Neuroendocrine Tumors; Small Cell Lung Carcinoma; Squamous Cell Carcinoma of Head and Neck; Stomach Carcinoma; Stomach Neoplasms; Triple Negative Breast Neoplasms; Urethral Neoplasms; Urinary Bladder Neoplasms",United States
Expanded Access Protocol for Subjects Previously Treated With Gedatolisib in a Celcuity-Sponsored Clinical Study (B2151009),III,Open,Celcuity,Oncology: Breast,(N/A); Line of therapy N/A,Breast Neoplasms; Neoplasms,United States
"A Randomized, Double-blind, Phase III Study of Tucatinib or Placebo in Combination With Trastuzumab and Pertuzumab as Maintenance Therapy for Metastatic HER2+ Breast Cancer (HER2CLIMB-05).",III,Open,"Merck & Co./Merck Sharp & Dohme (MSD)
Seagen",Oncology: Breast; Oncology: Metastatic Cancer,CNS mets; Estrogen receptor positive; First line; HER2 positive; Maintenance/Consolidation; Progesterone receptor positive; Stage III; Stage IV,Brain Neoplasms; Breast Neoplasms; Central Nervous System Neoplasms; Neoplasm Metastasis,"Australia; Austria; Belgium; Brazil; Canada; China; Czech Republic; Finland; France; Germany; Greece; Italy; Japan; Poland; Portugal; Russia; South Korea; Spain; Switzerland; Taiwan, China; United Kingdom; United States"
"Phase III, Open-Label, Randomized, Study Comparing Gedatolisib Combined With Fulvestrant & With or Without Palbociclib to Standard-of-Care Therapies in Patients With HR-Positive, HER2-Negative Advanced Breast Cancer Previously Treated With a CDK4/6 Inhibitor in Combination w/Non-Steroidal Aromatase Inhibitor Therapy",III,Open,Celcuity,Oncology: Breast,Estrogen receptor positive; HER2 negative; Progesterone receptor positive; Second line; Stage III; Stage IV,Breast Neoplasms,"Argentina; Australia; Austria; Belgium; Brazil; Bulgaria; China; Czech Republic; France; Greece; Hungary; India; Mexico; Poland; Romania; Singapore; South Korea; Spain; Taiwan, China; United States"
A Phase II Multi-center Open-label Basket Trial of ABI-009 (Nab Sirolimus) for Adult and Adolescent Patients With Solid Tumors Harboring Pathogenic Inactivating Alterations in TSC1 or TSC2 Genes,II,Open,Aadi Bioscience,"Oncology: Bladder; Oncology: Breast; Oncology: Cervical; Oncology: Colorectal; Oncology: Endometrial; Oncology: Esophageal; Oncology: Gastric; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Ovarian; Oncology: Pancreas; Oncology: Renal; Oncology: Soft Tissue Sarcoma; Oncology: Thyroid; Oncology: Unspecified Solid Tumor",(N/A); Second line; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Colorectal Neoplasms; Endometrial Neoplasms; Esophageal Neoplasms; Fibrosarcoma; Kidney Neoplasms; Leiomyosarcoma; Liposarcoma; Liver Neoplasms; Melanoma; Neoplasm Metastasis; Neoplasms; Neoplasms, Unknown Primary; Ovarian Neoplasms; Pancreatic Neoplasms; Rhabdomyosarcoma; Sarcoma; Stomach Neoplasms; Synovial Sarcoma; Thyroid Neoplasms; Urethral Neoplasms; Urinary Bladder Neoplasms; Uterine Cervical Neoplasms; Wilms Tumor",Puerto Rico; United States
"An Umbrella, Randomized, Controlled, Pre-Operative Trial Testing Integrative Subtype-Targeted Therapeutics in Hormone Receptor-Positive, HER2-Negative Breast Cancer",II,Open,"Stanford University Medical Center
(Other government agency)",Oncology: Breast,(N/A); Estrogen receptor positive; HER2 negative; Neoadjuvant; Progesterone receptor positive,Breast Neoplasms,United States
"A Randomized, Open-label, Phase III Study of Sacituzumab Govitecan and Pembrolizumab Versus Treatment of Physician's Choice and Pembrolizumab in Patients With Previously Untreated, Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer, Whose Tumors Express PD-L1",III,Open,"Gilead Sciences;
Merck & Co./Merck Sharp & Dohme (MSD)",Oncology: Breast,First line; HER2 negative; PD-L1 Positive; Second line; Stage III; Stage IV; Triple receptor negative,Breast Neoplasms; Triple Negative Breast Neoplasms,"Argentina; Australia; Austria; Belgium; Brazil; Canada; Chile; Czech Republic; France; Germany; Hong Kong, S.A.R., China; Hungary; Israel; Italy; Japan; Mexico; Netherlands; Peru; Poland; Puerto Rico; South Africa; South Korea; Spain; Switzerland; Taiwan, China; Turkey; United Kingdom; United States"
"Phase II Study of PI3K Inhibitor Copanlisib in Combination With Fulvestrant in Selected ER+ and/or PR+ Cancers With PI3K (PIK3CA, PIK3R1) and/or PTEN Alterations",II,Open,"MD Anderson Cancer Center University of Texas;
Bayer AG",Oncology: Breast; Oncology: Endometrial; Oncology: Ovarian,Estrogen receptor positive; Progesterone receptor positive; Second line; Stage I; Stage II; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Endometrioid; Endometrial Neoplasms; Ovarian Cancer; Ovarian Neoplasms",United States
Phase 2 Randomized Control Trial of Evexomostat (SDX-7320) in Combination With Eribulin for Patients With Metastatic Triple-Negative Breast Cancer and Metabolic Dysfunction: The ARETHA Study,II,Open,"Memorial Sloan-Kettering Cancer Center
SynDevRx",Oncology: Breast,(N/A); HER2 negative; Second line; Third line; Triple receptor negative,Breast Neoplasms,United States
A Phase II Clinical Trial Assessing the Safety of Neoadjuvant Palbociclib in Combination With Endocrine Therapy for Post and Pre-menopausal Patients With Early Stage Hormone Receptor Positive and Her-2/Neu Negative Breast Cancer,II,Open,University of Nebraska Medical Center,Oncology: Breast,Estrogen receptor positive; HER2 negative; Neoadjuvant; Progesterone receptor positive; Stage II; Stage III,Breast Neoplasms,United States
"Phase II Study of Pembrolizumab in Combination With Lenvatinib in Patients With TNBC, NSCLC, and Other Tumor Types and Brain Metastases",II,Open,"Eisai
(Other Hospital/Academic/Medical Center);","Oncology: Breast; Oncology: Colorectal; Oncology: Endometrial; Oncology: Gastric; Oncology: Lung, Non-Small Cell; Oncology: Metastatic Cancer; Oncology: Renal",CNS mets; HER2 negative; Line of therapy N/A; Stage IV; Triple receptor negative,"Brain Neoplasms; Breast Neoplasms; Carcinoma, Endometrioid; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Central Nervous System Neoplasms; Colorectal Neoplasms; Endometrial Neoplasms; Kidney Neoplasms; Neoplasm Metastasis; Renal Cancer; Stomach Carcinoma; Stomach Neoplasms; Wilms Tumor",United States
"An International, Randomized, Phase III, Multicenter, Open-Label Study of Kisqali (ribociclib) versus Ibrance (palbociclib), both in combination with Endocrine Therapy, in Patients with Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-negative (HR+/HER2-) Advanced or Metastatic Breast Cancer with a HER2-enriched (HER2E) intrinsic subtype",III,Open,"Novartis;
(Other Cooperative Group);",Oncology: Breast,Estrogen receptor positive; HER2 negative; Progesterone receptor positive; Second line; Stage III; Stage IV; Triple receptor negative,Breast Neoplasms,Portugal; Spain; United States
The Gut Microbiome and Immune Checkpoint Inhibitor Therapy in Solid Tumors,IV,Open,VastBiome,"Oncology: Breast; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Renal",HER2 negative; Line of therapy N/A; Stage I; Stage II; Stage III; Stage IV; Triple receptor negative,"Breast Neoplasms; Carcinoma; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Kidney Neoplasms; Melanoma; Renal Cancer; Triple Negative Breast Neoplasms; Wilms Tumor",United States
A Phase II Single-Arm Open-Label Pilot Trial Evaluating Zanidatamab (ZW25) in Patients With Early Stage HER2/Neu Positive (HER2+) Breast Cancer (BC),II,Open,"MD Anderson Cancer Center University of Texas;
Zymeworks",Oncology: Breast,Estrogen receptor positive; HER2 positive; Neoadjuvant; Stage I; Stage II,Breast Neoplasms,United States
"Time Restricted Eating And Metformin (TEAM) in Invasive Breast Cancer (IBC) or Ductal Carcinoma in Situ (DCIS). A Randomized, Phase IIb, Window of Opportunity Presurgical Trial.",II,Open,National Cancer Research Institute,Oncology: Breast,Estrogen receptor positive; HER2 positive; Neoadjuvant; Progesterone receptor positive; Stage 0; Stage I; Stage II; Stage III; Stage IV,"Breast Neoplasms; Carcinoma; Carcinoma in Situ; Carcinoma, Ductal; Carcinoma, Ductal, Breast; Carcinoma, Intraductal, Noninfiltrating",Italy; United States
"Alpelisib, Fulvestrant and Dapagliflozin for the Treatment of HR+, HER2 -, PIK3CA Mutant Metastatic Breast Cancer",II,Open,"Novartis;
(Other Hospital/Academic/Medical Center);",Oncology: Breast,Estrogen receptor positive; HER2 negative; Progesterone receptor positive; Second line; Stage III; Stage IV,Breast Neoplasms,United States
A Phase II Study of Tazemetostat in Solid Tumors Harboring an ARID1A Mutation,II,Open,"Ipsen
Ipsen {Epizyme}
Prisma Health/Prisma Health-Upstate","Oncology: Bile Duct (Cholangiocarcinoma); Oncology: Breast; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Ovarian; Oncology: Pancreas; Oncology: Unspecified Solid Tumor",Second line; Stage III; Stage IV,"Bile Duct Neoplasms; Breast Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Cholangiocarcinoma; Liver Cancer; Liver Neoplasms; Neoplasms; Neoplasms, Unknown Primary; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms",United States
A Phase II Trial to Correlate Early Clinical Response to Pathologic Outcome With Neoadjuvant Systemic Therapy in Patients With Early Stage Breast Cancer,II,Open,(Other Hospital/Academic/Medical Center);,Oncology: Breast,Estrogen receptor positive; HER2 negative; HER2 positive; Neoadjuvant; Stage II; Stage III; Triple receptor negative,Breast Neoplasms; Neoplasms; Triple Negative Breast Neoplasms,United States
A Phase II Study of Palliative Radiation in Combination With Pembrolizumab in Subjects With Unresectable Metastatic Stage IV Breast Cancer: Twisted Pink,II,Open,"University of Louisville
(Other Hospital/Academic/Medical Center);",Oncology: Breast,Estrogen receptor positive; HER2 negative; Progesterone receptor positive; Second line; Stage IV; Third line; Triple receptor negative,Breast Neoplasms,United States
Genomically Guided Phase II Study to Evaluate the Clinical Benefit of Niraparib in Tumors Metastatic to the CNS,II,Open,"GlaxoSmithKline
Massachusetts General Hospital",Oncology: Breast; Oncology: Metastatic Cancer; Oncology: Ovarian; Oncology: Unspecified Solid Tumor,BRCA; CNS mets; HER2 negative; Second line; Stage IV; Triple receptor negative,"Brain Neoplasms; Breast Neoplasms; Central Nervous System Neoplasms; Neoplasm Metastasis; Neoplasms, Unknown Primary; Nervous System Neoplasms; Ovarian Cancer; Ovarian Neoplasms",United States
"A Multicenter, Open-label, Phase II Basket Study of MK-7684A, a Co-formation of Vibostolimab (MK-7684) With Pembrolizumab (MK-3475), With or Without Other Anticancer Therapies in Participants With Selected Solid Tumors",II,Open,Merck & Co./Merck Sharp & Dohme (MSD),Oncology: Bile Duct (Cholangiocarcinoma); Oncology: Breast; Oncology: Cervical; Oncology: Endometrial; Oncology: Esophageal; Oncology: Gallbladder; Oncology: Gastric; Oncology: Head/Neck; Oncology: Liver; Oncology: Ovarian,Adenocarcinoma; First line; HER2 negative; Intrahepatic; Second line; Squamous Cell; Stage III; Stage IV; Third line; Triple receptor negative; Unresectable; Untreated,"Bile Duct Neoplasms; Breast Neoplasms; Carcinoma; Carcinoma, Endometrioid; Carcinoma, Hepatocellular; Cholangiocarcinoma; Cholangiocarcinoma; Endometrial Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Gallbladder Neoplasms; Head and Neck Neoplasms; Liver Cancer; Liver Neoplasms; Neoplasms; Ovarian Neoplasms; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms; Triple Negative Breast Neoplasms; Urinary Bladder Neoplasms; Uterine Cervical Neoplasms","Canada; Chile; Colombia; France; Germany; Israel; Italy; Japan; Netherlands; Poland; South Korea; Spain; Taiwan, China; Turkey; United States"
"A Phase III, Randomized, Open-label, Multicenter Study of Arv-471(PF-07850327) plus Palbociclib Versus Letrozole plus Palbociclib for the Treatment of Participants with Estrogen Receptor-positive, Her2-negative Breast Cancer Who Have Not Received Any Prior Systemic Anti-cancer Treatment for Advanced Disease (VERITAC-3)",III,Open,"Pfizer;
Arvinas;",Oncology: Breast,Estrogen receptor positive; First line; HER2 negative; Stage III; Stage IV,Breast Neoplasms,United States
An Open-Label Phase II Trial of Neratinib Plus Capecitabine in Subjects With HER2-Negative Metastatic Breast Cancer With Brain Metastases and Abnormally Active HER2 Signaling,II,Open,University of Roche;ster,Oncology: Breast; Oncology: Metastatic Cancer,CNS mets; Estrogen receptor positive; HER2 negative; Second line; Stage IV; Triple receptor negative,Brain Neoplasms; Breast Neoplasms; Central Nervous System Neoplasms; Neoplasm Metastasis,United States
"A Phase III, Double-blind, Randomised Study to Assess Switching to AZD9833 (a Next Generation, Oral SERD) + CDK4/6 Inhibitor (Palbociclib or Abemaciclib) vs Continuing Aromatase Inhibitor (Letrozole or Anastrozole)+ CDK4/6 Inhibitor in HR+/HER2-MBC Patients With Detectable ESR1Mutation Without Disease Progression During 1L Treatment With Aromatase Inhibitor+ CDK4/6 Inhibitor- A ctDNA Guided Early Switch Study",III,Open,AstraZeneca;,Oncology: Breast,Estrogen receptor positive; First line; HER2 negative; Progesterone receptor positive; Stage IV,Breast Neoplasms; Disease Progression,"Australia; Austria; Belgium; Bulgaria; Canada; France; Germany; Hungary; Italy; Japan; Norway; Poland; Portugal; Russia; Slovakia; South Korea; Spain; Switzerland; Taiwan, China; Turkey; United Kingdom; United States"
"A Phase III, Randomized, Open-Label, Multicenter Study Evaluating the Efficacy and Safety of Adjuvant Giredestrant Compared With Physician's Choice of Adjuvant Endocrine Monotherapy in Patients With Estrogen Receptor-Positive, HER2-Negative Early Breast Cancer",III,Open,Roche; {F. Hoffmann-La Roche;},Oncology: Breast,Adjuvant; Estrogen receptor positive; HER2 negative; Stage I; Stage II; Stage III,Breast Neoplasms,"Argentina; Australia; Austria; Azerbaijan; Belarus; Belgium; Bosnia and Herzegovina; Brazil; Bulgaria; Canada; Chile; China; Colombia; Costa Rica; Croatia; Czech Republic; Egypt; Finland; France; Georgia; Germany; Greece; Guatemala; Hong Kong, S.A.R., China; Hungary; India; Ireland; Israel; Italy; Japan; Kenya; Latvia; Macedonia; Malaysia; Mexico; Netherlands; Pakistan; Peru; Philippines; Poland; Portugal; Romania; Russia; Serbia; Slovakia; Slovenia; South Africa; South Korea; Spain; Sweden; Switzerland; Taiwan, China; Thailand; Turkey; Uganda; Ukraine; United Kingdom; United States; Vietnam"
"A Phase II Study of Magrolimab Combination Therapy in Patients With Unresectable, Locally Advanced or Metastatic Triple-Negative Breast Cancer",II,Open,Gilead Sciences;,Oncology: Breast; Oncology: Unspecified Solid Tumor,First line; HER2 negative; PD-1 Refractory; PD-L1 Positive; PD-L1 Refractory; Second line; Stage III; Stage IV; Third line; Triple receptor negative,"Breast Neoplasms; Neoplasms, Unknown Primary; Triple Negative Breast Neoplasms","Australia; Hong Kong, S.A.R., China; United Kingdom; United States"
Systemic Assessment of CIPN Risk Using Molecular Aging Trajectories,IV,Open,"University of Alabama; Birmingham
University of North Carolina
Sapere Bio",Oncology: Breast; Oncology: Supportive Care,Adjuvant; Neoadjuvant; Neurotoxicity; Stage I; Stage II; Stage III,Breast Neoplasms; Palliative Care; Peripheral Nervous System Diseases,United States
P3 Efficacy Evaluation of Enobosarm in Combo With Abemaciclib Compared to Estrogen Blocking Agent for 2nd Line Treatment of ER+HER2- MBC in Patients Who Have Shown Previous Disease Progression on an Estrogen Blocking Agent Plus Palbociclib.,III,Open,Veru,Oncology: Breast,Estrogen receptor positive; HER2 negative; Second line; Stage IV,Breast Neoplasms,United States
"EMBER-3: A Phase III, Randomized, Open-Label Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Patients With Estrogen Receptor Positive, HER2 Negative Locally Advanced or Metastatic Breast Cancer Previously Treated With Endocrine Therapy",III,Open,Eli Lilly,Oncology: Breast,Estrogen receptor positive; HER2 negative; Second line; Stage III; Stage IV,Breast Neoplasms; Neoplasm Metastasis; Neoplasms,"Argentina; Australia; Austria; Belgium; Brazil; China; Czech Republic; France; Germany; Greece; India; Italy; Japan; Mexico; Netherlands; Russia; South Korea; Spain; Taiwan, China; Turkey; Ukraine; United States"
"A Multicenter, Open-label, Phase 2 Study of Intratumoral Vidutolimod (CMP-001) in Combination With Intravenous Cemiplimab in Subjects With Selected Types of Advanced or Metastatic Cancer",II,Open,Regeneron/Checkmate Pharmaceuticals,"Oncology: Breast; Oncology: Lung, Non-Small Cell; Oncology: Neuroendocrine; Oncology: Skin, Squamous Cell Carcinoma (cSCC)",First line; HER2 negative; Merkel; PD-L1 High; Second line; Stage III; Stage IV; Triple receptor negative,"Breast Neoplasms; Carcinoma; Carcinoma, Merkel Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Neoplasm Metastasis; Neoplasms; Neoplasms, Second Primary; Neuroendocrine Tumors; Triple Negative Breast Neoplasms",United States
"Phase III,Single Arm,Open-Label Study Evaluating Ovarian Suppression Following 3 Month Leuprolide Acetate For Injectable Suspension (TOL2506) in Combination With Endocrine Therapy in Premenopausal Subjects With Hormone-Receptor-Positive (HR+),Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer",III,Open,Tolmar Pharmaceuticals,Oncology: Breast,Estrogen receptor positive; HER2 negative; Line of therapy N/A; Progesterone receptor positive; Stage I; Stage II; Stage III,Breast Neoplasms,Puerto Rico; United States
"A Double-blind, Phase II Randomized Study of Brain-directed Stereotactic Radiation With or Without AGuIX Gadolinium-based Nanoparticles in the Management of Brain Metastases at Higher Risk of Local Recurrence With Radiation Alone",II,Open,"Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute;
NH TherAguix","Oncology: Breast; Oncology: Colorectal; Oncology: Gastric; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Metastatic Cancer; Oncology: Unspecified Solid Tumor",CNS mets; First line; HER2 positive; Other mets; Stage IV,"Brain Neoplasms; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Central Nervous System Neoplasms; Colorectal Neoplasms; Gastrointestinal Neoplasms; Melanoma; Neoplasm Metastasis; Neoplasms, Second Primary; Neoplasms, Unknown Primary; Stomach Carcinoma; Stomach Neoplasms",United States
"A Phase II Study to Evaluate the Efficacy and Safety of an Adjuvant Therapeutic Cancer Vaccine (AST-301, pNGVL3-hICD) in Patients With HER2 Low Breast Cancer (Cornerstone-001)",II,Open,Aston Sci.,Oncology: Breast,Adjuvant; HER2 positive; Stage I; Stage II; Stage III,Breast Neoplasms,"Australia; Taiwan, China; United States"
A Randomized Phase II Trial of Adjuvant Trastuzumab Emtansine (T-DM1) Followed by Subcutaneous Trastuzumab Versus Paclitaxel in Combination With Subcutaneous Trastuzumab for Stage I HER2-positive Breast Cancer (ATEMPT 2.0),II,Open,"Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute;
Roche;Genentech;",Oncology: Breast,Adjuvant; First line; HER2 negative; HER2 positive; Stage I,Breast Neoplasms,United States
"A Randomized, Double-blind, Placebo-controlled, Phase III Study of Pembrolizumab Plus Chemotherapy Versus Placebo Plus Chemotherapy for the Treatment of Chemotherapy-Candidate Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (HR+/HER2-) Locally Recurrent Inoperable or Metastatic Breast Cancer (KEYNOTE-B49)",III,Open,Merck & Co./Merck Sharp & Dohme (MSD),Oncology: Breast,Estrogen receptor positive; HER2 negative; PD-1 Naive; PD-L1 Naive; PD-L1 Positive; Progesterone receptor positive; Second line; Stage III; Stage IV; Third line,Breast Neoplasms,Argentina; Australia; Austria; Brazil; Canada; Chile; China; France; Germany; Greece; Guatemala; Hungary; Ireland; Israel; Italy; Japan; Malaysia; Mexico; Netherlands; Philippines; Poland; Portugal; Russia; South Korea; Spain; Sweden; Turkey; United Kingdom; United States
BRE-04: Window of Opportunity Trial of Preoperative Low Dose Azacitidine in High-Risk Early Stage Breast Cancer.,II,Open,(Other Hospital/Academic/Medical Center);,Oncology: Breast,Estrogen receptor positive; HER2 negative; HER2 positive; Neoadjuvant; Stage I; Stage II; Stage III; Triple receptor negative,Breast Neoplasms,United States
"An Open Label, Phase II Trial of Pre-operative Neratinib and Endocrine Therapy With Trastuzumab in Triple Positive Breast Cancers Hoosier Cancer Research Network BRE17-141",II,Open,"University of Roche;ster
Puma Biotechnology",Oncology: Breast,Adjuvant; Estrogen receptor positive; HER2 positive; Neoadjuvant; Progesterone receptor positive; Stage I; Stage II; Stage III,Breast Neoplasms,United States
"A Phase Ib/III Randomised Study of Capivasertib Plus Palbociclib and Fulvestrant Versus Placebo Plus Palbociclib and Fulvestrant in Hormone Receptor-Positive and Human Epidermal Growth Factor Receptor 2-Negative Locally Advanced, Unresectable or Metastatic Breast Cancer",III,Open,AstraZeneca;,Oncology: Breast,Estrogen receptor positive; First line; HER2 negative; Progesterone receptor positive; Second line; Stage III; Stage IV,Breast Neoplasms,Australia; Belgium; Canada; China; Denmark; France; India; Japan; Poland; Spain; Sweden; Thailand; United States
"A Phase III Clinical Trial Evaluating De-Escalation of Breast Radiation for Conservative Treatment of Stage I, Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer",III,Open,"National Institutes of Health/National Cancer Institute;
NRG Oncology",Oncology: Breast,Adjuvant; Estrogen receptor positive; HER2 negative; Progesterone receptor positive; Stage I,Breast Neoplasms; Recurrence,Canada; Lebanon; United States
"A Phase II Circulating Tumor DNA Enriched, Genomically Directed Post-neoadjuvant Trial for Patients With Residual Triple Negative Breast Cancer (PERSEVERE)",II,Open,"Pfizer;
Indiana University Cancer Center
(Other Hospital/Academic/Medical Center);
Roche;Genentech;
Roche;/Foundation Medicine
Epic Sciences",Oncology: Breast,Adjuvant; HER2 negative; Stage I; Stage II; Stage III; Triple receptor negative,Breast Neoplasms; Triple Negative Breast Neoplasms,United States
Precision Performance Status Assessment in Breast Cancer Patients Receiving Neoadjuvant Chemotherapy,Other,Open,MD Anderson Cancer Center University of Texas;,Oncology: Breast,HER2 negative; Neoadjuvant; Stage I; Stage II; Stage III; Triple receptor negative,Breast Neoplasms; Triple Negative Breast Neoplasms,United States
A Phase II Trial of Avelumab or Hydroxychloroquine With or Without Palbociclib to Eliminate Dormant Breast Cancer (PALAVY),II,Open,"(Other Cooperative Group);
Pfizer;
Johns Hopkins University
Abramson Cancer Center at University of Pennsylvania Medical Center;;
Breast Cancer Research Foundation",Oncology: Breast,Estrogen receptor positive; HER2 negative; Neoadjuvant; Stage II; Stage III,Breast Neoplasms,United States
"A Phase II Study of NirAparib, Dostarlimab and Radiotherapy in Metastatic, PD-L1 Negative or Immunotherapy-Refractory Triple-Negative Breast Cancer (NADiR)",II,Open,"Johns Hopkins University
Duke University Medical Center
University of Pennsylvania
Massachusetts General Hospital
(Other Hospital/Academic/Medical Center);",Oncology: Breast,Estrogen receptor positive; HER2 negative; PD-1 Refractory; PD-L1 Refractory; Progesterone receptor positive; Second line; Stage IV; Third line; Triple receptor negative,Breast Neoplasms; Triple Negative Breast Neoplasms,United States
"A Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate the Efficacy and Safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine for Her2-Positive Breast Cancer at High Risk of Recurrence Following Preoperative Therapy",III,Open,Roche; {F. Hoffmann-La Roche;},Oncology: Breast,Adjuvant; HER2 positive; PD-L1 Positive; Stage I; Stage II; Stage III,Breast Neoplasms; Recurrence,"Australia; Austria; Belgium; Brazil; Bulgaria; China; Czech Republic; Denmark; France; Germany; Greece; Hong Kong, S.A.R., China; Hungary; India; Italy; Kenya; Mexico; New Zealand; Poland; Portugal; Romania; Russia; Singapore; South Korea; Spain; Taiwan, China; Thailand; Turkey; Uganda; Ukraine; United Kingdom; United States"
Phase II Study of Avapritinib in Patients With CKIT or PDGFRA Mutation-Positive Malignant Solid Tumors,II,Open,"MD Anderson Cancer Center University of Texas;
National Institutes of Health/National Cancer Institute;","Oncology: Breast; Oncology: CNS, Glioblastoma; Oncology: Colorectal; Oncology: Esophageal; Oncology: Gastric; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Soft Tissue Sarcoma; Oncology: Unspecified Solid Tumor",Second line; Stage III; Stage IV,"Adenocarcinoma; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Central Nervous System Neoplasms; Colorectal Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Fibrosarcoma; Glioblastoma; Leiomyosarcoma; Liposarcoma; Lung Neoplasms; Melanoma; Neoplasms; Neoplasms, Unknown Primary; Nervous System Neoplasms; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Stomach Carcinoma; Stomach Neoplasms; Synovial Sarcoma",United States
Phase II Trial of Circulating Tumor DNA Monitoring During Adjuvant Capecitabine in Patients With Triple-negative Breast Cancer and Residual Disease Following Standard Neoadjuvant Chemotherapy,II,Open,Stanford University Medical Center,Oncology: Breast,Adjuvant; Estrogen receptor positive; HER2 negative; Neoadjuvant; Progesterone receptor positive; Second line; Stage I; Stage II; Stage III; Triple receptor negative,Breast Neoplasms; Triple Negative Breast Neoplasms,United States
"A Phase II, Single Arm, Non-randomized Study of Alpelisib (BYL719) in Combination With Continued Endocrine Therapy Following Progression on Endocrine Therapy in Hormone Receptor Positive, HER2 Negative, PIK3CA Mutant Metastatic Breast Cancer",II,Open,"Novartis;
University of Wisconsin",Oncology: Breast,Estrogen receptor positive; HER2 negative; Progesterone receptor positive; Second line; Stage III; Stage IV; Third line,Breast Neoplasms,United States
A Phase II Clinical Trial of Talazoparib Monotherapy for PALB2 Mutation Associated Advanced Breast Cancer,II,Open,"Pfizer;
(Other Hospital/Academic/Medical Center);",Oncology: Breast,First line; Fourth line or greater; HER2 negative; Second line; Stage IV; Third line,Breast Neoplasms,United States
"A Randomized, Multicenter, Double-Blind, Placebo-Controlled Phase III Study of the Efficacy and Safety of Trastuzumab Emtansine in Combination With Atezolizumab or Placebo in Patients With HER2-Positive and PD-L1-Positive Locally Advanced or Metastatic Breast Cancer Who Have Received Prior Trastuzumab- (+/- Pertuzumab) and Taxane-Based Therapy (KATE3).",III,Open,Roche; {F. Hoffmann-La Roche;},Oncology: Breast,HER2 positive; PD-L1 Positive; Second line; Stage III; Stage IV; Third line,Breast Neoplasms,Australia; Brazil; Canada; China; Colombia; Croatia; Egypt; Finland; France; Germany; Greece; Hungary; Italy; Mexico; Norway; Philippines; Poland; Portugal; Russia; Slovenia; South Korea; Spain; Turkey; United Kingdom; United States
"SERENA-4: A Randomised, Multicentre, Double-Blind, Phase III Study of AZD9833 (an Oral SERD) Plus Palbociclib Versus Anastrozole Plus Palbociclib for the Treatment of Patients With Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer Who Have Not Received Any Systemic Treatment for Advanced Disease.",III,Open,AstraZeneca;,Oncology: Breast,Estrogen receptor positive; First line; HER2 negative; Stage III; Stage IV,Breast Neoplasms,"Austria; Belgium; Bulgaria; Canada; Chile; China; Czech Republic; Finland; France; Germany; Hungary; India; Italy; Japan; Malaysia; Mexico; Norway; Poland; Portugal; Russia; Slovakia; South Korea; Spain; Switzerland; Taiwan, China; Turkey; United Kingdom; United States"
Expasnion Study of ARV-471 in ER+/HER2- Metastatic Breast Cancer,II,Planned,Arvinas;,Oncology: Breast,Estrogen receptor positive; HER2 negative; Second line; Stage IV; Third line,Breast Neoplasms,United States
A Phase II Study of U3-1402 in Patients With Metastatic Breast Cancer,II,Open,Daiichi Sankyo,Oncology: Breast,BRCA; Estrogen receptor positive; Fourth line or greater; HER2 negative; Progesterone receptor positive; Second line; Stage III; Stage IV; Third line; Triple receptor negative,Breast Neoplasms,United States
"Phase III Study of Trastuzumab Deruxtecan (T-DXd) With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive, First-line Metastatic Breast Cancer (DESTINY-Breast09)",III,Open,"AstraZeneca;
Baxter International
Daiichi Sankyo",Oncology: Breast,Estrogen receptor positive; First line; HER2 positive; Progesterone receptor positive; Stage III; Stage IV,Breast Neoplasms,"Argentina; Australia; Austria; Belgium; Brazil; Canada; China; Denmark; France; Germany; Hungary; India; Israel; Italy; Japan; Mexico; Peru; Philippines; Romania; Russia; Saudi Arabia; South Africa; South Korea; Spain; Sweden; Taiwan, China; Turkey; United Kingdom; United States"
Phase II Study of Pembrolizumab and Ablative Radiotherapy With or Without Olaparib in Metastatic Triple-Negative or Hormone-Receptor Positive/Her2 Negative Breast Cancers : Initial Test Cohorts of a Platform Trial to Sequentially Investigate Immunotherapy Combinations for the Augmentation of Immune Responses,II,Open,Memorial Sloan-Kettering Cancer Center,Oncology: Breast,HER2 negative; PD-1 Refractory; PD-L1 Refractory; Second line; Stage IV; Third line; Triple receptor negative,Breast Neoplasms; Triple Negative Breast Neoplasms,United States
Impact of Vitamin D Supplementation on the Rate of Pathologic Complete Response in Vitamin D Deficient Patients Receiving Neoadjuvant Chemotherapy for Operable Triple Negative Breast Cancer,II,Open,"National Institutes of Health/National Cancer Institute;
(Other Hospital/Academic/Medical Center);",Oncology: Breast,(N/A); HER2 negative; Neoadjuvant; Triple receptor negative,Breast Neoplasms; Triple Negative Breast Neoplasms; Vitamin D Deficiency,United States
"Open-label, Multi-cohort, Phase II Trial, Evaluating the Efficacy and Safety of Tusamitamab Ravtansine (SAR408701) Monotherapy and in Combination in Patients With CEACAM5-positive Advanced Solid Tumors",II,Open,Sanofi;,Oncology: Breast; Oncology: Pancreas,Fourth line or greater; HER2 negative; Second line; Stage III; Stage IV; Third line; Triple receptor negative,Breast Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms,"Argentina; Chile; France; Hungary; Netherlands; Russia; South Korea; Spain; Taiwan, China; Turkey; United States"
A Phase II Trial of Sacituzumab Govitecan (IMMU-132) (NSC #820016) for Patients With HER2-Negative Breast Cancer and Brain Metastases,II,Open,"Southwest Oncology Group
National Institutes of Health/National Cancer Institute;
Gilead Sciences;/Immunomedics",Oncology: Breast; Oncology: Metastatic Cancer,CNS mets; Estrogen receptor positive; HER2 negative; Progesterone receptor positive; Second line; Stage IV; Triple receptor negative,Brain Neoplasms; Breast Neoplasms; Carcinoma; Central Nervous System Neoplasms; Neoplasm Metastasis; Neoplasms,United States
"ARGONAUT: Development and Analysis of a Blood and Stool Sample Bank for Cancer Patients, Enabling the Systematic Study of the Effect of Gut Microbiomes on Response to Treatment",IV,Open,"Johnson & Johnson/Janssen R&D {Johnson & Johnson/J&JPRD {Johnson & Johnson/Janssen-Cilag/Janssen Research Foundation}}
Persephone Biosciences","Oncology: Breast; Oncology: Colorectal; Oncology: Lung, Non-Small Cell; Oncology: Pancreas",First line; HER2 negative; Stage III; Stage IV; Triple receptor negative,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Triple Negative Breast Neoplasms",United States
Single Cell Immune and Non-immune Correlates of Response to Neoadjuvant Abemaciclib and Letrozole in Hormone Receptor Positive Breast Cancer,II,Open,"Eli Lilly
University of Texas Southwest Medical Center
(Other government agency)",Oncology: Breast,Estrogen receptor positive; HER2 negative; Neoadjuvant; Progesterone receptor positive; Stage I; Stage II; Stage III,Breast Neoplasms,United States
"A Phase III, Multicenter, Randomized, Open-Label, Active-Controlled Study of Trastuzumab Deruxtecan (T-DXd) Versus Trastuzumab Emtansine (T-DM1) in Participants With High-Risk HER2-Positive Primary Breast Cancer Who Have Residual Invasive Disease in Breast or Axillary Lymph Nodes Following Neoadjuvant Therapy (DESTINY-Breast05)",III,Open,"AstraZeneca;
National Surgical Adjuvant Breast and Bowel Project (NSABP)
Spanish Breast Cancer Research Group
Baxter International/Baxter Oncology {ASTA Medica Oncology}
German Breast Group
Daiichi Sankyo",Oncology: Breast,Adjuvant; Estrogen receptor positive; HER2 positive; Progesterone receptor positive; Stage I; Stage II; Stage III,Breast Neoplasms,"Argentina; Australia; Belgium; Brazil; Canada; Chile; China; Czech Republic; Denmark; France; Germany; Greece; Hong Kong, S.A.R., China; Ireland; Israel; Italy; Japan; Mexico; Netherlands; Peru; Poland; Portugal; Romania; Russia; Singapore; South Korea; Spain; Taiwan, China; Turkey; United Kingdom; United States"
"A Randomized, Multicenter, Placebo-controlled, Phase III Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/Neu Positive Subjects With Residual Disease or High-Risk PCR After Both Neoadjuvant and Postoperative Adjuvant Trastuzumab-based Therapy (FLAMINGO-01).",III,Open,Greenwich LifeSciences,Oncology: Breast,Adjuvant; HER2 positive; Neoadjuvant; Stage I; Stage II; Stage III,Breast Neoplasms; Unspecified,France; Germany; Spain; United States
Phase III Trial of Salvage Stereotactic Radiosurgery (SRS) or SRS + Hippocampal-Avoidant Whole Brain Radiotherapy (HA-WBRT) for First or Second Distant Brain Relapse After Upfront SRS With Brain Metastasis Velocity > or = 4 Brain Metastases/Year,III,Open,"National Institutes of Health/National Cancer Institute;
NRG Oncology","Oncology: Breast; Oncology: Gastric; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Metastatic Cancer; Oncology: Renal",CNS mets; Second line; Stage IV; Third line,"Brain Neoplasms; Breast Neoplasms; Carcinoma; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Central Nervous System Neoplasms; Kidney Neoplasms; Lung Neoplasms; Melanoma; Neoplasm Metastasis; Neoplasms; Renal Cancer; Stomach Carcinoma; Stomach Neoplasms; Wilms Tumor",United States
A Phase II Study of Niraparib With Dostarlimab Therapy as Neoadjuvant Treatment for Patients With BRCA-mutated Breast Cancer,II,Open,"GlaxoSmithKline
Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute;
Johns Hopkins University
Breast Cancer Research Foundation",Oncology: Breast,BRCA; Estrogen receptor positive; HER2 negative; Neoadjuvant; Progesterone receptor positive; Stage I; Stage II; Stage III; Triple receptor negative,Breast Neoplasms,United States
"A Single Arm Phase II Study of Adjuvant Endocrine Therapy, Pertuzumab, and Trastuzumab for Patients With Anatomic Stage I Hormone Receptor-positive, HER2-positive Breast Cancer (ADEPT)",II,Open,"Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute;
Roche;Genentech;",Oncology: Breast,Adjuvant; Estrogen receptor positive; HER2 negative; HER2 positive; Progesterone receptor positive; Stage I,Breast Neoplasms; Neoplasm Micrometastasis,United States
A Phase IIB Randomized Trial of Oral Tamoxifen vs. Topical 4-hydroxytamoxifen Gel vs. Control in Women With Atypical Hyperplasia or Lobular Carcinoma In Situ,II/III,Open,(Other Cooperative Group);,Oncology: Breast,(N/A); Line of therapy N/A,"Breast Carcinoma In Situ; Breast Neoplasms; Carcinoma; Carcinoma in Situ; Carcinoma, Lobular; Hyperplasia",United States
Phase II Study of Neoadjuvant ArOMatase Inhibitor Therapy for ER+ Breast Cancer (NAOMI),II,Open,Dartmouth-Hitchcock Medical Center,Oncology: Breast,Estrogen receptor positive; HER2 negative; Neoadjuvant; Stage I; Stage II; Stage III,Breast Neoplasms,United States
"A Randomized Phase II Trial of Circulating Tumor DNA-Guided Second Line Adjuvant Therapy For High Residual Risk, Stage II-III, Hormone Receptor Positive, HER2 Negative Breast Cancer",II,Open,(Other Industry Sponsor),Oncology: Breast,Adjuvant; Estrogen receptor positive; HER2 negative; Progesterone receptor positive; Second line; Stage II; Stage III,Breast Neoplasms,United States
CIMER: Combined Immunotherapies in Metastatic ER+ Breast Cancer,II,Open,Weill Medical College of Cornell University,Oncology: Breast,Estrogen receptor positive; First line; HER2 negative; Progesterone receptor positive; Stage IV,Breast Neoplasms,United States
"A Phase II, Multicenter, Open-Label Trial to Evaluate the Safety and Efficacy of Trastuzumab Deruxtecan (DS-8201a) With or Without Anastrozole for HER2 Low Hormone Receptor Positive (HR+) Breast Cancer in the Neoadjuvant Setting",II,Open,"Jonsson Comprehensive Cancer Center; UCLA
Organisation for Oncology and Translational Research
Daiichi Sankyo",Oncology: Breast,Adjuvant; Estrogen receptor positive; HER2 negative; Neoadjuvant; Progesterone receptor positive; Stage I; Stage II; Stage III,Breast Neoplasms,United States
"A Pharmacodynamics-Driven Trial of Talazoparib, an Oral PARP Inhibitor, in Patients With Advanced Solid Tumors and Aberrations in Genes Involved in DNA Damage Response",II,Open,National Institutes of Health/National Cancer Institute;,Oncology: Bile Duct (Cholangiocarcinoma); Oncology: Breast; Oncology: Gastric; Oncology: Ovarian; Oncology: Pancreas; Oncology: Prostate; Oncology: Renal; Oncology: Unspecified Solid Tumor,BRCA; Fourth line or greater; HER2 positive; Hormone refractory; Second line; Stage II; Stage III; Stage IV; Third line,"Bile Duct Neoplasms; Breast Neoplasms; Carcinoma; Carcinoma, Ovarian Epithelial; Carcinoma, Renal Cell; Cholangiocarcinoma; Kidney Neoplasms; Neoplasms; Neoplasms, Unknown Primary; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Prostatic Neoplasms; Renal Cancer; Stomach Carcinoma; Stomach Neoplasms; Wilms Tumor",United States
"A Phase II Basket Trial of an ERK1/2 Inhibitor (LY3214996) in Combination With Abemaciclib for Patients Whose Tumors Harbor Pathogenic Alterations in BRAF, RAF1, MEK1/2, ERK1/2, and NF1",II,Open,"Eli Lilly
(Other Hospital/Academic/Medical Center);","Oncology: Breast; Oncology: Colorectal; Oncology: Endometrial; Oncology: Lung, Non-Small Cell; Oncology: Pancreas; Oncology: Thyroid; Oncology: Unspecified Solid Tumor",BRAF; Line of therapy N/A; Metastatic; Second line; Stage III; Stage IV; Unresectable,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Endometrial Neoplasms; Neoplasms, Unknown Primary; Pancreatic Neoplasms; Thyroid Neoplasms; Unspecified",United States
A Phase II Pilot Study of (Lutetium (177Lu)-DOTATATE in Patients With Metastatic Breast Cancer,II,Planned,"OHSU Cancer Institute
Oregon Health and Science University
Novartis;/Advanced Accelerator Applications",Oncology: Breast,Second line; Stage IV; Third line,Breast Neoplasms; Carcinoma,United States
"A Phase II Pilot Trial of ABemacicliB or Abemaciclib and HydroxYchloroquine to Target Minimal Residual Disease in Breast Cancer Patients (""ABBY"")",II,Open,Abramson Cancer Center at University of Pennsylvania Medical Center;;,Oncology: Breast,Second line; Stage I; Stage II; Stage III; Stage IV,"Breast Neoplasms; Neoplasm, Residual",United States
An Expanded Access Program with Plinabulin for Patients Suffering from Chemotherapy-induced Neutropenia,IV,Open,BeyondSpring Pharmaceuticals,Oncology: Breast; Oncology: Supportive Care,(N/A); Line of therapy N/A; Neutropenia,Breast Neoplasms; Neutropenia; Palliative Care,United States
"The CompassHER2 Trials (Comprehensive Use of Pathologic Response Assessment to Optimize Therapy in HER2-Positive Breast Cancer) CompassHER2 Residual Disease (RD), a Double-Blinded, Phase III Randomized Trial of T-DM1 Compared With T-DM1 and Tucatinib.",III,Open,"National Institutes of Health/National Cancer Institute;
Alliance for Clinical Trials in Oncology
Seagen",Oncology: Breast; Oncology: Metastatic Cancer,CNS mets; Estrogen receptor positive; HER2 positive; Progesterone receptor positive; Second line; Stage I; Stage II; Stage III,Brain Neoplasms; Breast Neoplasms; Carcinoma; Central Nervous System Neoplasms; Neoplasm Metastasis,Canada; United States
IRENE Study: Phase II Study of INCMGA00012 and the Oncolytic Virus Pelareorep in Metastatic Triple Negative Breast Cancer,II,Open,"National Institutes of Health/National Cancer Institute;
Oncolytics Biotech
(Other Hospital/Academic/Medical Center);
Incyte Corporation",Oncology: Breast,HER2 negative; PD-1 Refractory; PD-L1 Positive; PD-L1 Refractory; Second line; Stage III; Stage IV; Third line; Triple receptor negative,Breast Neoplasms; Carcinoma; Triple Negative Breast Neoplasms,United States
"P-RAD: A Randomized Study of Preoperative Chemotherapy, Pembrolizumab and No, Low or High Dose RADiation in Node-Positive, HER2-Negative Breast Cancer",II,Open,"(Other Cooperative Group);
Merck & Co./Merck Sharp & Dohme (MSD)
Breast Cancer Research Foundation",Oncology: Breast,Estrogen receptor positive; HER2 negative; Neoadjuvant; Progesterone receptor positive; Stage I; Stage II; Triple receptor negative,Breast Neoplasms; Triple Negative Breast Neoplasms,United States
Margetuximab or Trastuzumab (MARGOT): A Phase II Study Comparing Neoadjuvant Paclitaxel/Margetuximab/Pertuzumab to Paclitaxel/Trastuzumab/Pertuzumab in Patients With Stage II-III HER2-positive Breast Cancer,II,Open,"(Other Cooperative Group);
Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute;
MacroGenics",Oncology: Breast,Adjuvant; HER2 positive; Neoadjuvant; Stage II; Stage III,Breast Neoplasms,United States
Roll Over Study for Patients Who Have Completed a Previous Oncology Study With Olaparib and Are Judged by the Investigator to Clinically Benefit From Continued Treatment,III,Open,AstraZeneca;,Oncology: Breast; Oncology: Endometrial; Oncology: Ovarian,BRCA; HER2 negative; Line of therapy N/A; Stage IV,"Breast Neoplasms; Carcinoma, Endometrioid; Endometrial Neoplasms; Ovarian Cancer; Ovarian Neoplasms; Unspecified","Belgium; Bulgaria; Canada; Czech Republic; Denmark; Finland; France; Germany; Hungary; Israel; Italy; Netherlands; Norway; Poland; Portugal; Russia; Slovenia; South Korea; Spain; Sweden; Taiwan, China; Turkey; United Kingdom; United States"
A Feasibility Study of De-escalation of Chemotherapy in Patients With Early-Stage HER2 Positive Breast Cancer,II,Planned,University of Roche;ster,Oncology: Breast,Adjuvant; HER2 positive; Neoadjuvant; Stage II; Stage III,Breast Neoplasms,United States
Saci-IO HR+: Randomized Phase II Study of Sacituzumab Govitecan With or Without Pembrolizumab in Hormone Receptor-positive (HR+) / HER2- Metastatic Breast Cancer (MBC),II,Open,"Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute;
Gilead Sciences;/Immunomedics
Merck & Co./Merck Sharp & Dohme (MSD)",Oncology: Breast,Estrogen receptor positive; First line; HER2 negative; PD-1 Naive; PD-L1 Naive; PD-L1 Positive; Progesterone receptor positive; Second line; Stage III; Stage IV,Breast Neoplasms,United States
Saci-IO TNBC: Randomized Phase II Study of Sacituzumab Govitecan With or Without Pembrolizumab in PD-L1-negative Metastatic Triple Negative Breast Cancer (TNBC),II,Open,"Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute;
Gilead Sciences;/Immunomedics
Merck & Co./Merck Sharp & Dohme (MSD)",Oncology: Breast,First line; HER2 negative; PD-1 Naive; PD-L1 Naive; Stage III; Stage IV; Triple receptor negative,Breast Neoplasms; Triple Negative Breast Neoplasms,United States
Genomic/Molecular Profiling of Residual Disease After Neoadjuvant Chemotherapy in Hispanic/ Latino Women With Triple-negative Breast Cancer,II,Open,Texas Tech University Health Sciences Center,Oncology: Breast,HER2 negative; Neoadjuvant; Stage I; Stage II; Stage III; Stage IV; Triple receptor negative,Breast Neoplasms; Triple Negative Breast Neoplasms,United States
A Phase IIa Study of Dendritic Cell Vaccines Against Her2/Her3 and Pembrolizumab in Patients With Asymptomatic Brain Metastasis From Triple Negative Breast Cancer (TNBC) or HER2+ Breast Cancer (HER2+BC),II,Open,"Roswell Park Cancer Institute
US Department of Defense",Oncology: Breast; Oncology: Metastatic Cancer,CNS mets; HER2 negative; HER2 positive; Maintenance/Consolidation; Stage IV; Triple receptor negative,Brain Neoplasms; Breast Neoplasms; Central Nervous System Neoplasms; Neoplasm Metastasis; Neoplasms; Triple Negative Breast Neoplasms,United States
An Open-Label Phase II Trial to Evaluate the Efficacy and Safety of Neoadjuvant Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel Plus Trastuzumab and Pertuzumab in Early Stage HER2-Negative Breast Cancer Patients Selected With a Test Measuring Live Cell HER2 Signaling Transduction (FACT 1),II,Open,"National Surgical Adjuvant Breast and Bowel Project (NSABP)
Roche;Genentech;
Celcuity",Oncology: Breast,Estrogen receptor positive; HER2 negative; Neoadjuvant; Stage 0; Stage I; Stage II,Breast Neoplasms,United States
A Phase II Study of Concurrent WOKVAC Vaccination With Neoadjuvant Chemotherapy and HER2-Targeted Monoclonal Antibody Therapy,II,Open,"National Institutes of Health/National Cancer Institute;
University of Washington
US Department of Defense",Oncology: Breast,HER2 positive; Neoadjuvant; Stage I; Stage II; Stage III,Breast Neoplasms,United States
A Phase IIA Trial Assessing the Tolerability of Abemaciclib in Combination With Endocrine Therapy in Patients Age 70 and Older With Hormone Receptor Positive Metastatic Breast Cancer Who Have Progressed on or After Prior CDK 4/6 Inhibition,II,Open,"National Institutes of Health/National Cancer Institute;
City of Hope Comprehensive Cancer Center",Oncology: Breast,Estrogen receptor positive; HER2 negative; Progesterone receptor positive; Second line; Stage IV,Breast Neoplasms; Carcinoma,United States
A Phase II Single Arm Trial Evaluating the Safety and Efficacy of Anhydrous Enol-Oxaloacetate on Improving Cognitive Complaints in Breast Cancer Survivors,II,Open,"Jonsson Comprehensive Cancer Center; UCLA
Breast Cancer Research Foundation
MetVital",Oncology: Breast; Oncology: Supportive Care,Neurotoxicity; Second line; Stage 0; Stage I; Stage II; Stage III,Breast Carcinoma In Situ; Breast Neoplasms; Palliative Care,United States
Pre-Operative Window of Adjuvant Endocrine Therapy to Inform Radiation Therapy Decisions In Older Women With Early-Stage Breast Cancer,II,Open,University of Virginia,Oncology: Breast,Adjuvant; Estrogen receptor positive; HER2 negative; Neoadjuvant; Progesterone receptor positive; Stage I,Breast Neoplasms,United States
(CompassHER2-pCR): Preoperative THP and Postoperative HP in Patients Who Achieve a Pathologic Complete Response,II,Open,"National Institutes of Health/National Cancer Institute;
ECOG-ACRIN Cancer Research Group",Oncology: Breast,Adjuvant; Estrogen receptor positive; HER2 positive; Neoadjuvant; Progesterone receptor positive; Stage II; Stage III,Breast Neoplasms,Puerto Rico; United States
INTERACT- Integrated Evaluation of Resistance and Actionability Using Circulating Tumor DNA in HR Positive Metastatic Breast Cancers,II,Open,"MD Anderson Cancer Center University of Texas;
National Institutes of Health/National Cancer Institute;",Oncology: Breast,Estrogen receptor positive; First line; HER2 positive; Progesterone receptor positive; Stage IV,Breast Neoplasms,United States
Phase II Study of PD-1 Inhibition With Cemiplimab in Locally Advanced Hormone Receptor (HR) Positive HER2 Negative or Triple-Negative Breast Cancer Patients Undergoing Standard Neoadjuvant Chemotherapy,II,Open,Medical College of Wisconsin Cancer Center,Oncology: Breast,Estrogen receptor positive; HER2 negative; Line of therapy N/A; PD-L1 Positive; Progesterone receptor positive; Stage I; Stage II; Stage III; Triple receptor negative,Breast Neoplasms; Triple Negative Breast Neoplasms,United States
The incidence of febrile neutropenia (FN) for chemotherapy patients receiving pegfilgrastim by an on-body injector (pegfilgrastim OBI) versus other FN prophylaxis strategies,IV,Open,(Other Hospital/Academic/Medical Center);,"Oncology: Breast; Oncology: Lung, Non-Small Cell; Oncology: Lung, Small Cell; Oncology: Lymphoma, Non-Hodgkin's; Oncology: Neuroendocrine; Oncology: Prostate; Oncology: Supportive Care",Adjuvant; Aggressive; First line; Indolent; Neoadjuvant; Neutropenia; Pulmonary; Stage III; Stage IV; Untreated,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Lymphoma, Large-Cell, Anaplastic; Lymphoma, Non-Hodgkin; Neuroendocrine Tumors; Neutropenia; Palliative Care; Prostatic Neoplasms; Small Cell Lung Carcinoma",United States
A Phase II Study of Response-guided Neoadjuvant Sacituzumab Govitecan (IMMU-132) in Patients With Localized Triple-Negative Breast Cancer (NeoSTAR),II,Open,"Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute;
Gilead Sciences;/Immunomedics
Massachusetts General Hospital",Oncology: Breast,Adjuvant; HER2 negative; Neoadjuvant; Stage I; Stage II; Stage III; Triple receptor negative,Breast Neoplasms; Triple Negative Breast Neoplasms,United States
Phase II Trial to Evaluate Immune-Related Biomarkers for Pathological Response in Stage II-III HER2-Positive Breast Cancer Receiving Neoadjuvant Chemotherapy With Subsequent Randomization to Multi-Epitope HER2 Vaccine vs. Placebo in Patients With Residual Disease Post-Neoadjuvant Chemotherapy,II,Open,"National Institutes of Health/National Cancer Institute;
Mayo Clinic;
Academic and Community Cancer Research United",Oncology: Breast,HER2 positive; Maintenance/Consolidation; Neoadjuvant; Stage II; Stage III,Breast Neoplasms,United States
"A Phase III, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Inavolisib  Plus Palbociclib and Fulvestrant Versus Placebo Plus Palbociclib and Fulvestrant in Patients With PIK3CA-Mutant, Hormone Receptor-Positive, Her2-Negative, Locally Advanced or Metastatic Breast Cancer",II/III,Open,Roche; {F. Hoffmann-La Roche;},Oncology: Breast,Estrogen receptor positive; First line; HER2 negative; Progesterone receptor positive; Stage III; Stage IV,Breast Neoplasms,"Australia; Austria; Belgium; Canada; China; Denmark; France; Georgia; Germany; Greece; Hong Kong, S.A.R., China; Hungary; Italy; Malaysia; New Zealand; Poland; Portugal; Russia; Singapore; South Korea; Spain; Taiwan, China; Thailand; Turkey; Ukraine; United Kingdom; United States"
Self-Reported Pain and Nadir White Blood Cell/Absolute Neutrophil Count in Women 45 and Under Compared to Older Women Receiving Pegfilgrastim (or Biosimilar Substitution) While Undergoing Chemotherapy for Non-Metastatic Breast Cancer,III,Open,"(Other Cooperative Group);
(Other Hospital/Academic/Medical Center);
Atrium Health",Oncology: Breast; Oncology: Supportive Care,Adjuvant; Neoadjuvant; Neutropenia; Other; Stage I; Stage II; Stage III,Breast Neoplasms; Neutropenia; Palliative Care; Unspecified,United States
"Phase III Postneoadjuvant Study Evaluating Sacituzumab Govitecan, an Antibody Drug Conjugate in Primary HER2-negative Breast Cancer Patients With High Relapse Risk After Standard Neoadjuvant Treatment - SASCIA",III,Open,"Gilead Sciences;/Immunomedics
Cancer Trials Ireland {Irish Clinical Oncology Research Group}
Austrian Breast & Colorectal Cancer Study Group
Spanish Breast Cancer Research Group
German Breast Group",Oncology: Breast,Adjuvant; BRCA; Estrogen receptor positive; HER2 negative; Neoadjuvant; Progesterone receptor positive; Stage I; Stage II; Stage III; Triple receptor negative,Breast Neoplasms; Triple Negative Breast Neoplasms,Australia; Austria; Belgium; France; Germany; Ireland; Italy; South Korea; Spain; Switzerland; United States
Alleviation by NIAGEN of Persistent Chemotherapy-Induced Peripheral Neuropathy in Cancer Survivors,II,Open,"(Other Academic Cancer Center)
University of Iowa","CNS: Pain (neuropathic); Oncology: Breast; Oncology: Colorectal; Oncology: Endometrial; Oncology: Head/Neck; Oncology: Lung, Small Cell; Oncology: Neuroendocrine; Oncology: Ovarian; Oncology: Supportive Care",(N/A); Cancers-related; First line; Neurotoxicity; Pulmonary; Second line; Untreated,"Breast Neoplasms; Cancer pain; Cancer Pain; Carcinoma, Endometrioid; Carcinoma, Small Cell; Colorectal Neoplasms; Endometrial Neoplasms; Head and Neck Neoplasms; Neuralgia; Neuroendocrine Tumors; Ovarian Cancer; Ovarian Neoplasms; Palliative Care; Peripheral Nervous System Diseases; Small Cell Lung Carcinoma",United States
Phase II Study of Docetaxel Chemotherapy With Pembrolizumab and Interleukin-12 Gene Therapy in Patients With Anthracycline- Refractory Triple Negative Breast Cancer (INTEGRAL),II,Open,"(Other Hospital/Academic/Medical Center);
Merck & Co./Merck Sharp & Dohme (MSD)",Oncology: Breast,HER2 negative; Neoadjuvant; Stage 0; Stage I; Stage II; Triple receptor negative,Breast Neoplasms; Triple Negative Breast Neoplasms,United States
Phase II Trial of Radium-223 Dichloride in Combination with Paclitaxel in Patients With Bone Metastatic Breast Cancer,II,Open,"National Institutes of Health/National Cancer Institute;
University Health Network; Toronto/Princess Margaret Cancer Centre {Princess Margaret Hospital}",Oncology: Breast; Oncology: Metastatic Cancer,Bone mets; Estrogen receptor positive; HER2 negative; Progesterone receptor positive; Second line; Stage IV; Triple receptor negative,Breast Neoplasms; Carcinoma; Neoplasm Metastasis; Neoplasms,United States
Overcoming PARP Inhibitor Resistance in BRCA Germline Mutation Positive Advanced Breast Cancer,II,Open,"MD Anderson Cancer Center University of Texas;
National Institutes of Health/National Cancer Institute;",Oncology: Breast,BRCA; Estrogen receptor positive; HER2 negative; Second line; Stage III; Stage IV; Triple receptor negative,Breast Neoplasms; Carcinoma,United States
Randomized Clinical Trial of RANKL Inhibition With Denosumab on Mammographic Density in Premenopausal Women With Dense Breasts (TRIDENT).,II,Open,"Washington University School of Medicine
National Institutes of Health",Oncology: Breast,(N/A); Line of therapy N/A,Breast Neoplasms; Unspecified,United States
A Pilot Study of PD-L1 and IRF-1 expression on CTC (Circulating tumor cell),II,Open,"Fred Hutchinson Cancer Research Center
University of Washington
RareCyte","Oncology: Breast; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Unspecified Solid Tumor",Line of therapy N/A; Stage IV,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Head and Neck Neoplasms; Neoplasms, Unknown Primary",United States
"Evaluation of Talazoparib, a PARP Inhibitor, in Patients With Somatic BRCA Mutant Metastatic Breast Cancer: Genotyping Based Clinical Trial.",II,Open,"Pfizer;
Massachusetts General Hospital",Oncology: Breast,BRCA; Estrogen receptor positive; HER2 negative; Progesterone receptor positive; Second line; Stage IV; Triple receptor negative,Breast Neoplasms,United States
"Window Trial of Abemaciclib for Surgically Resectable, Chemotherapy-Resistant, Triple Negative Breast Cancer (a BEAUTY Study)",II,Open,"National Institutes of Health/National Cancer Institute;
Mayo Clinic;",Oncology: Breast,HER2 negative; Neoadjuvant; Stage I; Stage II; Stage III; Stage IV; Triple receptor negative,"Breast Carcinoma In Situ; Breast Neoplasms; Carcinoma; Carcinoma in Situ; Carcinoma, Ductal; Carcinoma, Ductal, Breast; Carcinoma, Intraductal, Noninfiltrating; Carcinoma, Lobular; Fibrocystic Breast Disease; Triple Negative Breast Neoplasms",United States
"Innovative Combination Immunotherapy for Metastatic Triple Negative Breast Cancer (TNBC): A Multicenter, Multi-Arm Translational Breast Cancer Research Consortium Study.",II,Open,"(Other Cooperative Group);
Pfizer;
Johns Hopkins University
Pfizer; {Array BioPharma}
Breast Cancer Research Foundation",Oncology: Breast,First line; HER2 negative; PD-L1 Positive; Second line; Stage III; Stage IV; Third line; Triple receptor negative,Breast Neoplasms; Carcinoma; Triple Negative Breast Neoplasms,United States
Genomically-Guided Treatment Trial in Brain Metastases,II,Open,"National Institutes of Health/National Cancer Institute;
Kazia Therapeutics {Novogen}
Roche;Genentech;
Alliance for Clinical Trials in Oncology","Oncology: Breast; Oncology: CNS, Glioblastoma; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Metastatic Cancer; Oncology: Unspecified Solid Tumor",BRAF; CNS mets; Estrogen receptor positive; HER2 negative; HER2 positive; PD-1 Refractory; PD-L1 Refractory; Progesterone receptor positive; Second line; Stage IV; Triple receptor negative,"Brain Neoplasms; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Central Nervous System Neoplasms; Glioblastoma; Melanoma; Neoplasm Metastasis; Neoplasms; Neoplasms, Unknown Primary",United States
Therapeutic Targeting of ER Beta in Triple Negative Breast Cancer,II,Open,"National Institutes of Health/National Cancer Institute;
Mayo Clinic;",Oncology: Breast,Estrogen receptor positive; Fourth line or greater; HER2 negative; PD-1 Refractory; PD-L1 Refractory; Second line; Stage III; Stage IV; Third line; Triple receptor negative,Breast Neoplasms; Carcinoma,United States
"A Phase III Randomized Placebo-controlled Double-blind Study of Romiplostim for the Treatment of Chemotherapy-induced Thrombocytopenia in Patients Receiving Chemotherapy for Treatment of Non-small Cell Lung Cancer (NSCLC), Ovarian Cancer, or Breast Cancer",III,Open,Amgen,"Oncology: Breast; Oncology: Fallopian Tube; Oncology: Lung, Non-Small Cell; Oncology: Metastatic Cancer; Oncology: Ovarian; Oncology: Supportive Care; Oncology: Unspecified Cancer",Fourth line or greater; PD-1 Refractory; PD-L1 Refractory; Peritoneal mets; Second line; Stage I; Stage II; Stage III; Stage IV; Third line; Thrombocytopenia,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Ovarian Epithelial; Fallopian Tube Neoplasms; Lung Neoplasms; Neoplasm Metastasis; Neoplasms; Ovarian Cancer; Ovarian Neoplasms; Palliative Care; Peritoneal Neoplasms; Thrombocytopenia",Argentina; Austria; Brazil; Bulgaria; Canada; Chile; Colombia; Greece; Hungary; Mexico; Peru; Poland; Portugal; Romania; Russia; Spain; Turkey; Ukraine; United States
DURVA+ : Evaluation of the Safety and Pharmacodynamics of Anti-PD-L1 Antibody Durvalumab in Combination With Chemotherapy in Patients With Advanced Solid Tumors,II,Open,National Institutes of Health/National Cancer Institute;,Oncology: Anal; Oncology: Breast; Oncology: Colorectal; Oncology: Head/Neck; Oncology: Pancreas; Oncology: Prostate; Oncology: Unspecified Solid Tumor,Fourth line or greater; PD-1 Refractory; PD-L1 Refractory; Second line; Stage III; Stage IV; Third line,"Anus Neoplasms; Breast Neoplasms; Colorectal Neoplasms; Head and Neck Neoplasms; Neoplasms; Neoplasms, Unknown Primary; Pancreatic Cancer; Pancreatic Neoplasms; Prostatic Neoplasms",United States
Multicenter Phase II Trial of Durvalumab (MEDI4736) With Trastuzumab and Pertuzumab Combination in HER2-Enriched and HER2-Amplified Breast Cancer (DTP Trial),II,Open,"AstraZeneca;
(Other Hospital/Academic/Medical Center);",Oncology: Breast,HER2 positive; Line of therapy N/A; Stage I; Stage II,Breast Neoplasms,United States
Phase II Trial Evaluating the Efficacy and Safety of Neoadjuvant Neratinib and Chemotherapy in Early Stage Triple-Negative Breast Cancer Patients Who Exhibit Enhanced HER2 Signaling by Live Cell HER2 Signaling Transduction Analysis (FACT-2),II,Open,"(Other Hospital/Academic/Medical Center);
Puma Biotechnology
Celcuity",Oncology: Breast,HER2 negative; HER2 positive; Neoadjuvant; Stage I; Stage II; Stage III; Stage IV; Triple receptor negative,Breast Neoplasms; Triple Negative Breast Neoplasms,United States
PROMISE-005: A Phase II Randomized Study Assessing the Efficacy of Stereotactic Body Radiotherapy (SBRT) in Patients With Oligometastatic Breast or Lung Cancer,II,Open,Memorial Sloan-Kettering Cancer Center,"Oncology: Breast; Oncology: Lung, Non-Small Cell",ALK; EGFR; Estrogen receptor positive; First line; HER2 negative; Stage IV; Triple receptor negative,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Lung Neoplasms; Triple Negative Breast Neoplasms",United States
Converting HR+ Breast Cancer Into an Individualized Vaccine,II,Open,"Weill Medical College of Cornell University
US Department of Defense
Celldex Therapeutics {AVANT Immunotherapeutics}
Merck & Co./Merck Sharp & Dohme (MSD)",Oncology: Breast,Estrogen receptor positive; First line; HER2 negative; Neoadjuvant; Progesterone receptor positive; Stage I; Stage II; Stage III,Breast Neoplasms,United States
"A Phase II, Open-Label, Study of Olaparib in Combination With Either Durvalumab (MEDI4736), Selumetinib or Capivasertib, or Ceralasertib Monotherapy in Patients With Metastatic Triple-Negative Breast Cancer",II,Open,"AstraZeneca;
Oregon Health and Science University",Oncology: Breast,HER2 negative; PD-1 Naive; PD-L1 Naive; PD-L1 Positive; Second line; Stage IV; Third line; Triple receptor negative,Breast Neoplasms; Triple Negative Breast Neoplasms,United States
A Phase III Randomized Pivotal Study of LiPlaCis in Advanced or Metastatic Breast Cancer,III,Planned,Allarity Therapeutics,Oncology: Breast,Line of therapy N/A; Stage III; Stage IV,Breast Neoplasms,United States
A Phase IIB Study of ZEN003694 in Combination With Talazoparib in Patients With Triple-Negative Breast Cancer,II,Open,"Pfizer;
Zenith Epigenetics
Newsoara Biopharma Co.",Oncology: Breast,Fourth line or greater; HER2 negative; Second line; Stage III; Stage IV; Third line; Triple receptor negative,Breast Neoplasms; Triple Negative Breast Neoplasms,Belgium; China; Spain; United States
"An Open Label, Multicenter Extension Study In Patients Previously Enrolled In A Genentech; And/Or  F. Hoffmann-La Roche, Ltd Sponsored Atezolizumab Study",IV,Open,"Roche;/Chugai Pharmaceutical
Roche; {F. Hoffmann-La Roche;}","Oncology: Bladder; Oncology: Breast; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Renal; Oncology: Unspecified Solid Tumor",(N/A); HER2 negative; Line of therapy N/A; Stage III; Stage IV; Triple receptor negative,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Head and Neck Neoplasms; Kidney Neoplasms; Neoplasms, Unknown Primary; Renal Cancer; Unspecified; Urethral Neoplasms; Urinary Bladder Neoplasms; Wilms Tumor","Belgium; Brazil; Bulgaria; Canada; Chile; Czech Republic; Denmark; France; Germany; Greece; Guatemala; Hong Kong, S.A.R., China; Hungary; Israel; Italy; Japan; Latvia; Malaysia; Mexico; Netherlands; Norway; Poland; Portugal; Romania; Russia; Singapore; Slovakia; Slovenia; South Korea; Spain; Switzerland; Taiwan, China; Thailand; Turkey; Ukraine; United Kingdom; United States"
Phase II Trial of GDC-0084 in Combination With Trastuzumab for Patients With HER2-Positive Breast Cancer Brain Metastases,II,Open,"Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute;
Kazia Therapeutics {Novogen}",Oncology: Breast; Oncology: Metastatic Cancer,CNS mets; HER2 positive; Neoadjuvant; Stage IV,Brain Neoplasms; Breast Neoplasms; Central Nervous System Neoplasms; Neoplasm Metastasis,United States
Neoadjuvant HER2-Targeted Therapy and Immunotherapy with Pembrolizumab (neoHIP),II,Open,"University of Texas
Merck & Co./Merck Sharp & Dohme (MSD)",Oncology: Breast,HER2 positive; Neoadjuvant; Stage I; Stage II; Stage III,Breast Neoplasms,United States
"A Phase II Study of Olaparib Monotherapy in Participants With Previously Treated, Homologous Recombination Repair Mutation (HRRm) or Homologous Recombination Deficiency (HRD) Positive Advanced Cancer",II,Open,"AstraZeneca;
Merck & Co./Merck Sharp & Dohme (MSD)",Oncology: Breast; Oncology: Unspecified Solid Tumor,BRCA; Fourth line or greater; Second line; Stage III; Stage IV; Third line,"Breast Neoplasms; Neoplasms, Unknown Primary; Unspecified",Argentina; Australia; Canada; Colombia; Denmark; France; Guatemala; Ireland; Israel; Italy; Japan; Mexico; New Zealand; Peru; Romania; Russia; South Korea; Spain; Switzerland; Turkey; United Kingdom; United States
"A Pilot Trial of Ifetroban, A Thromboxane A2 Receptor Antagonist, in Patients With Malignant Solid Tumors at High Risk of Metastatic Recurrence",II,Open,"Vanderbilt-Ingram Cancer Center
Cumberland Pharmaceuticals","Oncology: Breast; Oncology: Esophageal; Oncology: Gastric; Oncology: Lung, Non-Small Cell; Oncology: Lung, Small Cell; Oncology: Neuroendocrine; Oncology: Pancreas",HER2 negative; Limited; Pulmonary; Second line; Stage I; Stage II; Stage III; Triple receptor negative,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Esophageal Cancer; Esophageal Neoplasms; Neoplasms; Neuroendocrine Tumors; Pancreatic Cancer; Pancreatic Neoplasms; Recurrence; Small Cell Lung Carcinoma; Stomach Carcinoma; Stomach Neoplasms",United States
Randomized Phase II Clinical Trial of Nab-Paclitaxel + MEDI4736 (Durvalumab) + Tremelimumab + Neoantigen Vaccine Vs. Nab-Paclitaxel + MEDI4736 (Durvalumab) + Tremelimumab in Patients With Metastatic Triple Negative Breast Cancer,II,Open,National Institutes of Health/National Cancer Institute;,Oncology: Breast,Estrogen receptor positive; First line; HER2 negative; Progesterone receptor positive; Stage IV; Triple receptor negative,Breast Neoplasms; Carcinoma; Triple Negative Breast Neoplasms,United States
A Phase II Randomized Trial of Olaparib (NSC-747856) Administered Concurrently With Radiotherapy Versus Radiotherapy Alone for Inflammatory Breast Cancer,II,Open,National Institutes of Health/National Cancer Institute;,Oncology: Breast,First line; HER2 positive; Second line; Stage III,Breast Neoplasms; Inflammatory Breast Neoplasms,Canada; Puerto Rico; United States
Gut and Intratumoral Microbiome Effect on the Neoadjuvant Chemotherapy-induced Immunosurveillance in Triple Negative Breast Cancer,IV,Open,"(Other Hospital/Academic/Medical Center);
Breast Cancer Research Foundation",Oncology: Breast,(N/A); First line; HER2 negative; Neoadjuvant; Triple receptor negative,Breast Neoplasms; Triple Negative Breast Neoplasms,United States
Monitoring Response to Neoadjuvant Chemotherapy (NAC) in HER2 Negative Breast Cancer (HNBC) Using High-speed MR Spectroscopic Imaging (MRSI),II,Open,(Other Cooperative Group);,Oncology: Breast,Estrogen receptor positive; HER2 negative; Neoadjuvant; Progesterone receptor positive; Stage II; Stage III,Breast Neoplasms,United States
Botulinum Toxin A for the Treatment of Chemotherapy Induced Peripheral Neuropathy,II,Open,(Other Hospital/Academic/Medical Center);,CNS: Pain (neuropathic); Oncology: Breast; Oncology: Supportive Care,Cancers-related; Line of therapy N/A; Neurotoxicity; Stage 0; Stage I; Stage II; Stage III; Stage IV,Breast Neoplasms; Cancer pain; Cancer Pain; Neuralgia; Palliative Care; Peripheral Nervous System Diseases,United States
"BRCA-P: A Randomized, Double-Blind, Placebo-Controlled, Multi-Center, International Phase III Study to Determine the Preventive Effect of Denosumab on Breast Cancer in Women Carrying a BRCA1 Germline Mutation",III,Open,"National Institutes of Health/National Cancer Institute;
Austrian Breast & Colorectal Cancer Study Group
Alliance for Clinical Trials in Oncology",Oncology: Breast,BRCA; HER2 negative; Line of therapy N/A; Stage I; Stage II; Stage III; Stage IV; Triple receptor negative,Breast Diseases; Breast Neoplasms; Neoplasms; Ovarian Cancer; Ovarian Neoplasms,Australia; Austria; Germany; Israel; Spain; United Kingdom; United States
"A Global, Multicenter, Three Arms, Open-Label Randomized Study To Evaluate The Efficacy And Safety Of Nanosomal Docetaxel Lipid Suspension Compared To Taxotere (Docetaxel Injection Concentrate) In Triple-Negative Breast Cancer Patients With Locally Advanced Or Metastatic Breast Cancer After Failure To Prior Chemotherapy",III/IV,Open,Intas Pharmaceuticals/Jina Pharmaceuticals,Oncology: Breast,HER2 negative; Second line; Stage III; Stage IV; Triple receptor negative,Breast Neoplasms; Triple Negative Breast Neoplasms,India; Russia; United States
"A Single Arm Phase II Study of Peri-Operative Ipilimumab, Nivolumab and Cryoablation in Women With Hormone Receptor-Negative, HER2-Negative Early Stage/Resectable Breast Cancer.",II,Open,"Memorial Sloan-Kettering Cancer Center
University of Texas Southwest Medical Center",Oncology: Breast,Adjuvant; HER2 negative; Neoadjuvant; Stage I; Stage II; Triple receptor negative,Breast Neoplasms,United States
Preoperative Palbociclib in Patients With DCIS of the Breast That Are Candidates for Surgery,II,Open,"Pfizer;
Georgetown University Medical Center",Oncology: Breast,Estrogen receptor positive; HER2 negative; Neoadjuvant; Progesterone receptor positive; Stage 0; Stage I; Triple receptor negative,"Breast Neoplasms; Carcinoma, Intraductal, Noninfiltrating",United States
Prospective Evaluation of Determinants of Resistance to Endocrine Therapy and a Cyclin-dependent Kinases 4 and 6 (CDK4/6) Inhibitor in Hormone Receptor (HR) Positive Metastatic Breast Cancer (MBC),II,Open,Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins {Johns Hopkins Oncology Center},Oncology: Breast,Estrogen receptor positive; First line; HER2 negative; Progesterone receptor positive; Stage III; Stage IV,Breast Neoplasms,United States
A Basket Trial of Pembrolizumab in Patients With Advanced Solid Tumors and Genomic Instability,II,Open,"National Institutes of Health/National Cancer Institute;
(Other Hospital/Academic/Medical Center);",Oncology: Breast; Oncology: Ovarian; Oncology: Unspecified Solid Tumor,Second line; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Ovarian Epithelial; Genomic Instability; Neoplasms; Neoplasms, Unknown Primary; Ovarian Cancer; Ovarian Neoplasms",United States
A Phase II Study Using the Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in Patients with Metastatic Cancer,II,Open,National Institutes of Health/National Cancer Institute;,"Oncology: Bladder; Oncology: Breast; Oncology: Colorectal; Oncology: Gastric; Oncology: Lung, Non-Small Cell; Oncology: Lung, Small Cell; Oncology: Multiple Myeloma; Oncology: Neuroendocrine; Oncology: Ovarian; Oncology: Prostate; Oncology: Renal; Oncology: Testicular; Oncology: Unspecified Solid Tumor",HER2 negative; HER2 positive; Pulmonary; Second line; Stage IV; Third line; Triple receptor negative,"Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Carcinoma, Small Cell; Colorectal Neoplasms; Endocrine Gland Neoplasms; Kidney Neoplasms; Multiple Myeloma; Neoplasm Metastasis; Neoplasms, Unknown Primary; Neuroendocrine Tumors; Ovarian Cancer; Ovarian Neoplasms; Prostatic Neoplasms; Renal Cancer; Small Cell Lung Carcinoma; Stomach Carcinoma; Stomach Neoplasms; Testicular Cancer; Testicular Neoplasms; Urethral Neoplasms; Urinary Bladder Neoplasms; Urogenital Neoplasms; Wilms Tumor",United States
Pharmacodynamic Biomarkers of Standard Anti-microtubule Drugs as Assessed by Early Tumor Biopsy,IV,Open,"National Institutes of Health/National Cancer Institute;
University of Wisconsin Comprehensive Cancer Center",Oncology: Breast,Line of therapy N/A; Stage III; Stage IV,Breast Neoplasms,United States
"A Phase III, Randomised, Double-Blind, Placebo-Controlled, Multicentre Study Of The Efficacy And Safety Of Atezolizumab Plus Chemotherapy For Patients With Early Relapsing Recurrent (Inoperable Locally Advanced Or Metastatic) Triple-Negative Breast Cancer",III,Open,Roche; {F. Hoffmann-La Roche;},Oncology: Breast,First line; HER2 negative; PD-L1 Positive; Second line; Stage III; Stage IV; Triple receptor negative,Breast Neoplasms; Triple Negative Breast Neoplasms,"Algeria; Argentina; Bosnia and Herzegovina; Brazil; Chile; China; Cuba; Egypt; Finland; France; Germany; Hong Kong, S.A.R., China; Hungary; Italy; Kazakhstan; Mexico; Montenegro; Morocco; Panama; Peru; Portugal; Russia; Serbia; Singapore; South Africa; South Korea; Spain; Turkey; United Kingdom; United States"
Treatment of Refractory Nausea,III,Open,"National Institutes of Health/National Cancer Institute;
University of Roche;ster",Oncology: Breast; Oncology: Supportive Care,(N/A); Emesis; First line,Breast Neoplasms; Palliative Care; Vomiting,United States
A Phase II Study of Olaparib Monotherapy in Metastatic Breast Cancer Patients With Germline or Somatic Mutations in DNA Repair Genes (Olaparib Expanded),II,Open,"AstraZeneca;
Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute;
Johns Hopkins University",Oncology: Breast,BRCA; Estrogen receptor positive; HER2 negative; HER2 positive; Progesterone receptor positive; Second line; Stage IV,Breast Neoplasms,United States
A Phase II Single Arm Trial of Adding Simvastatin to Dual Anti-HER2 Therapy in Patients With HER2-Positive Metastatic Breast Cancer,II,Open,(Other Hospital/Academic/Medical Center);,Oncology: Breast,Estrogen receptor positive; HER2 positive; Progesterone receptor positive; Second line; Stage IV,Breast Neoplasms,United States
"Phase II Study of CDK 4/6 Inhibitor, LEE011 (Ribociclib), in Combination With Adjuvant Endocrine Therapy at Varying Duration for ER-positive Breast Cancer (LEADER).",II,Open,"Novartis;
Massachusetts General Hospital",Oncology: Breast,Adjuvant; Estrogen receptor positive; HER2 negative; Stage I; Stage II; Stage III; Stage IV,Breast Neoplasms,United States
Randomized Trial of Neo-adjuvant Chemotherapy With or Without Metformin for HER2 Positive Operable Breast Cancer,II,Open,(Other Hospital/Academic/Medical Center);,Oncology: Breast,HER2 positive; Neoadjuvant; Stage I; Stage II; Stage III,Breast Neoplasms,United States
"I-CURE-1: A Phase II, Single Arm Study of Pembrolizumab Combined With Carboplatin in Patients With Circulating Tumor Cells (CTCs) Positive Her-2 Negative Metastatic Breast Cancer (MBC)",II,Open,"National Institutes of Health/National Cancer Institute;
Northwestern University
Merck & Co./Merck Sharp & Dohme (MSD)",Oncology: Breast,Estrogen receptor positive; HER2 negative; Second line; Stage IV; Triple receptor negative,"Breast Neoplasms; Carcinoma; Neoplastic Cells, Circulating",United States
"Phase II Trial to Evaluate the Efficacy of the FASN Inhibitor, TVB-2640, in Combination With Trastuzumab Plus Paclitaxel or Endocrine Therapy in Patients With HER2+ Metastatic Breast Cancer Resistant to Trastuzumab-Based Therapy",II,Open,"National Institutes of Health/National Cancer Institute;
Mayo Clinic;",Oncology: Breast,Estrogen receptor positive; First line; Fourth line or greater; HER2 positive; Second line; Stage III; Stage IV; Third line,Breast Neoplasms; Carcinoma,United States
A Pivotal Phase III Study to Evaluate Reolysin in Combination with Paclitaxel in Patients with HR Positive/HER2 Negative Metastatic Breast Cancer,III,Planned,Oncolytics Biotech,Oncology: Breast,Estrogen receptor positive; HER2 negative; Progesterone receptor positive; Second line; Stage IV; Third line,Breast Neoplasms,United States
"A Randomized Phase II Study of Pembrolizumab, an Anti-Programmed Cell Death (PD)-1 Antibody, in Combination With Carboplatin Compared to Carboplatin Alone in Breast Cancer Patients With Chest Wall Disease",II,Open,"(Other Cooperative Group);
Johns Hopkins University
Massachusetts General Hospital
University of California; San Francisco
Mayo Clinic;
Merck & Co./Merck Sharp & Dohme (MSD)",Oncology: Breast,Estrogen receptor positive; Fourth line or greater; HER2 negative; HER2 positive; PD-1 Refractory; PD-L1 Positive; PD-L1 Refractory; Progesterone receptor positive; Second line; Stage III; Stage IV; Third line; Triple receptor negative,Breast Neoplasms,United States
"Open Label, Phase II Pilot Study of Immune Checkpoint Inhibition With Pembrolizumab in Combination With PARP Inhibition With Olaparib in Advanced BRCA-mutated or HDR-defect Breast Cancers",II,Open,"Cedars-Sinai Medical Center
Merck & Co./Merck Sharp & Dohme (MSD)",Oncology: Breast,BRCA; Estrogen receptor positive; HER2 negative; HER2 positive; Progesterone receptor positive; Second line; Stage III; Stage IV; Triple receptor negative,Breast Neoplasms,United States
"A Managed Access Program Of Neratinib in Patients with Early Stage HER2-Positive Breast Cancer (Extended Adjuvant Setting), HER-2 positive Metastatic Breast Cancer, and HER2-Mutated Solid Tumors",III,Open,Puma Biotechnology,Oncology: Breast; Oncology: Unspecified Solid Tumor,Adjuvant; HER2 positive; Stage I; Stage IV,"Breast Neoplasms; Neoplasms, Unknown Primary",United States
A Phase II Clinical Study of Elenagen in Ovarian and Breast Cancer Patients,II,Planned,CureLab Oncology,Oncology: Breast; Oncology: Ovarian,HER2 negative; Line of therapy N/A; Stage IV; Triple receptor negative,"Breast Neoplasms; Carcinoma, Endometrioid; Carcinoma, Renal Cell; Endometrial Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Prostatic Neoplasms; Renal Cancer; Stomach Carcinoma; Stomach Neoplasms",United States
Phase IIB Trial of Neoadjuvant Oral Tamoxifen Versus Transdermal 4-hydroxytamoxifen in Women With DCIS of the Breast,II,Open,"National Institutes of Health/National Cancer Institute;
Northwestern University
BHR Pharma",Oncology: Breast,(N/A); Estrogen receptor positive; First line; Neoadjuvant; Second line,"Breast Carcinoma In Situ; Breast Neoplasms; Carcinoma; Carcinoma in Situ; Carcinoma, Ductal, Breast; Carcinoma, Intraductal, Noninfiltrating",United States
TBCRC 042 - A Randomized Phase II Window-of-Opportunity Trial of Ruxolitinib in Patients With High Risk and Premalignant Breast Conditions,II,Open,"(Other Cooperative Group);
Incyte Corporation",Oncology: Breast,Neoadjuvant; Stage 0,"Breast Carcinoma In Situ; Breast Diseases; Breast Neoplasms; Carcinoma; Carcinoma in Situ; Carcinoma, Ductal; Carcinoma, Intraductal, Noninfiltrating; Carcinoma, Lobular; Hyperplasia; Precancerous Conditions",United States
Phase II Trial of Primary Endocrine Therapy With Combination of Fulvestrant and Palbociclib in Elderly Patients With Hormone Responsive Breast Cancer Who Have Inoperable Tumor Or Operable Tumor But Cannot Undergo Surgery Due to Frailty Or Who Refuse Surgery,II,Open,"Pfizer;
Ohio State University",Oncology: Breast,Estrogen receptor positive; First line; HER2 negative; Progesterone receptor positive; Stage I; Stage II; Stage III,Breast Neoplasms,United States
A Phase II Randomized-double Blinded Placebo Controlled Window of Opportunity Trial Comparing Conjugated Estrogens/Bazedoxifene to Placebo in Women Undergoing Surgical Therapy for Ductal Carcinoma in Situ (DCIS),II,Open,"National Institutes of Health/National Cancer Institute;
Pfizer;
University of Chicago Cancer Research Center
Northwestern University
University of California; San Francisco",Oncology: Breast,Estrogen receptor positive; Neoadjuvant; Stage 0,"Breast Carcinoma In Situ; Breast Neoplasms; Carcinoma; Carcinoma in Situ; Carcinoma, Ductal, Breast; Carcinoma, Intraductal, Noninfiltrating",United States
Targeted Agent and Profiling Utilization Registry (TAPUR) Study,II,Open,"AstraZeneca;
Bristol-Myers Squibb
Eli Lilly
(Other Cooperative Group);
Pfizer;
Seagen {Seattle Genetics}
Bayer AG/Bayer Pharmaceuticals
Otsuka Holdings/Taiho Pharmaceutical
Merck & Co./Merck Sharp & Dohme (MSD)
Roche;Genentech;","Oncology: Anal; Oncology: Bile Duct (Cholangiocarcinoma); Oncology: Breast; Oncology: Cervical; Oncology: Colorectal; Oncology: Endometrial; Oncology: Esophageal; Oncology: Gallbladder; Oncology: Gastric; Oncology: GIST; Oncology: Head/Neck; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Lymphoma, Non-Hodgkin's; Oncology: Melanoma; Oncology: Mesothelioma; Oncology: Multiple Myeloma; Oncology: Neuroendocrine; Oncology: Ovarian; Oncology: Pancreas; Oncology: Primary Peritoneal; Oncology: Prostate; Oncology: Renal; Oncology: Skin, Basal Cell Carcinoma; Oncology: Soft Tissue Sarcoma; Oncology: Thyroid; Oncology: Unspecified Solid Tumor; Oncology: Vaginal",(N/A); Advanced; Aggressive; Anaplastic; BRAF; BRCA; Diffuse large B-cell lymphoma (DLBCL); Extranodal marginal zone B-cell lymphoma (MALT); FGFR; First line; Follicular lymphoma (FL); Fourth line or greater; Indolent; Lymphoblastic lymphoma (LBL); Mantle cell lymphoma (MCL); MET Amplification/Alteration; MSI-L; MSS/pMMR; Other subtype; Second line; Small lymphocytic lymphoma (SLL); Stage III; Stage IV; Third line; Unspecified; Waldenstrom's macroglobulinemia (WM),"Anus Neoplasms; Bile Duct Neoplasms; Breast Neoplasms; Carcinoma, Basal Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Cholangiocarcinoma; Colorectal Neoplasms; Endometrial Neoplasms; Esophageal Neoplasms; Fibrosarcoma; Gallbladder Neoplasms; Gastrointestinal Stromal Tumors; Head and Neck Neoplasms; Kidney Neoplasms; Leiomyosarcoma; Liposarcoma; Liver Neoplasms; Lymphoma, B-Cell, Marginal Zone; Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Large-Cell, Anaplastic; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Melanoma; Mesothelioma; Multiple Myeloma; Neoplasms, Unknown Primary; Neuroendocrine Tumors; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Peritoneal Neoplasms; Prostatic Neoplasms; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Stomach Neoplasms; Synovial Sarcoma; Thyroid Neoplasms; Uterine Cervical Neoplasms; Vaginal Neoplasms; Waldenstrom Macroglobulinemia; Wilms Tumor",United States
A Phase IIB Study of Neoadjuvant ZT Regimen (Enzalutamide) Therapy in Combination With Weekly Paclitaxel) for Androgen Receptor (AR)-Positive Triple-Negative Breast Cancer,II,Open,"MD Anderson Cancer Center University of Texas;
National Institutes of Health/National Cancer Institute;
Astellas Pharma",Oncology: Breast,First line; HER2 negative; Neoadjuvant; Stage I; Stage II; Stage III; Triple receptor negative,Breast Neoplasms; Carcinoma; Triple Negative Breast Neoplasms,United States
"Women's Triple-Negative First-Line Study: A Phase II Trial of Panitumumab, Carboplatin and Paclitaxel (PaCT) in Patients With Localized Triple-Negative Breast Cancer (TNBC) With Tumors Predicted Insensitive to Standard Neoadjuvant Chemotherapy",II,Open,"MD Anderson Cancer Center University of Texas;
National Institutes of Health/National Cancer Institute;",Oncology: Breast,HER2 negative; Neoadjuvant; Stage I; Stage II; Stage III; Triple receptor negative,Breast Neoplasms,United States
A Phase II Study of Intratumoral Injection of LTX-315 in Combination With Pembrolizumab in Patients With Percutaneously Accessible Lesions With Advanced Melanoma Refractory to Pembrolizumab,II,Open,Lytix Biopharma,"Oncology: Bladder; Oncology: Breast; Oncology: Cervical; Oncology: Colorectal; Oncology: Esophageal; Oncology: Gastric; Oncology: Head/Neck; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Lung, Small Cell; Oncology: Melanoma; Oncology: Neuroendocrine; Oncology: Renal",BRAF; Fourth line or greater; HER2 negative; Merkel; MSI-H/dMMR; PD-1 Refractory; PD-L1 Positive; PD-L1 Refractory; Pulmonary; Second line; Stage III; Stage IV; Third line; Triple receptor negative,"Breast Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Carcinoma, Small Cell; Colorectal Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Head and Neck Neoplasms; Kidney Neoplasms; Liver Cancer; Liver Neoplasms; Melanoma; Neuroendocrine Tumors; Renal Cancer; Small Cell Lung Carcinoma; Stomach Carcinoma; Stomach Neoplasms; Urethral Neoplasms; Urinary Bladder Neoplasms; Uterine Cervical Neoplasms; Wilms Tumor",France; Norway; Spain; United States
"A Phase II, Double-Blind, Randomized, Multi-Center, Placebo-Controlled Study to Evaluate the Efficacy of TPIV-200 in Prolonging Disease-Free Survival in Women With Advanced Triple Negative Breast Cancer",II,Open,"Mayo Clinic;
US Department of Defense
Marker Therapeutics {TapImmune {GeneMax}}",Oncology: Breast,HER2 negative; Second line; Stage I; Stage II; Stage III; Stage IV; Triple receptor negative,Breast Neoplasms; Triple Negative Breast Neoplasms,United States
A Phase II Basket Study of the Oral TRK Inhibitor Larotrectinib in Subjects With NTRK Fusion-positive Tumors.,II,Open,"Bayer AG
Eli Lilly/Loxo Oncology
PCI Pharma Services
Bayer AG/Bayer China","Oncology: Bile Duct (Cholangiocarcinoma); Oncology: Breast; Oncology: CNS, Glioblastoma; Oncology: CNS, Medulloblastoma; Oncology: CNS, Other; Oncology: Colorectal; Oncology: Esophageal; Oncology: Gallbladder; Oncology: Gastric; Oncology: Head/Neck; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Ovarian; Oncology: Pancreas; Oncology: Renal; Oncology: Soft Tissue Sarcoma; Oncology: Thyroid; Oncology: Unspecified Solid Tumor",Adenocarcinoma; Anaplastic; Estrogen receptor positive; Follicular; Fourth line or greater; HER2 negative; MSI-H/dMMR; Papillary; Pediatric or Adolescent; Second line; Stage III; Stage IV; Third line; Triple receptor negative,"Bile Duct Neoplasms; Breast Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Central Nervous System Neoplasms; Cholangiocarcinoma; Colorectal Neoplasms; Esophageal Neoplasms; Fibrosarcoma; Gallbladder Neoplasms; Glioblastoma; Head and Neck Neoplasms; Kidney Neoplasms; Leiomyosarcoma; Liposarcoma; Liver Cancer; Liver Neoplasms; Medulloblastoma; Melanoma; Neoplasms; Neoplasms, Unknown Primary; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Renal Cancer; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Stomach Neoplasms; Synovial Sarcoma; Thyroid Neoplasms; Wilms Tumor","Argentina; Australia; Belgium; Brazil; China; Colombia; Czech Republic; Denmark; France; Germany; Greece; Hungary; India; Ireland; Italy; Japan; New Zealand; Norway; Poland; Portugal; Russia; Singapore; Slovakia; South Korea; Spain; Sweden; Taiwan, China; Turkey; United Kingdom; United States"
A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel With or Without Carboplatin for Node-Positive or High-Risk Node-Negative Triple-Negative Invasive Breast Cancer,III,Open,"National Institutes of Health/National Cancer Institute;
NRG Oncology",Oncology: Breast,Adjuvant; HER2 negative; Stage I; Stage II; Stage III; Triple receptor negative,Breast Neoplasms,Canada; United States
Endocrine Treatment Alone as Primary Treatment for Elderly Patients With Estrogen Receptor Positive Operable Breast Cancer and Low Recurrence Score,II,Open,"Washington University School of Medicine
Exact Sciences {Genomic Health}",Oncology: Breast,Estrogen receptor positive; HER2 negative; Neoadjuvant; Stage I; Stage II,Breast Neoplasms; Recurrence,United States
Traditional Incision and Drainage of Cutaneous Abscess Vs. Minimally Invasive Incision and Drainage With Vessel Loop: A Randomized Controlled Trail,II,Open,"Comprehensive Cancer Center of Wake Forest University
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins {Johns Hopkins Oncology Center}",Oncology: Breast; Oncology: Metastatic Cancer,CNS mets; First line; HER2 negative; HER2 positive; Second line; Stage IV; Third line; Triple receptor negative,Brain Neoplasms; Breast Neoplasms; Central Nervous System Neoplasms; Neoplasm Metastasis,United States
"Atavistic Chemotherapy and Immunotherapy in Advanced, Metastatic, and Otherwise Incurable and Lethal Cancers Under Conventional Treatments",II,Open,(Other Hospital/Academic/Medical Center);,"Oncology: Breast; Oncology: CNS, Glioblastoma; Oncology: Colorectal; Oncology: Esophageal; Oncology: Head/Neck; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Pancreas; Oncology: Soft Tissue Sarcoma",First line; Locally advanced; Metastatic; Second line; Stage III; Stage IV,"Breast Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Fibrosarcoma; Glioblastoma; Head and Neck Neoplasms; Leiomyosarcoma; Liposarcoma; Liver Cancer; Liver Neoplasms; Melanoma; Pancreatic Cancer; Pancreatic Neoplasms; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Soft Tissue Sarcoma; Synovial Sarcoma; Unspecified",Mexico; United States
p16INK4a Expression and Chemotherapy Toxicity in Women with Early Stage Breast Cancer,Other,Open,(Other Hospital/Academic/Medical Center);,Oncology: Breast,Adjuvant; HER2 negative; HER2 positive; Neoadjuvant; Stage I; Stage II; Stage III; Triple receptor negative,Breast Neoplasms,United States
ARTEMIS: A Robust TNBC Evaluation FraMework to Improve Survival,II,Open,"MD Anderson Cancer Center University of Texas;
National Institutes of Health/National Cancer Institute;
National Comprehensive Cancer Network",Oncology: Breast,HER2 negative; Neoadjuvant; Stage I; Stage II; Stage III; Triple receptor negative,Breast Neoplasms; Carcinoma,United States
A Trial of Endocrine Response in Women With Invasive Lobular Breast Cancer.,Other,Open,"AstraZeneca;
(Other Cooperative Group);
University of Pittsburgh",Oncology: Breast,Estrogen receptor positive; HER2 negative; Neoadjuvant; Progesterone receptor positive; Stage I; Stage II; Stage III,Breast Neoplasms,United States
"The GLORIA Study: A Phase III, Randomized, Open-Label Study of the Anti-Globo H Vaccine Adagloxad Simolenin (OBI-822)/OBI-821 in the Adjuvant Treatment of Patients With High Risk, Early Stage Globo H-Positive Triple Negative Breast Cancer",III,Open,OBI Pharma,Oncology: Breast,Adjuvant; Estrogen receptor positive; HER2 negative; Neoadjuvant; Progesterone receptor positive; Stage 0; Stage I; Stage II; Stage III; Triple receptor negative,Breast Neoplasms; Triple Negative Breast Neoplasms,"Argentina; Australia; Brazil; China; France; Germany; Hong Kong, S.A.R., China; Mexico; Peru; Poland; Russia; South Africa; South Korea; Spain; Taiwan, China; Ukraine; United States"
Randomized Study Evaluating Molecular Profiling and Targeted Agents in Metastatic Cancer: Initiative for Molecular Profiling and Advanced Cancer Therapy (IMPACT II),II,Open,"MD Anderson Cancer Center University of Texas;
(Other Hospital/Academic/Medical Center);","Oncology: Breast; Oncology: Melanoma; Oncology: Skin, Basal Cell Carcinoma; Oncology: Unspecified Cancer",KRAS; Second line; Stage IV,"Breast Neoplasms; Carcinoma, Basal Cell; Melanoma; Neoplasm Metastasis; Neoplasms; Neoplasms, Basal Cell; Recurrence",United States
GCC 1366: A Prospective Study of Neoadjuvant Non-Steroidal Aromatase Inhibitors to Evaluate Anti-Proliferative Response in Obese and Overweight Patients,II,Open,University of Maryland Greenebaum Cancer Center,Oncology: Breast,HER2 negative; Neoadjuvant; Stage I; Stage II; Stage III,Breast Neoplasms; Overweight,United States
"A Randomized, Phase II Clinical Trial of a Controlled Diet Prior to Selected Chemotherapy Treatment in Breast and Prostate Cancer to Evaluate the Impact on Toxicity and Efficacy",II,Open,"National Institutes of Health/National Cancer Institute;
University of Southern California
Mayo Clinic;",Oncology: Breast; Oncology: Prostate; Oncology: Supportive Care,Adjuvant; Cachexia; Emesis; Hormone refractory; Mucositis; Neoadjuvant; Neurotoxicity; Second line; Stage IV,Breast Neoplasms; Cachexia; Mucositis; Palliative Care; Prostatic Neoplasms; Vomiting,United States
Effect of Vitamin D Replacement on Tumor Response and Survival Parameters for Vitamin D Insufficient Patients With Cancer,II,Open,"National Institutes of Health/National Cancer Institute;
Mayo Clinic;","Oncology: Breast; Oncology: Colorectal; Oncology: Leukemia, Chronic Lymphocytic; Oncology: Lymphoma, Non-Hodgkin's",Aggressive; Cutaneous T-cell lymphoma (CTCL); Diffuse large B-cell lymphoma (DLBCL); First line; Indolent; Other subtype; Peripheral T-cell lymphoma (PTCL); Small lymphocytic lymphoma (SLL); Stage 0; Stage I; Stage II; Stage III; Stage IV; Untreated,"Breast Neoplasms; Chronic Lymphocytic Leukemia; Colorectal Neoplasms; Enteropathy-Associated T-Cell Lymphoma; Immunoblastic Lymphadenopathy; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma; Lymphoma, B-Cell; Lymphoma, Extranodal NK-T-Cell; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Large-Cell, Anaplastic; Lymphoma, Non-Hodgkin; Lymphoma, Primary Cutaneous Anaplastic Large Cell; Lymphoma, T-Cell; Lymphoma, T-Cell, Cutaneous; Lymphoma, T-Cell, Peripheral; Panniculitis",United States
"A Phase II Study Using Short-Term Cultured, Autologous Tumor-Infiltrating Lymphocytes Following a Lymphodepleting Regimen in Metastatic Cancers Plus the Administration of Pembrolizumab",II,Open,National Institutes of Health/National Cancer Institute;,"Oncology: Bladder; Oncology: Breast; Oncology: CNS, Glioblastoma; Oncology: Colorectal; Oncology: Endometrial; Oncology: Esophageal; Oncology: Gastric; Oncology: Liver; Oncology: Ovarian; Oncology: Pancreas; Oncology: Renal",Estrogen receptor positive; HER2 negative; Second line; Stage IV; Third line,"Breast Neoplasms; Carcinoma, Endometrioid; Carcinoma, Hepatocellular; Carcinoma, Renal Cell; Colorectal Neoplasms; Endocrine Gland Neoplasms; Endometrial Neoplasms; Esophageal Cancer; Esophageal Neoplasms; Glioblastoma; Kidney Neoplasms; Liver Cancer; Liver Neoplasms; Neoplasm Metastasis; Neoplasms; Neuroendocrine Tumors; Ovarian Cancer; Ovarian Neoplasms; Pancreatic Cancer; Pancreatic Neoplasms; Renal Cancer; Stomach Carcinoma; Stomach Neoplasms; Urethral Neoplasms; Urinary Bladder Neoplasms; Wilms Tumor",United States
I-SPY 2 Trial (Investigation of Serial Studies to Predict Your Therapeutic Response With Imaging And moLecular Analysis 2),II,Open,"(Other Cooperative Group);
National Institutes of Health/National Cancer Institute;
American College of Radiology Imaging Network (ACRIN)",Oncology: Breast,BRCA; Estrogen receptor positive; HER2 negative; HER2 positive; Neoadjuvant; Progesterone receptor positive; Stage II; Stage III; Stage IV; Triple receptor negative,Breast Neoplasms; Hemangiosarcoma; Triple Negative Breast Neoplasms,Canada; United States
"An Open-Label, Multicenter Extension Study of Trastuzumab Emtansine Administered as a Single Agent or in Combination With Other Anti-Cancer Therapies in Patients Previously Enrolled in a Genentech; and/or F. Hoffmann-La Roche, Ltd-Sponsored Trastuzumab Emtansine Study",II,Open,"Roche;Genentech; {Genentech;}
Roche;/Chugai Pharmaceutical
Roche; {F. Hoffmann-La Roche;}",Oncology: Breast,First line; HER2 positive; Second line; Stage III; Stage IV,Breast Neoplasms; Neoplasm Metastasis,"Argentina; Australia; Austria; Belgium; Bosnia and Herzegovina; Brazil; Bulgaria; Canada; Chile; China; Croatia; Czech Republic; Denmark; Finland; France; Germany; Guatemala; Hong Kong, S.A.R., China; Hungary; Israel; Italy; Japan; Luxembourg; Macedonia; Mexico; New Zealand; Norway; Panama; Peru; Philippines; Poland; Portugal; Russia; Serbia; Singapore; Slovakia; Slovenia; South Korea; Spain; Sweden; Switzerland; Taiwan, China; Thailand; United Kingdom; United States; Venezuela"
"Effect of Neoadjuvant or Adjuvant Systemic Therapy on Breast Cancers, Bone Marrow Cancer Cells, and Circulating Cancer Cells",Other,Open,Washington University School of Medicine,Oncology: Breast,Adjuvant; HER2 positive; Neoadjuvant; Stage II; Stage III; Stage IV,Bone Marrow Neoplasms; Breast Neoplasms,United States